Discharge Planning Scale

Article Type
Changed
Sun, 05/28/2017 - 22:02
Display Headline
Discharge planning scale: Community physicians' perspective

Preventable adverse events occur when patients transition from hospital to outpatient care.1, 2 The most common cause for postdischarge adverse events is poor communication between inpatient healthcare providers and outpatient primary care physicians.1 Adverse events also occur because of inadequate processes to communicate unresolved problems, monitor drug therapies, or monitor the patient's overall condition.1 Efforts to reduce adverse events logically focus on effective discharge planning and communication.

Systematic reviews have evaluated clinical trials to improve discharge planning and communication.36 Reviewers often reported inconclusive results because of a shortage of high‐quality trials with validated outcome measures.35 Reviewers recommended future studies to develop and validate outcome measures that assessed the discharge process from various perspectives.4 One important perspective was the assessment by the outpatient, primary care physician who was responsible for patient care after discharge.79

One of the authors (K.G.S.) developed the Physician‐PREPARED questionnaire to measure perceptions of outpatient physicians about the quality of hospital discharge. Item content came from studies in Australia that investigated barriers to best practice in discharge planning for older patients.1013 Fifteen items asked community physicians about their awareness of discharge planning processes for their patients. Items also assessed the adequacy of information provided about discharge plans. The Physician‐PREPARED items underwent assessment in Australia. Evaluation revealed well‐worded text, unambiguous response options, face validity, and content validity.

We reconsidered the Physician‐PREPARED questionnaire when we designed a clinical trial to assess the value of a discharge intervention in the United States. Our goal was a comprehensive survey instrument and scale to measure the perceptions of outpatient physicians after the discharge intervention. We found no other appropriate, validated questionnaires except the Physician‐PREPARED. However, we recognized some limitations to the Physician‐PREPARED. The items were developed for Australian physicians who treated elderly patients. We wanted to assess North American physicians who cared for a broad age range of adults. The Physician‐PREPARED did not have a scale with validated, psychometric performance characteristics in our population. We decided to address the above limitations with a scale development and validation study in the United States.

In the present work, we describe item development for the Physician‐PREPARED that occurred in Australia. Then we present item reduction and validation for the Modified Physician‐PREPARED that occurred in the United States. Our primary objective was to validate a scale to measure perceptions of outpatient physicians about qualities of discharge planning and communication. The secondary objectives were to quantify the scale's internal consistency and construct validity. Our goal was a brief scale with acceptable, defined statistical properties for clinicians and researchers.

PATIENTS AND METHODS

Item Development for the Physician‐PREPARED

Australian investigators designed the Physician‐PREPARED survey instrument to measure the quality of discharge planning activities and communication. The investigators developed the survey with the following process that was not published previously. First, a literature review identified survey content germane to outpatient practitioners.10 Investigators conducted interviews, focus groups, and pilot surveys to prioritize items for the survey instrument. The volunteer subjects for item development were general medical practitioners in Adelaide and Sydney, the capital cities of two states in Australia. The draft instrument was circulated to a small group of general medical practitioners for comment on layout, wording, and question intent. After feedback, minor modifications were made to item content and response categories. The result of development in Australia was a survey instrument with 15 items (see Appendix). The items reflected the following key areas of discharge quality: timeliness of communication, patient health status at discharge, adequacy of discharge support services, discharge medication information, and reasons for medication changes. These areas were congruent with the results of other investigators who assessed the quality of discharge planning and communication.14, 15

Validation of the Modified Physician‐PREPARED

The validation study for the Modified Physician‐PREPARED occurred in Illinois. The Peoria Institutional Review Board approved and monitored the human research. The patient sample for validation was a prospective cohort from a cluster randomized clinical trial. Willing patients or their proxies provided written consent for study participation. Patient enrollment occurred between December 2004 and August 2006. The subjects for scale analysis were the outpatient primary care physicians or practitioners designated by patients in the cohort. Outpatient physicians and practitioners gave implied consent when they completed and returned questionnaires. Follow‐up was 10 or more days after the patient's discharge from an acute care, 730‐bed, teaching hospital.

Patient Inclusion Criteria

Trained research coordinators identified all consecutive adult inpatients who were discharged to home by internal medicine hospitalist physicians. Patient inclusion in the cluster‐randomized trial required a probability of repeat admission (Pra) score greater than or equal to 0.40.16, 17 Consequently, the patients in the scale analysis cohort had the same high probability for repeat admission. The Pra score came from patient or proxy responses to questions about age, prior hospitalizations, prior doctor visits, self‐rated health status, and other health‐related questions.16, 17 In previous validation studies with elderly outpatients, a Pra score above 0.5 predicted that patients would have 1 hospital admission per person‐year of survival.16 In other validation studies with inpatients aged 18 to 101 years, the Pra items predicted nonroutine discharge planning needs.18

Exclusion Criteria

The exclusion criteria were designed to enroll a cohort with homogeneous risk for readmission. We excluded patients if their discharge destination was a nursing home, another acute care hospital, or an inpatient rehabilitation unit. Hospice patients were excluded if life expectancy was less than 6 months as estimated by the hospitalist. We also used exclusion criteria to avoid illogical enrollments. If the designated outpatient primary care physician or practitioner also managed the patient during the index hospitalization, then there was no perceived barrier to communication and the patient was excluded. Cognitive impairment was a conditional exclusion criterion. We defined cognitive impairment as a score less than 9 on the 10‐point clock test.19 A patient with cognitive impairment could participate with consent from a legally authorized representative. Before we enrolled a cognitively impaired patient, we required a proxy who spent a minimum of 3 hours daily with the patient and who agreed to answer interview questions.

Baseline Assessment

During the index hospitalization, trained data abstractors recorded baseline patient data to calculate the Pra: age, gender, diabetes mellitus, and ischemic heart disease. Patients or proxies provided the number of hospital admissions and doctor visits during the year before the index hospitalization. We recorded the availability of an informal caregiver in response to the question, Is there a friend, relative or neighbor who would take care of you for a few days, if necessary? Patients rated their health status on the following scale: poor, fair, good, very good, and excellent. In addition, we recorded heart failure and chronic obstructive pulmonary disease because of their possible association with readmission.20, 21 Information about outpatient physicians or practitioners came from the hospital's administrative database and was limited to specialty training.

Discharge Process

At the end of the index hospitalization, hospitalists and ward nurses used standardized forms for discharge diagnoses, prescriptions, instructions, and appointments. Discharge planning nurses or social workers consulted with hospitalists and ward nurses and then coordinated service providers including home health nurses, physical therapists, home health aides, homemaker service providers, durable medical equipment vendors, home oxygen vendors, home infusion pharmacists, social workers, rehabilitation service providers, legal aid providers, and others. Patients designated an outpatient primary care physician or nurse practitioner or physician assistant to receive discharge reports and results of diagnostic tests. Ten days after discharge, research personnel mailed the Physician‐PREPARED questionnaire to the designated outpatient primary care professional.

Item Reduction and Scoring

To develop a scale, we selected items from the Physician‐PREPARED survey instrument (see Appendix). Our goal was a parsimonious, comprehensive, and valid scale for use in clinical and research environments. We applied item reduction techniques according to the following steps that were defined a priori. First, we deleted items with nominal response categories that lacked graded or ordinal characteristics. This exclusion criterion caused us to delete the following items from the questionnaire in the appendix: (1a) Who made you aware of the admission, (2a) Who made you aware of the patient's discharge, and (5a) How did you receive this information? We deleted open‐ended questions, such as: (13) Have you any suggestions how the patient's discharge could have been improved? Next, we excluded items with a large proportion of missing responses because respondents checked Not applicable. Only item 12 from the Physician‐PREPARED fulfilled the latter criterion (see Appendix). Question 12 asked, Has the patient's caretaker voiced any concerns that they have not been coping since the patient was discharged? Among 403 respondents, 52% answered question 12 as Not applicable.

Measures of Construct Validity

We used 3 measures of construct validity in our assessment of the Modified Physician‐PREPARED scale. The first construct item asked the outpatient practitioner, Were you involved at all in planning the patient's discharge? The first construct was relevant because involvement by outpatient physicians improves the quality of hospital discharges.22 The second construct item asked, Are you aware of any community support services that are involved in providing assistance to the patient since discharge? For the third construct, we asked (Appendix item 11), Has the patient voiced any concerns that they have not been coping since discharge? We chose community support services and patient coping because these are clinically relevant and correlated with patients' perceptions of discharge preparedness.23 When we assessed construct validity, our hypotheses were significantly higher Modified Physician‐PREPARED scale values for respondents who answered yes to the construct questions about involvement and awareness and answered no to the question about patient‐voiced concerns.

Analysis

Analyses were performed with SPSS PC (version 14.0.2; SPSS Inc, Chicago, Illinois). We reported descriptive statistics as means, standard deviations (SDs), and range for interval variables; median and range for ordinal variables; and percentages for nominal variables. While developing the scale, the unit of analysis was the physician response to a unique patient. Specific descriptive analyses used the unique respondent as the unit of analysis. To determine the internal consistency of the scale, we calculated Cronbach's alpha with SPSS RELIABILITY. We assessed the distribution of the Modified Physician‐PREPARED scale with visual and statistical tests for skewness. While using the SPSS FACTOR program, we performed principal components extractions and then rotated components using the oblique promax technique. Component scores were saved using the regression score procedure. Component loadings above 0.30 were considered for interpretation.24 Statistical inference tests were the Mann‐Whitney U for median differences for 2 groups, the Kruskal‐Wallis for more than 2 groups, and Spearman correlation for associations. The accepted level of significance was P < 0.05.

RESULTS

Description of Validation Cohort for the Modified Physician‐PREPARED

We sent questionnaires to the primary care physician, nurse practitioner, or physician assistant designated by 549 patients. The survey response rate was 76% (417/549). If a respondent failed to check any response option for 2 or more scale items, then the questionnaire was excluded from analysis. We excluded 3% (14/549) of questionnaires for failure to respond to items. The responses from the remaining 403 questionnaires were analyzed. We did not exclude questionnaires from respondents who followed homebound patients or other patients who failed to come to the clinic for postdischarge visits. Our analysis included 90 questionnaires (22%) from respondents who had no contact with the patient after discharge.

The patient characteristics appear in Table 1. Most of the patients were less than 65 years old (77%, 310/403). Many patients had chronic diseases including diabetes mellitus, ischemic heart disease, heart failure, or chronic obstructive pulmonary disease. Most patients, 81% (327/403), rated their health as poor or fair and 55% (223/403) had 1 or more hospital admissions during the year before their index admission. The questionnaire respondents were primary care physicians who practiced internal medicine (41%, 167/403), medicine‐pediatrics (27%, 108/403), family practice (24%, 97/403), or other specialties (3%, 10/403). Nurse practitioners or physician assistants completed 5% (21/403) of questionnaires.

Baseline Characteristics of 403 Patients in the Sample Used to Develop the Modified Physician‐PREPARED Scale
CharacteristicNumber (%)
  • Abbreviation: Pra, probability of repeat admission.

  • Values are mean (SD) [range].

Gender, female235 (58.3%)
Race 
White284 (70.5%)
Black116 (28.8%)
Other3 (0.7%)
Self‐rated health status 
Poor125 (31.0%)
Fair202 (50.1%)
Good61 (15.1%)
Very good13 (3.2%)
Excellent2 (0.5%)
Diabetes mellitus226 (56.1%)
Chronic obstructive pulmonary disease76 (18.9%)
Ischemic heart disease165 (40.9%)
Heart failure90 (22.3%)
Hospital admissions during prior year (includes index admission)2.2 (2.0) [0‐15]*
Age (years)53.6 (15.1) [19‐98]*
Pra score0.49 (0.07) [0.40‐0.70]*

We conducted descriptive analyses that treated the respondent as the unit of analysis. There were 172 unique respondents. The number of questionnaires per respondent ranged from 1 to 20 with a median of 1 questionnaire. Respondents varied in the time to return a questionnaire. We measured response time as the difference between the date we received the questionnaire and the date of discharge. The response time ranged from 10 to 90 days with a median of 21 days after discharge.

Modified Physician‐PREPARED: Item Reduction, Internal Consistency, and Score Distributions

The questionnaire items appear in the Appendix. After item reduction, there were 8 items included in the Modified Physician‐PREPARED scale analysis (Table 2). None of the 8 items caused substantive reduction in Cronbach's alpha, so all were retained. The 8‐item scale had acceptable internal consistency (Cronbach's alpha = 0.86). For an individual questionnaire, the sum of the scores for eight items yielded the Modified Physician‐PREPARED scale value. High scale values reflected high perceptions of discharge quality. Each of the 8 items correlated significantly and positively with the scale value (P < 0.001, 2‐tailed).

Modified Physician‐PREPARED Items from 403 Questionnaires with Descriptors for Response Scoring System and Number of Respondents for Each Score, n (%)
Item TextDescriptor for Score = 1Descriptor for Score = 2Descriptor for Score = 3No Score
1.When were you made aware that this patient had been admitted to hospital?Not at all; 55 (13.6%)After patient was discharged; 65 (16.1%)Prior to hospitalization; while patient was in hospital; or on the day of discharge; 281 (69.7%)Missing response; 2 (0.5%)
2.When were you made aware that the patient was going to be discharged?Not at all; 115 (28.5%)Within a week after discharge; or longer than a week after discharge; 61 (15.1%)While patient was still in hospital; or on day of discharge; or within 1‐2 days after discharge; 225 (55.8%)Missing response; 2 (0.5%)
3.How soon after discharge did you receive any information (in any form) relating to this patient's hospital admission and discharge plans?Longer than a week; or not received; or other 115 (28.5%)Within a week; 186 (46.2%)Within 1‐2 days; 101 (25.1%)Missing response; 1 (0.2%)
4.Was this sufficient notice to address this patient's postdischarge needs?Less than sufficient; 98 (24.3%)Sufficient; 246 (61.0%)More than sufficient; 46 (11.4%)Missing response; 13 (3.2%)
5.Have you received adequate information about this patient's discharge health status?No; 103 (25.6%) Yes; 295 (73.2%)Missing response; 5 (1.2%)
6.Have you received adequate written information about the patient's medicines and medication management?Less than adequate; or no information at all; 103 (25.6%)Adequate; 262 (65.0%)More than adequate; 38 (9.4%)Missing response; 0 (0%)
7.Did you receive sufficient reasons for changes in medication? (For example, why 1 type of medication is used in preference to another?)Less than sufficient; or no information at all; 129 (32.0%)Sufficient; or not applicable (there was no change in medications); 240 (59.6%)More than sufficient; 29 (7.2%)Missing response; 5 (1.2%)
8.In your opinion, how adequate were the discharge plans to assist this patient to assume safe, independent community living?Less than adequate; or no discharge plans; 82 (20.3%)Adequate; 276 (68.5%)More than adequate; 32 (7.9%)Missing response; 13 (3.2%)

Table 2 shows the distribution of responses to each item in the Modified Physician‐PREPARED questionnaire. There were substantial ceiling effects for 2 individual items. One of the 7 items with 3 response options had ceiling effects approaching 70% (item 1). One item had 2 response options and 73% responded yes (item 5). The distribution of Modified Physician‐PREPARED scale values for 403 questionnaires had mean 16.6 4.0 SD and skew 0.6 (standard error of skew = 0.1). When scale values of patients 64 years and younger were compared with those of 65 and older, there were no significant differences (P = 0.606). The scale values did not have noteworthy floor or ceiling effects. The distribution of scale values showed 1.2% (5/403) of respondents had the lowest score of 8 and 1.7% (7/403) had the highest score of 24.

Modified Physician‐PREPARED: Principal Component Analysis

The purpose of the principal component analysis was to evaluate the relationships between the items and domains. In the component analysis, we evaluated the correlation matrix of the 8 items in the Modified Physician‐PREPARED scale. The Kaiser‐Meyer‐Olkin statistic of 0.89 indicated sufficient sampling adequacy to extract components from the matrix. Principal components extracted 66% of the variance associated with the 8‐item scale. After inspection of scree plots, we determined that 2 components were extracted before the eigenvalue fell substantially below 1. The pattern matrix for the promax rotation was inspected and the factor loading for each item appears in Table 3. The item content identified 1 component as timeliness of communication. The other component was adequacy of discharge plan/transmission. Within the adequacy component, the item content addressed patient health status, medication information, and reasons for medication changes. All items loaded primarily on 1 of the components; except item 3, which loaded on both components.

Pattern Matrix from Principal Component Analysis of 403 Questionnaires: Oblique Factor Loadings for 8 Items in Modified Physician‐PREPARED Scale
 Item TextComponent
Adequacy of Discharge Plan/TransmissionTimeliness of Communication
7Did you receive sufficient reasons for changes in medication? (For example, why one type of medication is used in preference to another?)0.9000.132
6Have you received adequate written information about the patient's medicines and medication management?0.8490.056
4Was this sufficient notice to address this patient's postdischarge needs?0.7960.050
5Have you received adequate information about this patient's discharge health status?0.7740.012
8In your opinion, how adequate were the discharge plans to assist this patient to assume safe, independent community living?0.7440.132
3How soon after discharge did you receive any information (in any form) relating to this patient's hospital admission and discharge plans?0.4030.373
1When were you made aware that this patient had been admitted to hospital?0.1540.964
2When were you made aware that the patient was going to be discharged?0.1230.779

Modified Physician‐PREPARED: Construct Validity

We compared Modified Physician‐PREPARED scale values between dichotomous groups defined by construct variables. When considering the discharge planning and communication for a specific patient, outpatient primary care practitioners reported higher scale values when they were involved in the discharge planning (median [25%, 75%] = 19 [19, 20.5]) than when they were not involved (17 [12.4, 19], P < 0.001). In addition, outpatient practitioners responded with higher scale values when they were aware of community support services (18 [16, 20]) than when they were unaware (17 [12, 19], P = 0.002). There was a nonsignificant trend to higher scale values if patients voiced no concern about coping after discharge (18 [15, 19]) versus concern (17 [12, 19], P = 0.059). For all 3 constructs, the analysis revealed higher Modified Physician‐PREPARED scale values that were in the same direction as hypothesized. We approximated the construct analysis with subscales defined by the principal components (data not shown). The subscale analysis confirmed the direction and significance of the analysis with the full, 8‐item, Modified Physician‐PREPARED scale.

Modified Physician‐PREPARED: Correlations with Baseline Characteristics

We evaluated the correlations between a patient's Modified Physician‐PREPARED scale value and baseline characteristics in Table 1. Patient characteristics were not associated with scale values. We also assessed the median differences between the scale values by practitioner specialty and found no significant differences.

DISCUSSION

The Modified Physician‐PREPARED scale measured the quality of discharge planning and communication from the perspective of the outpatient primary care physician or practitioner. We described the derivation of the scale items. We demonstrated the reliability and validity of the scale among physicians and practitioners who provided postdischarge care to patients at high risk for readmission to the hospital. The item content included timeliness, adequacy, patient health status, medication information, and reasons for medication changes.

According to expert consensus guidelines for hospital discharge care, the communication with the outpatient primary care physician should occur as soon as possible after discharge.25 Recommended data elements in the communication include condition at discharge, diagnoses, medications added, medications discontinued, and medications changed.25 We found the Modified Physician‐PREPARED scale items included content that was consistent with expert consensus guidelines. The items also assessed timeliness and adequacy, 2 domains important to outpatient physicians.14, 26

The Modified Physician‐PREPARED is one of several questionnaires developed to measure qualities of discharge processes from the perspective of outpatient physicians.8, 15, 2733 Previous questionnaires did not report psychometrics except 1 that assessed the quality of discharge summaries and measured test‐retest reliability.33 We are not aware of other physician questionnaires with reliable or valid scales besides the Modified Physician‐PREPARED.

We believe 1 application of the Modified Physician‐PREPARED questionnaire is in quality improvement efforts within hospitals. Most hospitals and inpatient physicians rely on discharge letters or summaries to communicate information about the hospitalization to outpatient practitioners.6 However, systematic problems with generation and transmission of letters and summaries make them sometimes unreliable as sources of consistent, timely, accurate, or important information.6 When patients arrive for their posthospital visits, their outpatient physicians have received no discharge letter for 16% to 53% of patients and no discharge summary for 66% to 88%.6 Among outpatient physicians, 41% attribute preventable adverse events for at least 1 of their patients to inadequate discharge communication.34 One hospital accreditation organization includes discharge communication improvement as a national patient safety goal in the United States.35 Hospitals have multiple motivations to pursue quality improvement projects related to discharge communication: reduction in adverse events, relation with referring physicians, and accreditation by regulators. When surveying physicians, hospital personnel may wish to use a reliable and validated instrument like the Modified Physician‐PREPARED questionnaire.

Another application of the Modified Physician‐PREPARED scale is in research. An example is our randomized, controlled trial to measure the value of a discharge intervention. We published the rationale and design for our intervention.36 In the future, we will analyze the results of our trial and we will need validated scales. One of the trial outcomes is the perspective of the outpatient physician. We expect to compare the scores on the Modified Physician‐PREPARED scale values from community practitioners who treated test patients versus control patients. The statistical properties of the Modified Physician‐PREPARED scale that we validated in the current work will allow us to estimate the precision of between‐group differences and to perform tests of inference.

The results of our study should be interpreted in the context of strengths and limitations. We were able to generalize the validity of the Modified Physician‐PREPARED to North American primary care physicians who treated adult outpatients with a broad age range. We minimized biases with the high survey response rate and low proportion of missing responses. During validation, we asked physicians to evaluate patient transitions from hospital to home. Consequently, the Modified Physician‐PREPARED scale may not apply when doctors follow patients after discharge to nursing homes or other acute care facilities. We excluded patients with low probability of repeat admission: hospice patients and patients with low Pra scores. The purpose of our exclusion criteria was to enrich the sample with patients likely to benefit from interventions to improve discharge processes. We recognize that the Modified Physician‐PREPARED may not generalize to physicians who treat hospice patients or patients with low probability for readmission.

Additional limitations relate to test‐retest reliability and to the clinical meaning of small changes in scale values. In our study, physician respondents returned questionnaires approximately 3 weeks after hospital discharge. We did not ask physicians to complete the questionnaire again after they returned the first questionnaire. Therefore, the test‐retest reliability for the Modified Physician‐PREPARED is unknown. Our protocol was not designed to detect the minimum important difference in the scale values. Consequently, small changes in scale values have uncertain clinical relevance. Future studies are necessary to assess the minimum important difference in the scale values.

CONCLUSION

The Modified Physician‐PREPARED scale was a reliable and valid measure of outpatient physician perceptions of quality and communication after hospital discharge. Clinicians and researchers may find the scale useful to guide, assess, and compare discharge‐planning activities.

APPENDIX

PHYSICIAN‐PREPARED QUESTIONNAIRE

0

ItemQuestionResponse Options
1When were you made aware that this patient had been admitted to hospital?Prior to hospitalization
While patient was in hospital
On the day of discharge
After patient was discharged
Not at all
1aWho made you aware of the admission?Hospital ward staff
Discharge planner
Hospital medical staff
Ambulance
Patient
Patient's family/friends
Other, please specify _________________________
2When were you made aware that the patient was going to be discharged?While patient was still in hospital
On day of discharge
Within 1‐2 days after discharge
Within a week after discharge
Longer than a week after discharge
Not at all
2aWho made you aware of the patient's discharge?Hospital ward staff
Discharge planner
Hospital medical staff
Patient
Patient's family/friends
Other, please specify _________________________
3How soon after discharge did you receive any information (in any form) relating to this patient's hospital admission and discharge plans?Within 1‐2 days
Within a week
Longer than a week
Not received
Other, please specify _________________________
4Was this sufficient notice to address this patient's postdischarge needs?More than sufficient
Sufficient
Less than sufficient
5Have you received adequate information about this patient's discharge health status?Yes
No
5aHow did you receive this information? (Check all that apply)Telephone call
Fax
Electronic mail system
Written/typed letter
6Have you received adequate written information about the patient's medicines and medication management?More than adequate
Adequate
Less than adequate
No information at all
7Did you receive sufficient reasons for changes in medication? (For example, why 1 type of medication is used in preference to another?)Not applicable (there was no change in medications)
More than sufficient
Sufficient
Less than sufficient
No information at all
8In your opinion, how adequate were the discharge plans to assist this patient to assume safe, independent community living?More than adequate
Adequate
Less than adequate
No discharge plans
9Were you involved at all in planning the patient's discharge?Yes
No
10Are you aware of any community support services that are involved in providing assistance to the patient since discharge?Yes
No
11Has the patient voiced any concerns that they have not been coping since discharge?Yes
No
Not applicable (no contact with patient since discharge)
12Has the patient's caretaker voiced any concerns that they have not been coping since the patient was discharged?Not applicable (no caretaker)
Yes
No
Not applicable (no contact with caretaker since discharge)
13Have you any suggestions how the patient's discharge could have been improved?__________________________________________
__________________________________________
__________________________________________
References
  1. Forster AJ,Murff HJ,Peterson JF,Gandhi TK,Bates DW.The incidence and severity of adverse events affecting patients after discharge from the hospital.Ann Intern Med.2003;138:161167.
  2. Forster AJ,Clark HD,Menard A, et al.Adverse events among medical patients after discharge from hospital.CMAJ.2004;170:345349.
  3. Johnson A,Sandford J,Tyndall J.Written and verbal information versus verbal information only for patients being discharged from acute hospital settings to home.Cochrane Database Syst Rev.2003;(4):CD003716.
  4. Shepperd S,Parkes J,McClaren J,Phillips C.Discharge planning from hospital to home.Cochrane Database Syst Rev.2004;(1):CD000313.
  5. Ward D,Severs M,Dean T,Brooks N.Care home versus hospital and own home environments for rehabilitation of older people.Cochrane Database Syst Rev.2003;(2):CD003164.
  6. Kripalani S,LeFevre F,Phillips CO,Williams MV,Basaviah P,Baker DW.Deficits in communication and information transfer between hospital‐based and primary care physicians: implications for patient safety and continuity of care.JAMA.2007;297:831841.
  7. Auerbach AD,Nelson EA,Lindenauer PK,Pantilat SZ,Katz PP,Wachter RM.Physician attitudes toward and prevalence of the hospitalist model of care: results of a national survey.Am J Med.2000;109:648653.
  8. Preen DB,Bailey BE,Wright A, et al.Effects of a multidisciplinary, post‐discharge continuance of care intervention on quality of life, discharge satisfaction, and hospital length of stay: a randomized controlled trial.Int J Qual Health Care.2005;17:4351.
  9. McAlearney AS.Hospitalists and family physicians: understanding opportunities and risks.J Fam Pract.2004;53:473481.
  10. Hedges G,Grimmer K,Moss J,Falco J.performance indicators for discharge planning: a focused review of the literature.Aust J Adv Nurs.1999;16:2028.
  11. Informing discharge plans. Assessments of elderly patients in Australian public hospitals: a field study. Available at: http://ijahsp.nova.edu/articles/Vol2number3/Grimmer‐Discharge_Plans.htm. Accessed January2008.
  12. Grimmer K,Moss J,Falco J.Experiences of elderly patients regarding independent community living after discharge from hospital: a longitudinal study.Int J Qual Health Care.2004;16:465472.
  13. Grimmer K,Moss J,Falco J.Life Post‐Discharge: Longitudinal Qualitative and Quantitative Study of 100 Elderly People Post Discharge from Hospital. Technical Report Produced for South Australian Department of Human Services. South Australia: South Australian Department of Human Services;2002.
  14. Bolton P,Mira M,Kennedy P,Lahra MM.The quality of communication between hospitals and general practitioners: an assessment.J Qual Clin Pract.1998;18:241247.
  15. Munday A,Kelly B,Forrester JW,Timoney A,McGovern E.Do general practitioners and community pharmacists want information on the reasons for drug therapy changes implemented by secondary care?Br J Gen Pract.1997;47:563566.
  16. Pacala JT,Boult C,Boult L.Predictive validity of a questionnaire that identifies older persons at risk for hospital admission.J Am Geriatr Soc.1995;43:374377.
  17. Pacala JT,Boult C,Reed RL,Aliberti E.Predictive validity of the Pra instrument among older recipients of managed care.J Am Geriatr Soc.1997;45:614617.
  18. Holland DE,Harris MR,Pankratz VS,Closson DC,Matt‐Hensrud NN,Severson MA.Prospective evaluation of a screen for complex discharge planning in hospitalized adults.J Am Geriatr Soc.2003;51:678682.
  19. Manos PJ,Wu R.The ten point clock test: a quick screen and grading method for cognitive impairment in medical and surgical patients.Int J Psychiatry Med.1994;24:229244.
  20. Naylor MD,Brooten D,Campbell R, et al.comprehensive discharge planning and home follow‐up of hospitalized elders: a randomized clinical trial.JAMA.1999;281:613620.
  21. Smith DM,Giobbie‐Hurder A,Weinberger M, et al.Predicting non‐elective hospital readmissions: a multi‐site study. Department of Veterans Affairs Cooperative Study Group on Primary Care and Readmissions.J Clin Epidemiol.2000;53:11131118.
  22. McInnes E,Mira M,Atkin N,Kennedy P,Cullen J.Can GP input into discharge planning result in better outcomes for the frail aged: results from a randomized controlled trial.Fam Pract.1999;16:289293.
  23. Grimmer K,Moss J.The development, validity and application of a new instrument to assess the quality of discharge planning activities from the community perspective.Int J Qual Health Care.2001;13:109116.
  24. Floyd FJ,Widaman KF.Factor analysis in the development and refinement of clinical assessment instruments.Psychol Assess.1995;7:286299.
  25. Halasyamani L,Kripalani S,Coleman E, et al.Transition of care for hospitalized elderly patients—development of a discharge checklist for hospitalists.J Hosp Med.2006;1:354360.
  26. Meara JR,Wood JL,Wilson MA,Hart MC.Home from hospital: a survey of hospital discharge arrangements in Northamptonshire.J Public Health Med.1992;14:145150.
  27. Pagliari C,Gilmour M,Sullivan F.Electronic clinical communications implementation (ECCI) in Scotland: a mixed‐methods programme evaluation.J Eval Clin Pract.2004;10:1120.
  28. Williams EI,Fitton F.General practitioner response to elderly patients discharged from hospital.BMJ.1990;300:159161.
  29. Wagstaff R,Berlin A,Stacy R,Spencer J,Bhopal RA.Information about patients' deaths: general practitioners' current practice and views on receiving a death register.Br J Gen Pract.1994;44:315316.
  30. Pantilat SZ,Lindenauer PK,Katz PP,Wachter RM.Primary care physician attitudes regarding communication with hospitalists.Am J Med.2001;111:15S20S.
  31. Al‐Rashed SA,Wright DJ,Roebuck N,Sunter W,Chrystyn H.The value of inpatient pharmaceutical counselling to elderly patients prior to discharge.Br J Clin Pharmacol.2002;54:657664.
  32. Bado W,Williams CJ.Usefulness of letters from hospitals to general practitioners.Br Med J (Clin Res Ed).1984;288:18131814.
  33. van Walraven C,Rokosh E.What is necessary for high‐quality discharge summaries?Am J Med Qual.1999;14:160169.
  34. O'Leary KJ,Liebovitz DM,Feinglass J,Liss DT,Baker DW.Outpatient physicians' satisfaction with discharge summaries and perceived need for an electronic discharge summary.J Hosp Med.2006;1:317320.
  35. 2007 Hospital/critical access hospital national patient safety goals. Available at: http://www.jointcommission.org/PatientSafety/NationalPatientSafetyGoals. Accessed January2008.
  36. Nace GS,Graumlich JF,Aldag JC.Software design to facilitate information transfer at hospital discharge.Inform Prim Care.2006;14:109119.
Article PDF
Issue
Journal of Hospital Medicine - 3(6)
Page Number
455-464
Legacy Keywords
continuity of patient care, patient discharge, psychometrics, health care surveys
Sections
Article PDF
Article PDF

Preventable adverse events occur when patients transition from hospital to outpatient care.1, 2 The most common cause for postdischarge adverse events is poor communication between inpatient healthcare providers and outpatient primary care physicians.1 Adverse events also occur because of inadequate processes to communicate unresolved problems, monitor drug therapies, or monitor the patient's overall condition.1 Efforts to reduce adverse events logically focus on effective discharge planning and communication.

Systematic reviews have evaluated clinical trials to improve discharge planning and communication.36 Reviewers often reported inconclusive results because of a shortage of high‐quality trials with validated outcome measures.35 Reviewers recommended future studies to develop and validate outcome measures that assessed the discharge process from various perspectives.4 One important perspective was the assessment by the outpatient, primary care physician who was responsible for patient care after discharge.79

One of the authors (K.G.S.) developed the Physician‐PREPARED questionnaire to measure perceptions of outpatient physicians about the quality of hospital discharge. Item content came from studies in Australia that investigated barriers to best practice in discharge planning for older patients.1013 Fifteen items asked community physicians about their awareness of discharge planning processes for their patients. Items also assessed the adequacy of information provided about discharge plans. The Physician‐PREPARED items underwent assessment in Australia. Evaluation revealed well‐worded text, unambiguous response options, face validity, and content validity.

We reconsidered the Physician‐PREPARED questionnaire when we designed a clinical trial to assess the value of a discharge intervention in the United States. Our goal was a comprehensive survey instrument and scale to measure the perceptions of outpatient physicians after the discharge intervention. We found no other appropriate, validated questionnaires except the Physician‐PREPARED. However, we recognized some limitations to the Physician‐PREPARED. The items were developed for Australian physicians who treated elderly patients. We wanted to assess North American physicians who cared for a broad age range of adults. The Physician‐PREPARED did not have a scale with validated, psychometric performance characteristics in our population. We decided to address the above limitations with a scale development and validation study in the United States.

In the present work, we describe item development for the Physician‐PREPARED that occurred in Australia. Then we present item reduction and validation for the Modified Physician‐PREPARED that occurred in the United States. Our primary objective was to validate a scale to measure perceptions of outpatient physicians about qualities of discharge planning and communication. The secondary objectives were to quantify the scale's internal consistency and construct validity. Our goal was a brief scale with acceptable, defined statistical properties for clinicians and researchers.

PATIENTS AND METHODS

Item Development for the Physician‐PREPARED

Australian investigators designed the Physician‐PREPARED survey instrument to measure the quality of discharge planning activities and communication. The investigators developed the survey with the following process that was not published previously. First, a literature review identified survey content germane to outpatient practitioners.10 Investigators conducted interviews, focus groups, and pilot surveys to prioritize items for the survey instrument. The volunteer subjects for item development were general medical practitioners in Adelaide and Sydney, the capital cities of two states in Australia. The draft instrument was circulated to a small group of general medical practitioners for comment on layout, wording, and question intent. After feedback, minor modifications were made to item content and response categories. The result of development in Australia was a survey instrument with 15 items (see Appendix). The items reflected the following key areas of discharge quality: timeliness of communication, patient health status at discharge, adequacy of discharge support services, discharge medication information, and reasons for medication changes. These areas were congruent with the results of other investigators who assessed the quality of discharge planning and communication.14, 15

Validation of the Modified Physician‐PREPARED

The validation study for the Modified Physician‐PREPARED occurred in Illinois. The Peoria Institutional Review Board approved and monitored the human research. The patient sample for validation was a prospective cohort from a cluster randomized clinical trial. Willing patients or their proxies provided written consent for study participation. Patient enrollment occurred between December 2004 and August 2006. The subjects for scale analysis were the outpatient primary care physicians or practitioners designated by patients in the cohort. Outpatient physicians and practitioners gave implied consent when they completed and returned questionnaires. Follow‐up was 10 or more days after the patient's discharge from an acute care, 730‐bed, teaching hospital.

Patient Inclusion Criteria

Trained research coordinators identified all consecutive adult inpatients who were discharged to home by internal medicine hospitalist physicians. Patient inclusion in the cluster‐randomized trial required a probability of repeat admission (Pra) score greater than or equal to 0.40.16, 17 Consequently, the patients in the scale analysis cohort had the same high probability for repeat admission. The Pra score came from patient or proxy responses to questions about age, prior hospitalizations, prior doctor visits, self‐rated health status, and other health‐related questions.16, 17 In previous validation studies with elderly outpatients, a Pra score above 0.5 predicted that patients would have 1 hospital admission per person‐year of survival.16 In other validation studies with inpatients aged 18 to 101 years, the Pra items predicted nonroutine discharge planning needs.18

Exclusion Criteria

The exclusion criteria were designed to enroll a cohort with homogeneous risk for readmission. We excluded patients if their discharge destination was a nursing home, another acute care hospital, or an inpatient rehabilitation unit. Hospice patients were excluded if life expectancy was less than 6 months as estimated by the hospitalist. We also used exclusion criteria to avoid illogical enrollments. If the designated outpatient primary care physician or practitioner also managed the patient during the index hospitalization, then there was no perceived barrier to communication and the patient was excluded. Cognitive impairment was a conditional exclusion criterion. We defined cognitive impairment as a score less than 9 on the 10‐point clock test.19 A patient with cognitive impairment could participate with consent from a legally authorized representative. Before we enrolled a cognitively impaired patient, we required a proxy who spent a minimum of 3 hours daily with the patient and who agreed to answer interview questions.

Baseline Assessment

During the index hospitalization, trained data abstractors recorded baseline patient data to calculate the Pra: age, gender, diabetes mellitus, and ischemic heart disease. Patients or proxies provided the number of hospital admissions and doctor visits during the year before the index hospitalization. We recorded the availability of an informal caregiver in response to the question, Is there a friend, relative or neighbor who would take care of you for a few days, if necessary? Patients rated their health status on the following scale: poor, fair, good, very good, and excellent. In addition, we recorded heart failure and chronic obstructive pulmonary disease because of their possible association with readmission.20, 21 Information about outpatient physicians or practitioners came from the hospital's administrative database and was limited to specialty training.

Discharge Process

At the end of the index hospitalization, hospitalists and ward nurses used standardized forms for discharge diagnoses, prescriptions, instructions, and appointments. Discharge planning nurses or social workers consulted with hospitalists and ward nurses and then coordinated service providers including home health nurses, physical therapists, home health aides, homemaker service providers, durable medical equipment vendors, home oxygen vendors, home infusion pharmacists, social workers, rehabilitation service providers, legal aid providers, and others. Patients designated an outpatient primary care physician or nurse practitioner or physician assistant to receive discharge reports and results of diagnostic tests. Ten days after discharge, research personnel mailed the Physician‐PREPARED questionnaire to the designated outpatient primary care professional.

Item Reduction and Scoring

To develop a scale, we selected items from the Physician‐PREPARED survey instrument (see Appendix). Our goal was a parsimonious, comprehensive, and valid scale for use in clinical and research environments. We applied item reduction techniques according to the following steps that were defined a priori. First, we deleted items with nominal response categories that lacked graded or ordinal characteristics. This exclusion criterion caused us to delete the following items from the questionnaire in the appendix: (1a) Who made you aware of the admission, (2a) Who made you aware of the patient's discharge, and (5a) How did you receive this information? We deleted open‐ended questions, such as: (13) Have you any suggestions how the patient's discharge could have been improved? Next, we excluded items with a large proportion of missing responses because respondents checked Not applicable. Only item 12 from the Physician‐PREPARED fulfilled the latter criterion (see Appendix). Question 12 asked, Has the patient's caretaker voiced any concerns that they have not been coping since the patient was discharged? Among 403 respondents, 52% answered question 12 as Not applicable.

Measures of Construct Validity

We used 3 measures of construct validity in our assessment of the Modified Physician‐PREPARED scale. The first construct item asked the outpatient practitioner, Were you involved at all in planning the patient's discharge? The first construct was relevant because involvement by outpatient physicians improves the quality of hospital discharges.22 The second construct item asked, Are you aware of any community support services that are involved in providing assistance to the patient since discharge? For the third construct, we asked (Appendix item 11), Has the patient voiced any concerns that they have not been coping since discharge? We chose community support services and patient coping because these are clinically relevant and correlated with patients' perceptions of discharge preparedness.23 When we assessed construct validity, our hypotheses were significantly higher Modified Physician‐PREPARED scale values for respondents who answered yes to the construct questions about involvement and awareness and answered no to the question about patient‐voiced concerns.

Analysis

Analyses were performed with SPSS PC (version 14.0.2; SPSS Inc, Chicago, Illinois). We reported descriptive statistics as means, standard deviations (SDs), and range for interval variables; median and range for ordinal variables; and percentages for nominal variables. While developing the scale, the unit of analysis was the physician response to a unique patient. Specific descriptive analyses used the unique respondent as the unit of analysis. To determine the internal consistency of the scale, we calculated Cronbach's alpha with SPSS RELIABILITY. We assessed the distribution of the Modified Physician‐PREPARED scale with visual and statistical tests for skewness. While using the SPSS FACTOR program, we performed principal components extractions and then rotated components using the oblique promax technique. Component scores were saved using the regression score procedure. Component loadings above 0.30 were considered for interpretation.24 Statistical inference tests were the Mann‐Whitney U for median differences for 2 groups, the Kruskal‐Wallis for more than 2 groups, and Spearman correlation for associations. The accepted level of significance was P < 0.05.

RESULTS

Description of Validation Cohort for the Modified Physician‐PREPARED

We sent questionnaires to the primary care physician, nurse practitioner, or physician assistant designated by 549 patients. The survey response rate was 76% (417/549). If a respondent failed to check any response option for 2 or more scale items, then the questionnaire was excluded from analysis. We excluded 3% (14/549) of questionnaires for failure to respond to items. The responses from the remaining 403 questionnaires were analyzed. We did not exclude questionnaires from respondents who followed homebound patients or other patients who failed to come to the clinic for postdischarge visits. Our analysis included 90 questionnaires (22%) from respondents who had no contact with the patient after discharge.

The patient characteristics appear in Table 1. Most of the patients were less than 65 years old (77%, 310/403). Many patients had chronic diseases including diabetes mellitus, ischemic heart disease, heart failure, or chronic obstructive pulmonary disease. Most patients, 81% (327/403), rated their health as poor or fair and 55% (223/403) had 1 or more hospital admissions during the year before their index admission. The questionnaire respondents were primary care physicians who practiced internal medicine (41%, 167/403), medicine‐pediatrics (27%, 108/403), family practice (24%, 97/403), or other specialties (3%, 10/403). Nurse practitioners or physician assistants completed 5% (21/403) of questionnaires.

Baseline Characteristics of 403 Patients in the Sample Used to Develop the Modified Physician‐PREPARED Scale
CharacteristicNumber (%)
  • Abbreviation: Pra, probability of repeat admission.

  • Values are mean (SD) [range].

Gender, female235 (58.3%)
Race 
White284 (70.5%)
Black116 (28.8%)
Other3 (0.7%)
Self‐rated health status 
Poor125 (31.0%)
Fair202 (50.1%)
Good61 (15.1%)
Very good13 (3.2%)
Excellent2 (0.5%)
Diabetes mellitus226 (56.1%)
Chronic obstructive pulmonary disease76 (18.9%)
Ischemic heart disease165 (40.9%)
Heart failure90 (22.3%)
Hospital admissions during prior year (includes index admission)2.2 (2.0) [0‐15]*
Age (years)53.6 (15.1) [19‐98]*
Pra score0.49 (0.07) [0.40‐0.70]*

We conducted descriptive analyses that treated the respondent as the unit of analysis. There were 172 unique respondents. The number of questionnaires per respondent ranged from 1 to 20 with a median of 1 questionnaire. Respondents varied in the time to return a questionnaire. We measured response time as the difference between the date we received the questionnaire and the date of discharge. The response time ranged from 10 to 90 days with a median of 21 days after discharge.

Modified Physician‐PREPARED: Item Reduction, Internal Consistency, and Score Distributions

The questionnaire items appear in the Appendix. After item reduction, there were 8 items included in the Modified Physician‐PREPARED scale analysis (Table 2). None of the 8 items caused substantive reduction in Cronbach's alpha, so all were retained. The 8‐item scale had acceptable internal consistency (Cronbach's alpha = 0.86). For an individual questionnaire, the sum of the scores for eight items yielded the Modified Physician‐PREPARED scale value. High scale values reflected high perceptions of discharge quality. Each of the 8 items correlated significantly and positively with the scale value (P < 0.001, 2‐tailed).

Modified Physician‐PREPARED Items from 403 Questionnaires with Descriptors for Response Scoring System and Number of Respondents for Each Score, n (%)
Item TextDescriptor for Score = 1Descriptor for Score = 2Descriptor for Score = 3No Score
1.When were you made aware that this patient had been admitted to hospital?Not at all; 55 (13.6%)After patient was discharged; 65 (16.1%)Prior to hospitalization; while patient was in hospital; or on the day of discharge; 281 (69.7%)Missing response; 2 (0.5%)
2.When were you made aware that the patient was going to be discharged?Not at all; 115 (28.5%)Within a week after discharge; or longer than a week after discharge; 61 (15.1%)While patient was still in hospital; or on day of discharge; or within 1‐2 days after discharge; 225 (55.8%)Missing response; 2 (0.5%)
3.How soon after discharge did you receive any information (in any form) relating to this patient's hospital admission and discharge plans?Longer than a week; or not received; or other 115 (28.5%)Within a week; 186 (46.2%)Within 1‐2 days; 101 (25.1%)Missing response; 1 (0.2%)
4.Was this sufficient notice to address this patient's postdischarge needs?Less than sufficient; 98 (24.3%)Sufficient; 246 (61.0%)More than sufficient; 46 (11.4%)Missing response; 13 (3.2%)
5.Have you received adequate information about this patient's discharge health status?No; 103 (25.6%) Yes; 295 (73.2%)Missing response; 5 (1.2%)
6.Have you received adequate written information about the patient's medicines and medication management?Less than adequate; or no information at all; 103 (25.6%)Adequate; 262 (65.0%)More than adequate; 38 (9.4%)Missing response; 0 (0%)
7.Did you receive sufficient reasons for changes in medication? (For example, why 1 type of medication is used in preference to another?)Less than sufficient; or no information at all; 129 (32.0%)Sufficient; or not applicable (there was no change in medications); 240 (59.6%)More than sufficient; 29 (7.2%)Missing response; 5 (1.2%)
8.In your opinion, how adequate were the discharge plans to assist this patient to assume safe, independent community living?Less than adequate; or no discharge plans; 82 (20.3%)Adequate; 276 (68.5%)More than adequate; 32 (7.9%)Missing response; 13 (3.2%)

Table 2 shows the distribution of responses to each item in the Modified Physician‐PREPARED questionnaire. There were substantial ceiling effects for 2 individual items. One of the 7 items with 3 response options had ceiling effects approaching 70% (item 1). One item had 2 response options and 73% responded yes (item 5). The distribution of Modified Physician‐PREPARED scale values for 403 questionnaires had mean 16.6 4.0 SD and skew 0.6 (standard error of skew = 0.1). When scale values of patients 64 years and younger were compared with those of 65 and older, there were no significant differences (P = 0.606). The scale values did not have noteworthy floor or ceiling effects. The distribution of scale values showed 1.2% (5/403) of respondents had the lowest score of 8 and 1.7% (7/403) had the highest score of 24.

Modified Physician‐PREPARED: Principal Component Analysis

The purpose of the principal component analysis was to evaluate the relationships between the items and domains. In the component analysis, we evaluated the correlation matrix of the 8 items in the Modified Physician‐PREPARED scale. The Kaiser‐Meyer‐Olkin statistic of 0.89 indicated sufficient sampling adequacy to extract components from the matrix. Principal components extracted 66% of the variance associated with the 8‐item scale. After inspection of scree plots, we determined that 2 components were extracted before the eigenvalue fell substantially below 1. The pattern matrix for the promax rotation was inspected and the factor loading for each item appears in Table 3. The item content identified 1 component as timeliness of communication. The other component was adequacy of discharge plan/transmission. Within the adequacy component, the item content addressed patient health status, medication information, and reasons for medication changes. All items loaded primarily on 1 of the components; except item 3, which loaded on both components.

Pattern Matrix from Principal Component Analysis of 403 Questionnaires: Oblique Factor Loadings for 8 Items in Modified Physician‐PREPARED Scale
 Item TextComponent
Adequacy of Discharge Plan/TransmissionTimeliness of Communication
7Did you receive sufficient reasons for changes in medication? (For example, why one type of medication is used in preference to another?)0.9000.132
6Have you received adequate written information about the patient's medicines and medication management?0.8490.056
4Was this sufficient notice to address this patient's postdischarge needs?0.7960.050
5Have you received adequate information about this patient's discharge health status?0.7740.012
8In your opinion, how adequate were the discharge plans to assist this patient to assume safe, independent community living?0.7440.132
3How soon after discharge did you receive any information (in any form) relating to this patient's hospital admission and discharge plans?0.4030.373
1When were you made aware that this patient had been admitted to hospital?0.1540.964
2When were you made aware that the patient was going to be discharged?0.1230.779

Modified Physician‐PREPARED: Construct Validity

We compared Modified Physician‐PREPARED scale values between dichotomous groups defined by construct variables. When considering the discharge planning and communication for a specific patient, outpatient primary care practitioners reported higher scale values when they were involved in the discharge planning (median [25%, 75%] = 19 [19, 20.5]) than when they were not involved (17 [12.4, 19], P < 0.001). In addition, outpatient practitioners responded with higher scale values when they were aware of community support services (18 [16, 20]) than when they were unaware (17 [12, 19], P = 0.002). There was a nonsignificant trend to higher scale values if patients voiced no concern about coping after discharge (18 [15, 19]) versus concern (17 [12, 19], P = 0.059). For all 3 constructs, the analysis revealed higher Modified Physician‐PREPARED scale values that were in the same direction as hypothesized. We approximated the construct analysis with subscales defined by the principal components (data not shown). The subscale analysis confirmed the direction and significance of the analysis with the full, 8‐item, Modified Physician‐PREPARED scale.

Modified Physician‐PREPARED: Correlations with Baseline Characteristics

We evaluated the correlations between a patient's Modified Physician‐PREPARED scale value and baseline characteristics in Table 1. Patient characteristics were not associated with scale values. We also assessed the median differences between the scale values by practitioner specialty and found no significant differences.

DISCUSSION

The Modified Physician‐PREPARED scale measured the quality of discharge planning and communication from the perspective of the outpatient primary care physician or practitioner. We described the derivation of the scale items. We demonstrated the reliability and validity of the scale among physicians and practitioners who provided postdischarge care to patients at high risk for readmission to the hospital. The item content included timeliness, adequacy, patient health status, medication information, and reasons for medication changes.

According to expert consensus guidelines for hospital discharge care, the communication with the outpatient primary care physician should occur as soon as possible after discharge.25 Recommended data elements in the communication include condition at discharge, diagnoses, medications added, medications discontinued, and medications changed.25 We found the Modified Physician‐PREPARED scale items included content that was consistent with expert consensus guidelines. The items also assessed timeliness and adequacy, 2 domains important to outpatient physicians.14, 26

The Modified Physician‐PREPARED is one of several questionnaires developed to measure qualities of discharge processes from the perspective of outpatient physicians.8, 15, 2733 Previous questionnaires did not report psychometrics except 1 that assessed the quality of discharge summaries and measured test‐retest reliability.33 We are not aware of other physician questionnaires with reliable or valid scales besides the Modified Physician‐PREPARED.

We believe 1 application of the Modified Physician‐PREPARED questionnaire is in quality improvement efforts within hospitals. Most hospitals and inpatient physicians rely on discharge letters or summaries to communicate information about the hospitalization to outpatient practitioners.6 However, systematic problems with generation and transmission of letters and summaries make them sometimes unreliable as sources of consistent, timely, accurate, or important information.6 When patients arrive for their posthospital visits, their outpatient physicians have received no discharge letter for 16% to 53% of patients and no discharge summary for 66% to 88%.6 Among outpatient physicians, 41% attribute preventable adverse events for at least 1 of their patients to inadequate discharge communication.34 One hospital accreditation organization includes discharge communication improvement as a national patient safety goal in the United States.35 Hospitals have multiple motivations to pursue quality improvement projects related to discharge communication: reduction in adverse events, relation with referring physicians, and accreditation by regulators. When surveying physicians, hospital personnel may wish to use a reliable and validated instrument like the Modified Physician‐PREPARED questionnaire.

Another application of the Modified Physician‐PREPARED scale is in research. An example is our randomized, controlled trial to measure the value of a discharge intervention. We published the rationale and design for our intervention.36 In the future, we will analyze the results of our trial and we will need validated scales. One of the trial outcomes is the perspective of the outpatient physician. We expect to compare the scores on the Modified Physician‐PREPARED scale values from community practitioners who treated test patients versus control patients. The statistical properties of the Modified Physician‐PREPARED scale that we validated in the current work will allow us to estimate the precision of between‐group differences and to perform tests of inference.

The results of our study should be interpreted in the context of strengths and limitations. We were able to generalize the validity of the Modified Physician‐PREPARED to North American primary care physicians who treated adult outpatients with a broad age range. We minimized biases with the high survey response rate and low proportion of missing responses. During validation, we asked physicians to evaluate patient transitions from hospital to home. Consequently, the Modified Physician‐PREPARED scale may not apply when doctors follow patients after discharge to nursing homes or other acute care facilities. We excluded patients with low probability of repeat admission: hospice patients and patients with low Pra scores. The purpose of our exclusion criteria was to enrich the sample with patients likely to benefit from interventions to improve discharge processes. We recognize that the Modified Physician‐PREPARED may not generalize to physicians who treat hospice patients or patients with low probability for readmission.

Additional limitations relate to test‐retest reliability and to the clinical meaning of small changes in scale values. In our study, physician respondents returned questionnaires approximately 3 weeks after hospital discharge. We did not ask physicians to complete the questionnaire again after they returned the first questionnaire. Therefore, the test‐retest reliability for the Modified Physician‐PREPARED is unknown. Our protocol was not designed to detect the minimum important difference in the scale values. Consequently, small changes in scale values have uncertain clinical relevance. Future studies are necessary to assess the minimum important difference in the scale values.

CONCLUSION

The Modified Physician‐PREPARED scale was a reliable and valid measure of outpatient physician perceptions of quality and communication after hospital discharge. Clinicians and researchers may find the scale useful to guide, assess, and compare discharge‐planning activities.

APPENDIX

PHYSICIAN‐PREPARED QUESTIONNAIRE

0

ItemQuestionResponse Options
1When were you made aware that this patient had been admitted to hospital?Prior to hospitalization
While patient was in hospital
On the day of discharge
After patient was discharged
Not at all
1aWho made you aware of the admission?Hospital ward staff
Discharge planner
Hospital medical staff
Ambulance
Patient
Patient's family/friends
Other, please specify _________________________
2When were you made aware that the patient was going to be discharged?While patient was still in hospital
On day of discharge
Within 1‐2 days after discharge
Within a week after discharge
Longer than a week after discharge
Not at all
2aWho made you aware of the patient's discharge?Hospital ward staff
Discharge planner
Hospital medical staff
Patient
Patient's family/friends
Other, please specify _________________________
3How soon after discharge did you receive any information (in any form) relating to this patient's hospital admission and discharge plans?Within 1‐2 days
Within a week
Longer than a week
Not received
Other, please specify _________________________
4Was this sufficient notice to address this patient's postdischarge needs?More than sufficient
Sufficient
Less than sufficient
5Have you received adequate information about this patient's discharge health status?Yes
No
5aHow did you receive this information? (Check all that apply)Telephone call
Fax
Electronic mail system
Written/typed letter
6Have you received adequate written information about the patient's medicines and medication management?More than adequate
Adequate
Less than adequate
No information at all
7Did you receive sufficient reasons for changes in medication? (For example, why 1 type of medication is used in preference to another?)Not applicable (there was no change in medications)
More than sufficient
Sufficient
Less than sufficient
No information at all
8In your opinion, how adequate were the discharge plans to assist this patient to assume safe, independent community living?More than adequate
Adequate
Less than adequate
No discharge plans
9Were you involved at all in planning the patient's discharge?Yes
No
10Are you aware of any community support services that are involved in providing assistance to the patient since discharge?Yes
No
11Has the patient voiced any concerns that they have not been coping since discharge?Yes
No
Not applicable (no contact with patient since discharge)
12Has the patient's caretaker voiced any concerns that they have not been coping since the patient was discharged?Not applicable (no caretaker)
Yes
No
Not applicable (no contact with caretaker since discharge)
13Have you any suggestions how the patient's discharge could have been improved?__________________________________________
__________________________________________
__________________________________________

Preventable adverse events occur when patients transition from hospital to outpatient care.1, 2 The most common cause for postdischarge adverse events is poor communication between inpatient healthcare providers and outpatient primary care physicians.1 Adverse events also occur because of inadequate processes to communicate unresolved problems, monitor drug therapies, or monitor the patient's overall condition.1 Efforts to reduce adverse events logically focus on effective discharge planning and communication.

Systematic reviews have evaluated clinical trials to improve discharge planning and communication.36 Reviewers often reported inconclusive results because of a shortage of high‐quality trials with validated outcome measures.35 Reviewers recommended future studies to develop and validate outcome measures that assessed the discharge process from various perspectives.4 One important perspective was the assessment by the outpatient, primary care physician who was responsible for patient care after discharge.79

One of the authors (K.G.S.) developed the Physician‐PREPARED questionnaire to measure perceptions of outpatient physicians about the quality of hospital discharge. Item content came from studies in Australia that investigated barriers to best practice in discharge planning for older patients.1013 Fifteen items asked community physicians about their awareness of discharge planning processes for their patients. Items also assessed the adequacy of information provided about discharge plans. The Physician‐PREPARED items underwent assessment in Australia. Evaluation revealed well‐worded text, unambiguous response options, face validity, and content validity.

We reconsidered the Physician‐PREPARED questionnaire when we designed a clinical trial to assess the value of a discharge intervention in the United States. Our goal was a comprehensive survey instrument and scale to measure the perceptions of outpatient physicians after the discharge intervention. We found no other appropriate, validated questionnaires except the Physician‐PREPARED. However, we recognized some limitations to the Physician‐PREPARED. The items were developed for Australian physicians who treated elderly patients. We wanted to assess North American physicians who cared for a broad age range of adults. The Physician‐PREPARED did not have a scale with validated, psychometric performance characteristics in our population. We decided to address the above limitations with a scale development and validation study in the United States.

In the present work, we describe item development for the Physician‐PREPARED that occurred in Australia. Then we present item reduction and validation for the Modified Physician‐PREPARED that occurred in the United States. Our primary objective was to validate a scale to measure perceptions of outpatient physicians about qualities of discharge planning and communication. The secondary objectives were to quantify the scale's internal consistency and construct validity. Our goal was a brief scale with acceptable, defined statistical properties for clinicians and researchers.

PATIENTS AND METHODS

Item Development for the Physician‐PREPARED

Australian investigators designed the Physician‐PREPARED survey instrument to measure the quality of discharge planning activities and communication. The investigators developed the survey with the following process that was not published previously. First, a literature review identified survey content germane to outpatient practitioners.10 Investigators conducted interviews, focus groups, and pilot surveys to prioritize items for the survey instrument. The volunteer subjects for item development were general medical practitioners in Adelaide and Sydney, the capital cities of two states in Australia. The draft instrument was circulated to a small group of general medical practitioners for comment on layout, wording, and question intent. After feedback, minor modifications were made to item content and response categories. The result of development in Australia was a survey instrument with 15 items (see Appendix). The items reflected the following key areas of discharge quality: timeliness of communication, patient health status at discharge, adequacy of discharge support services, discharge medication information, and reasons for medication changes. These areas were congruent with the results of other investigators who assessed the quality of discharge planning and communication.14, 15

Validation of the Modified Physician‐PREPARED

The validation study for the Modified Physician‐PREPARED occurred in Illinois. The Peoria Institutional Review Board approved and monitored the human research. The patient sample for validation was a prospective cohort from a cluster randomized clinical trial. Willing patients or their proxies provided written consent for study participation. Patient enrollment occurred between December 2004 and August 2006. The subjects for scale analysis were the outpatient primary care physicians or practitioners designated by patients in the cohort. Outpatient physicians and practitioners gave implied consent when they completed and returned questionnaires. Follow‐up was 10 or more days after the patient's discharge from an acute care, 730‐bed, teaching hospital.

Patient Inclusion Criteria

Trained research coordinators identified all consecutive adult inpatients who were discharged to home by internal medicine hospitalist physicians. Patient inclusion in the cluster‐randomized trial required a probability of repeat admission (Pra) score greater than or equal to 0.40.16, 17 Consequently, the patients in the scale analysis cohort had the same high probability for repeat admission. The Pra score came from patient or proxy responses to questions about age, prior hospitalizations, prior doctor visits, self‐rated health status, and other health‐related questions.16, 17 In previous validation studies with elderly outpatients, a Pra score above 0.5 predicted that patients would have 1 hospital admission per person‐year of survival.16 In other validation studies with inpatients aged 18 to 101 years, the Pra items predicted nonroutine discharge planning needs.18

Exclusion Criteria

The exclusion criteria were designed to enroll a cohort with homogeneous risk for readmission. We excluded patients if their discharge destination was a nursing home, another acute care hospital, or an inpatient rehabilitation unit. Hospice patients were excluded if life expectancy was less than 6 months as estimated by the hospitalist. We also used exclusion criteria to avoid illogical enrollments. If the designated outpatient primary care physician or practitioner also managed the patient during the index hospitalization, then there was no perceived barrier to communication and the patient was excluded. Cognitive impairment was a conditional exclusion criterion. We defined cognitive impairment as a score less than 9 on the 10‐point clock test.19 A patient with cognitive impairment could participate with consent from a legally authorized representative. Before we enrolled a cognitively impaired patient, we required a proxy who spent a minimum of 3 hours daily with the patient and who agreed to answer interview questions.

Baseline Assessment

During the index hospitalization, trained data abstractors recorded baseline patient data to calculate the Pra: age, gender, diabetes mellitus, and ischemic heart disease. Patients or proxies provided the number of hospital admissions and doctor visits during the year before the index hospitalization. We recorded the availability of an informal caregiver in response to the question, Is there a friend, relative or neighbor who would take care of you for a few days, if necessary? Patients rated their health status on the following scale: poor, fair, good, very good, and excellent. In addition, we recorded heart failure and chronic obstructive pulmonary disease because of their possible association with readmission.20, 21 Information about outpatient physicians or practitioners came from the hospital's administrative database and was limited to specialty training.

Discharge Process

At the end of the index hospitalization, hospitalists and ward nurses used standardized forms for discharge diagnoses, prescriptions, instructions, and appointments. Discharge planning nurses or social workers consulted with hospitalists and ward nurses and then coordinated service providers including home health nurses, physical therapists, home health aides, homemaker service providers, durable medical equipment vendors, home oxygen vendors, home infusion pharmacists, social workers, rehabilitation service providers, legal aid providers, and others. Patients designated an outpatient primary care physician or nurse practitioner or physician assistant to receive discharge reports and results of diagnostic tests. Ten days after discharge, research personnel mailed the Physician‐PREPARED questionnaire to the designated outpatient primary care professional.

Item Reduction and Scoring

To develop a scale, we selected items from the Physician‐PREPARED survey instrument (see Appendix). Our goal was a parsimonious, comprehensive, and valid scale for use in clinical and research environments. We applied item reduction techniques according to the following steps that were defined a priori. First, we deleted items with nominal response categories that lacked graded or ordinal characteristics. This exclusion criterion caused us to delete the following items from the questionnaire in the appendix: (1a) Who made you aware of the admission, (2a) Who made you aware of the patient's discharge, and (5a) How did you receive this information? We deleted open‐ended questions, such as: (13) Have you any suggestions how the patient's discharge could have been improved? Next, we excluded items with a large proportion of missing responses because respondents checked Not applicable. Only item 12 from the Physician‐PREPARED fulfilled the latter criterion (see Appendix). Question 12 asked, Has the patient's caretaker voiced any concerns that they have not been coping since the patient was discharged? Among 403 respondents, 52% answered question 12 as Not applicable.

Measures of Construct Validity

We used 3 measures of construct validity in our assessment of the Modified Physician‐PREPARED scale. The first construct item asked the outpatient practitioner, Were you involved at all in planning the patient's discharge? The first construct was relevant because involvement by outpatient physicians improves the quality of hospital discharges.22 The second construct item asked, Are you aware of any community support services that are involved in providing assistance to the patient since discharge? For the third construct, we asked (Appendix item 11), Has the patient voiced any concerns that they have not been coping since discharge? We chose community support services and patient coping because these are clinically relevant and correlated with patients' perceptions of discharge preparedness.23 When we assessed construct validity, our hypotheses were significantly higher Modified Physician‐PREPARED scale values for respondents who answered yes to the construct questions about involvement and awareness and answered no to the question about patient‐voiced concerns.

Analysis

Analyses were performed with SPSS PC (version 14.0.2; SPSS Inc, Chicago, Illinois). We reported descriptive statistics as means, standard deviations (SDs), and range for interval variables; median and range for ordinal variables; and percentages for nominal variables. While developing the scale, the unit of analysis was the physician response to a unique patient. Specific descriptive analyses used the unique respondent as the unit of analysis. To determine the internal consistency of the scale, we calculated Cronbach's alpha with SPSS RELIABILITY. We assessed the distribution of the Modified Physician‐PREPARED scale with visual and statistical tests for skewness. While using the SPSS FACTOR program, we performed principal components extractions and then rotated components using the oblique promax technique. Component scores were saved using the regression score procedure. Component loadings above 0.30 were considered for interpretation.24 Statistical inference tests were the Mann‐Whitney U for median differences for 2 groups, the Kruskal‐Wallis for more than 2 groups, and Spearman correlation for associations. The accepted level of significance was P < 0.05.

RESULTS

Description of Validation Cohort for the Modified Physician‐PREPARED

We sent questionnaires to the primary care physician, nurse practitioner, or physician assistant designated by 549 patients. The survey response rate was 76% (417/549). If a respondent failed to check any response option for 2 or more scale items, then the questionnaire was excluded from analysis. We excluded 3% (14/549) of questionnaires for failure to respond to items. The responses from the remaining 403 questionnaires were analyzed. We did not exclude questionnaires from respondents who followed homebound patients or other patients who failed to come to the clinic for postdischarge visits. Our analysis included 90 questionnaires (22%) from respondents who had no contact with the patient after discharge.

The patient characteristics appear in Table 1. Most of the patients were less than 65 years old (77%, 310/403). Many patients had chronic diseases including diabetes mellitus, ischemic heart disease, heart failure, or chronic obstructive pulmonary disease. Most patients, 81% (327/403), rated their health as poor or fair and 55% (223/403) had 1 or more hospital admissions during the year before their index admission. The questionnaire respondents were primary care physicians who practiced internal medicine (41%, 167/403), medicine‐pediatrics (27%, 108/403), family practice (24%, 97/403), or other specialties (3%, 10/403). Nurse practitioners or physician assistants completed 5% (21/403) of questionnaires.

Baseline Characteristics of 403 Patients in the Sample Used to Develop the Modified Physician‐PREPARED Scale
CharacteristicNumber (%)
  • Abbreviation: Pra, probability of repeat admission.

  • Values are mean (SD) [range].

Gender, female235 (58.3%)
Race 
White284 (70.5%)
Black116 (28.8%)
Other3 (0.7%)
Self‐rated health status 
Poor125 (31.0%)
Fair202 (50.1%)
Good61 (15.1%)
Very good13 (3.2%)
Excellent2 (0.5%)
Diabetes mellitus226 (56.1%)
Chronic obstructive pulmonary disease76 (18.9%)
Ischemic heart disease165 (40.9%)
Heart failure90 (22.3%)
Hospital admissions during prior year (includes index admission)2.2 (2.0) [0‐15]*
Age (years)53.6 (15.1) [19‐98]*
Pra score0.49 (0.07) [0.40‐0.70]*

We conducted descriptive analyses that treated the respondent as the unit of analysis. There were 172 unique respondents. The number of questionnaires per respondent ranged from 1 to 20 with a median of 1 questionnaire. Respondents varied in the time to return a questionnaire. We measured response time as the difference between the date we received the questionnaire and the date of discharge. The response time ranged from 10 to 90 days with a median of 21 days after discharge.

Modified Physician‐PREPARED: Item Reduction, Internal Consistency, and Score Distributions

The questionnaire items appear in the Appendix. After item reduction, there were 8 items included in the Modified Physician‐PREPARED scale analysis (Table 2). None of the 8 items caused substantive reduction in Cronbach's alpha, so all were retained. The 8‐item scale had acceptable internal consistency (Cronbach's alpha = 0.86). For an individual questionnaire, the sum of the scores for eight items yielded the Modified Physician‐PREPARED scale value. High scale values reflected high perceptions of discharge quality. Each of the 8 items correlated significantly and positively with the scale value (P < 0.001, 2‐tailed).

Modified Physician‐PREPARED Items from 403 Questionnaires with Descriptors for Response Scoring System and Number of Respondents for Each Score, n (%)
Item TextDescriptor for Score = 1Descriptor for Score = 2Descriptor for Score = 3No Score
1.When were you made aware that this patient had been admitted to hospital?Not at all; 55 (13.6%)After patient was discharged; 65 (16.1%)Prior to hospitalization; while patient was in hospital; or on the day of discharge; 281 (69.7%)Missing response; 2 (0.5%)
2.When were you made aware that the patient was going to be discharged?Not at all; 115 (28.5%)Within a week after discharge; or longer than a week after discharge; 61 (15.1%)While patient was still in hospital; or on day of discharge; or within 1‐2 days after discharge; 225 (55.8%)Missing response; 2 (0.5%)
3.How soon after discharge did you receive any information (in any form) relating to this patient's hospital admission and discharge plans?Longer than a week; or not received; or other 115 (28.5%)Within a week; 186 (46.2%)Within 1‐2 days; 101 (25.1%)Missing response; 1 (0.2%)
4.Was this sufficient notice to address this patient's postdischarge needs?Less than sufficient; 98 (24.3%)Sufficient; 246 (61.0%)More than sufficient; 46 (11.4%)Missing response; 13 (3.2%)
5.Have you received adequate information about this patient's discharge health status?No; 103 (25.6%) Yes; 295 (73.2%)Missing response; 5 (1.2%)
6.Have you received adequate written information about the patient's medicines and medication management?Less than adequate; or no information at all; 103 (25.6%)Adequate; 262 (65.0%)More than adequate; 38 (9.4%)Missing response; 0 (0%)
7.Did you receive sufficient reasons for changes in medication? (For example, why 1 type of medication is used in preference to another?)Less than sufficient; or no information at all; 129 (32.0%)Sufficient; or not applicable (there was no change in medications); 240 (59.6%)More than sufficient; 29 (7.2%)Missing response; 5 (1.2%)
8.In your opinion, how adequate were the discharge plans to assist this patient to assume safe, independent community living?Less than adequate; or no discharge plans; 82 (20.3%)Adequate; 276 (68.5%)More than adequate; 32 (7.9%)Missing response; 13 (3.2%)

Table 2 shows the distribution of responses to each item in the Modified Physician‐PREPARED questionnaire. There were substantial ceiling effects for 2 individual items. One of the 7 items with 3 response options had ceiling effects approaching 70% (item 1). One item had 2 response options and 73% responded yes (item 5). The distribution of Modified Physician‐PREPARED scale values for 403 questionnaires had mean 16.6 4.0 SD and skew 0.6 (standard error of skew = 0.1). When scale values of patients 64 years and younger were compared with those of 65 and older, there were no significant differences (P = 0.606). The scale values did not have noteworthy floor or ceiling effects. The distribution of scale values showed 1.2% (5/403) of respondents had the lowest score of 8 and 1.7% (7/403) had the highest score of 24.

Modified Physician‐PREPARED: Principal Component Analysis

The purpose of the principal component analysis was to evaluate the relationships between the items and domains. In the component analysis, we evaluated the correlation matrix of the 8 items in the Modified Physician‐PREPARED scale. The Kaiser‐Meyer‐Olkin statistic of 0.89 indicated sufficient sampling adequacy to extract components from the matrix. Principal components extracted 66% of the variance associated with the 8‐item scale. After inspection of scree plots, we determined that 2 components were extracted before the eigenvalue fell substantially below 1. The pattern matrix for the promax rotation was inspected and the factor loading for each item appears in Table 3. The item content identified 1 component as timeliness of communication. The other component was adequacy of discharge plan/transmission. Within the adequacy component, the item content addressed patient health status, medication information, and reasons for medication changes. All items loaded primarily on 1 of the components; except item 3, which loaded on both components.

Pattern Matrix from Principal Component Analysis of 403 Questionnaires: Oblique Factor Loadings for 8 Items in Modified Physician‐PREPARED Scale
 Item TextComponent
Adequacy of Discharge Plan/TransmissionTimeliness of Communication
7Did you receive sufficient reasons for changes in medication? (For example, why one type of medication is used in preference to another?)0.9000.132
6Have you received adequate written information about the patient's medicines and medication management?0.8490.056
4Was this sufficient notice to address this patient's postdischarge needs?0.7960.050
5Have you received adequate information about this patient's discharge health status?0.7740.012
8In your opinion, how adequate were the discharge plans to assist this patient to assume safe, independent community living?0.7440.132
3How soon after discharge did you receive any information (in any form) relating to this patient's hospital admission and discharge plans?0.4030.373
1When were you made aware that this patient had been admitted to hospital?0.1540.964
2When were you made aware that the patient was going to be discharged?0.1230.779

Modified Physician‐PREPARED: Construct Validity

We compared Modified Physician‐PREPARED scale values between dichotomous groups defined by construct variables. When considering the discharge planning and communication for a specific patient, outpatient primary care practitioners reported higher scale values when they were involved in the discharge planning (median [25%, 75%] = 19 [19, 20.5]) than when they were not involved (17 [12.4, 19], P < 0.001). In addition, outpatient practitioners responded with higher scale values when they were aware of community support services (18 [16, 20]) than when they were unaware (17 [12, 19], P = 0.002). There was a nonsignificant trend to higher scale values if patients voiced no concern about coping after discharge (18 [15, 19]) versus concern (17 [12, 19], P = 0.059). For all 3 constructs, the analysis revealed higher Modified Physician‐PREPARED scale values that were in the same direction as hypothesized. We approximated the construct analysis with subscales defined by the principal components (data not shown). The subscale analysis confirmed the direction and significance of the analysis with the full, 8‐item, Modified Physician‐PREPARED scale.

Modified Physician‐PREPARED: Correlations with Baseline Characteristics

We evaluated the correlations between a patient's Modified Physician‐PREPARED scale value and baseline characteristics in Table 1. Patient characteristics were not associated with scale values. We also assessed the median differences between the scale values by practitioner specialty and found no significant differences.

DISCUSSION

The Modified Physician‐PREPARED scale measured the quality of discharge planning and communication from the perspective of the outpatient primary care physician or practitioner. We described the derivation of the scale items. We demonstrated the reliability and validity of the scale among physicians and practitioners who provided postdischarge care to patients at high risk for readmission to the hospital. The item content included timeliness, adequacy, patient health status, medication information, and reasons for medication changes.

According to expert consensus guidelines for hospital discharge care, the communication with the outpatient primary care physician should occur as soon as possible after discharge.25 Recommended data elements in the communication include condition at discharge, diagnoses, medications added, medications discontinued, and medications changed.25 We found the Modified Physician‐PREPARED scale items included content that was consistent with expert consensus guidelines. The items also assessed timeliness and adequacy, 2 domains important to outpatient physicians.14, 26

The Modified Physician‐PREPARED is one of several questionnaires developed to measure qualities of discharge processes from the perspective of outpatient physicians.8, 15, 2733 Previous questionnaires did not report psychometrics except 1 that assessed the quality of discharge summaries and measured test‐retest reliability.33 We are not aware of other physician questionnaires with reliable or valid scales besides the Modified Physician‐PREPARED.

We believe 1 application of the Modified Physician‐PREPARED questionnaire is in quality improvement efforts within hospitals. Most hospitals and inpatient physicians rely on discharge letters or summaries to communicate information about the hospitalization to outpatient practitioners.6 However, systematic problems with generation and transmission of letters and summaries make them sometimes unreliable as sources of consistent, timely, accurate, or important information.6 When patients arrive for their posthospital visits, their outpatient physicians have received no discharge letter for 16% to 53% of patients and no discharge summary for 66% to 88%.6 Among outpatient physicians, 41% attribute preventable adverse events for at least 1 of their patients to inadequate discharge communication.34 One hospital accreditation organization includes discharge communication improvement as a national patient safety goal in the United States.35 Hospitals have multiple motivations to pursue quality improvement projects related to discharge communication: reduction in adverse events, relation with referring physicians, and accreditation by regulators. When surveying physicians, hospital personnel may wish to use a reliable and validated instrument like the Modified Physician‐PREPARED questionnaire.

Another application of the Modified Physician‐PREPARED scale is in research. An example is our randomized, controlled trial to measure the value of a discharge intervention. We published the rationale and design for our intervention.36 In the future, we will analyze the results of our trial and we will need validated scales. One of the trial outcomes is the perspective of the outpatient physician. We expect to compare the scores on the Modified Physician‐PREPARED scale values from community practitioners who treated test patients versus control patients. The statistical properties of the Modified Physician‐PREPARED scale that we validated in the current work will allow us to estimate the precision of between‐group differences and to perform tests of inference.

The results of our study should be interpreted in the context of strengths and limitations. We were able to generalize the validity of the Modified Physician‐PREPARED to North American primary care physicians who treated adult outpatients with a broad age range. We minimized biases with the high survey response rate and low proportion of missing responses. During validation, we asked physicians to evaluate patient transitions from hospital to home. Consequently, the Modified Physician‐PREPARED scale may not apply when doctors follow patients after discharge to nursing homes or other acute care facilities. We excluded patients with low probability of repeat admission: hospice patients and patients with low Pra scores. The purpose of our exclusion criteria was to enrich the sample with patients likely to benefit from interventions to improve discharge processes. We recognize that the Modified Physician‐PREPARED may not generalize to physicians who treat hospice patients or patients with low probability for readmission.

Additional limitations relate to test‐retest reliability and to the clinical meaning of small changes in scale values. In our study, physician respondents returned questionnaires approximately 3 weeks after hospital discharge. We did not ask physicians to complete the questionnaire again after they returned the first questionnaire. Therefore, the test‐retest reliability for the Modified Physician‐PREPARED is unknown. Our protocol was not designed to detect the minimum important difference in the scale values. Consequently, small changes in scale values have uncertain clinical relevance. Future studies are necessary to assess the minimum important difference in the scale values.

CONCLUSION

The Modified Physician‐PREPARED scale was a reliable and valid measure of outpatient physician perceptions of quality and communication after hospital discharge. Clinicians and researchers may find the scale useful to guide, assess, and compare discharge‐planning activities.

APPENDIX

PHYSICIAN‐PREPARED QUESTIONNAIRE

0

ItemQuestionResponse Options
1When were you made aware that this patient had been admitted to hospital?Prior to hospitalization
While patient was in hospital
On the day of discharge
After patient was discharged
Not at all
1aWho made you aware of the admission?Hospital ward staff
Discharge planner
Hospital medical staff
Ambulance
Patient
Patient's family/friends
Other, please specify _________________________
2When were you made aware that the patient was going to be discharged?While patient was still in hospital
On day of discharge
Within 1‐2 days after discharge
Within a week after discharge
Longer than a week after discharge
Not at all
2aWho made you aware of the patient's discharge?Hospital ward staff
Discharge planner
Hospital medical staff
Patient
Patient's family/friends
Other, please specify _________________________
3How soon after discharge did you receive any information (in any form) relating to this patient's hospital admission and discharge plans?Within 1‐2 days
Within a week
Longer than a week
Not received
Other, please specify _________________________
4Was this sufficient notice to address this patient's postdischarge needs?More than sufficient
Sufficient
Less than sufficient
5Have you received adequate information about this patient's discharge health status?Yes
No
5aHow did you receive this information? (Check all that apply)Telephone call
Fax
Electronic mail system
Written/typed letter
6Have you received adequate written information about the patient's medicines and medication management?More than adequate
Adequate
Less than adequate
No information at all
7Did you receive sufficient reasons for changes in medication? (For example, why 1 type of medication is used in preference to another?)Not applicable (there was no change in medications)
More than sufficient
Sufficient
Less than sufficient
No information at all
8In your opinion, how adequate were the discharge plans to assist this patient to assume safe, independent community living?More than adequate
Adequate
Less than adequate
No discharge plans
9Were you involved at all in planning the patient's discharge?Yes
No
10Are you aware of any community support services that are involved in providing assistance to the patient since discharge?Yes
No
11Has the patient voiced any concerns that they have not been coping since discharge?Yes
No
Not applicable (no contact with patient since discharge)
12Has the patient's caretaker voiced any concerns that they have not been coping since the patient was discharged?Not applicable (no caretaker)
Yes
No
Not applicable (no contact with caretaker since discharge)
13Have you any suggestions how the patient's discharge could have been improved?__________________________________________
__________________________________________
__________________________________________
References
  1. Forster AJ,Murff HJ,Peterson JF,Gandhi TK,Bates DW.The incidence and severity of adverse events affecting patients after discharge from the hospital.Ann Intern Med.2003;138:161167.
  2. Forster AJ,Clark HD,Menard A, et al.Adverse events among medical patients after discharge from hospital.CMAJ.2004;170:345349.
  3. Johnson A,Sandford J,Tyndall J.Written and verbal information versus verbal information only for patients being discharged from acute hospital settings to home.Cochrane Database Syst Rev.2003;(4):CD003716.
  4. Shepperd S,Parkes J,McClaren J,Phillips C.Discharge planning from hospital to home.Cochrane Database Syst Rev.2004;(1):CD000313.
  5. Ward D,Severs M,Dean T,Brooks N.Care home versus hospital and own home environments for rehabilitation of older people.Cochrane Database Syst Rev.2003;(2):CD003164.
  6. Kripalani S,LeFevre F,Phillips CO,Williams MV,Basaviah P,Baker DW.Deficits in communication and information transfer between hospital‐based and primary care physicians: implications for patient safety and continuity of care.JAMA.2007;297:831841.
  7. Auerbach AD,Nelson EA,Lindenauer PK,Pantilat SZ,Katz PP,Wachter RM.Physician attitudes toward and prevalence of the hospitalist model of care: results of a national survey.Am J Med.2000;109:648653.
  8. Preen DB,Bailey BE,Wright A, et al.Effects of a multidisciplinary, post‐discharge continuance of care intervention on quality of life, discharge satisfaction, and hospital length of stay: a randomized controlled trial.Int J Qual Health Care.2005;17:4351.
  9. McAlearney AS.Hospitalists and family physicians: understanding opportunities and risks.J Fam Pract.2004;53:473481.
  10. Hedges G,Grimmer K,Moss J,Falco J.performance indicators for discharge planning: a focused review of the literature.Aust J Adv Nurs.1999;16:2028.
  11. Informing discharge plans. Assessments of elderly patients in Australian public hospitals: a field study. Available at: http://ijahsp.nova.edu/articles/Vol2number3/Grimmer‐Discharge_Plans.htm. Accessed January2008.
  12. Grimmer K,Moss J,Falco J.Experiences of elderly patients regarding independent community living after discharge from hospital: a longitudinal study.Int J Qual Health Care.2004;16:465472.
  13. Grimmer K,Moss J,Falco J.Life Post‐Discharge: Longitudinal Qualitative and Quantitative Study of 100 Elderly People Post Discharge from Hospital. Technical Report Produced for South Australian Department of Human Services. South Australia: South Australian Department of Human Services;2002.
  14. Bolton P,Mira M,Kennedy P,Lahra MM.The quality of communication between hospitals and general practitioners: an assessment.J Qual Clin Pract.1998;18:241247.
  15. Munday A,Kelly B,Forrester JW,Timoney A,McGovern E.Do general practitioners and community pharmacists want information on the reasons for drug therapy changes implemented by secondary care?Br J Gen Pract.1997;47:563566.
  16. Pacala JT,Boult C,Boult L.Predictive validity of a questionnaire that identifies older persons at risk for hospital admission.J Am Geriatr Soc.1995;43:374377.
  17. Pacala JT,Boult C,Reed RL,Aliberti E.Predictive validity of the Pra instrument among older recipients of managed care.J Am Geriatr Soc.1997;45:614617.
  18. Holland DE,Harris MR,Pankratz VS,Closson DC,Matt‐Hensrud NN,Severson MA.Prospective evaluation of a screen for complex discharge planning in hospitalized adults.J Am Geriatr Soc.2003;51:678682.
  19. Manos PJ,Wu R.The ten point clock test: a quick screen and grading method for cognitive impairment in medical and surgical patients.Int J Psychiatry Med.1994;24:229244.
  20. Naylor MD,Brooten D,Campbell R, et al.comprehensive discharge planning and home follow‐up of hospitalized elders: a randomized clinical trial.JAMA.1999;281:613620.
  21. Smith DM,Giobbie‐Hurder A,Weinberger M, et al.Predicting non‐elective hospital readmissions: a multi‐site study. Department of Veterans Affairs Cooperative Study Group on Primary Care and Readmissions.J Clin Epidemiol.2000;53:11131118.
  22. McInnes E,Mira M,Atkin N,Kennedy P,Cullen J.Can GP input into discharge planning result in better outcomes for the frail aged: results from a randomized controlled trial.Fam Pract.1999;16:289293.
  23. Grimmer K,Moss J.The development, validity and application of a new instrument to assess the quality of discharge planning activities from the community perspective.Int J Qual Health Care.2001;13:109116.
  24. Floyd FJ,Widaman KF.Factor analysis in the development and refinement of clinical assessment instruments.Psychol Assess.1995;7:286299.
  25. Halasyamani L,Kripalani S,Coleman E, et al.Transition of care for hospitalized elderly patients—development of a discharge checklist for hospitalists.J Hosp Med.2006;1:354360.
  26. Meara JR,Wood JL,Wilson MA,Hart MC.Home from hospital: a survey of hospital discharge arrangements in Northamptonshire.J Public Health Med.1992;14:145150.
  27. Pagliari C,Gilmour M,Sullivan F.Electronic clinical communications implementation (ECCI) in Scotland: a mixed‐methods programme evaluation.J Eval Clin Pract.2004;10:1120.
  28. Williams EI,Fitton F.General practitioner response to elderly patients discharged from hospital.BMJ.1990;300:159161.
  29. Wagstaff R,Berlin A,Stacy R,Spencer J,Bhopal RA.Information about patients' deaths: general practitioners' current practice and views on receiving a death register.Br J Gen Pract.1994;44:315316.
  30. Pantilat SZ,Lindenauer PK,Katz PP,Wachter RM.Primary care physician attitudes regarding communication with hospitalists.Am J Med.2001;111:15S20S.
  31. Al‐Rashed SA,Wright DJ,Roebuck N,Sunter W,Chrystyn H.The value of inpatient pharmaceutical counselling to elderly patients prior to discharge.Br J Clin Pharmacol.2002;54:657664.
  32. Bado W,Williams CJ.Usefulness of letters from hospitals to general practitioners.Br Med J (Clin Res Ed).1984;288:18131814.
  33. van Walraven C,Rokosh E.What is necessary for high‐quality discharge summaries?Am J Med Qual.1999;14:160169.
  34. O'Leary KJ,Liebovitz DM,Feinglass J,Liss DT,Baker DW.Outpatient physicians' satisfaction with discharge summaries and perceived need for an electronic discharge summary.J Hosp Med.2006;1:317320.
  35. 2007 Hospital/critical access hospital national patient safety goals. Available at: http://www.jointcommission.org/PatientSafety/NationalPatientSafetyGoals. Accessed January2008.
  36. Nace GS,Graumlich JF,Aldag JC.Software design to facilitate information transfer at hospital discharge.Inform Prim Care.2006;14:109119.
References
  1. Forster AJ,Murff HJ,Peterson JF,Gandhi TK,Bates DW.The incidence and severity of adverse events affecting patients after discharge from the hospital.Ann Intern Med.2003;138:161167.
  2. Forster AJ,Clark HD,Menard A, et al.Adverse events among medical patients after discharge from hospital.CMAJ.2004;170:345349.
  3. Johnson A,Sandford J,Tyndall J.Written and verbal information versus verbal information only for patients being discharged from acute hospital settings to home.Cochrane Database Syst Rev.2003;(4):CD003716.
  4. Shepperd S,Parkes J,McClaren J,Phillips C.Discharge planning from hospital to home.Cochrane Database Syst Rev.2004;(1):CD000313.
  5. Ward D,Severs M,Dean T,Brooks N.Care home versus hospital and own home environments for rehabilitation of older people.Cochrane Database Syst Rev.2003;(2):CD003164.
  6. Kripalani S,LeFevre F,Phillips CO,Williams MV,Basaviah P,Baker DW.Deficits in communication and information transfer between hospital‐based and primary care physicians: implications for patient safety and continuity of care.JAMA.2007;297:831841.
  7. Auerbach AD,Nelson EA,Lindenauer PK,Pantilat SZ,Katz PP,Wachter RM.Physician attitudes toward and prevalence of the hospitalist model of care: results of a national survey.Am J Med.2000;109:648653.
  8. Preen DB,Bailey BE,Wright A, et al.Effects of a multidisciplinary, post‐discharge continuance of care intervention on quality of life, discharge satisfaction, and hospital length of stay: a randomized controlled trial.Int J Qual Health Care.2005;17:4351.
  9. McAlearney AS.Hospitalists and family physicians: understanding opportunities and risks.J Fam Pract.2004;53:473481.
  10. Hedges G,Grimmer K,Moss J,Falco J.performance indicators for discharge planning: a focused review of the literature.Aust J Adv Nurs.1999;16:2028.
  11. Informing discharge plans. Assessments of elderly patients in Australian public hospitals: a field study. Available at: http://ijahsp.nova.edu/articles/Vol2number3/Grimmer‐Discharge_Plans.htm. Accessed January2008.
  12. Grimmer K,Moss J,Falco J.Experiences of elderly patients regarding independent community living after discharge from hospital: a longitudinal study.Int J Qual Health Care.2004;16:465472.
  13. Grimmer K,Moss J,Falco J.Life Post‐Discharge: Longitudinal Qualitative and Quantitative Study of 100 Elderly People Post Discharge from Hospital. Technical Report Produced for South Australian Department of Human Services. South Australia: South Australian Department of Human Services;2002.
  14. Bolton P,Mira M,Kennedy P,Lahra MM.The quality of communication between hospitals and general practitioners: an assessment.J Qual Clin Pract.1998;18:241247.
  15. Munday A,Kelly B,Forrester JW,Timoney A,McGovern E.Do general practitioners and community pharmacists want information on the reasons for drug therapy changes implemented by secondary care?Br J Gen Pract.1997;47:563566.
  16. Pacala JT,Boult C,Boult L.Predictive validity of a questionnaire that identifies older persons at risk for hospital admission.J Am Geriatr Soc.1995;43:374377.
  17. Pacala JT,Boult C,Reed RL,Aliberti E.Predictive validity of the Pra instrument among older recipients of managed care.J Am Geriatr Soc.1997;45:614617.
  18. Holland DE,Harris MR,Pankratz VS,Closson DC,Matt‐Hensrud NN,Severson MA.Prospective evaluation of a screen for complex discharge planning in hospitalized adults.J Am Geriatr Soc.2003;51:678682.
  19. Manos PJ,Wu R.The ten point clock test: a quick screen and grading method for cognitive impairment in medical and surgical patients.Int J Psychiatry Med.1994;24:229244.
  20. Naylor MD,Brooten D,Campbell R, et al.comprehensive discharge planning and home follow‐up of hospitalized elders: a randomized clinical trial.JAMA.1999;281:613620.
  21. Smith DM,Giobbie‐Hurder A,Weinberger M, et al.Predicting non‐elective hospital readmissions: a multi‐site study. Department of Veterans Affairs Cooperative Study Group on Primary Care and Readmissions.J Clin Epidemiol.2000;53:11131118.
  22. McInnes E,Mira M,Atkin N,Kennedy P,Cullen J.Can GP input into discharge planning result in better outcomes for the frail aged: results from a randomized controlled trial.Fam Pract.1999;16:289293.
  23. Grimmer K,Moss J.The development, validity and application of a new instrument to assess the quality of discharge planning activities from the community perspective.Int J Qual Health Care.2001;13:109116.
  24. Floyd FJ,Widaman KF.Factor analysis in the development and refinement of clinical assessment instruments.Psychol Assess.1995;7:286299.
  25. Halasyamani L,Kripalani S,Coleman E, et al.Transition of care for hospitalized elderly patients—development of a discharge checklist for hospitalists.J Hosp Med.2006;1:354360.
  26. Meara JR,Wood JL,Wilson MA,Hart MC.Home from hospital: a survey of hospital discharge arrangements in Northamptonshire.J Public Health Med.1992;14:145150.
  27. Pagliari C,Gilmour M,Sullivan F.Electronic clinical communications implementation (ECCI) in Scotland: a mixed‐methods programme evaluation.J Eval Clin Pract.2004;10:1120.
  28. Williams EI,Fitton F.General practitioner response to elderly patients discharged from hospital.BMJ.1990;300:159161.
  29. Wagstaff R,Berlin A,Stacy R,Spencer J,Bhopal RA.Information about patients' deaths: general practitioners' current practice and views on receiving a death register.Br J Gen Pract.1994;44:315316.
  30. Pantilat SZ,Lindenauer PK,Katz PP,Wachter RM.Primary care physician attitudes regarding communication with hospitalists.Am J Med.2001;111:15S20S.
  31. Al‐Rashed SA,Wright DJ,Roebuck N,Sunter W,Chrystyn H.The value of inpatient pharmaceutical counselling to elderly patients prior to discharge.Br J Clin Pharmacol.2002;54:657664.
  32. Bado W,Williams CJ.Usefulness of letters from hospitals to general practitioners.Br Med J (Clin Res Ed).1984;288:18131814.
  33. van Walraven C,Rokosh E.What is necessary for high‐quality discharge summaries?Am J Med Qual.1999;14:160169.
  34. O'Leary KJ,Liebovitz DM,Feinglass J,Liss DT,Baker DW.Outpatient physicians' satisfaction with discharge summaries and perceived need for an electronic discharge summary.J Hosp Med.2006;1:317320.
  35. 2007 Hospital/critical access hospital national patient safety goals. Available at: http://www.jointcommission.org/PatientSafety/NationalPatientSafetyGoals. Accessed January2008.
  36. Nace GS,Graumlich JF,Aldag JC.Software design to facilitate information transfer at hospital discharge.Inform Prim Care.2006;14:109119.
Issue
Journal of Hospital Medicine - 3(6)
Issue
Journal of Hospital Medicine - 3(6)
Page Number
455-464
Page Number
455-464
Article Type
Display Headline
Discharge planning scale: Community physicians' perspective
Display Headline
Discharge planning scale: Community physicians' perspective
Legacy Keywords
continuity of patient care, patient discharge, psychometrics, health care surveys
Legacy Keywords
continuity of patient care, patient discharge, psychometrics, health care surveys
Sections
Article Source

Copyright © 2008 Society of Hospital Medicine

Disallow All Ads
Correspondence Location
Department of Medicine, 530 NE Glen Oak Avenue, Peoria, IL 61637
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Article PDF Media

Factors of Care Plan Discussions at Admission

Article Type
Changed
Sun, 05/28/2017 - 22:01
Display Headline
Factors associated with discussion of care plans and code status at the time of hospital admission: Results from the Multicenter Hospitalist Study

Despite an ideal of dying at home, most Americans die in hospitals.1 Patients and families are clear about what they need from the healthcare system at the end of life: relief of distressing symptoms, the opportunity to communicate with physicians and others about death and dying, and the assurance that they will be attended to and comforted by their physicians as they approach death.2, 3 However, discussions about patient preferences for care occur infrequently,47 even though patients want to discuss care with their doctor,68 and physicians believe these discussions are their responsibility.9

The most prominent work in this area occurred in the Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments (SUPPORT) study, which focused on patients with advanced disease, often in the intensive care unit.4 Furthermore, few studies have focused on general medical patients, and healthcare has changed in important ways since SUPPORT's publication. First, the Patient Self‐Determination Act (PSDA) requires that all patients be asked about their care wishes at the time of admission and document the presence of an advanced directive.10, 11 Second, there is growing awareness of the need to improve palliative care for all hospitalized patients, with many advocating that hospitalization itself is a reason to ask about patient's preferences for care regardless of a patient's level of chronic or acute illness.12 Finally, emergence of hospitalists,1316 movement toward closed intensive care units,17, 18 and changes in residency training have increased segmentation in care of hospitalized patients.15, 18

To overcome limitations of previous literature and update our knowledge of how care discussions take place in the current healthcare environment, we analyzed data from a large study of patients admitted to general medicine services at 6 academic centers. Using this robust dataset, which included prospectively collected information about preferences for communication with their physician, we performed statistical analyses to understand which patient clinical, sociodemographic, and preference‐related factors, as well as factors related to their site of care, were associated with documentation that a code status discussion took place at the time of hospital admission.

PATIENTS AND METHODS

Sites

The Multicenter Hospitalist Study (MCHS) was a multicenter trial of general medical services that enrolled patients at 6 geographically diverse centers: The University of Chicago (which also served as the coordinating center), University of Iowa Hospitals and Clinics, University of California San Francisco, University of Wisconsin, University of New Mexico, and Brigham and Women's Hospital.19

Each site was selected to participate in the MCHS because patients on their general medicine service were admitted to hospitalist and nonhospitalist physicians in a random fashion (eg, based on predetermined call schedule based on day of the week). As teaching hospitals, house officers provided direct care to patients hospitalized at each center; nonteaching services were not present at the sites during the period of this study.

During the period of this study, each site complied with PSDA requirements for noting that patients had been informed about their right to create an advance directive, but no sites had a guideline or other program in place specifically intended to facilitate physician‐patient communication about care wishes. Two sites had active Hospice or Palliative Care services, and another 2 had Geriatrics Consultation services, but none had standard protocols mandating involvement of these consultants at the time of admission, the time when our key outcomes were documented.

Patients

Patients were eligible for inclusion in the MCHS if they were older than 18 years of age and were admitted at random to a hospitalist or nonhospitalist physician; we excluded patients from MCHS if they were admitted specifically under the care of their primary care physician or subspecialist (eg, admitted for chemotherapy) or were a prison inmate. Patients meeting these eligibility criteria were then approached for purposes of informed consent.

Data Collection

Data for this study were obtained from administrative data, patient interview, and chart abstraction as in previous work.14 Administrative data were drawn from cost‐accounting databases at each participating hospital; administrative data were used to provide cost and length of stay data, as well as information about patient insurance type, age, and sex.

We interviewed patients immediately after informed consent was obtained, with both taking place generally within 24 hours of admission. Interviews collected data about patient preferences for care and functional status,20 and other data not reliably available from administrative sources (such as housing situation).

Patient care plan before admission was taken from notes and orders written in the first 24 hours of hospitalization, as mentioned above. Using criteria we employed in previous work,21 a care discussion (CD) was defined as documentation of a discussion between patients (or family) and at least 1 physician (primary physician, hospitalist, consulting physician, or house officer) during the first 24 hours of hospitalization. CDs needed to specify that the person who wrote the note had actually spoken with the patient or their family for the purposes of determining preferences for care, and that this discussion resulted in a specific care plan. Thus, notations such as do not resuscitate/do not intubate, or spoke with family, questions answered, did not qualify as CDs, but a note stating the patient continues to want full efforts was counted as a CD.

Principal investigators at each site were responsible for training and overseeing interviewing and chart abstraction activities at each site, with central oversight of data quality provided by the central coordinating center. Upon receipt at the data coordinating center, all data were examined for missing, nonsensical, or outlier data with errors referred back to the participating sites for correction.

Statistical Analysis

For bivariable comparisons of patients with and without CDs, we used chi‐squared or Mann‐Whitney U‐tests, as appropriate.

Variables with P < 0.20 in bivariable comparisons were selected for initial inclusion in models. Then, using automated forward and stepwise selection techniques as well as manually entered variables, we fit multivariable generalized estimating equations permitting clustering of effects at the physician level to determine the independent association between the multiple factors tested and presence of a CD. In order to guard against the threat of multiple testing, we retained variables at a significance level of P < 0.01; variables were also retained because of observed confounding with other independent variables, or to maintain face validity of the model. All analyses were performed using SAS 9.0 for Windows (SAS Institute Inc., Cary, NC).

RESULTS

Patient Sociodemographics (Table 1)

A total of 17,097 of 33,638 patients (50.8%) were interviewed and gave consent for chart abstraction. Of these patients, 1776 (10.3%) had a CD documented in the first 24 hours of hospitalization. Patients with documented CDs were older, more often white, had completed more years of education, were more likely to have lived in a nursing home prior to admission, and more likely to have been hospitalized in the last 12 months. The proportion of patients with CDs was highly variable across site of enrollment, from 2.8%‐24.9%.

Patient Sociodemographics (total n = 17097)
ValueNo Documented CD (n = 15321, 89.7%)Documented CD (n = 1776, 10.3%)P*
  • P value from Mann‐Whitney U Test, all others from chi‐squared tests.

  • Totals may not sum to 100% due to rounding.

Age (Median, 95%CI)*56 (55, 56)69 (67, 71)< 0.0001
Female (n, %)8390 (54.8%)990 (55.7%)0.4312
Race (n, %)
White6640 (43.3%)938 (52.8%)< 0.0001
African American4673 (30.5%)280 (15.8%) 
Asian532 (3.5%)167 (9.4%) 
American Indian325 (2.1%)26 (1.5%) 
Other1951 (12.7%)241 (13.6%) 
Refused/Don't know1200 (7.8%)124 (7.0%) 
Ethnicity (n, %)
Hispanic or Latino Ethnicity1724 (11.3%)183 (10.3%)0.0039
Insurance type (n, %)
Charity481 (3.4%)14 (0.8%)< 0.0001
Indemnity3983 (28.2%)327 (19.3%) 
Medicaid2487 (17.6%)195 (11.5%) 
Medicare6418 (45.5%)1114 (65.9%) 
Other105 (0.7%)4 (0.2%) 
Self pay628 (4.5%)36 (2.1%) 
Self‐reported education (n, %)
Junior high school or less1297 (8.5%)217 (12.2%)< 0.0001
Some high school2146 (14.0%)182 (10.2%) 
High school graduate4435 (28.9%)465 (26.2%) 
Some college or junior college3521 (23.0%)347 (19.5%) 
College graduate1729 (11.3%)255 (14.4%) 
Post‐graduate1191 (7.8%)173 (9.7%) 
Refused/Don't know1002 (6.5%)137 (7.7%) 
Self reported income (n, %)
$2,500 or less1079 (7.0%)108 (6.1%)0.0002
$2,501 to $5,000424 (2.8%)33 (1.9%) 
$5,001 to $10,0001436 (9.4%)211 (11.9%) 
$10,001 to $15,0001080 (7.0%)141 (7.9%) 
$15,001 to $25,0001054 (6.9%)134 (7.5%) 
$25,001 to $35,000837 (5.5%)74 (4.2%) 
$35,001 to $50,000882 (5.8%)94 (5.3%) 
$50,001 to $100,0001027 (6.7%)125 (7.0%) 
$100,001 to $200,000357 (2.3%)57 (3.2%) 
Over $200,000245 (1.6%)34 (1.9%) 
Don't know/refused6900 (45.0%)765 (43.1%) 
Housing situation (n, %)
Own apartment or house11887 (77.6%)1264 (71.2%)< 0.0001
A relative or friend's apartment or house1804 (11.8%)217 (12.2%) 
A nursing home, group home, or long‐term care facility663 (4.3%)204 (11.5%) 
A homeless shelter258 (1.7%)27 (1.5%) 
Other709 (4.6%)64 (3.6%) 
Marital status (n, %)
Married4992 (32.6%)603 (34.0%)< 0.0001
Living as if married440 (2.9%)32 (1.8%) 
Divorced2027 (13.2%)199 (11.2%) 
Separated569 (3.7%)30 (1.7%) 
Widowed2577 (16.8%)487 (27.4%) 
Single4074 (26.6%)364 (20.5%) 
Refused642 (4.2%)61 (3.4%) 
Hospitalized in the last 12 months (n, %)7602 (49.6%)1011 (56.9%)< 0.0001
Site of enrollment (n, %)
A4602 (30.0%)135 (7.6%)< 0.0001
B1595 (10.4%)158 (8.9%) 
C3017 (19.7%)998 (56.2%) 
D2387 (15.6%)212 (11.9%) 
E2057 (13.4%)131 (7.4%) 
F1663 (10.9%)142 (8.0%) 

Patient Self‐Reported Health Status and Comorbid Illness (Table 2)

Patients with CDs more often reported a lot of difficulties with bathing, eating, or dressing; household chores; and moderate activities. Patients with CDs were more likely to report accomplishing less than they would like due to their health. They were more likely to have cancer, depression, a history of stroke, and heart disease, but less likely to have diabetes or human immunodeficiency virus.

Patient Self‐Reported Health Status and Comorbid Disease (Total n = 17097)*
ValueNo Documented CD (n = 15321, 89.7%)Documented CD (n = 1776, 10.3%)P**
  • Self reported data collected at time of intake interview, performed within 24 hours of admission.

  • Calculated using chi‐squared tests.

  • Totals may not sum to 100% due to rounding.

Thinking back again to one month ago, did any impairment or health problem cause you to need help of other persons with personal care needs, such as eating, bathing, dressing, or getting around the home? (n, %)
No10673 (69.7%)973 (54.8%)< 0.0001
Yes, a little1933 (12.6%)268 (15.1%) 
Yes, a lot2127 (13.9%)487 (27.4%) 
Don't know588 (3.8%)48 (2.7%) 
Thinking back to one month ago, did any impairment or health problem cause you to need help in handling everyday household chores, necessary business, shopping, or getting around for other purposes? (n, %)
No7262 (47.4%)566 (31.9%)< 0.0001
Yes, a little2692 (17.6%)324 (18.2%) 
Yes, a lot4126 (26.9%)825 (46.5%) 
Don't know1241 (8.1%)61 (3.4%) 
As far as you know do you have any of the following health conditions at the present time? (n, %)
Cancer
No13281 (86.7%)1376 (77.5%)< 0.0001
Yes1751 (11.4%)351 (19.8%) 
Not sure289 (1.9%)49 (2.8%) 
Depression
No10269 (67.0%)1099 (61.9%)< 0.0001
Yes4730 (30.9%)624 (35.1%) 
Not sure322 (2.1%)53 (3.0%) 
Diabetes
No10902 (71.2%)1356 (76.4%)< 0.0001
Yes4132 (27.0%)394 (22.2%) 
Not sure287 (1.9%)26 (1.5%) 
Heart trouble
No10251 (66.9%)1080 (60.8%)< 0.0001
Yes4491 (29.3%)627 (35.3%) 
Not sure579 (3.8%)69 (3.9%) 
HIV or AIDS
No14300 (93.3%)1679 (94.5%)0.026
Yes912 (6.0%)80 (4.5%) 
Not sure109 (0.7%)17 (1.0%) 
Stroke
No13344 (87.1%)1494 (84.1%)0.0005
Yes1722 (11.2%)236 (13.3%) 
Not sure255 (1.7%)46 (2.6%) 

Patient Preferences, Care Plan Documentation, and Care Coordination at Admission (Table 3)

Patients who had documented CDs were less likely to prefer my doctor give me choices regarding my care, and more often disagreed with the statement I prefer to leave care decisions to my physician. These patients were also more likely to have a durable power of attorney or living will in their chart, or have an alternate decision‐maker noted. The majority of patients without a documented CD (79.9%) had no notation of their care wishes, compared to 29.7% in patients with a documented CD. Patients with a documented CD were more likely to have a regular medical provider and a note in the chart from their primary care physician.

Patient Decision‐Making Preferences, Care Plan Documentation, and Care Coordination at Admission (Total n = 17097)
ValueNo Documented CD (n = 15321, 89.7%)Documented CD (n = 1776, 10.3%)P*
  • Calculated using chi‐squared tests.

  • Collected during intake interview performed within 24 hours of admission.

    All other items collected via chart abstraction.

I prefer my doctor give me choices regarding my care** (n, %)
Definitely agree11619 (75.8%)1247 (70.2%)< 0.0001
Somewhat agree1912 (12.5%)252 (14.2%) 
Somewhat disagree488 (3.2%)76 (4.3%) 
Definitely disagree414 (2.7%)87 (4.9%) 
Don't know888 (5.8%)114 (6.4%) 
I prefer to leave care decisions to my physician** (n, %)
Definitely agree5660 (36.9%)613 (34.5%)< 0.0001
Somewhat agree4539 (29.6%)493 (27.8%) 
Somewhat disagree2265 (14.8%)257 (14.5%) 
Definitely disagree1956 (12.8%)304 (17.1%) 
Don't know901 (5.9%)109 (6.1%) 
Documentation of care wishes before hospitalization (n, %)
No documentation12238 (79.9%)527 (29.7%)< 0.0001
Full support2624 (17.1%)742 (41.8%) 
Do not resuscitate or intubate (DNR/DNI)264 (1.7%)370 (20.8%) 
Hospice53 (0.3%)22 (1.2%) 
Other limitation (eg, no pressors)142 (0.9%)115 (6.5%) 
Had durable power of attorney in chart (n, %)286 (1.9%)133 (7.5%)< 0.0001
Had a living will in chart (n, %)266 (1.7%)142 (8.0%)< 0.0001
Alternate decision maker named in chart (n, %)2770 (18.1%)638 (35.9%)< 0.0001
Patient noted to be unable to participate in their care at admission (eg, confused, unable to respond) (n, %)1227 (8.0%)431 (24.3%)< 0.0001
Inpatient team documented discussion with primary care physician (n, %)627 (4.1%)136 (7.7%)< 0.0001
Do not have a regular medical provider** (n, %)3836 (25.0%)254 (14.3%)< 0.0001
Note from primary care physician in chart (n, %)148 (1.0%)39 (2.2%)< 0.0001

Factors Associated with Documented Care Discussions (Table 4)

Using predictor variables presented in Tables 1‐3, we then constructed multivariable models seeking to understand factors independently associated with documentation of code status in the entire cohort, as well as among patients who had no preexisting care wishes.

Factors Associated with Code Status Discussion in Entire Cohort and Patients with No Previous Documentation
 Entire Cohort (n = 17097)Patients with No Documentation of Preadmission Wishes (n = 12765)
Adjusted Odds Ratio (95% CI)P ValueAdjusted Odds Ratio (95% CI)P Value
Preadmission Code Status
No documentationReferent NA 
Full support3.22 (2.28, 4.55)< 0.0001NA 
Do not resuscitate or intubate (DNR/DNI)11.32 (8.52, 15.04)< 0.0001NA 
Hospice4.02 (2.33, 6.94)< 0.0001NA 
Other limitation (eg, no pressors)10.13 (7.35, 13.96)< 0.0001NA 
Insurance type
MedicareReferent Referent 
Charity care0.50 (0.30, 0.85)0.00990.56 (0.25, 1.25)0.1589
Commercial0.81 (0.69, 0.95)0.00900.66 (0.52, 0.85)0.0009
Medicaid0.69 (0.57, 0.82)< 0.00010.49 (0.36, 0.67)< 0.0001
Other0.46 (0.18, 1.13)0.09120.60 (0.17, 2.12)0.4302
Self pay0.70 (0.52, 0.95)0.02030.49 (0.29, 0.81)0.0060
Any limitations in bathing, toileting, dressing or feeding self?
NoReferent Referent 
Yes, a little1.25 (1.10, 1.42)0.00071.31 (1.03, 1.67)0.0272
Yes, a lot1.25 (1.09, 1.43)0.00151.42 (1.11, 1.81)0.0055
Unable to respond0.81 (0.59, 1.12)0.20060.80 (0.45, 1.41)0.4299
Patient has a documented surrogate decision maker1.72 (1.47, 2.02)< 0.00012.08 (1.62, 2.66)< 0.0001
Patient noted to be unable to participate in their care at admission (eg, confused, unable to respond)1.63 (1.37, 1.94)< 0.00012.20 (1.60, 3.02)< 0.0001
Notation that team had spoken to primary care physician at admission1.65 (1.29, 2.11)< 0.00011.45 (0.92, 2.28)0.1116
History of cancer
NoReferent Referent 
Yes1.31 (1.13, 1.51)0.00031.26 (0.96, 1.65)0.0960
Not sure1.26 (0.87, 1.82)0.21621.80 (1.03, 3.15)0.0396
History of diabetes
NoReferent Referent 
Yes0.87 (0.75, 1.003)0.05430.79 (0.62, 0.997)0.0467
Not sure0.61 (0.38, 0.99)0.04450.84 (0.43, 1.65)0.6183
Housing situation
Own house or apartmentReferent Referent 
Relative or friend's apartment or house1.22 (1.03, 1.45)0.02291.29 (0.97, 1.71)0.0783
Nursing home, group home, or long‐term care facility1.42 (1.16, 1.74)0.00061.74 (1.27, 2.40)0.0007
Homeless shelter1.12 (0.72, 1.73)0.62040.87 (0.46, 1.63)0.6559
Other/Don't know1.02 (0.75, 1.40)0.89871.35 (0.78, 2.36)0.2859
Age Group
<50Referent Referent 
50591.19 (0.99, 1.43)0.06471.18 (0.88, 1.59)0.2583
60691.18 (0.99, 1.40)0.05851.20 (0.88, 1.66)0.2549
70791.10 (0.91, 1.33)0.31781.19 (0.85, 1.67)0.3033
80891.23 (1.03, 1.47)0.02071.34 (0.96, 1.88)0.0879
90+1.45 (1.12, 1.88)0.00451.44 (0.94, 2.20)0.0934
Site of Enrollment
AReferent Referent 
B1.74 (1.16, 2.61)0.0074.95 (2.90, 8.45)< 0.0001
C5.14 (3.42, 7.74)< 0.000126.36 (17.28, 40.23)< 0.0001
D4.19 (2.64, 6.66)< 0.00018.06 (4.63, 14.03)< 0.0001
E3.00 (1.82, 4.9)< 0.00015.30 (2.71, 10.38)< 0.0001
F4.09 (2.69, 6.23)< 0.00012.32 (1.32, 4.08)0.0037

In the entire cohort, insurance type was independently associated with likelihood of a care discussion, with patients with Medicare having greater adjusted odds ratio for a CD than patients with all other forms of insurance, even after adjusting for age. Patients who had functional limitations with bathing, toileting, and feeding; had a documented surrogate decision maker; were unable to participate in their care; had cancer; or did not live in their own home were more likely to have a documented CD. Subjects with diabetes were less likely to have a CD, although this was of borderline significance. Patients whose team had documented a CD with the patients' primary physician were also more likely to have a discussion noted. However, the magnitude of these predictors was small compared to the independent effects attributable to the site the patient was enrolled or whether the patient had any preexisting documentation. Whereas the adjusted odds ratio associated with clinical or functional measures (such as age, cancer) were generally between 1.5 and 2.5, the range of odds ratios associated with having any documentation of care wishes (compared to no documentation) were all greater than 3, and the odds ratios associated with site of enrollment were 1.7 or higher.

We observed similar findings in analyses limited to patients with no preexisting care documentation. While clinical, sociodemographic, and functional factors remained statistically associated with a CD (albeit with wider confidence intervals due to smaller sample sizes), the effect of the patient's site of enrollment became even more striking (Table 4).

DISCUSSION

In this multicenter study of hospitalized general medical patients, documentation of CDs were highly dependent on where patients received care and whether patients had previous documentation of a care plan. In contrast, although clinical, prognostic, and socioeconomic factors were also associated with whether physicians documented asking patients about their wishes for care, the influence of these factors was modest.

Improving communication between patients and their physicians during an episode of acute illness has been a long‐standing goal, with the Study to Understand Prognoses and Preferences for Outcomes of Treatment (SUPPORT) trial providing the most notable example of an effort to improve patient care through aligning patient wishes, prognosis, and aggressiveness for care. However, even the SUPPORT interventiona robust, well‐implemented, and highly labor‐intensive strategywas not able to achieve this goal. In their summary of SUPPORT study findings, the authors suggested that the likelihood of and effectiveness of communication in seriously ill patients may be powerfully influenced by patient and caregiver culture4; our findings may partially confirm SUPPORT's conclusions.

Preexisting documentation in our study would not have included mandated documentation that someone had given the patient information about advance directives (as mandated by the PSDA), but rather a specification for that advance care plan. This distinction means that preexisting documentation in our study represented a previous decision by the patient (or the patient and their physician) to have made a plan, and an association with hospital discussions may be because the first conversation is the hardest to undertake; subsequent discussions then represent confirmatory or clarifying discussions that may be less difficult to broach (particularly for less experienced trainees). A CD may have also been prompted when documentation was unclear, or when a change in prognosis took place (eg, a new diagnosis of metastatic cancer).22 Alternatively, a preexisting plan may serve as a reminder for clinicians to discuss code status, signify patients who are more willing to broach this subject, and either seem more approachable or bring up the topic themselves.

The influence of site on documentation and CD provides additional evidence that caregiver culture played a role in CDs. Although this variation may have been in part due to culture around documentation practices more generally, it is important to note that none of our participating centers had a policy for documentation of care wishes or patient‐doctor communication, or a policy mandating these discussions in any specific patient group. Furthermore, site‐related differences were seen even in patients with no preexisting documentation, and were seen after adjustment for other documentation or communication practices (eg, documenting a discussion with the patient's primary care provider), making it unlikely that documentation practices are solely responsible for our results. Persistence of variations in care documentation raises interesting questions, particularly when one considers recent data describing variations in end‐of‐life care between similar academic centers (one of which was a participating site in this trial).23 Given that the sites in our study represent diverse institutions yet share a number of characteristics, understanding the specific practices or aspects of medical culture that promote conversations may provide insights in how to improve this promotion elsewhere.

Our results would argue that mandates to document code status on admission may be unlikely to improve communication unless sites also develop an approach to using this newly documented information as a prompt for subsequent discussions. In nursing home settings, documentation of advance directives may reduce resource use, but it is unclear whether similar effects will be seen in hospital settings.24 It is also a challenge to insure that documentation of a care plan in the nursing home is communicated to the providers in the hospital.25 The PSDA was a first step in this direction, but its effects on improving communication are uncertain.26 Our results would confirm that the PSDA or systems to mandate documentation are not solutions in themselves, but are 2 steps in a larger process.

We do not want to discount our findings of less frequent CDs among patients of lower socioeconomic status, where gaps in quality of care, communication, and outcomes are well‐recognized.27 As such, our results delineate yet another area where practice can and should be improved for vulnerable patients. However, factors related to site of care and documentation may provide opportunities to improve care even more profoundly and within a fairly discrete (if complex) acute episode of care. Having said this, our results also demonstrate a potential pitfall of using code status documentation for risk‐adjustment, because such notation may be more dependent on local documentation patterns than clinical appropriateness.

Our study has a number of limitations. As an observational study, our findings are likely prone to biases related to unadjusted confounding due to comorbidity. The influence of comorbidity would seem to have been most important in biasing the effects of preexisting documentation, where documentation would be associated with more unaccounted comorbidity. However, there were no differences in documentation even after accounting for prognosis by adjusting for age, functional status, and a valid comorbidity score.28 As we have pointed out, our key outcome is based on documentation of communication and not actual communication, and as such may be biased in subtle ways not related to site of care or the items tested in our model. While we cannot directly eliminate the possibility of documentation biases in our results using statistical methods, it is important to point out that our chart abstraction protocol used highly specific criteria to detect these discussions, and therefore may under‐detect discussions which may have been documented in less detail. Our study did not examine whether documentation of CDs influenced subsequent care. However, previous studies have shown that advance care planning has only a minor influence on care.29 However, communication about preferences at the time of admission, when the need for specific care decisions may be more evident, may be more likely to influence hospital care. Our results show that previous documentation is associated with discussions early in an admission. Such discussion may affect care, even if the decision made is different than what was previously documented. In addition, patients who were included in our study (those able to provide consent and participate in an interview) may be healthier or more cognitively intact than a general population of hospitalized patients. However, how this would have affected our results is unclear. Being able to speak and consent for oneself are key facilitators to communication, but sicker patients who cannot consent or speak for themselves might also be more likely to have care planning decisions made based on illness severity; documentation in these patients may be more driven by whether such notes were required because of the involvement of home health services (or skilled nursing facilities). Finally, although our study is one of the largest examinations of in‐hospital communication to date and its implications for resident education are worth noting, the sites involved in the MCHS may not be representative of nonteaching hospitals, or community‐based teaching hospitals.

Our results suggest that, although comorbid illness and socioeconomic status play an important role in determining which patients receive CDs at the time of admission, these factors are substantially less powerful than preexisting documentation practices and culture or care practices specific to their site of care. These results suggest that future work should consider organizational characteristics and culture as important targets for interventions to improve care planning in hospitalized patients.

References
  1. Committee on Care at the End of Life, Institute of Medicine.Approaching Death: Improving Care at the End of Life.Field MJ,Cassel CK, eds.Washington, DC:National Academy Press;1997.
  2. Steinhauser KE,Christakis NA,Clipp EC,McNeilly M,McIntyre L,Tulsky JA.Factors considered important at the end of life by patients, family, physicians, and other care providers.JAMA.2000;284(19):24762482.
  3. Steinhauser KE,Clipp EC,McNeilly M,Christakis NA,McIntyre LM,Tulsky JA.In search of a good death: observations of patients, families, and providers.Ann Intern Med.2000;132(10):825832.
  4. The SUPPORT Principal Investigators.A controlled trial to improve care for seriously ill hospitalized patients. The study to understand prognoses and preferences for outcomes and risks of treatments (SUPPORT).JAMA.1995;274(20):15911598.
  5. Bedell SE,Delbanco TL.Choices about cardiopulmonary resuscitation in the hospital. When do physicians talk with patients?N Engl J Med.1984;310(17):10891093.
  6. Hofmann JC,Wenger NS,Davis RB, et al.Patient preferences for communication with physicians about end‐of‐life decisions. SUPPORT Investigators. Study to Understand Prognoses and Preference for Outcomes and Risks of Treatment.Ann Intern Med.1997;127(1):112.
  7. Shmerling RH,Bedell SE,Lilienfeld A,Delbanco TL.Discussing cardiopulmonary resuscitation: a study of elderly outpatients.J Gen Intern Med.1988;3(4):317321.
  8. Schonwetter RS,Teasdale TA,Taffet G,Robinson BE,Luchi RJ.Educating the elderly: cardiopulmonary resuscitation decisions before and after intervention.J Am Geriatr Soc.1991;39(4):372377.
  9. Miller DL,Gorbien MJ,Simbartl LA,Jahnigen DW.Factors influencing physicians in recommending in‐hospital cardiopulmonary resuscitation.Arch Intern Med.1993;153(17):19992003.
  10. Federal Register. 42 USC 1395‐1396. Patient Self‐Determination Act1990.
  11. La Puma J,Orentlicher D,Moss RJ.Advance directives on admission. Clinical implications and analysis of the Patient Self‐Determination Act of 1990.JAMA.1991;266(3):402405.
  12. Pantilat SZ,Alpers A,Wachter RM.A new doctor in the house: ethical issues in hospitalist systems.JAMA.1999;282(2):171174.
  13. Auerbach A,Wachter R,Katz P,Showstack J,Baron R,Goldman L.Implementation of a hospitalist service at a community teaching hospital: improving clinical efficiency and patient outcomes.Ann Intern Med.2002;137:859865.
  14. Meltzer D,Morrison J,Guth T, et al.Effects of hospitalist physicians on an academic general medical service: results of a randomized trial.Ann Intern Med.2002;137:866874.
  15. Wachter RM,Goldman L.The hospitalist movement 5 years later.JAMA.2002;287(4):487494.
  16. Wachter RM,Katz P,Showstack J,Bindman AB,Goldman L.Reorganizing an academic medical service: impact on cost, quality, patient satisfaction, and education.JAMA.1998;279(19):15601565.
  17. Pronovost PJ,Angus DC,Dorman T,Robinson KA,Dremsizov TT,Young TL.Physician staffing patterns and clinical outcomes in critically ill patients: a systematic review.JAMA.2002;288(17):21512162.
  18. Pronovost PJ,Jenckes MW,Dorman T, et al.Organizational characteristics of intensive care units related to outcomes of abdominal aortic surgery.JAMA.1999;281(14):13101317.
  19. Meltzer DO,Arora V,Zhang JX, et al.Effects of inpatient experience on outcomes and costs in a multicenter trial of academic hospitalists.J Gen Intern Med.2005;20(Suppl 1):141142.
  20. Ware J,Kosinski M,Keller S.SF‐12: How to Score the SF‐12 Physical and Mental Health Summary Scales.2nd ed.Boston, MA:New England Medical Center, The Health Institute;1995.
  21. Auerbach AD,Pantilat SZ.End‐of‐life care in a voluntary hospitalist model: effects on communication, processes of care, and patient symptoms.Am J Med.2004;116(10):669675.
  22. Teno JM,Stevens M,Spernak S,Lynn J.Role of written advance directives in decision making: insights from qualitative and quantitative data.J Gen Intern Med.1998;13(7):439446.
  23. Wennberg JE,Fisher ES,Baker L,Sharp SM,Bronner KK.Evaluating the efficiency of California providers in caring for patients with chronic illnesses.Health Aff (Millwood).2005 Jul‐Dec;Suppl Web Exclusives:W5–52643.
  24. Molloy DW,Guyatt GH,Russo R, et al.Systematic implementation of an advance directive program in nursing homes: a randomized controlled trial.JAMA.2000;283(11):14371444.
  25. Hanson LC,Ersek M.Meeting palliative care needs in post‐acute care settings: “to help them live until they die”.JAMA.2006;295(6):681686.
  26. Teno J,Lynn J,Wenger N, et al.Advance directives for seriously ill hospitalized patients: effectiveness with the patient self‐determination act and the SUPPORT intervention. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment.J Am Geriatr Soc.1997;45(4):500507.
  27. Institute of Medicine.Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care.Smedley BD,Stith AY,Nelson AR, eds.Washington, DC:National Academies Press;2003.
  28. Chaudhry S,Jin L,Meltzer D.Use of a self‐report‐generated Charlson Comorbidity Index for predicting mortality.Med Care.2005;43(6):607615.
  29. Hanson LC,Tulsky JA,Danis M.Can clinical interventions change care at the end of life?Ann Intern Med.1997;126(5):381388.
Article PDF
Issue
Journal of Hospital Medicine - 3(6)
Page Number
437-445
Legacy Keywords
care discussion, hospital admission, patient care planning
Sections
Article PDF
Article PDF

Despite an ideal of dying at home, most Americans die in hospitals.1 Patients and families are clear about what they need from the healthcare system at the end of life: relief of distressing symptoms, the opportunity to communicate with physicians and others about death and dying, and the assurance that they will be attended to and comforted by their physicians as they approach death.2, 3 However, discussions about patient preferences for care occur infrequently,47 even though patients want to discuss care with their doctor,68 and physicians believe these discussions are their responsibility.9

The most prominent work in this area occurred in the Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments (SUPPORT) study, which focused on patients with advanced disease, often in the intensive care unit.4 Furthermore, few studies have focused on general medical patients, and healthcare has changed in important ways since SUPPORT's publication. First, the Patient Self‐Determination Act (PSDA) requires that all patients be asked about their care wishes at the time of admission and document the presence of an advanced directive.10, 11 Second, there is growing awareness of the need to improve palliative care for all hospitalized patients, with many advocating that hospitalization itself is a reason to ask about patient's preferences for care regardless of a patient's level of chronic or acute illness.12 Finally, emergence of hospitalists,1316 movement toward closed intensive care units,17, 18 and changes in residency training have increased segmentation in care of hospitalized patients.15, 18

To overcome limitations of previous literature and update our knowledge of how care discussions take place in the current healthcare environment, we analyzed data from a large study of patients admitted to general medicine services at 6 academic centers. Using this robust dataset, which included prospectively collected information about preferences for communication with their physician, we performed statistical analyses to understand which patient clinical, sociodemographic, and preference‐related factors, as well as factors related to their site of care, were associated with documentation that a code status discussion took place at the time of hospital admission.

PATIENTS AND METHODS

Sites

The Multicenter Hospitalist Study (MCHS) was a multicenter trial of general medical services that enrolled patients at 6 geographically diverse centers: The University of Chicago (which also served as the coordinating center), University of Iowa Hospitals and Clinics, University of California San Francisco, University of Wisconsin, University of New Mexico, and Brigham and Women's Hospital.19

Each site was selected to participate in the MCHS because patients on their general medicine service were admitted to hospitalist and nonhospitalist physicians in a random fashion (eg, based on predetermined call schedule based on day of the week). As teaching hospitals, house officers provided direct care to patients hospitalized at each center; nonteaching services were not present at the sites during the period of this study.

During the period of this study, each site complied with PSDA requirements for noting that patients had been informed about their right to create an advance directive, but no sites had a guideline or other program in place specifically intended to facilitate physician‐patient communication about care wishes. Two sites had active Hospice or Palliative Care services, and another 2 had Geriatrics Consultation services, but none had standard protocols mandating involvement of these consultants at the time of admission, the time when our key outcomes were documented.

Patients

Patients were eligible for inclusion in the MCHS if they were older than 18 years of age and were admitted at random to a hospitalist or nonhospitalist physician; we excluded patients from MCHS if they were admitted specifically under the care of their primary care physician or subspecialist (eg, admitted for chemotherapy) or were a prison inmate. Patients meeting these eligibility criteria were then approached for purposes of informed consent.

Data Collection

Data for this study were obtained from administrative data, patient interview, and chart abstraction as in previous work.14 Administrative data were drawn from cost‐accounting databases at each participating hospital; administrative data were used to provide cost and length of stay data, as well as information about patient insurance type, age, and sex.

We interviewed patients immediately after informed consent was obtained, with both taking place generally within 24 hours of admission. Interviews collected data about patient preferences for care and functional status,20 and other data not reliably available from administrative sources (such as housing situation).

Patient care plan before admission was taken from notes and orders written in the first 24 hours of hospitalization, as mentioned above. Using criteria we employed in previous work,21 a care discussion (CD) was defined as documentation of a discussion between patients (or family) and at least 1 physician (primary physician, hospitalist, consulting physician, or house officer) during the first 24 hours of hospitalization. CDs needed to specify that the person who wrote the note had actually spoken with the patient or their family for the purposes of determining preferences for care, and that this discussion resulted in a specific care plan. Thus, notations such as do not resuscitate/do not intubate, or spoke with family, questions answered, did not qualify as CDs, but a note stating the patient continues to want full efforts was counted as a CD.

Principal investigators at each site were responsible for training and overseeing interviewing and chart abstraction activities at each site, with central oversight of data quality provided by the central coordinating center. Upon receipt at the data coordinating center, all data were examined for missing, nonsensical, or outlier data with errors referred back to the participating sites for correction.

Statistical Analysis

For bivariable comparisons of patients with and without CDs, we used chi‐squared or Mann‐Whitney U‐tests, as appropriate.

Variables with P < 0.20 in bivariable comparisons were selected for initial inclusion in models. Then, using automated forward and stepwise selection techniques as well as manually entered variables, we fit multivariable generalized estimating equations permitting clustering of effects at the physician level to determine the independent association between the multiple factors tested and presence of a CD. In order to guard against the threat of multiple testing, we retained variables at a significance level of P < 0.01; variables were also retained because of observed confounding with other independent variables, or to maintain face validity of the model. All analyses were performed using SAS 9.0 for Windows (SAS Institute Inc., Cary, NC).

RESULTS

Patient Sociodemographics (Table 1)

A total of 17,097 of 33,638 patients (50.8%) were interviewed and gave consent for chart abstraction. Of these patients, 1776 (10.3%) had a CD documented in the first 24 hours of hospitalization. Patients with documented CDs were older, more often white, had completed more years of education, were more likely to have lived in a nursing home prior to admission, and more likely to have been hospitalized in the last 12 months. The proportion of patients with CDs was highly variable across site of enrollment, from 2.8%‐24.9%.

Patient Sociodemographics (total n = 17097)
ValueNo Documented CD (n = 15321, 89.7%)Documented CD (n = 1776, 10.3%)P*
  • P value from Mann‐Whitney U Test, all others from chi‐squared tests.

  • Totals may not sum to 100% due to rounding.

Age (Median, 95%CI)*56 (55, 56)69 (67, 71)< 0.0001
Female (n, %)8390 (54.8%)990 (55.7%)0.4312
Race (n, %)
White6640 (43.3%)938 (52.8%)< 0.0001
African American4673 (30.5%)280 (15.8%) 
Asian532 (3.5%)167 (9.4%) 
American Indian325 (2.1%)26 (1.5%) 
Other1951 (12.7%)241 (13.6%) 
Refused/Don't know1200 (7.8%)124 (7.0%) 
Ethnicity (n, %)
Hispanic or Latino Ethnicity1724 (11.3%)183 (10.3%)0.0039
Insurance type (n, %)
Charity481 (3.4%)14 (0.8%)< 0.0001
Indemnity3983 (28.2%)327 (19.3%) 
Medicaid2487 (17.6%)195 (11.5%) 
Medicare6418 (45.5%)1114 (65.9%) 
Other105 (0.7%)4 (0.2%) 
Self pay628 (4.5%)36 (2.1%) 
Self‐reported education (n, %)
Junior high school or less1297 (8.5%)217 (12.2%)< 0.0001
Some high school2146 (14.0%)182 (10.2%) 
High school graduate4435 (28.9%)465 (26.2%) 
Some college or junior college3521 (23.0%)347 (19.5%) 
College graduate1729 (11.3%)255 (14.4%) 
Post‐graduate1191 (7.8%)173 (9.7%) 
Refused/Don't know1002 (6.5%)137 (7.7%) 
Self reported income (n, %)
$2,500 or less1079 (7.0%)108 (6.1%)0.0002
$2,501 to $5,000424 (2.8%)33 (1.9%) 
$5,001 to $10,0001436 (9.4%)211 (11.9%) 
$10,001 to $15,0001080 (7.0%)141 (7.9%) 
$15,001 to $25,0001054 (6.9%)134 (7.5%) 
$25,001 to $35,000837 (5.5%)74 (4.2%) 
$35,001 to $50,000882 (5.8%)94 (5.3%) 
$50,001 to $100,0001027 (6.7%)125 (7.0%) 
$100,001 to $200,000357 (2.3%)57 (3.2%) 
Over $200,000245 (1.6%)34 (1.9%) 
Don't know/refused6900 (45.0%)765 (43.1%) 
Housing situation (n, %)
Own apartment or house11887 (77.6%)1264 (71.2%)< 0.0001
A relative or friend's apartment or house1804 (11.8%)217 (12.2%) 
A nursing home, group home, or long‐term care facility663 (4.3%)204 (11.5%) 
A homeless shelter258 (1.7%)27 (1.5%) 
Other709 (4.6%)64 (3.6%) 
Marital status (n, %)
Married4992 (32.6%)603 (34.0%)< 0.0001
Living as if married440 (2.9%)32 (1.8%) 
Divorced2027 (13.2%)199 (11.2%) 
Separated569 (3.7%)30 (1.7%) 
Widowed2577 (16.8%)487 (27.4%) 
Single4074 (26.6%)364 (20.5%) 
Refused642 (4.2%)61 (3.4%) 
Hospitalized in the last 12 months (n, %)7602 (49.6%)1011 (56.9%)< 0.0001
Site of enrollment (n, %)
A4602 (30.0%)135 (7.6%)< 0.0001
B1595 (10.4%)158 (8.9%) 
C3017 (19.7%)998 (56.2%) 
D2387 (15.6%)212 (11.9%) 
E2057 (13.4%)131 (7.4%) 
F1663 (10.9%)142 (8.0%) 

Patient Self‐Reported Health Status and Comorbid Illness (Table 2)

Patients with CDs more often reported a lot of difficulties with bathing, eating, or dressing; household chores; and moderate activities. Patients with CDs were more likely to report accomplishing less than they would like due to their health. They were more likely to have cancer, depression, a history of stroke, and heart disease, but less likely to have diabetes or human immunodeficiency virus.

Patient Self‐Reported Health Status and Comorbid Disease (Total n = 17097)*
ValueNo Documented CD (n = 15321, 89.7%)Documented CD (n = 1776, 10.3%)P**
  • Self reported data collected at time of intake interview, performed within 24 hours of admission.

  • Calculated using chi‐squared tests.

  • Totals may not sum to 100% due to rounding.

Thinking back again to one month ago, did any impairment or health problem cause you to need help of other persons with personal care needs, such as eating, bathing, dressing, or getting around the home? (n, %)
No10673 (69.7%)973 (54.8%)< 0.0001
Yes, a little1933 (12.6%)268 (15.1%) 
Yes, a lot2127 (13.9%)487 (27.4%) 
Don't know588 (3.8%)48 (2.7%) 
Thinking back to one month ago, did any impairment or health problem cause you to need help in handling everyday household chores, necessary business, shopping, or getting around for other purposes? (n, %)
No7262 (47.4%)566 (31.9%)< 0.0001
Yes, a little2692 (17.6%)324 (18.2%) 
Yes, a lot4126 (26.9%)825 (46.5%) 
Don't know1241 (8.1%)61 (3.4%) 
As far as you know do you have any of the following health conditions at the present time? (n, %)
Cancer
No13281 (86.7%)1376 (77.5%)< 0.0001
Yes1751 (11.4%)351 (19.8%) 
Not sure289 (1.9%)49 (2.8%) 
Depression
No10269 (67.0%)1099 (61.9%)< 0.0001
Yes4730 (30.9%)624 (35.1%) 
Not sure322 (2.1%)53 (3.0%) 
Diabetes
No10902 (71.2%)1356 (76.4%)< 0.0001
Yes4132 (27.0%)394 (22.2%) 
Not sure287 (1.9%)26 (1.5%) 
Heart trouble
No10251 (66.9%)1080 (60.8%)< 0.0001
Yes4491 (29.3%)627 (35.3%) 
Not sure579 (3.8%)69 (3.9%) 
HIV or AIDS
No14300 (93.3%)1679 (94.5%)0.026
Yes912 (6.0%)80 (4.5%) 
Not sure109 (0.7%)17 (1.0%) 
Stroke
No13344 (87.1%)1494 (84.1%)0.0005
Yes1722 (11.2%)236 (13.3%) 
Not sure255 (1.7%)46 (2.6%) 

Patient Preferences, Care Plan Documentation, and Care Coordination at Admission (Table 3)

Patients who had documented CDs were less likely to prefer my doctor give me choices regarding my care, and more often disagreed with the statement I prefer to leave care decisions to my physician. These patients were also more likely to have a durable power of attorney or living will in their chart, or have an alternate decision‐maker noted. The majority of patients without a documented CD (79.9%) had no notation of their care wishes, compared to 29.7% in patients with a documented CD. Patients with a documented CD were more likely to have a regular medical provider and a note in the chart from their primary care physician.

Patient Decision‐Making Preferences, Care Plan Documentation, and Care Coordination at Admission (Total n = 17097)
ValueNo Documented CD (n = 15321, 89.7%)Documented CD (n = 1776, 10.3%)P*
  • Calculated using chi‐squared tests.

  • Collected during intake interview performed within 24 hours of admission.

    All other items collected via chart abstraction.

I prefer my doctor give me choices regarding my care** (n, %)
Definitely agree11619 (75.8%)1247 (70.2%)< 0.0001
Somewhat agree1912 (12.5%)252 (14.2%) 
Somewhat disagree488 (3.2%)76 (4.3%) 
Definitely disagree414 (2.7%)87 (4.9%) 
Don't know888 (5.8%)114 (6.4%) 
I prefer to leave care decisions to my physician** (n, %)
Definitely agree5660 (36.9%)613 (34.5%)< 0.0001
Somewhat agree4539 (29.6%)493 (27.8%) 
Somewhat disagree2265 (14.8%)257 (14.5%) 
Definitely disagree1956 (12.8%)304 (17.1%) 
Don't know901 (5.9%)109 (6.1%) 
Documentation of care wishes before hospitalization (n, %)
No documentation12238 (79.9%)527 (29.7%)< 0.0001
Full support2624 (17.1%)742 (41.8%) 
Do not resuscitate or intubate (DNR/DNI)264 (1.7%)370 (20.8%) 
Hospice53 (0.3%)22 (1.2%) 
Other limitation (eg, no pressors)142 (0.9%)115 (6.5%) 
Had durable power of attorney in chart (n, %)286 (1.9%)133 (7.5%)< 0.0001
Had a living will in chart (n, %)266 (1.7%)142 (8.0%)< 0.0001
Alternate decision maker named in chart (n, %)2770 (18.1%)638 (35.9%)< 0.0001
Patient noted to be unable to participate in their care at admission (eg, confused, unable to respond) (n, %)1227 (8.0%)431 (24.3%)< 0.0001
Inpatient team documented discussion with primary care physician (n, %)627 (4.1%)136 (7.7%)< 0.0001
Do not have a regular medical provider** (n, %)3836 (25.0%)254 (14.3%)< 0.0001
Note from primary care physician in chart (n, %)148 (1.0%)39 (2.2%)< 0.0001

Factors Associated with Documented Care Discussions (Table 4)

Using predictor variables presented in Tables 1‐3, we then constructed multivariable models seeking to understand factors independently associated with documentation of code status in the entire cohort, as well as among patients who had no preexisting care wishes.

Factors Associated with Code Status Discussion in Entire Cohort and Patients with No Previous Documentation
 Entire Cohort (n = 17097)Patients with No Documentation of Preadmission Wishes (n = 12765)
Adjusted Odds Ratio (95% CI)P ValueAdjusted Odds Ratio (95% CI)P Value
Preadmission Code Status
No documentationReferent NA 
Full support3.22 (2.28, 4.55)< 0.0001NA 
Do not resuscitate or intubate (DNR/DNI)11.32 (8.52, 15.04)< 0.0001NA 
Hospice4.02 (2.33, 6.94)< 0.0001NA 
Other limitation (eg, no pressors)10.13 (7.35, 13.96)< 0.0001NA 
Insurance type
MedicareReferent Referent 
Charity care0.50 (0.30, 0.85)0.00990.56 (0.25, 1.25)0.1589
Commercial0.81 (0.69, 0.95)0.00900.66 (0.52, 0.85)0.0009
Medicaid0.69 (0.57, 0.82)< 0.00010.49 (0.36, 0.67)< 0.0001
Other0.46 (0.18, 1.13)0.09120.60 (0.17, 2.12)0.4302
Self pay0.70 (0.52, 0.95)0.02030.49 (0.29, 0.81)0.0060
Any limitations in bathing, toileting, dressing or feeding self?
NoReferent Referent 
Yes, a little1.25 (1.10, 1.42)0.00071.31 (1.03, 1.67)0.0272
Yes, a lot1.25 (1.09, 1.43)0.00151.42 (1.11, 1.81)0.0055
Unable to respond0.81 (0.59, 1.12)0.20060.80 (0.45, 1.41)0.4299
Patient has a documented surrogate decision maker1.72 (1.47, 2.02)< 0.00012.08 (1.62, 2.66)< 0.0001
Patient noted to be unable to participate in their care at admission (eg, confused, unable to respond)1.63 (1.37, 1.94)< 0.00012.20 (1.60, 3.02)< 0.0001
Notation that team had spoken to primary care physician at admission1.65 (1.29, 2.11)< 0.00011.45 (0.92, 2.28)0.1116
History of cancer
NoReferent Referent 
Yes1.31 (1.13, 1.51)0.00031.26 (0.96, 1.65)0.0960
Not sure1.26 (0.87, 1.82)0.21621.80 (1.03, 3.15)0.0396
History of diabetes
NoReferent Referent 
Yes0.87 (0.75, 1.003)0.05430.79 (0.62, 0.997)0.0467
Not sure0.61 (0.38, 0.99)0.04450.84 (0.43, 1.65)0.6183
Housing situation
Own house or apartmentReferent Referent 
Relative or friend's apartment or house1.22 (1.03, 1.45)0.02291.29 (0.97, 1.71)0.0783
Nursing home, group home, or long‐term care facility1.42 (1.16, 1.74)0.00061.74 (1.27, 2.40)0.0007
Homeless shelter1.12 (0.72, 1.73)0.62040.87 (0.46, 1.63)0.6559
Other/Don't know1.02 (0.75, 1.40)0.89871.35 (0.78, 2.36)0.2859
Age Group
<50Referent Referent 
50591.19 (0.99, 1.43)0.06471.18 (0.88, 1.59)0.2583
60691.18 (0.99, 1.40)0.05851.20 (0.88, 1.66)0.2549
70791.10 (0.91, 1.33)0.31781.19 (0.85, 1.67)0.3033
80891.23 (1.03, 1.47)0.02071.34 (0.96, 1.88)0.0879
90+1.45 (1.12, 1.88)0.00451.44 (0.94, 2.20)0.0934
Site of Enrollment
AReferent Referent 
B1.74 (1.16, 2.61)0.0074.95 (2.90, 8.45)< 0.0001
C5.14 (3.42, 7.74)< 0.000126.36 (17.28, 40.23)< 0.0001
D4.19 (2.64, 6.66)< 0.00018.06 (4.63, 14.03)< 0.0001
E3.00 (1.82, 4.9)< 0.00015.30 (2.71, 10.38)< 0.0001
F4.09 (2.69, 6.23)< 0.00012.32 (1.32, 4.08)0.0037

In the entire cohort, insurance type was independently associated with likelihood of a care discussion, with patients with Medicare having greater adjusted odds ratio for a CD than patients with all other forms of insurance, even after adjusting for age. Patients who had functional limitations with bathing, toileting, and feeding; had a documented surrogate decision maker; were unable to participate in their care; had cancer; or did not live in their own home were more likely to have a documented CD. Subjects with diabetes were less likely to have a CD, although this was of borderline significance. Patients whose team had documented a CD with the patients' primary physician were also more likely to have a discussion noted. However, the magnitude of these predictors was small compared to the independent effects attributable to the site the patient was enrolled or whether the patient had any preexisting documentation. Whereas the adjusted odds ratio associated with clinical or functional measures (such as age, cancer) were generally between 1.5 and 2.5, the range of odds ratios associated with having any documentation of care wishes (compared to no documentation) were all greater than 3, and the odds ratios associated with site of enrollment were 1.7 or higher.

We observed similar findings in analyses limited to patients with no preexisting care documentation. While clinical, sociodemographic, and functional factors remained statistically associated with a CD (albeit with wider confidence intervals due to smaller sample sizes), the effect of the patient's site of enrollment became even more striking (Table 4).

DISCUSSION

In this multicenter study of hospitalized general medical patients, documentation of CDs were highly dependent on where patients received care and whether patients had previous documentation of a care plan. In contrast, although clinical, prognostic, and socioeconomic factors were also associated with whether physicians documented asking patients about their wishes for care, the influence of these factors was modest.

Improving communication between patients and their physicians during an episode of acute illness has been a long‐standing goal, with the Study to Understand Prognoses and Preferences for Outcomes of Treatment (SUPPORT) trial providing the most notable example of an effort to improve patient care through aligning patient wishes, prognosis, and aggressiveness for care. However, even the SUPPORT interventiona robust, well‐implemented, and highly labor‐intensive strategywas not able to achieve this goal. In their summary of SUPPORT study findings, the authors suggested that the likelihood of and effectiveness of communication in seriously ill patients may be powerfully influenced by patient and caregiver culture4; our findings may partially confirm SUPPORT's conclusions.

Preexisting documentation in our study would not have included mandated documentation that someone had given the patient information about advance directives (as mandated by the PSDA), but rather a specification for that advance care plan. This distinction means that preexisting documentation in our study represented a previous decision by the patient (or the patient and their physician) to have made a plan, and an association with hospital discussions may be because the first conversation is the hardest to undertake; subsequent discussions then represent confirmatory or clarifying discussions that may be less difficult to broach (particularly for less experienced trainees). A CD may have also been prompted when documentation was unclear, or when a change in prognosis took place (eg, a new diagnosis of metastatic cancer).22 Alternatively, a preexisting plan may serve as a reminder for clinicians to discuss code status, signify patients who are more willing to broach this subject, and either seem more approachable or bring up the topic themselves.

The influence of site on documentation and CD provides additional evidence that caregiver culture played a role in CDs. Although this variation may have been in part due to culture around documentation practices more generally, it is important to note that none of our participating centers had a policy for documentation of care wishes or patient‐doctor communication, or a policy mandating these discussions in any specific patient group. Furthermore, site‐related differences were seen even in patients with no preexisting documentation, and were seen after adjustment for other documentation or communication practices (eg, documenting a discussion with the patient's primary care provider), making it unlikely that documentation practices are solely responsible for our results. Persistence of variations in care documentation raises interesting questions, particularly when one considers recent data describing variations in end‐of‐life care between similar academic centers (one of which was a participating site in this trial).23 Given that the sites in our study represent diverse institutions yet share a number of characteristics, understanding the specific practices or aspects of medical culture that promote conversations may provide insights in how to improve this promotion elsewhere.

Our results would argue that mandates to document code status on admission may be unlikely to improve communication unless sites also develop an approach to using this newly documented information as a prompt for subsequent discussions. In nursing home settings, documentation of advance directives may reduce resource use, but it is unclear whether similar effects will be seen in hospital settings.24 It is also a challenge to insure that documentation of a care plan in the nursing home is communicated to the providers in the hospital.25 The PSDA was a first step in this direction, but its effects on improving communication are uncertain.26 Our results would confirm that the PSDA or systems to mandate documentation are not solutions in themselves, but are 2 steps in a larger process.

We do not want to discount our findings of less frequent CDs among patients of lower socioeconomic status, where gaps in quality of care, communication, and outcomes are well‐recognized.27 As such, our results delineate yet another area where practice can and should be improved for vulnerable patients. However, factors related to site of care and documentation may provide opportunities to improve care even more profoundly and within a fairly discrete (if complex) acute episode of care. Having said this, our results also demonstrate a potential pitfall of using code status documentation for risk‐adjustment, because such notation may be more dependent on local documentation patterns than clinical appropriateness.

Our study has a number of limitations. As an observational study, our findings are likely prone to biases related to unadjusted confounding due to comorbidity. The influence of comorbidity would seem to have been most important in biasing the effects of preexisting documentation, where documentation would be associated with more unaccounted comorbidity. However, there were no differences in documentation even after accounting for prognosis by adjusting for age, functional status, and a valid comorbidity score.28 As we have pointed out, our key outcome is based on documentation of communication and not actual communication, and as such may be biased in subtle ways not related to site of care or the items tested in our model. While we cannot directly eliminate the possibility of documentation biases in our results using statistical methods, it is important to point out that our chart abstraction protocol used highly specific criteria to detect these discussions, and therefore may under‐detect discussions which may have been documented in less detail. Our study did not examine whether documentation of CDs influenced subsequent care. However, previous studies have shown that advance care planning has only a minor influence on care.29 However, communication about preferences at the time of admission, when the need for specific care decisions may be more evident, may be more likely to influence hospital care. Our results show that previous documentation is associated with discussions early in an admission. Such discussion may affect care, even if the decision made is different than what was previously documented. In addition, patients who were included in our study (those able to provide consent and participate in an interview) may be healthier or more cognitively intact than a general population of hospitalized patients. However, how this would have affected our results is unclear. Being able to speak and consent for oneself are key facilitators to communication, but sicker patients who cannot consent or speak for themselves might also be more likely to have care planning decisions made based on illness severity; documentation in these patients may be more driven by whether such notes were required because of the involvement of home health services (or skilled nursing facilities). Finally, although our study is one of the largest examinations of in‐hospital communication to date and its implications for resident education are worth noting, the sites involved in the MCHS may not be representative of nonteaching hospitals, or community‐based teaching hospitals.

Our results suggest that, although comorbid illness and socioeconomic status play an important role in determining which patients receive CDs at the time of admission, these factors are substantially less powerful than preexisting documentation practices and culture or care practices specific to their site of care. These results suggest that future work should consider organizational characteristics and culture as important targets for interventions to improve care planning in hospitalized patients.

Despite an ideal of dying at home, most Americans die in hospitals.1 Patients and families are clear about what they need from the healthcare system at the end of life: relief of distressing symptoms, the opportunity to communicate with physicians and others about death and dying, and the assurance that they will be attended to and comforted by their physicians as they approach death.2, 3 However, discussions about patient preferences for care occur infrequently,47 even though patients want to discuss care with their doctor,68 and physicians believe these discussions are their responsibility.9

The most prominent work in this area occurred in the Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments (SUPPORT) study, which focused on patients with advanced disease, often in the intensive care unit.4 Furthermore, few studies have focused on general medical patients, and healthcare has changed in important ways since SUPPORT's publication. First, the Patient Self‐Determination Act (PSDA) requires that all patients be asked about their care wishes at the time of admission and document the presence of an advanced directive.10, 11 Second, there is growing awareness of the need to improve palliative care for all hospitalized patients, with many advocating that hospitalization itself is a reason to ask about patient's preferences for care regardless of a patient's level of chronic or acute illness.12 Finally, emergence of hospitalists,1316 movement toward closed intensive care units,17, 18 and changes in residency training have increased segmentation in care of hospitalized patients.15, 18

To overcome limitations of previous literature and update our knowledge of how care discussions take place in the current healthcare environment, we analyzed data from a large study of patients admitted to general medicine services at 6 academic centers. Using this robust dataset, which included prospectively collected information about preferences for communication with their physician, we performed statistical analyses to understand which patient clinical, sociodemographic, and preference‐related factors, as well as factors related to their site of care, were associated with documentation that a code status discussion took place at the time of hospital admission.

PATIENTS AND METHODS

Sites

The Multicenter Hospitalist Study (MCHS) was a multicenter trial of general medical services that enrolled patients at 6 geographically diverse centers: The University of Chicago (which also served as the coordinating center), University of Iowa Hospitals and Clinics, University of California San Francisco, University of Wisconsin, University of New Mexico, and Brigham and Women's Hospital.19

Each site was selected to participate in the MCHS because patients on their general medicine service were admitted to hospitalist and nonhospitalist physicians in a random fashion (eg, based on predetermined call schedule based on day of the week). As teaching hospitals, house officers provided direct care to patients hospitalized at each center; nonteaching services were not present at the sites during the period of this study.

During the period of this study, each site complied with PSDA requirements for noting that patients had been informed about their right to create an advance directive, but no sites had a guideline or other program in place specifically intended to facilitate physician‐patient communication about care wishes. Two sites had active Hospice or Palliative Care services, and another 2 had Geriatrics Consultation services, but none had standard protocols mandating involvement of these consultants at the time of admission, the time when our key outcomes were documented.

Patients

Patients were eligible for inclusion in the MCHS if they were older than 18 years of age and were admitted at random to a hospitalist or nonhospitalist physician; we excluded patients from MCHS if they were admitted specifically under the care of their primary care physician or subspecialist (eg, admitted for chemotherapy) or were a prison inmate. Patients meeting these eligibility criteria were then approached for purposes of informed consent.

Data Collection

Data for this study were obtained from administrative data, patient interview, and chart abstraction as in previous work.14 Administrative data were drawn from cost‐accounting databases at each participating hospital; administrative data were used to provide cost and length of stay data, as well as information about patient insurance type, age, and sex.

We interviewed patients immediately after informed consent was obtained, with both taking place generally within 24 hours of admission. Interviews collected data about patient preferences for care and functional status,20 and other data not reliably available from administrative sources (such as housing situation).

Patient care plan before admission was taken from notes and orders written in the first 24 hours of hospitalization, as mentioned above. Using criteria we employed in previous work,21 a care discussion (CD) was defined as documentation of a discussion between patients (or family) and at least 1 physician (primary physician, hospitalist, consulting physician, or house officer) during the first 24 hours of hospitalization. CDs needed to specify that the person who wrote the note had actually spoken with the patient or their family for the purposes of determining preferences for care, and that this discussion resulted in a specific care plan. Thus, notations such as do not resuscitate/do not intubate, or spoke with family, questions answered, did not qualify as CDs, but a note stating the patient continues to want full efforts was counted as a CD.

Principal investigators at each site were responsible for training and overseeing interviewing and chart abstraction activities at each site, with central oversight of data quality provided by the central coordinating center. Upon receipt at the data coordinating center, all data were examined for missing, nonsensical, or outlier data with errors referred back to the participating sites for correction.

Statistical Analysis

For bivariable comparisons of patients with and without CDs, we used chi‐squared or Mann‐Whitney U‐tests, as appropriate.

Variables with P < 0.20 in bivariable comparisons were selected for initial inclusion in models. Then, using automated forward and stepwise selection techniques as well as manually entered variables, we fit multivariable generalized estimating equations permitting clustering of effects at the physician level to determine the independent association between the multiple factors tested and presence of a CD. In order to guard against the threat of multiple testing, we retained variables at a significance level of P < 0.01; variables were also retained because of observed confounding with other independent variables, or to maintain face validity of the model. All analyses were performed using SAS 9.0 for Windows (SAS Institute Inc., Cary, NC).

RESULTS

Patient Sociodemographics (Table 1)

A total of 17,097 of 33,638 patients (50.8%) were interviewed and gave consent for chart abstraction. Of these patients, 1776 (10.3%) had a CD documented in the first 24 hours of hospitalization. Patients with documented CDs were older, more often white, had completed more years of education, were more likely to have lived in a nursing home prior to admission, and more likely to have been hospitalized in the last 12 months. The proportion of patients with CDs was highly variable across site of enrollment, from 2.8%‐24.9%.

Patient Sociodemographics (total n = 17097)
ValueNo Documented CD (n = 15321, 89.7%)Documented CD (n = 1776, 10.3%)P*
  • P value from Mann‐Whitney U Test, all others from chi‐squared tests.

  • Totals may not sum to 100% due to rounding.

Age (Median, 95%CI)*56 (55, 56)69 (67, 71)< 0.0001
Female (n, %)8390 (54.8%)990 (55.7%)0.4312
Race (n, %)
White6640 (43.3%)938 (52.8%)< 0.0001
African American4673 (30.5%)280 (15.8%) 
Asian532 (3.5%)167 (9.4%) 
American Indian325 (2.1%)26 (1.5%) 
Other1951 (12.7%)241 (13.6%) 
Refused/Don't know1200 (7.8%)124 (7.0%) 
Ethnicity (n, %)
Hispanic or Latino Ethnicity1724 (11.3%)183 (10.3%)0.0039
Insurance type (n, %)
Charity481 (3.4%)14 (0.8%)< 0.0001
Indemnity3983 (28.2%)327 (19.3%) 
Medicaid2487 (17.6%)195 (11.5%) 
Medicare6418 (45.5%)1114 (65.9%) 
Other105 (0.7%)4 (0.2%) 
Self pay628 (4.5%)36 (2.1%) 
Self‐reported education (n, %)
Junior high school or less1297 (8.5%)217 (12.2%)< 0.0001
Some high school2146 (14.0%)182 (10.2%) 
High school graduate4435 (28.9%)465 (26.2%) 
Some college or junior college3521 (23.0%)347 (19.5%) 
College graduate1729 (11.3%)255 (14.4%) 
Post‐graduate1191 (7.8%)173 (9.7%) 
Refused/Don't know1002 (6.5%)137 (7.7%) 
Self reported income (n, %)
$2,500 or less1079 (7.0%)108 (6.1%)0.0002
$2,501 to $5,000424 (2.8%)33 (1.9%) 
$5,001 to $10,0001436 (9.4%)211 (11.9%) 
$10,001 to $15,0001080 (7.0%)141 (7.9%) 
$15,001 to $25,0001054 (6.9%)134 (7.5%) 
$25,001 to $35,000837 (5.5%)74 (4.2%) 
$35,001 to $50,000882 (5.8%)94 (5.3%) 
$50,001 to $100,0001027 (6.7%)125 (7.0%) 
$100,001 to $200,000357 (2.3%)57 (3.2%) 
Over $200,000245 (1.6%)34 (1.9%) 
Don't know/refused6900 (45.0%)765 (43.1%) 
Housing situation (n, %)
Own apartment or house11887 (77.6%)1264 (71.2%)< 0.0001
A relative or friend's apartment or house1804 (11.8%)217 (12.2%) 
A nursing home, group home, or long‐term care facility663 (4.3%)204 (11.5%) 
A homeless shelter258 (1.7%)27 (1.5%) 
Other709 (4.6%)64 (3.6%) 
Marital status (n, %)
Married4992 (32.6%)603 (34.0%)< 0.0001
Living as if married440 (2.9%)32 (1.8%) 
Divorced2027 (13.2%)199 (11.2%) 
Separated569 (3.7%)30 (1.7%) 
Widowed2577 (16.8%)487 (27.4%) 
Single4074 (26.6%)364 (20.5%) 
Refused642 (4.2%)61 (3.4%) 
Hospitalized in the last 12 months (n, %)7602 (49.6%)1011 (56.9%)< 0.0001
Site of enrollment (n, %)
A4602 (30.0%)135 (7.6%)< 0.0001
B1595 (10.4%)158 (8.9%) 
C3017 (19.7%)998 (56.2%) 
D2387 (15.6%)212 (11.9%) 
E2057 (13.4%)131 (7.4%) 
F1663 (10.9%)142 (8.0%) 

Patient Self‐Reported Health Status and Comorbid Illness (Table 2)

Patients with CDs more often reported a lot of difficulties with bathing, eating, or dressing; household chores; and moderate activities. Patients with CDs were more likely to report accomplishing less than they would like due to their health. They were more likely to have cancer, depression, a history of stroke, and heart disease, but less likely to have diabetes or human immunodeficiency virus.

Patient Self‐Reported Health Status and Comorbid Disease (Total n = 17097)*
ValueNo Documented CD (n = 15321, 89.7%)Documented CD (n = 1776, 10.3%)P**
  • Self reported data collected at time of intake interview, performed within 24 hours of admission.

  • Calculated using chi‐squared tests.

  • Totals may not sum to 100% due to rounding.

Thinking back again to one month ago, did any impairment or health problem cause you to need help of other persons with personal care needs, such as eating, bathing, dressing, or getting around the home? (n, %)
No10673 (69.7%)973 (54.8%)< 0.0001
Yes, a little1933 (12.6%)268 (15.1%) 
Yes, a lot2127 (13.9%)487 (27.4%) 
Don't know588 (3.8%)48 (2.7%) 
Thinking back to one month ago, did any impairment or health problem cause you to need help in handling everyday household chores, necessary business, shopping, or getting around for other purposes? (n, %)
No7262 (47.4%)566 (31.9%)< 0.0001
Yes, a little2692 (17.6%)324 (18.2%) 
Yes, a lot4126 (26.9%)825 (46.5%) 
Don't know1241 (8.1%)61 (3.4%) 
As far as you know do you have any of the following health conditions at the present time? (n, %)
Cancer
No13281 (86.7%)1376 (77.5%)< 0.0001
Yes1751 (11.4%)351 (19.8%) 
Not sure289 (1.9%)49 (2.8%) 
Depression
No10269 (67.0%)1099 (61.9%)< 0.0001
Yes4730 (30.9%)624 (35.1%) 
Not sure322 (2.1%)53 (3.0%) 
Diabetes
No10902 (71.2%)1356 (76.4%)< 0.0001
Yes4132 (27.0%)394 (22.2%) 
Not sure287 (1.9%)26 (1.5%) 
Heart trouble
No10251 (66.9%)1080 (60.8%)< 0.0001
Yes4491 (29.3%)627 (35.3%) 
Not sure579 (3.8%)69 (3.9%) 
HIV or AIDS
No14300 (93.3%)1679 (94.5%)0.026
Yes912 (6.0%)80 (4.5%) 
Not sure109 (0.7%)17 (1.0%) 
Stroke
No13344 (87.1%)1494 (84.1%)0.0005
Yes1722 (11.2%)236 (13.3%) 
Not sure255 (1.7%)46 (2.6%) 

Patient Preferences, Care Plan Documentation, and Care Coordination at Admission (Table 3)

Patients who had documented CDs were less likely to prefer my doctor give me choices regarding my care, and more often disagreed with the statement I prefer to leave care decisions to my physician. These patients were also more likely to have a durable power of attorney or living will in their chart, or have an alternate decision‐maker noted. The majority of patients without a documented CD (79.9%) had no notation of their care wishes, compared to 29.7% in patients with a documented CD. Patients with a documented CD were more likely to have a regular medical provider and a note in the chart from their primary care physician.

Patient Decision‐Making Preferences, Care Plan Documentation, and Care Coordination at Admission (Total n = 17097)
ValueNo Documented CD (n = 15321, 89.7%)Documented CD (n = 1776, 10.3%)P*
  • Calculated using chi‐squared tests.

  • Collected during intake interview performed within 24 hours of admission.

    All other items collected via chart abstraction.

I prefer my doctor give me choices regarding my care** (n, %)
Definitely agree11619 (75.8%)1247 (70.2%)< 0.0001
Somewhat agree1912 (12.5%)252 (14.2%) 
Somewhat disagree488 (3.2%)76 (4.3%) 
Definitely disagree414 (2.7%)87 (4.9%) 
Don't know888 (5.8%)114 (6.4%) 
I prefer to leave care decisions to my physician** (n, %)
Definitely agree5660 (36.9%)613 (34.5%)< 0.0001
Somewhat agree4539 (29.6%)493 (27.8%) 
Somewhat disagree2265 (14.8%)257 (14.5%) 
Definitely disagree1956 (12.8%)304 (17.1%) 
Don't know901 (5.9%)109 (6.1%) 
Documentation of care wishes before hospitalization (n, %)
No documentation12238 (79.9%)527 (29.7%)< 0.0001
Full support2624 (17.1%)742 (41.8%) 
Do not resuscitate or intubate (DNR/DNI)264 (1.7%)370 (20.8%) 
Hospice53 (0.3%)22 (1.2%) 
Other limitation (eg, no pressors)142 (0.9%)115 (6.5%) 
Had durable power of attorney in chart (n, %)286 (1.9%)133 (7.5%)< 0.0001
Had a living will in chart (n, %)266 (1.7%)142 (8.0%)< 0.0001
Alternate decision maker named in chart (n, %)2770 (18.1%)638 (35.9%)< 0.0001
Patient noted to be unable to participate in their care at admission (eg, confused, unable to respond) (n, %)1227 (8.0%)431 (24.3%)< 0.0001
Inpatient team documented discussion with primary care physician (n, %)627 (4.1%)136 (7.7%)< 0.0001
Do not have a regular medical provider** (n, %)3836 (25.0%)254 (14.3%)< 0.0001
Note from primary care physician in chart (n, %)148 (1.0%)39 (2.2%)< 0.0001

Factors Associated with Documented Care Discussions (Table 4)

Using predictor variables presented in Tables 1‐3, we then constructed multivariable models seeking to understand factors independently associated with documentation of code status in the entire cohort, as well as among patients who had no preexisting care wishes.

Factors Associated with Code Status Discussion in Entire Cohort and Patients with No Previous Documentation
 Entire Cohort (n = 17097)Patients with No Documentation of Preadmission Wishes (n = 12765)
Adjusted Odds Ratio (95% CI)P ValueAdjusted Odds Ratio (95% CI)P Value
Preadmission Code Status
No documentationReferent NA 
Full support3.22 (2.28, 4.55)< 0.0001NA 
Do not resuscitate or intubate (DNR/DNI)11.32 (8.52, 15.04)< 0.0001NA 
Hospice4.02 (2.33, 6.94)< 0.0001NA 
Other limitation (eg, no pressors)10.13 (7.35, 13.96)< 0.0001NA 
Insurance type
MedicareReferent Referent 
Charity care0.50 (0.30, 0.85)0.00990.56 (0.25, 1.25)0.1589
Commercial0.81 (0.69, 0.95)0.00900.66 (0.52, 0.85)0.0009
Medicaid0.69 (0.57, 0.82)< 0.00010.49 (0.36, 0.67)< 0.0001
Other0.46 (0.18, 1.13)0.09120.60 (0.17, 2.12)0.4302
Self pay0.70 (0.52, 0.95)0.02030.49 (0.29, 0.81)0.0060
Any limitations in bathing, toileting, dressing or feeding self?
NoReferent Referent 
Yes, a little1.25 (1.10, 1.42)0.00071.31 (1.03, 1.67)0.0272
Yes, a lot1.25 (1.09, 1.43)0.00151.42 (1.11, 1.81)0.0055
Unable to respond0.81 (0.59, 1.12)0.20060.80 (0.45, 1.41)0.4299
Patient has a documented surrogate decision maker1.72 (1.47, 2.02)< 0.00012.08 (1.62, 2.66)< 0.0001
Patient noted to be unable to participate in their care at admission (eg, confused, unable to respond)1.63 (1.37, 1.94)< 0.00012.20 (1.60, 3.02)< 0.0001
Notation that team had spoken to primary care physician at admission1.65 (1.29, 2.11)< 0.00011.45 (0.92, 2.28)0.1116
History of cancer
NoReferent Referent 
Yes1.31 (1.13, 1.51)0.00031.26 (0.96, 1.65)0.0960
Not sure1.26 (0.87, 1.82)0.21621.80 (1.03, 3.15)0.0396
History of diabetes
NoReferent Referent 
Yes0.87 (0.75, 1.003)0.05430.79 (0.62, 0.997)0.0467
Not sure0.61 (0.38, 0.99)0.04450.84 (0.43, 1.65)0.6183
Housing situation
Own house or apartmentReferent Referent 
Relative or friend's apartment or house1.22 (1.03, 1.45)0.02291.29 (0.97, 1.71)0.0783
Nursing home, group home, or long‐term care facility1.42 (1.16, 1.74)0.00061.74 (1.27, 2.40)0.0007
Homeless shelter1.12 (0.72, 1.73)0.62040.87 (0.46, 1.63)0.6559
Other/Don't know1.02 (0.75, 1.40)0.89871.35 (0.78, 2.36)0.2859
Age Group
<50Referent Referent 
50591.19 (0.99, 1.43)0.06471.18 (0.88, 1.59)0.2583
60691.18 (0.99, 1.40)0.05851.20 (0.88, 1.66)0.2549
70791.10 (0.91, 1.33)0.31781.19 (0.85, 1.67)0.3033
80891.23 (1.03, 1.47)0.02071.34 (0.96, 1.88)0.0879
90+1.45 (1.12, 1.88)0.00451.44 (0.94, 2.20)0.0934
Site of Enrollment
AReferent Referent 
B1.74 (1.16, 2.61)0.0074.95 (2.90, 8.45)< 0.0001
C5.14 (3.42, 7.74)< 0.000126.36 (17.28, 40.23)< 0.0001
D4.19 (2.64, 6.66)< 0.00018.06 (4.63, 14.03)< 0.0001
E3.00 (1.82, 4.9)< 0.00015.30 (2.71, 10.38)< 0.0001
F4.09 (2.69, 6.23)< 0.00012.32 (1.32, 4.08)0.0037

In the entire cohort, insurance type was independently associated with likelihood of a care discussion, with patients with Medicare having greater adjusted odds ratio for a CD than patients with all other forms of insurance, even after adjusting for age. Patients who had functional limitations with bathing, toileting, and feeding; had a documented surrogate decision maker; were unable to participate in their care; had cancer; or did not live in their own home were more likely to have a documented CD. Subjects with diabetes were less likely to have a CD, although this was of borderline significance. Patients whose team had documented a CD with the patients' primary physician were also more likely to have a discussion noted. However, the magnitude of these predictors was small compared to the independent effects attributable to the site the patient was enrolled or whether the patient had any preexisting documentation. Whereas the adjusted odds ratio associated with clinical or functional measures (such as age, cancer) were generally between 1.5 and 2.5, the range of odds ratios associated with having any documentation of care wishes (compared to no documentation) were all greater than 3, and the odds ratios associated with site of enrollment were 1.7 or higher.

We observed similar findings in analyses limited to patients with no preexisting care documentation. While clinical, sociodemographic, and functional factors remained statistically associated with a CD (albeit with wider confidence intervals due to smaller sample sizes), the effect of the patient's site of enrollment became even more striking (Table 4).

DISCUSSION

In this multicenter study of hospitalized general medical patients, documentation of CDs were highly dependent on where patients received care and whether patients had previous documentation of a care plan. In contrast, although clinical, prognostic, and socioeconomic factors were also associated with whether physicians documented asking patients about their wishes for care, the influence of these factors was modest.

Improving communication between patients and their physicians during an episode of acute illness has been a long‐standing goal, with the Study to Understand Prognoses and Preferences for Outcomes of Treatment (SUPPORT) trial providing the most notable example of an effort to improve patient care through aligning patient wishes, prognosis, and aggressiveness for care. However, even the SUPPORT interventiona robust, well‐implemented, and highly labor‐intensive strategywas not able to achieve this goal. In their summary of SUPPORT study findings, the authors suggested that the likelihood of and effectiveness of communication in seriously ill patients may be powerfully influenced by patient and caregiver culture4; our findings may partially confirm SUPPORT's conclusions.

Preexisting documentation in our study would not have included mandated documentation that someone had given the patient information about advance directives (as mandated by the PSDA), but rather a specification for that advance care plan. This distinction means that preexisting documentation in our study represented a previous decision by the patient (or the patient and their physician) to have made a plan, and an association with hospital discussions may be because the first conversation is the hardest to undertake; subsequent discussions then represent confirmatory or clarifying discussions that may be less difficult to broach (particularly for less experienced trainees). A CD may have also been prompted when documentation was unclear, or when a change in prognosis took place (eg, a new diagnosis of metastatic cancer).22 Alternatively, a preexisting plan may serve as a reminder for clinicians to discuss code status, signify patients who are more willing to broach this subject, and either seem more approachable or bring up the topic themselves.

The influence of site on documentation and CD provides additional evidence that caregiver culture played a role in CDs. Although this variation may have been in part due to culture around documentation practices more generally, it is important to note that none of our participating centers had a policy for documentation of care wishes or patient‐doctor communication, or a policy mandating these discussions in any specific patient group. Furthermore, site‐related differences were seen even in patients with no preexisting documentation, and were seen after adjustment for other documentation or communication practices (eg, documenting a discussion with the patient's primary care provider), making it unlikely that documentation practices are solely responsible for our results. Persistence of variations in care documentation raises interesting questions, particularly when one considers recent data describing variations in end‐of‐life care between similar academic centers (one of which was a participating site in this trial).23 Given that the sites in our study represent diverse institutions yet share a number of characteristics, understanding the specific practices or aspects of medical culture that promote conversations may provide insights in how to improve this promotion elsewhere.

Our results would argue that mandates to document code status on admission may be unlikely to improve communication unless sites also develop an approach to using this newly documented information as a prompt for subsequent discussions. In nursing home settings, documentation of advance directives may reduce resource use, but it is unclear whether similar effects will be seen in hospital settings.24 It is also a challenge to insure that documentation of a care plan in the nursing home is communicated to the providers in the hospital.25 The PSDA was a first step in this direction, but its effects on improving communication are uncertain.26 Our results would confirm that the PSDA or systems to mandate documentation are not solutions in themselves, but are 2 steps in a larger process.

We do not want to discount our findings of less frequent CDs among patients of lower socioeconomic status, where gaps in quality of care, communication, and outcomes are well‐recognized.27 As such, our results delineate yet another area where practice can and should be improved for vulnerable patients. However, factors related to site of care and documentation may provide opportunities to improve care even more profoundly and within a fairly discrete (if complex) acute episode of care. Having said this, our results also demonstrate a potential pitfall of using code status documentation for risk‐adjustment, because such notation may be more dependent on local documentation patterns than clinical appropriateness.

Our study has a number of limitations. As an observational study, our findings are likely prone to biases related to unadjusted confounding due to comorbidity. The influence of comorbidity would seem to have been most important in biasing the effects of preexisting documentation, where documentation would be associated with more unaccounted comorbidity. However, there were no differences in documentation even after accounting for prognosis by adjusting for age, functional status, and a valid comorbidity score.28 As we have pointed out, our key outcome is based on documentation of communication and not actual communication, and as such may be biased in subtle ways not related to site of care or the items tested in our model. While we cannot directly eliminate the possibility of documentation biases in our results using statistical methods, it is important to point out that our chart abstraction protocol used highly specific criteria to detect these discussions, and therefore may under‐detect discussions which may have been documented in less detail. Our study did not examine whether documentation of CDs influenced subsequent care. However, previous studies have shown that advance care planning has only a minor influence on care.29 However, communication about preferences at the time of admission, when the need for specific care decisions may be more evident, may be more likely to influence hospital care. Our results show that previous documentation is associated with discussions early in an admission. Such discussion may affect care, even if the decision made is different than what was previously documented. In addition, patients who were included in our study (those able to provide consent and participate in an interview) may be healthier or more cognitively intact than a general population of hospitalized patients. However, how this would have affected our results is unclear. Being able to speak and consent for oneself are key facilitators to communication, but sicker patients who cannot consent or speak for themselves might also be more likely to have care planning decisions made based on illness severity; documentation in these patients may be more driven by whether such notes were required because of the involvement of home health services (or skilled nursing facilities). Finally, although our study is one of the largest examinations of in‐hospital communication to date and its implications for resident education are worth noting, the sites involved in the MCHS may not be representative of nonteaching hospitals, or community‐based teaching hospitals.

Our results suggest that, although comorbid illness and socioeconomic status play an important role in determining which patients receive CDs at the time of admission, these factors are substantially less powerful than preexisting documentation practices and culture or care practices specific to their site of care. These results suggest that future work should consider organizational characteristics and culture as important targets for interventions to improve care planning in hospitalized patients.

References
  1. Committee on Care at the End of Life, Institute of Medicine.Approaching Death: Improving Care at the End of Life.Field MJ,Cassel CK, eds.Washington, DC:National Academy Press;1997.
  2. Steinhauser KE,Christakis NA,Clipp EC,McNeilly M,McIntyre L,Tulsky JA.Factors considered important at the end of life by patients, family, physicians, and other care providers.JAMA.2000;284(19):24762482.
  3. Steinhauser KE,Clipp EC,McNeilly M,Christakis NA,McIntyre LM,Tulsky JA.In search of a good death: observations of patients, families, and providers.Ann Intern Med.2000;132(10):825832.
  4. The SUPPORT Principal Investigators.A controlled trial to improve care for seriously ill hospitalized patients. The study to understand prognoses and preferences for outcomes and risks of treatments (SUPPORT).JAMA.1995;274(20):15911598.
  5. Bedell SE,Delbanco TL.Choices about cardiopulmonary resuscitation in the hospital. When do physicians talk with patients?N Engl J Med.1984;310(17):10891093.
  6. Hofmann JC,Wenger NS,Davis RB, et al.Patient preferences for communication with physicians about end‐of‐life decisions. SUPPORT Investigators. Study to Understand Prognoses and Preference for Outcomes and Risks of Treatment.Ann Intern Med.1997;127(1):112.
  7. Shmerling RH,Bedell SE,Lilienfeld A,Delbanco TL.Discussing cardiopulmonary resuscitation: a study of elderly outpatients.J Gen Intern Med.1988;3(4):317321.
  8. Schonwetter RS,Teasdale TA,Taffet G,Robinson BE,Luchi RJ.Educating the elderly: cardiopulmonary resuscitation decisions before and after intervention.J Am Geriatr Soc.1991;39(4):372377.
  9. Miller DL,Gorbien MJ,Simbartl LA,Jahnigen DW.Factors influencing physicians in recommending in‐hospital cardiopulmonary resuscitation.Arch Intern Med.1993;153(17):19992003.
  10. Federal Register. 42 USC 1395‐1396. Patient Self‐Determination Act1990.
  11. La Puma J,Orentlicher D,Moss RJ.Advance directives on admission. Clinical implications and analysis of the Patient Self‐Determination Act of 1990.JAMA.1991;266(3):402405.
  12. Pantilat SZ,Alpers A,Wachter RM.A new doctor in the house: ethical issues in hospitalist systems.JAMA.1999;282(2):171174.
  13. Auerbach A,Wachter R,Katz P,Showstack J,Baron R,Goldman L.Implementation of a hospitalist service at a community teaching hospital: improving clinical efficiency and patient outcomes.Ann Intern Med.2002;137:859865.
  14. Meltzer D,Morrison J,Guth T, et al.Effects of hospitalist physicians on an academic general medical service: results of a randomized trial.Ann Intern Med.2002;137:866874.
  15. Wachter RM,Goldman L.The hospitalist movement 5 years later.JAMA.2002;287(4):487494.
  16. Wachter RM,Katz P,Showstack J,Bindman AB,Goldman L.Reorganizing an academic medical service: impact on cost, quality, patient satisfaction, and education.JAMA.1998;279(19):15601565.
  17. Pronovost PJ,Angus DC,Dorman T,Robinson KA,Dremsizov TT,Young TL.Physician staffing patterns and clinical outcomes in critically ill patients: a systematic review.JAMA.2002;288(17):21512162.
  18. Pronovost PJ,Jenckes MW,Dorman T, et al.Organizational characteristics of intensive care units related to outcomes of abdominal aortic surgery.JAMA.1999;281(14):13101317.
  19. Meltzer DO,Arora V,Zhang JX, et al.Effects of inpatient experience on outcomes and costs in a multicenter trial of academic hospitalists.J Gen Intern Med.2005;20(Suppl 1):141142.
  20. Ware J,Kosinski M,Keller S.SF‐12: How to Score the SF‐12 Physical and Mental Health Summary Scales.2nd ed.Boston, MA:New England Medical Center, The Health Institute;1995.
  21. Auerbach AD,Pantilat SZ.End‐of‐life care in a voluntary hospitalist model: effects on communication, processes of care, and patient symptoms.Am J Med.2004;116(10):669675.
  22. Teno JM,Stevens M,Spernak S,Lynn J.Role of written advance directives in decision making: insights from qualitative and quantitative data.J Gen Intern Med.1998;13(7):439446.
  23. Wennberg JE,Fisher ES,Baker L,Sharp SM,Bronner KK.Evaluating the efficiency of California providers in caring for patients with chronic illnesses.Health Aff (Millwood).2005 Jul‐Dec;Suppl Web Exclusives:W5–52643.
  24. Molloy DW,Guyatt GH,Russo R, et al.Systematic implementation of an advance directive program in nursing homes: a randomized controlled trial.JAMA.2000;283(11):14371444.
  25. Hanson LC,Ersek M.Meeting palliative care needs in post‐acute care settings: “to help them live until they die”.JAMA.2006;295(6):681686.
  26. Teno J,Lynn J,Wenger N, et al.Advance directives for seriously ill hospitalized patients: effectiveness with the patient self‐determination act and the SUPPORT intervention. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment.J Am Geriatr Soc.1997;45(4):500507.
  27. Institute of Medicine.Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care.Smedley BD,Stith AY,Nelson AR, eds.Washington, DC:National Academies Press;2003.
  28. Chaudhry S,Jin L,Meltzer D.Use of a self‐report‐generated Charlson Comorbidity Index for predicting mortality.Med Care.2005;43(6):607615.
  29. Hanson LC,Tulsky JA,Danis M.Can clinical interventions change care at the end of life?Ann Intern Med.1997;126(5):381388.
References
  1. Committee on Care at the End of Life, Institute of Medicine.Approaching Death: Improving Care at the End of Life.Field MJ,Cassel CK, eds.Washington, DC:National Academy Press;1997.
  2. Steinhauser KE,Christakis NA,Clipp EC,McNeilly M,McIntyre L,Tulsky JA.Factors considered important at the end of life by patients, family, physicians, and other care providers.JAMA.2000;284(19):24762482.
  3. Steinhauser KE,Clipp EC,McNeilly M,Christakis NA,McIntyre LM,Tulsky JA.In search of a good death: observations of patients, families, and providers.Ann Intern Med.2000;132(10):825832.
  4. The SUPPORT Principal Investigators.A controlled trial to improve care for seriously ill hospitalized patients. The study to understand prognoses and preferences for outcomes and risks of treatments (SUPPORT).JAMA.1995;274(20):15911598.
  5. Bedell SE,Delbanco TL.Choices about cardiopulmonary resuscitation in the hospital. When do physicians talk with patients?N Engl J Med.1984;310(17):10891093.
  6. Hofmann JC,Wenger NS,Davis RB, et al.Patient preferences for communication with physicians about end‐of‐life decisions. SUPPORT Investigators. Study to Understand Prognoses and Preference for Outcomes and Risks of Treatment.Ann Intern Med.1997;127(1):112.
  7. Shmerling RH,Bedell SE,Lilienfeld A,Delbanco TL.Discussing cardiopulmonary resuscitation: a study of elderly outpatients.J Gen Intern Med.1988;3(4):317321.
  8. Schonwetter RS,Teasdale TA,Taffet G,Robinson BE,Luchi RJ.Educating the elderly: cardiopulmonary resuscitation decisions before and after intervention.J Am Geriatr Soc.1991;39(4):372377.
  9. Miller DL,Gorbien MJ,Simbartl LA,Jahnigen DW.Factors influencing physicians in recommending in‐hospital cardiopulmonary resuscitation.Arch Intern Med.1993;153(17):19992003.
  10. Federal Register. 42 USC 1395‐1396. Patient Self‐Determination Act1990.
  11. La Puma J,Orentlicher D,Moss RJ.Advance directives on admission. Clinical implications and analysis of the Patient Self‐Determination Act of 1990.JAMA.1991;266(3):402405.
  12. Pantilat SZ,Alpers A,Wachter RM.A new doctor in the house: ethical issues in hospitalist systems.JAMA.1999;282(2):171174.
  13. Auerbach A,Wachter R,Katz P,Showstack J,Baron R,Goldman L.Implementation of a hospitalist service at a community teaching hospital: improving clinical efficiency and patient outcomes.Ann Intern Med.2002;137:859865.
  14. Meltzer D,Morrison J,Guth T, et al.Effects of hospitalist physicians on an academic general medical service: results of a randomized trial.Ann Intern Med.2002;137:866874.
  15. Wachter RM,Goldman L.The hospitalist movement 5 years later.JAMA.2002;287(4):487494.
  16. Wachter RM,Katz P,Showstack J,Bindman AB,Goldman L.Reorganizing an academic medical service: impact on cost, quality, patient satisfaction, and education.JAMA.1998;279(19):15601565.
  17. Pronovost PJ,Angus DC,Dorman T,Robinson KA,Dremsizov TT,Young TL.Physician staffing patterns and clinical outcomes in critically ill patients: a systematic review.JAMA.2002;288(17):21512162.
  18. Pronovost PJ,Jenckes MW,Dorman T, et al.Organizational characteristics of intensive care units related to outcomes of abdominal aortic surgery.JAMA.1999;281(14):13101317.
  19. Meltzer DO,Arora V,Zhang JX, et al.Effects of inpatient experience on outcomes and costs in a multicenter trial of academic hospitalists.J Gen Intern Med.2005;20(Suppl 1):141142.
  20. Ware J,Kosinski M,Keller S.SF‐12: How to Score the SF‐12 Physical and Mental Health Summary Scales.2nd ed.Boston, MA:New England Medical Center, The Health Institute;1995.
  21. Auerbach AD,Pantilat SZ.End‐of‐life care in a voluntary hospitalist model: effects on communication, processes of care, and patient symptoms.Am J Med.2004;116(10):669675.
  22. Teno JM,Stevens M,Spernak S,Lynn J.Role of written advance directives in decision making: insights from qualitative and quantitative data.J Gen Intern Med.1998;13(7):439446.
  23. Wennberg JE,Fisher ES,Baker L,Sharp SM,Bronner KK.Evaluating the efficiency of California providers in caring for patients with chronic illnesses.Health Aff (Millwood).2005 Jul‐Dec;Suppl Web Exclusives:W5–52643.
  24. Molloy DW,Guyatt GH,Russo R, et al.Systematic implementation of an advance directive program in nursing homes: a randomized controlled trial.JAMA.2000;283(11):14371444.
  25. Hanson LC,Ersek M.Meeting palliative care needs in post‐acute care settings: “to help them live until they die”.JAMA.2006;295(6):681686.
  26. Teno J,Lynn J,Wenger N, et al.Advance directives for seriously ill hospitalized patients: effectiveness with the patient self‐determination act and the SUPPORT intervention. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment.J Am Geriatr Soc.1997;45(4):500507.
  27. Institute of Medicine.Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care.Smedley BD,Stith AY,Nelson AR, eds.Washington, DC:National Academies Press;2003.
  28. Chaudhry S,Jin L,Meltzer D.Use of a self‐report‐generated Charlson Comorbidity Index for predicting mortality.Med Care.2005;43(6):607615.
  29. Hanson LC,Tulsky JA,Danis M.Can clinical interventions change care at the end of life?Ann Intern Med.1997;126(5):381388.
Issue
Journal of Hospital Medicine - 3(6)
Issue
Journal of Hospital Medicine - 3(6)
Page Number
437-445
Page Number
437-445
Article Type
Display Headline
Factors associated with discussion of care plans and code status at the time of hospital admission: Results from the Multicenter Hospitalist Study
Display Headline
Factors associated with discussion of care plans and code status at the time of hospital admission: Results from the Multicenter Hospitalist Study
Legacy Keywords
care discussion, hospital admission, patient care planning
Legacy Keywords
care discussion, hospital admission, patient care planning
Sections
Article Source

Copyright © 2008 Society of Hospital Medicine

Disallow All Ads
Correspondence Location
UCSF Department of Hospital Medicine, 505 Parnassus Avenue, Box 0131, San Francisco, CA 94143
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Article PDF Media

Sleep in Hospitalized Medical Patients: Part 1

Article Type
Changed
Mon, 01/02/2017 - 19:34
Display Headline
Sleep in hospitalized medical patients, Part 1: Factors affecting sleep

Hospitalized patients often have difficulty initiating and maintaining sleep, or complain of early awakening and nonrestorative sleep.1 The etiology of sleep disruption is multifactorial and includes the patient's underlying illness(es), medical treatments, and the hospital environment. Often unrecognized and untreated during hospitalization, sleep disruption may lead to sleep deprivation, or a chronic lack of restorative sleep.

Even in healthy individuals, sleep deprivation can result in numerous physical and psychological consequences. Sleep deprivation is associated with hypertension,2, 3 impaired postural control,4 decreased ventilatory drive,5 increased sympathetic cardiovascular activation,6 blunted hypothalamic‐pituitary‐adrenal axis,7 impaired host defenses, and possibly diabetes mellitus and obesity.810 The lack of restorative sleep increases the risk of developing anxiety and mood disorders and delirium, especially in acutely ill older patients.11 In the presence of acute physical infirmity, inadequate sleep may further compound illness and impair recovery. We provide an overview of normal sleep architecture and discuss factors that lead to sleep disruption in hospitalized medical patients.

NORMAL SLEEP ARCHITECTURE AND REGULATION

Normal sleep architecture refers to a characteristic pattern of sleep, and consists of two major stages: nonrapid eye movement (NREM, pronounced non‐rem) and rapid eye movement (REM). (For a table of pertinent abbreviations and terms, see Table 1) Sleep is quantified by polysomnography (PSG), which includes an electroencephalogram (EEG), electromyogram (EMG), and electrooculogram (EOG). A PSG also includes an electrocardiogram (ECG), and measures of airflow, oxygen saturation, and body position. NREM sleep comprises 75% to 80% of total sleep time (TST), and is characterized by relatively quiescent brain activity and decreased metabolic rate.12 NREM sleep consists of four stages (S1‐S4), with each stage leading to a progressively deeper sleep (Figure 1). REM sleep follows slow wave sleep (SWS), or deep sleep, and increases over the night, comprising 20% to 25% of TST. REM sleep is characterized by an activated EEG pattern, muscle atonia, and episodic bursts of rapid eye movements.

Figure 1
Normal sleep architecture includes cycles of 2 main stages, non‐REM and REM sleep, as depicted in this hypnogram.
Pertinent Abbreviations and Terms
Acronym Term
BiPAP Bilevel positive airway pressure
CHF Congestive heart failure
CPAP Continuous positive airway pressure
COPD Chronic obstructive pulmonary disease
EEG Electroencephalogram
EOG Electroculogram
EMG Electromyogram
ESRD End‐stage renal disease
NPPV Noninvasive positive pressure ventilation
NREM Nonrapid eye movement
OSA Obstructive sleep apnea
PLMD Periodic limb movement disorder
PSG Polysomnography
RBD REM sleep behavior disorder
REM Rapid eye movement
RLS Restless leg syndrome
S1‐S4 4 Stages of sleep in NREM
SE Sleep efficiency; TST divided by total time in bed
SWS Slow wave sleep
TBI Traumatic brain injury
TST Total sleep time

Normal sleep provides a period of physiologic and mental rest. During sleep, sympathetic tone decreases and parasympathetic tone increases, leading to a reduction in heart rate, arterial blood pressure, and cardiac output.13 Deep sleep is theorized to be necessary for physiologic restoration. REM sleep is associated with dreaming, and is essential for maintaining emotional and cognitive well‐being. Sleep architecture undergoes characteristic changes as people age.14 The duration of SWS peaks in childhood and decreases with age. Consequently, people >60 years old tend to have lower arousal thresholds and to have more frequent awakenings. The results of the Sleep Heart Health Study found that increased age was associated with decreased percentage of REM sleep, worse sleep efficiency (SE, which is TST divided by total time in bed), and lower arousal thresholds.14 With the reduction of SE, older people need to spend more hours in bed to achieve the same amount of restorative sleep as when they were younger. Although sleep tends to become more disrupted as people age, insomnia should not be considered a normal part of aging, and needs to be addressed clinically.15 The results of a National Sleep Foundation telephone survey of subjects between the ages of 55 and 84 years old (n = 1,506) suggested that sleep complaints in older adults are frequently secondary to comorbid medical conditions.16

Multiple anatomic structures, pathways, and neurotransmitter systems are involved in controlling wakefulness and sleep. Neurotransmitters that promote wakefulness include acetylcholine, histamine, noradrenaline (norepinephrine), serotonin, dopamine, and hypocretin (orexin). Sleep‐promoting neurotransmitters include gamma aminobutyric acid (GABA), adenosine, and melatonin. Specific stages of sleep are regulated by the turning on and off of various neurons. REM on cells use GABA, acetylcholine, and glutamine, whereas REM off cells use norepinephrine and serotonin. SWS is promoted by GABA and serotonin.17

Sleep regulation is a balance between a homeostatic sleep need and an intrinsic body clock, or circadian pacemaker. Located in the suprachiasmic nucleus, the circadian pacemaker determines the onset and termination of sleep, and is partially regulated by environmental cues such as light and ambient temperature. Melatonin, a physiologic sleep promoter, is inhibited by ambient light, and its circulation is decreased during daylight hours. The adrenal secretion of cortisol, which is associated with wakefulness, follows a circadian pattern. Regulated by the hypothalamic‐pituitary axis, cortisol levels peak in the early morning hours in preparation for the increased metabolic demands during wakefulness.

SLEEP PROBLEMS IN HOSPITALIZED PATIENTS

Insomnia, which is characterized by difficulty initiating or maintaining sleep, is the most common sleep disorder in the United States. About one‐third of the adult population in the United States experiences insomnia at some point in their lives,18 and it is a persistent problem in approximately 10% of U.S. adults.19 Insomnia can be exacerbated during hospitalization.

Studies investigating sleep in hospitalized patients using PSG have been limited primarily to the setting of the intensive care unit (ICU). Critically ill patients, particularly those requiring mechanical ventilation, are prone to sleep disturbances and an associated delirium.2022 Critically ill patients have fragmented sleep, with decreased SE and SWS, and increased S1 and S2.23 Physician awareness of the impact of sleep disturbance in hospitalized patients is vital. Surveys reveal that approximately one‐half of patients admitted on general medical wards complain of sleep disruption.24, 25 Meissner et al.25 examined the prevalence of sleep complaints and physician recognition of these complaints among general medical patients admitted to a Veterans Affairs tertiary care center. Results showed that 47% (n = 222) of patients had complaints of either insomnia and/or excessive daytime sleepiness.

FACTORS AFFECTING SLEEP DURING HOSPITALIZATION

Many medical and neurologic illnesses, psychiatric disorders, pain, medication therapy and the hospital environment may impair sleep, and hinder recovery from illness.

General Medical Disorders

Primary sleep disorders, such as obstructive sleep apnea (OSA) and numerous other medical illnesses, can directly impair sleep physiology, leading to a cyclical interaction (Figure 2). Other conditions that disrupt sleep include congestive heart failure (CHF), diabetes mellitus, chronic obstructive pulmonary disease (COPD), gastroesophageal reflux, cardiovascular disease, thyroid disorders, renal disease, and severe liver disease.26 Table 2 lists selected medical and neurological conditions, their associated sleep‐related problems, and suggestions on how to ameliorate these problems.

Figure 2
Cyclical interaction: sleep and common medical illnesses. Abbreviations: CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CRF, chronic renal failure; CVA, cerebrovascular accident (stroke); GER, gastroesophageal reflux; HTN, hypertension; OSA, obstructive sleep apnea; PLMD, periodic limb movement disorder; PND, paroxysmal nocturnal dyspnea; RLS, restless leg syndrome.
Selected Medical and Neurological Conditions Associated with Sleep Problems and Recommended Interventions
Disease Problem Clinical Implications and Strategies to Improve Sleep
  • Abbreviations: BiPAP, bilevel positive airway pressure; CHF, congestive heart failure; CNS, central nervous system; COPD, chronic obstructive pulmonary disease; CPAP, continuous positive airway pressure; GER, gastroesophageal reflux; O2, oxygen; OSA, obstructive sleep apnea; PLMD, periodic limb movement disorder; RLS, restless leg syndrome.

Asthma Nocturnal exacerbation, nocturnal GER Inhaled corticosteroids and/or long‐acting inhaled beta‐adrenergic agents
CHF Orthopnea, paroxysmal nocturnal dyspnea, sleep‐disordered breathing, increased sympathetic tone, nighttime diuresis, Cheyne‐Stokes respiration Keep the head of bed elevated 30 degrees. Nocturnal O2 to keep O2 saturation >88%. Daytime diuresis. Optimize cardiac function to treat Cheyne‐Stokes respiration. Consider CPAP for CHF
COPD Persistent nocturnal hypoxemia with complications (e.g., cor pulmonale, polycythemia) O2 for COPD and persistent hypoxemia (PaO2 55‐60 mm Hg)
Sporadic nighttime desaturations PaO2 55 mm Hg monitor O2 saturation by pulse oximetry. If patient desaturates to 88% at night consistently, start nocturnal O2. For hypercapnia, adjust O2 to maintain O2 saturation at 88% to 90%
Early‐morning airflow obstruction Consider bedtime tiotropium and inhaled long‐acting beta‐adrenergic agonist agents
Inhibition of respiratory muscles in REM Avoid sedative‐hypnotics that cause respiratory depression
Decreased functional residual capacity from recumbent position during sleep Minimize recumbancy by keeping the head of bed up at 30 degrees
End‐stage renal disease Pruritus, nausea; increased risk of RLS and PLMD Ambulation may help with RLS. Consider ropinirole and pramipexole. Correct hyperphosphatemia and uremia. Consider antipruritic and antiemetic agents
Nocturnal GER Nocturnal GER decreased sleep, heartburn, coughing, asthma Avoid eating or drinking 2 hours before bedtime, especially those that delay gastric emptying, increase acid secretion, or decrease lower esophageal sphincter pressure; e.g., high‐fat foods, ethanol, chocolate, peppers, peppermint. Keep head of bed 30 degrees. Minimize medications that could worsen nocturnal GER; e.g., theophylline, calcium channel blockers, prostaglandins, bisphosphonates
OSA Snoring with upper airway obstruction No ethanol 2 hours before bedtime. Minimize CNS depressants. Avoid supine position. Consider CPAP, oral mandibular advancement device, and/or surgical correction. Long‐term plan should include weight loss
Stroke Focal neurologic deficits (e.g., dysphagia, weakness or paralysis) Keep head of bed 30 degrees. Regularly suction secretions. Post‐stroke patients have an increased risk of hypersomnia, insomnia, and/or OSA

Affecting approximately 24% of men and 9% of women in the United States, OSA is the most common primary sleep disorder,27, 28 and causes significant mental and physical morbidity. Risk factors for OSA include obesity, hypothyroidism‐induced muscle weakness, and structural abnormalities in the oropharynx region such as acromegaly, micrognathia, or retrognathia. OSA is characterized by episodes of complete or partial pharyngeal obstruction during sleep that cause snoring, apneic episodes, choking, dyspnea, and restlessness.28 These episodes are associated with intermittent nocturnal sympathetic activation leading to nocturnal awakenings and cortical arousals, all of which lead to daytime symptoms of fatigue, sleepiness, and cognitive impairment (Figure 2). In addition, chronic sympathetic activation causes numerous derangements in the vascular endothelium and platelet activation.29, 30 Sleep‐disordered breathing has been independently associated with cardiovascular diseases such as hypertension, CHF, ischemic heart disease, atrial fibrillation, and cerebrovascular disease.31, 32

OSA is also associated with sleep‐related gastroesophageal reflux, which is characterized by pain and nocturnal cough, and can induce nocturnal asthma attacks and laryngospasm.33 Green et al.29 found that OSA patients treated with continuous positive airway pressure (CPAP) had a 48% improvement in nocturnal reflux symptoms. Although the pathophysiology connecting OSA to the renal system is unknown, OSA has been found in up to 60% of patients with end‐stage renal disease and chronic renal failure.34

Patients with pulmonary disorders can be profoundly affected by the normal physiologic changes during sleep, particularly in REM sleep. During REM sleep, all respiratory muscles except the diaphragm become paralyzed. Thus, episodes of marked oxygen desaturation can occur in patients who rely on their accessory muscles for respiration. COPD patients have decreased TST, SWS, and REM sleep. Shortness of breath, nocturnal cough, and wheezing worsen sleep.35 The resulting fatigue and sleep deprivation negatively impact the work of breathing and impair gas exchange. Airflow obstruction tends to worsen in the early morning hours in patients with COPD and asthma, and may be related to the effect of REM on the accessory muscles for respiration. Although used to target CO2 retention, investigations using bilevel positive airway pressure ventilators (BiPAP) for improving sleep in COPD patients have been limited. Noninvasive positive pressure ventilation (NPPV) appears to acutely improve SE and TST in patients with hypercapnic COPD without significantly improving gas exchange. Other sleep parameters such as sleep architecture and the number of arousals during the night, remain unchanged during NPPV.36

CPAP has several side effects that could worsen sleep, which may explain its poor adherence rate among ambulatory patients.37 Side effects include nasal bridge discomfort, nasal congestion, swallowing air, dry nose, dry or red eyes, noise, ear pain, and rhinitis.38 During hospitalization, efforts should be made to improve patient comfort by resizing ill‐fitting masks, adding heated humidification or nasal steroids to alleviate nasal congestion, or adding a chin strap to reduce air leak and ingestion of air.

Endocrine disorders have also been associated with sleep disruption. Studies suggest that patients with diabetes mellitus have decreased TST and impaired sleep quality due to nocturia and neuropathic pain.39 Inadequate sleep may also affect glucose control. Inadequate quality or quantity of sleep has been shown to be a risk factor for developing Type 2 diabetes mellitus in large prospective studies.40 Sleep duration and quality were significant predictors of increased levels of glycosylated hemoglobin (HbA1c) in patients with Type 2 diabetes mellitus. Thyroid diseases often coexist with diabetes mellitus. Both hypo‐ and hyperthyroidism have been associated with sleep disruption. Hypothyroidism is associated with daytime somnolence and fatigue. Patients with hypothyroidism tend to have reduced SWS. Hyperthyroid patients often complain of insomnia, which has been attributed to a hypermetabolic state.

Approximately 50% of patients with chronic end‐stage renal disease (ESRD) have insomnia and other sleep disorders.41 Patients often complain of restless leg syndrome (RLS), periodic limb movement disorder (PLMD), bone pain, nausea, and pruritus. The etiology of sleep disorders appears to be related to metabolic derangements associated with ESRD or from coexisting diabetes mellitus.

RLS and PLMD are distinct problems that affect sleep differently. RLS is characterized by an unpleasant crampy, creeping or crawling sensation in the lower extremities that is relieved by movement of the legs.42 RLS symptoms typically occur soon after going to bed, and therefore tend to disrupt sleep onset. The requisite bed rest during hospitalization can worsen RLS, further exacerbating sleep problems.43 Since RLS may partially be caused by disrupted iron metabolism, serum ferritin levels should be evaluated.44 Other conditions associated with RLS include pregnancy, rheumatoid arthritis, fibromyalgia, multiple sclerosis, ESRD, and Parkinson's disease. The differential diagnosis for RLS and PLMD includes neuroleptic‐induced akathisia, peripheral neuropathy, and positional or nocturnal leg cramps. PLMD occurs in about 80% of those with RLS, and is characterized by involuntary limb movements that occur every 20 to 40 seconds during NREM sleep. Unaware of these movements, patients often experience frequent arousals throughout the night, and complain of daytime somnolence and fatigue.42

A pilot study of 35 patients with minimal hepatic encephalopathy found that nearly 50% complained of sleep difficulties.45 Hypothesizing that a dysregulation of histaminergic neurotransmission in cirrhosis alters the sleep‐wake cycle, Spahr et al.46 found that 40% of their patients reported subjective improvement in sleep when administered 25 mg of hydroxyzine, compared to none who received placebo.

Neurologic Disorders

Since the brain and its various neurotransmitter systems are critical in regulating sleep and wakefulness, patients with neurologic disorders have an increased risk of developing sleep disorders. Patients with dementia, other neurodegenerative disorders, epilepsy, and traumatic brain injury (TBI) have a higher prevalence of sleep disturbance and sleep disorders.47 Poststroke patients can develop insomnia or hypersomnia, a reduction in sleep latency, increased sleep, or excessive daytime sleepiness, and are at higher risk for OSA during the first several months after a stroke.48 Specific neurologic lesions may lead to uncommon problems such as inversion of the sleep‐wake cycle, parasomnias, and hallucinatory dream‐like states.

Both Parkinson's disease and Alzheimer's disease are associated with multiple sleep disturbances, which tend to worsen with disease progression.14 Common problems include increased sleep fragmentation and wakefulness, with increases of stage 1 sleep and reductions of SWS and REM. Patients with neurodegenerative disorders also have an increased risk of REM sleep behavior disorder, or RBD.49 RBD is characterized by vivid and unusual dreams, and physically vigorous sleep behaviors that may result in ecchymoses, lacerations, and fractures.50 Fifty percent of patients with TBI reported insomnia symptoms.51 Disorders in initiating and maintaining sleep were the most common complaints among hospitalized patients with TBI. Some patients with TBI may develop circadian rhythm disturbances.52

Pain

A majority of patients with chronic pain, 50% to 70%, complain of impaired sleep.53 Sleep disruption is so common in fibromyalgia (75%) that it is considered to be a key diagnostic symptom.54 In a study investigating the affect of pain on sleep in burn patients, pain was associated with increased intermittent awakenings and prolonged periods of wake time during the night.55 The following day, these patients had poorer pain tolerance and greater pain intensity. Pain causes sleep fragmentation by increasing cortical arousals. Recent evidence suggests that sleep deprivation can increase pain sensitivity by inhibiting opioid protein synthesis or reducing opioid receptor affinity.56

Psychiatric Disorders

Sleep problems are so common in psychiatric conditions that the Diagnostic and Statistical Manual of Mental Disorders (DMS‐IV‐TR) includes sleep disturbance as a diagnostic criterion for a manic episode, and for various depressive, anxiety, and substance abuse disorders.57 The presence of sleep disturbance in hospitalized patients may suggest the presence of an underlying psychiatric disorder that would otherwise go unrecognized. In a survey of 200 general medical patients in a Brazilian hospital, Rocha et al.58 found that 112 (56.5%) complained of insomnia, and 100 (50%) met criteria for at least 1 psychiatric disorder. However, only 3 out of the total number of 200 surveyed (1.5%) were identified as having psychiatric diagnoses in the medical record, and sleep history was not noted in the clinical evaluation. An episode of major depressive disorder was the most common psychiatric diagnosis (35%). In this study, hospitalized patients with insomnia had a 3.6 times higher risk of having major depressive disorder than inpatients without insomnia.

Insomnia has a profound effect on mental health by worsening health‐related quality of life. In a study of outpatients at family medicine, internal medicine, endocrinology, cardiology, and psychiatry clinics in 3 U.S. cities (n = 3,445), insomnia worsened health‐related quality of life nearly as much as CHF or major depressive disorder did.59 Another survey of outpatients found that those with chronic insomnia were nearly 40 times more likely to have major depression and 6 times more likely to have an anxiety disorder compared to those without insomnia.60 Longitudinal studies have found that prior insomnia was associated with 2‐ to 5‐fold increase in the odds of mood and anxiety disorders and suicide.61, 62 Examining prodromes and precursors to mental disorders, Eaton et al.63 found that 47% of those with onset of depression at the 1‐year follow‐up had sleep problems at baseline.

An estimated 65% of patients with major depression have difficulty falling asleep, frequent awakenings, or early morning awakenings.64 Three patterns of sleep architecture abnormalities have been observed in patients with major depression: 1) sleep continuity disturbances characterized by prolonged sleep‐onset, increased wake time during sleep, increased early morning wake time, and decreased TST; 2) decreased proportion and length of SWS; and 3) REM sleep abnormalities such as reduced time to REM sleep, prolonged first REM sleep episode, and increased REM sleep percentage.65 Sleep during a manic episode has been less studied than in depression, but the data suggest that abnormal sleep in mania includes disrupted sleep continuity, shortened REM latency, and increased REM density (REM eye movement activity/total REM sleep time).65

Substance use disorders are also associated with sleep problems. In a survey by Brower et al.66 of patients who were undergoing alcohol rehabilitation, 61% (n = 172) had symptoms of insomnia such as increased sleep latency during the 6 months prior to entering treatment. Approximately 45% of these patients reported using alcohol for the purpose of initiating sleep. Alcohol and illicit substance intoxication and withdrawal are known to be associated with disrupted sleep. However, sleep disturbances may persist long after withdrawal symptoms have abated. Drummond et al. found that some patients continued to have alcohol‐associated sleep problems even after 27 months of abstinence.67 Evidence also suggests that untreated insomnia and other sleep problems may increase the risk of developing substance abuse problems due to self‐medicating with alcohol and other substances to help with sleep.68

Drugs that Affect Sleep

Numerous drugs can alter sleep quantity and quality. Sedatives and opioids may initially help with sleep onset, but impair sleep architecture. Medications used to treat medical and psychiatric illnesses also disrupt sleep (Table 3). The most common agents that impair sleep include antiepileptic drugs, selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, antihypertensives, antihistamines, and corticosteroids.

Drugs that Affect Sleep, Mechanisms, and Clinical Implications
Drug Class Examples of Drugs Affect on Sleep Architecture Potential Mechanism Clinical Implications
  • Abbreviations: 5HT, serotonin, serotonergic; AED, antiepileptic drugs; BzRAs, benzodiazepines; CNS, central nervous system; DOPA, dopamine; GABA, gamma‐aminobutyric acid; GER, gastroesophageal reflux; H2, histamine2‐receptor; HCTZ, hydrochlorothiazide; MAOIs, monoamine oxidase inhibitors; NE, norepinephrine; NSAIDs, nonsteroidal anti‐inflammatory drugs; REM, rapid eye movement; SE, sleep efficiency; SNRI, serotonin norepinephrine reuptake inhibitor; SSRIs, selective serotonin reuptake inhibitors; SWS, slow‐wave sleep (stage 3 and 4, or deep sleep); TCA, tricyclic and tetracyclic antidepressants; TST, total sleep time; TWT, total wake time; , leads to or causes; , decrease or reduce; , increase.

CNS
AEDs Phenobarbital, carbamazepine, phenytoin Very sedating. AEDs tend to TST, sleep latency Inhibit neuronal calcium influx, adenosine, or 5HT activity Sedation is dose‐dependent, and tends to occur with acute use
TCAs Amoxapine, amitriptyline, imipramine, nortriptyline, desipramine, doxepin, clomipramine Very sedating. Suppresses REM sleep, TST, stage‐2 sleep Stimulate antimuscarinic‐receptor and alpha1‐receptor Suppressed REM sleep motor inhibition restlessness, psychomotor agitation during sleep subjectively sleep quality, daytime sleepiness
BzRAs Alprazolam, lorazepam, chlordiazepoxide, diazepam, oxazepam Very sedating. TST, sleep latency, SWS duration, REM, stage‐2 sleep Stimulate GABA type A receptor Minimize daytime use. Chronic BzRAs SWS long‐term sequelae unknown
MAOIs Phenylzine, tranylcypromine Very sedating. TST, REM, REM rebound if stop MAOIs Mechanism unknown Daytime sleepiness; dosing time does not affect daytime somnolence
SSRIs Sedating: paroxetine, fluvoxamine. Activating: fluoxetine, sertraline, citalopram TST, are less sedating than TCAs and MAOIs. May REM, TWT, TST, SE 5HT activity Some patients get the opposite reaction
SNRI Venlafaxine, duloxetine Activating in some patients; sedating in 12% to 31%. TST 5HT and NE activity If activating, switch to AM dosing. If sedating, switch to PM dosing
Mood stabilizer Lithium Sedating. TST, SWS, REM, REM latency daytime sedation. Dose at night
Stimulants Ephedrine, pseudoephedrine, modafinil Activating. TST, SWS, sleep latency DOPA, NE, and 5HT activity Avoid after 6 PM
Anti‐Parkinson Bromocriptine, levodopa Sedating. Nightmares, SWS DOPA Dose at night, if possible
Cardiac
Lipophilic beta‐blockers Propranolol, pindolol, metoprolol, timolol. Hydrophilic agents (atenolol and sotalol) lack these effects Activating. awakenings, TWT, REM, nightmares CNS beta‐blockade Lipophilic beta‐blockers daytime sleep when dosed in AM
CNS agents Norepinephrine, epinephrine Activating. REM, SWS Stimulate alpha1‐receptor Minimize use at night
Dopamine Activating. REM, SWS Stimulate dopamine2‐receptor and alpha1‐receptor Minimize use at night
Ca++ channel blockers Amlodipine, verapamil, nifedipine Exacerbate underlying medical condition Lower esophageal sphincter tone nocturnal GER sleep disturbance
Alpha2‐receptor agonist Clonidine Stage 1, REM, nightmares Stimulate alpha2‐receptor Alpha2‐agonists daytime sleep and sleepiness directly. Dose at night
Alpha1‐receptor blockers Doxazosin, prazosin, terazosin Inhibit alpha1‐receptor Alpha1‐receptor blockers daytime sleepiness
Diuretics HCTZ, furosemide Sedating. PM diuresis frequent awakenings
Other
Opioids Codeine, morphine Sedating. SWS, REM Stimulate mu‐receptor Minimize use at night
NSAIDs Ibuprofen, indomethcin, celecoxib TST, SE Inhibit prostaglandin synthesis Minimize use at night
Methylxanthine Theophylline Activating. stage 1, REM Causes less restful sleep
Antihistamines Diphenhydramine, promethazine Sedating H1 receptor blockade Minimize use at night
Corticosteroids Dexamethasone, prednisone Activating. REM, SWS, nightmares Melatonin secretion Can disrupt sleep, anxiety, induce mania or psychosis
H2 blockers Cimetidine, ranitidine, famotidine Sedating. TST H2 receptor blockade Sedating if >60 years old, renal impairment
Quinolone Ciprofloxacin, sparfloxacin, ofloxacin, grepafloxacin, levofloxacin Activating Stimulate GABA type A receptor Consider sleep agent after maximizing sleep hygiene. Linezolid rarely causes sleep disturbances

Lipophilic beta antagonists such as propranolol and timolol can increase total wake time, decrease REM sleep, and increase the incidence of nightmares and insomnia.69 Anabolic steroids and beta‐agonist bronchodilator therapy can cause severe anxiety, sleeplessness, and even psychosis. Vasopressor agents such as dopamine can cause cortical activation, leading to increased arousal and reduced SWS.

Hospital Environment

Environmental noise and patient care activities often interfere with sleep in the hospital. They account for about 30% of patient awakenings in ICU patients.70 Noise levels in the ICU have average sound peaks of 150 to 200 dB, and evening peaks >80 dB between midnight and 6 AM.71 By comparison, the front row seats at a rock concert have sound levels of 110 dB. The high noise level in hospitals has long been implicated as a sleep disruptor,72 but studies in the past decade have found that patient care activities probably contribute more to awakenings than does environmental noise.73 An analysis of critical care nursing routines found that activities such as taking vital signs and giving baths occurred a mean 42.6 times a night per patient.74 Tamburri et al.74 found that patients experienced 2 to 3 hours without interruption on only 6% of the 147 nights studied. Routine daily baths were provided on 55 of the 147 study nights between 2 AM and 5 AM, which is unlikely to be an opportune time for most patients.

CONCLUSION

Hospitalization often prevents patients from achieving adequate sleep and can affect recovery from illness. Understanding the major factors that impair sleep during hospitalization allows clinicians to systemically evaluate and treat sleep problems. More than just prescribing sedative/hypnotic agents, the treatment for sleep disruption includes addressing multiple medical, behavioral, and environmental factors, which will be discussed in Part 2 of this article.

References
  1. NIH State‐of‐the Science Conference Statement on Manifestations and Management of Chronic Insomnia in Adults.NIH Consens Sci Statements.2005;22(2):130.
  2. Gangwisch JE,Heymsfield SB,Boden‐Albala B, et al.Short sleep duration as a risk factor for hypertension: analyses of the first National Health and Nutrition Examination Survey.Hypertension.2006;47(5):833839.
  3. Ogawa Y,Kanbayashi T,Saito Y, et al.Total sleep deprivation elevates blood pressure through arterial baroreflex resetting: a study with microneurographic technique.Sleep.2003;26(8):986989.
  4. Fabbri M,Martoni M,Esposito MJ,Gianni B,Natale V.Postural control after a night without sleep.Neuropsychologia.2006;44(12):25202525.
  5. Schiffman PL.Sleep deprivation decreases ventilatory responses to CO2 but not load compensation.Chest.1983;84(6):695698.
  6. Zhong X,Hilton HJ,Gates GJ, et al.Increased sympathetic and decreased parasympathetic cardiovascular modulation in normal humans with acute sleep deprivation.J Appl Physiol.2005;98(6):20242032.
  7. Everson CA.Reductions in circulating anabolic hormones induced by sustained sleep deprivation in rats.Am J Physiol Endocrinol Metab.2004;286(6):E1060E1070.
  8. Knutson KL,Spiegel K,Penev P,Van Cauter E.The metabolic consequences of sleep deprivation.Sleep Med Rev.2007;11(3):163178.
  9. Irwin MR,Wang M,Campomayor CO,Collado‐Hidalgo A,Cole S.Sleep deprivation and activation of morning levels of cellular and genomic markers of inflammation.Arch Int Med.2006;166:17561752.
  10. Hui L,Hua F,Diandong H,Hong Y.Effects of sleep and sleep deprivation on immunoglobulins and complement in humans.Brain Behav Immun.2007;21:308310.
  11. Kahn‐Green ET,Killgore DB,Kamimori GH,Balkin TJ,Killgore WDS.The effects of sleep deprivation on symptoms of psychopathology in healthy adults.Sleep Med.2007;8:215221.
  12. Carskadon MA,Dement WC.Normal human sleep. In:Kryger MH,Roth T,Dement WC, editors.Principles and Practice of Sleep Medicine.3rd ed.Philadelphia:W.B. Saunders;2000:1516.
  13. Richardson G.Update on the Science, Diagnosis and Management of Insomnia.International Congress and Symposium Series 262.London:Royal Society of Medicine Press Ltd;2006.
  14. Redline S,Kirchner HL,Quan SF,Gottlieb DJ,Kapur V,Newman A.The effects of age, sex, ethnicity, and sleep‐disordered breathing on sleep architecture.Arch Intern Med.2004;164:40618.
  15. Cole C,Richards K.Sleep disruption in older adults.Am J Nurs.2007;107(5):4049.
  16. Foley D,Ancoli‐Israel S,Britz P,Walsh J.Sleep disturbances and chronic disease in older adults: results of the 2003 National Sleep Foundation Sleep in America Survey.J Psychosom Res.2004;56(5):497502.
  17. Hoyt BD.Sleep in patients with neurologic and psychiatric disorders.Prim Care.2005;32:535548.
  18. Mellinger GD,Balter MB,Uhlenhuth EH.Insomnia and its treatment: prevalence and correlates.Arch Gen Psychiatry.1985;42(3):225232.
  19. Ford DE,Kamerow DB.Epidemiologic study of sleep disturbances and psychiatric disorders: an opportunity for prevention?JAMA.1989;262:14791484.
  20. Cooper AB,Thornley KS,Young GB,Slutsky AS,Stewart TE,Hanly PJ.Sleep in critically ill patients requiring mechanical ventilation.Chest.2000;117:809818.
  21. Pandharipande P,Ely EW.Sedative and analgesic medications: risk factors for delirium and sleep disturbances in the critically ill.Crit Care Med.2006;22:313327.
  22. Friese RS,Diaz‐Arrastia R,McBride D,Frankel H,Gentilello LM.Quantity and quality of sleep in the surgical intensive care unit: are our patients sleeping?J Trauma.2007;63:12101214.
  23. BaHamman A.Sleep in acute care units.Sleep Breath.2006;10:615.
  24. Frighetto L,Marra C,Bandali S,Wilbur K,Naumann T,Jewesson P.An assessment of quality of sleep and the use of drugs with sedating properties in hospitalized adult patients.Health Qual Life Outcomes.2004;2:17.
  25. Meissner HH,Riemer A,Santiago SM,Stein M,Goldman MD,Williams AJ.Failure of physician documentation of sleep complaints in hospitalized patients.West J Med.1998;169:146149.
  26. Ballard RD.Sleep and medical disorders.Prim Care.2005;35:511533.
  27. Young T,Palta M,Dempsey J,Skatrud J,Weber S,Badr S.The occurrence of sleep‐disordered breathing among middle‐aged adults.N Engl J Med.1993;328:12301235.
  28. Bassiri AG,Guilleminault .Clinical features and evaluation of obstructive sleep apnea‐hypopnea syndrome. In:Kryger MH,Roth T,Dement WC, editors.Principles and Practice of Sleep Medicine.3rd ed.Philadelphia:W.B. Saunders;2000:869872.
  29. Green BT,Broughton WA,O'Connor JB.Marked improvement in nocturnal gastroesophageal reflux in a large cohort of patients with obstructive sleep apnea.Arch Intern Med.2003;163:4145.
  30. Berry RB,Harding SM.Sleep and medical disorders.Med Clin North Am.2004;88:679703.
  31. Wattanakit K,Boland L,Punjabi NM,Shahar E.Relation of sleep‐disordered breathing to carotid plaque and intima‐media thickness.Atherosclerosis.2008;197(1):125131.
  32. Shahar E,Whitney CW,Redline S, et al.Sleep‐disordered breathing and cardiovascular disease: cross‐sectional results of the Sleep Heart Health Study.Am J Respir Crit Care Med.2001;163:1925.
  33. Harding SM.Gastroesophageal reflux during sleep.Sleep Med Clin.2007;2:4150.
  34. Krause MA,Hamburger RJ.Sleep apnea in renal failure.Adv Perit Dial.1997;13:8892.
  35. Mohsenin V.Sleep in chronic obstructive pulmonary disease.Sleep Med Clin.2007;2:18.
  36. Krachman SL,Quaranta AJ,Berger TJ,Criner GJ.Effects of non‐invasive positive pressure ventilation on gas exchange and sleep in COPD patients.Chest.1997;112:623628.
  37. Weaver TE,Kribbs NB,Pack AI, et al.Night‐to‐night variability in CPAP use over the first three months of treatment.Sleep.1997;20(4):278283.
  38. Engleman HM,Wild MR.Improving CPAP use by patients with the sleep apnoea/hypopnoea syndrome (SAHS).Sleep Med Rev.2003;7(1):8199.
  39. Lamond N,Tiggermann M,Dawson D.Factors predicting sleep disruption in type II diabetes.Sleep.2000;23:415416.
  40. Yaggi Hk,Araujo AB,McKinlay JB.Sleep duration as a risk factor for the development of type 2 diabetes.Diabetes Care.2006;29:657661.
  41. Hanly P.Sleep disorders and end‐stage renal disease.Sleep Med Clin.2007;2:5966.
  42. Wolkove N,Elkholy O,Batzan M,Palayew M.Sleep and aging: 1. Sleep disorders commonly found in older people.CMAJ.2007;176(9):12991304.
  43. Hening W,Walters AS,Allen RP,Montplaisir J,Myers A,Ferini‐Strambi L.Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: The REST (RLS Epidemiology, Symptoms, and Treatment) primary care study.Sleep Med.2004;5(3):237246.
  44. Succoni M,Ferini‐Strambi L.Epidemiology and clinical findings of restless leg syndrome.Sleep Med.2004;5(3):293299.
  45. Cordoba J,Cabrera J,Lataif L,Peney P,Zee P,Blei AT.High prevalence of sleep disturbance in cirrhosis.Hepatology.1998;27:339345.
  46. Spahr L,Coeytaux A,Giostra E,Hadengue A,Annoni J‐M.Histamine H1 blocker hydroxyzine improves sleep in patients with cirrhosis and minimal hepatic encephalopathy: a randomized controlled pilot trial.Am J Gastroenterol.2007;102:744753.
  47. Hoyt BD.Sleep in patients with neurologic and psychiatric disorders.Prim Care.2005;32:535548.
  48. Shamsuzzaman AS,Gersh BJ,Somers VK.Obstructive sleep apnea: implications for cardiac and vascular disease.JAMA.2003;290(14):19061914.
  49. Boeve BF,Silber MH,Saper CB, et al.Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease.Brain.2007;130(Pt 11):27702788.
  50. Mahowald MW,Schenck CH.REM sleep parasomnias. In:Kryger MH,Roth T,Dement WC, editors.Principles and Practice of Sleep Medicine.3rd ed.Philadelphia:W.B. Saunders;2000:724725.
  51. Ouellet M‐C,Beaulieu‐Bonneau S,Morin CM.Insomnia in patients with traumatic brain injury.J Head Trauma Rehabil.2006;21(3):199212.
  52. Ayalon L,Borodkkin K,Dishon L,Kanety H,Dagan Y.Circadian rhythm sleep disorders following mild traumatic brain injury.Neurology.2007;68(14):11361140.
  53. Barczi SR,Juergens TM.Comorbidities: psychiatric, medical, medications, and substances.Sleep Med Clin.2006;231245.
  54. Lineberger MD,Means JK,Edinger JD.Sleep disturbance and fibromyalgia.Sleep Med Clin.2007;2:3139.
  55. Raymond I,Ancoli‐Israel S,Choiniere M.Sleep disturbances, pain and analgesia in adults hospitalized for burn injuries.Sleep Med.2004;5:551559.
  56. Lautenbader S,Kundermann B,Krieg J‐C.Sleep deprivation and pain perception.Sleep Med Rev.2006;10:357369.
  57. American Psychiatric Association.Diagnostic and Statistical Manual of Mental Disorders.4th ed. Text Revision.Washington, DC:American Psychiatric Association;2000.
  58. Rocha FL,Hara C,Rodriguez CV, et al.Is insomnia a marker for psychiatric disorders in general hospitals?Sleep Med.2005;6:549553.
  59. Katz DA,McHorney CA.The relationship between insomnia and health‐related quality of life in patients with chronic illness.J Fam Pract.2002;51(3):229235.
  60. Ford DE,Kamerow DB.Epidemiologic study of sleep disturbances and psychiatric disorders: an opportunity for prevention?JAMA.1989;262:14791484.
  61. Breslau N,Roth T,Rosenthal L,Andreski P.Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults.Biol Psychiatry.1996;39:411418.
  62. Weissman MM,Greenwald S,Nino‐Murcia G,Dement WC.The morbidity of insomnia uncomplicated by psychiatric disorders.Gen Hosp Psychiatry.1997;19:245250.
  63. Eaton WW,Badawi M,Melton B.Prodromes and precursors: epidemiologic data for primary prevention of disorders with slow onset.Am J Psychiatry.1995;152:967972.
  64. Perlis ML,Giles DE,Buysse DJ,Thase ME,Tu X,Kupfer DJ.Which depressive symptoms are related to which sleep electroencephalographic variables?Biol Psychol.1997;42:904913.
  65. Peterson MJ,Benca RM.Sleep in mood disorders.Psychiatr Clin North Am.2006;29:10091032.
  66. Brower KJ,Aldrich MS,Robinson EAR,Zucker RA,Greden JF.Insomnia, self‐medication, and relapse to alcoholism.Am J Psychiatry.2001;158:399404.
  67. Drummond SPA,Gillin JC,Smith TL,DeModena A.The sleep of abstinent pure primary alcoholic patients: natural course and relationship to relapse.Alcohol Clin Exp Res.1998;22:17961802.
  68. Teplin D,Raz B,Daiter J,Varenbut M,Tyrrell M.Screening for substance use patterns among patients referred for a variety of sleep complaints.Am J Drug Alcohol Abuse.2006;32:111120.
  69. Schweitzer PK.Drugs that disturb sleep and wakefulness. In:Kryger MH,Roth T,Dement WC, editors.Principles and Practice of Sleep Medicine.3rd ed.Philadelphia:W.B. Saunders;2000:441462.
  70. Gabor JY,Cooper AB,Crombach SA, et al.Contribution of the intensive care unit environment to sleep disruption in mechanically ventilated patients and healthy subjects.Am J Respir Crit Care Med.2003;167(5):708715.
  71. Meyer T,Eveloff S,Bauer M.Adverse environmental conditions in the respiratory and medical ICU settings.Chest.1994;105:12111216.
  72. Busch‐Vishniac IJ,West JE,Barnhill C,Hunter T,Orellana D,Chivukula R.Noise levels in Johns Hopkins Hospital.J Acoust Soc Am.2005;118(6):36293645.
  73. Freedman NS,Kotzer N,Schwab RJ.Patient perception of sleep quality and etiology of sleep disruption in the intensive care unit.Am J Respir Crit Care Med.1999;159:11551162.
  74. Tamburri LM,di Brienza R,Zozula R,Redeker NS.Nocturnal care interactions with patients in critical care units.Am J Crit Care.2004;13(2):102115.
Article PDF
Issue
Journal of Hospital Medicine - 3(6)
Page Number
473-482
Legacy Keywords
acute illness, comorbid insomnia, hospitalized medical patient, insomnia, sleep deprivation
Sections
Article PDF
Article PDF

Hospitalized patients often have difficulty initiating and maintaining sleep, or complain of early awakening and nonrestorative sleep.1 The etiology of sleep disruption is multifactorial and includes the patient's underlying illness(es), medical treatments, and the hospital environment. Often unrecognized and untreated during hospitalization, sleep disruption may lead to sleep deprivation, or a chronic lack of restorative sleep.

Even in healthy individuals, sleep deprivation can result in numerous physical and psychological consequences. Sleep deprivation is associated with hypertension,2, 3 impaired postural control,4 decreased ventilatory drive,5 increased sympathetic cardiovascular activation,6 blunted hypothalamic‐pituitary‐adrenal axis,7 impaired host defenses, and possibly diabetes mellitus and obesity.810 The lack of restorative sleep increases the risk of developing anxiety and mood disorders and delirium, especially in acutely ill older patients.11 In the presence of acute physical infirmity, inadequate sleep may further compound illness and impair recovery. We provide an overview of normal sleep architecture and discuss factors that lead to sleep disruption in hospitalized medical patients.

NORMAL SLEEP ARCHITECTURE AND REGULATION

Normal sleep architecture refers to a characteristic pattern of sleep, and consists of two major stages: nonrapid eye movement (NREM, pronounced non‐rem) and rapid eye movement (REM). (For a table of pertinent abbreviations and terms, see Table 1) Sleep is quantified by polysomnography (PSG), which includes an electroencephalogram (EEG), electromyogram (EMG), and electrooculogram (EOG). A PSG also includes an electrocardiogram (ECG), and measures of airflow, oxygen saturation, and body position. NREM sleep comprises 75% to 80% of total sleep time (TST), and is characterized by relatively quiescent brain activity and decreased metabolic rate.12 NREM sleep consists of four stages (S1‐S4), with each stage leading to a progressively deeper sleep (Figure 1). REM sleep follows slow wave sleep (SWS), or deep sleep, and increases over the night, comprising 20% to 25% of TST. REM sleep is characterized by an activated EEG pattern, muscle atonia, and episodic bursts of rapid eye movements.

Figure 1
Normal sleep architecture includes cycles of 2 main stages, non‐REM and REM sleep, as depicted in this hypnogram.
Pertinent Abbreviations and Terms
Acronym Term
BiPAP Bilevel positive airway pressure
CHF Congestive heart failure
CPAP Continuous positive airway pressure
COPD Chronic obstructive pulmonary disease
EEG Electroencephalogram
EOG Electroculogram
EMG Electromyogram
ESRD End‐stage renal disease
NPPV Noninvasive positive pressure ventilation
NREM Nonrapid eye movement
OSA Obstructive sleep apnea
PLMD Periodic limb movement disorder
PSG Polysomnography
RBD REM sleep behavior disorder
REM Rapid eye movement
RLS Restless leg syndrome
S1‐S4 4 Stages of sleep in NREM
SE Sleep efficiency; TST divided by total time in bed
SWS Slow wave sleep
TBI Traumatic brain injury
TST Total sleep time

Normal sleep provides a period of physiologic and mental rest. During sleep, sympathetic tone decreases and parasympathetic tone increases, leading to a reduction in heart rate, arterial blood pressure, and cardiac output.13 Deep sleep is theorized to be necessary for physiologic restoration. REM sleep is associated with dreaming, and is essential for maintaining emotional and cognitive well‐being. Sleep architecture undergoes characteristic changes as people age.14 The duration of SWS peaks in childhood and decreases with age. Consequently, people >60 years old tend to have lower arousal thresholds and to have more frequent awakenings. The results of the Sleep Heart Health Study found that increased age was associated with decreased percentage of REM sleep, worse sleep efficiency (SE, which is TST divided by total time in bed), and lower arousal thresholds.14 With the reduction of SE, older people need to spend more hours in bed to achieve the same amount of restorative sleep as when they were younger. Although sleep tends to become more disrupted as people age, insomnia should not be considered a normal part of aging, and needs to be addressed clinically.15 The results of a National Sleep Foundation telephone survey of subjects between the ages of 55 and 84 years old (n = 1,506) suggested that sleep complaints in older adults are frequently secondary to comorbid medical conditions.16

Multiple anatomic structures, pathways, and neurotransmitter systems are involved in controlling wakefulness and sleep. Neurotransmitters that promote wakefulness include acetylcholine, histamine, noradrenaline (norepinephrine), serotonin, dopamine, and hypocretin (orexin). Sleep‐promoting neurotransmitters include gamma aminobutyric acid (GABA), adenosine, and melatonin. Specific stages of sleep are regulated by the turning on and off of various neurons. REM on cells use GABA, acetylcholine, and glutamine, whereas REM off cells use norepinephrine and serotonin. SWS is promoted by GABA and serotonin.17

Sleep regulation is a balance between a homeostatic sleep need and an intrinsic body clock, or circadian pacemaker. Located in the suprachiasmic nucleus, the circadian pacemaker determines the onset and termination of sleep, and is partially regulated by environmental cues such as light and ambient temperature. Melatonin, a physiologic sleep promoter, is inhibited by ambient light, and its circulation is decreased during daylight hours. The adrenal secretion of cortisol, which is associated with wakefulness, follows a circadian pattern. Regulated by the hypothalamic‐pituitary axis, cortisol levels peak in the early morning hours in preparation for the increased metabolic demands during wakefulness.

SLEEP PROBLEMS IN HOSPITALIZED PATIENTS

Insomnia, which is characterized by difficulty initiating or maintaining sleep, is the most common sleep disorder in the United States. About one‐third of the adult population in the United States experiences insomnia at some point in their lives,18 and it is a persistent problem in approximately 10% of U.S. adults.19 Insomnia can be exacerbated during hospitalization.

Studies investigating sleep in hospitalized patients using PSG have been limited primarily to the setting of the intensive care unit (ICU). Critically ill patients, particularly those requiring mechanical ventilation, are prone to sleep disturbances and an associated delirium.2022 Critically ill patients have fragmented sleep, with decreased SE and SWS, and increased S1 and S2.23 Physician awareness of the impact of sleep disturbance in hospitalized patients is vital. Surveys reveal that approximately one‐half of patients admitted on general medical wards complain of sleep disruption.24, 25 Meissner et al.25 examined the prevalence of sleep complaints and physician recognition of these complaints among general medical patients admitted to a Veterans Affairs tertiary care center. Results showed that 47% (n = 222) of patients had complaints of either insomnia and/or excessive daytime sleepiness.

FACTORS AFFECTING SLEEP DURING HOSPITALIZATION

Many medical and neurologic illnesses, psychiatric disorders, pain, medication therapy and the hospital environment may impair sleep, and hinder recovery from illness.

General Medical Disorders

Primary sleep disorders, such as obstructive sleep apnea (OSA) and numerous other medical illnesses, can directly impair sleep physiology, leading to a cyclical interaction (Figure 2). Other conditions that disrupt sleep include congestive heart failure (CHF), diabetes mellitus, chronic obstructive pulmonary disease (COPD), gastroesophageal reflux, cardiovascular disease, thyroid disorders, renal disease, and severe liver disease.26 Table 2 lists selected medical and neurological conditions, their associated sleep‐related problems, and suggestions on how to ameliorate these problems.

Figure 2
Cyclical interaction: sleep and common medical illnesses. Abbreviations: CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CRF, chronic renal failure; CVA, cerebrovascular accident (stroke); GER, gastroesophageal reflux; HTN, hypertension; OSA, obstructive sleep apnea; PLMD, periodic limb movement disorder; PND, paroxysmal nocturnal dyspnea; RLS, restless leg syndrome.
Selected Medical and Neurological Conditions Associated with Sleep Problems and Recommended Interventions
Disease Problem Clinical Implications and Strategies to Improve Sleep
  • Abbreviations: BiPAP, bilevel positive airway pressure; CHF, congestive heart failure; CNS, central nervous system; COPD, chronic obstructive pulmonary disease; CPAP, continuous positive airway pressure; GER, gastroesophageal reflux; O2, oxygen; OSA, obstructive sleep apnea; PLMD, periodic limb movement disorder; RLS, restless leg syndrome.

Asthma Nocturnal exacerbation, nocturnal GER Inhaled corticosteroids and/or long‐acting inhaled beta‐adrenergic agents
CHF Orthopnea, paroxysmal nocturnal dyspnea, sleep‐disordered breathing, increased sympathetic tone, nighttime diuresis, Cheyne‐Stokes respiration Keep the head of bed elevated 30 degrees. Nocturnal O2 to keep O2 saturation >88%. Daytime diuresis. Optimize cardiac function to treat Cheyne‐Stokes respiration. Consider CPAP for CHF
COPD Persistent nocturnal hypoxemia with complications (e.g., cor pulmonale, polycythemia) O2 for COPD and persistent hypoxemia (PaO2 55‐60 mm Hg)
Sporadic nighttime desaturations PaO2 55 mm Hg monitor O2 saturation by pulse oximetry. If patient desaturates to 88% at night consistently, start nocturnal O2. For hypercapnia, adjust O2 to maintain O2 saturation at 88% to 90%
Early‐morning airflow obstruction Consider bedtime tiotropium and inhaled long‐acting beta‐adrenergic agonist agents
Inhibition of respiratory muscles in REM Avoid sedative‐hypnotics that cause respiratory depression
Decreased functional residual capacity from recumbent position during sleep Minimize recumbancy by keeping the head of bed up at 30 degrees
End‐stage renal disease Pruritus, nausea; increased risk of RLS and PLMD Ambulation may help with RLS. Consider ropinirole and pramipexole. Correct hyperphosphatemia and uremia. Consider antipruritic and antiemetic agents
Nocturnal GER Nocturnal GER decreased sleep, heartburn, coughing, asthma Avoid eating or drinking 2 hours before bedtime, especially those that delay gastric emptying, increase acid secretion, or decrease lower esophageal sphincter pressure; e.g., high‐fat foods, ethanol, chocolate, peppers, peppermint. Keep head of bed 30 degrees. Minimize medications that could worsen nocturnal GER; e.g., theophylline, calcium channel blockers, prostaglandins, bisphosphonates
OSA Snoring with upper airway obstruction No ethanol 2 hours before bedtime. Minimize CNS depressants. Avoid supine position. Consider CPAP, oral mandibular advancement device, and/or surgical correction. Long‐term plan should include weight loss
Stroke Focal neurologic deficits (e.g., dysphagia, weakness or paralysis) Keep head of bed 30 degrees. Regularly suction secretions. Post‐stroke patients have an increased risk of hypersomnia, insomnia, and/or OSA

Affecting approximately 24% of men and 9% of women in the United States, OSA is the most common primary sleep disorder,27, 28 and causes significant mental and physical morbidity. Risk factors for OSA include obesity, hypothyroidism‐induced muscle weakness, and structural abnormalities in the oropharynx region such as acromegaly, micrognathia, or retrognathia. OSA is characterized by episodes of complete or partial pharyngeal obstruction during sleep that cause snoring, apneic episodes, choking, dyspnea, and restlessness.28 These episodes are associated with intermittent nocturnal sympathetic activation leading to nocturnal awakenings and cortical arousals, all of which lead to daytime symptoms of fatigue, sleepiness, and cognitive impairment (Figure 2). In addition, chronic sympathetic activation causes numerous derangements in the vascular endothelium and platelet activation.29, 30 Sleep‐disordered breathing has been independently associated with cardiovascular diseases such as hypertension, CHF, ischemic heart disease, atrial fibrillation, and cerebrovascular disease.31, 32

OSA is also associated with sleep‐related gastroesophageal reflux, which is characterized by pain and nocturnal cough, and can induce nocturnal asthma attacks and laryngospasm.33 Green et al.29 found that OSA patients treated with continuous positive airway pressure (CPAP) had a 48% improvement in nocturnal reflux symptoms. Although the pathophysiology connecting OSA to the renal system is unknown, OSA has been found in up to 60% of patients with end‐stage renal disease and chronic renal failure.34

Patients with pulmonary disorders can be profoundly affected by the normal physiologic changes during sleep, particularly in REM sleep. During REM sleep, all respiratory muscles except the diaphragm become paralyzed. Thus, episodes of marked oxygen desaturation can occur in patients who rely on their accessory muscles for respiration. COPD patients have decreased TST, SWS, and REM sleep. Shortness of breath, nocturnal cough, and wheezing worsen sleep.35 The resulting fatigue and sleep deprivation negatively impact the work of breathing and impair gas exchange. Airflow obstruction tends to worsen in the early morning hours in patients with COPD and asthma, and may be related to the effect of REM on the accessory muscles for respiration. Although used to target CO2 retention, investigations using bilevel positive airway pressure ventilators (BiPAP) for improving sleep in COPD patients have been limited. Noninvasive positive pressure ventilation (NPPV) appears to acutely improve SE and TST in patients with hypercapnic COPD without significantly improving gas exchange. Other sleep parameters such as sleep architecture and the number of arousals during the night, remain unchanged during NPPV.36

CPAP has several side effects that could worsen sleep, which may explain its poor adherence rate among ambulatory patients.37 Side effects include nasal bridge discomfort, nasal congestion, swallowing air, dry nose, dry or red eyes, noise, ear pain, and rhinitis.38 During hospitalization, efforts should be made to improve patient comfort by resizing ill‐fitting masks, adding heated humidification or nasal steroids to alleviate nasal congestion, or adding a chin strap to reduce air leak and ingestion of air.

Endocrine disorders have also been associated with sleep disruption. Studies suggest that patients with diabetes mellitus have decreased TST and impaired sleep quality due to nocturia and neuropathic pain.39 Inadequate sleep may also affect glucose control. Inadequate quality or quantity of sleep has been shown to be a risk factor for developing Type 2 diabetes mellitus in large prospective studies.40 Sleep duration and quality were significant predictors of increased levels of glycosylated hemoglobin (HbA1c) in patients with Type 2 diabetes mellitus. Thyroid diseases often coexist with diabetes mellitus. Both hypo‐ and hyperthyroidism have been associated with sleep disruption. Hypothyroidism is associated with daytime somnolence and fatigue. Patients with hypothyroidism tend to have reduced SWS. Hyperthyroid patients often complain of insomnia, which has been attributed to a hypermetabolic state.

Approximately 50% of patients with chronic end‐stage renal disease (ESRD) have insomnia and other sleep disorders.41 Patients often complain of restless leg syndrome (RLS), periodic limb movement disorder (PLMD), bone pain, nausea, and pruritus. The etiology of sleep disorders appears to be related to metabolic derangements associated with ESRD or from coexisting diabetes mellitus.

RLS and PLMD are distinct problems that affect sleep differently. RLS is characterized by an unpleasant crampy, creeping or crawling sensation in the lower extremities that is relieved by movement of the legs.42 RLS symptoms typically occur soon after going to bed, and therefore tend to disrupt sleep onset. The requisite bed rest during hospitalization can worsen RLS, further exacerbating sleep problems.43 Since RLS may partially be caused by disrupted iron metabolism, serum ferritin levels should be evaluated.44 Other conditions associated with RLS include pregnancy, rheumatoid arthritis, fibromyalgia, multiple sclerosis, ESRD, and Parkinson's disease. The differential diagnosis for RLS and PLMD includes neuroleptic‐induced akathisia, peripheral neuropathy, and positional or nocturnal leg cramps. PLMD occurs in about 80% of those with RLS, and is characterized by involuntary limb movements that occur every 20 to 40 seconds during NREM sleep. Unaware of these movements, patients often experience frequent arousals throughout the night, and complain of daytime somnolence and fatigue.42

A pilot study of 35 patients with minimal hepatic encephalopathy found that nearly 50% complained of sleep difficulties.45 Hypothesizing that a dysregulation of histaminergic neurotransmission in cirrhosis alters the sleep‐wake cycle, Spahr et al.46 found that 40% of their patients reported subjective improvement in sleep when administered 25 mg of hydroxyzine, compared to none who received placebo.

Neurologic Disorders

Since the brain and its various neurotransmitter systems are critical in regulating sleep and wakefulness, patients with neurologic disorders have an increased risk of developing sleep disorders. Patients with dementia, other neurodegenerative disorders, epilepsy, and traumatic brain injury (TBI) have a higher prevalence of sleep disturbance and sleep disorders.47 Poststroke patients can develop insomnia or hypersomnia, a reduction in sleep latency, increased sleep, or excessive daytime sleepiness, and are at higher risk for OSA during the first several months after a stroke.48 Specific neurologic lesions may lead to uncommon problems such as inversion of the sleep‐wake cycle, parasomnias, and hallucinatory dream‐like states.

Both Parkinson's disease and Alzheimer's disease are associated with multiple sleep disturbances, which tend to worsen with disease progression.14 Common problems include increased sleep fragmentation and wakefulness, with increases of stage 1 sleep and reductions of SWS and REM. Patients with neurodegenerative disorders also have an increased risk of REM sleep behavior disorder, or RBD.49 RBD is characterized by vivid and unusual dreams, and physically vigorous sleep behaviors that may result in ecchymoses, lacerations, and fractures.50 Fifty percent of patients with TBI reported insomnia symptoms.51 Disorders in initiating and maintaining sleep were the most common complaints among hospitalized patients with TBI. Some patients with TBI may develop circadian rhythm disturbances.52

Pain

A majority of patients with chronic pain, 50% to 70%, complain of impaired sleep.53 Sleep disruption is so common in fibromyalgia (75%) that it is considered to be a key diagnostic symptom.54 In a study investigating the affect of pain on sleep in burn patients, pain was associated with increased intermittent awakenings and prolonged periods of wake time during the night.55 The following day, these patients had poorer pain tolerance and greater pain intensity. Pain causes sleep fragmentation by increasing cortical arousals. Recent evidence suggests that sleep deprivation can increase pain sensitivity by inhibiting opioid protein synthesis or reducing opioid receptor affinity.56

Psychiatric Disorders

Sleep problems are so common in psychiatric conditions that the Diagnostic and Statistical Manual of Mental Disorders (DMS‐IV‐TR) includes sleep disturbance as a diagnostic criterion for a manic episode, and for various depressive, anxiety, and substance abuse disorders.57 The presence of sleep disturbance in hospitalized patients may suggest the presence of an underlying psychiatric disorder that would otherwise go unrecognized. In a survey of 200 general medical patients in a Brazilian hospital, Rocha et al.58 found that 112 (56.5%) complained of insomnia, and 100 (50%) met criteria for at least 1 psychiatric disorder. However, only 3 out of the total number of 200 surveyed (1.5%) were identified as having psychiatric diagnoses in the medical record, and sleep history was not noted in the clinical evaluation. An episode of major depressive disorder was the most common psychiatric diagnosis (35%). In this study, hospitalized patients with insomnia had a 3.6 times higher risk of having major depressive disorder than inpatients without insomnia.

Insomnia has a profound effect on mental health by worsening health‐related quality of life. In a study of outpatients at family medicine, internal medicine, endocrinology, cardiology, and psychiatry clinics in 3 U.S. cities (n = 3,445), insomnia worsened health‐related quality of life nearly as much as CHF or major depressive disorder did.59 Another survey of outpatients found that those with chronic insomnia were nearly 40 times more likely to have major depression and 6 times more likely to have an anxiety disorder compared to those without insomnia.60 Longitudinal studies have found that prior insomnia was associated with 2‐ to 5‐fold increase in the odds of mood and anxiety disorders and suicide.61, 62 Examining prodromes and precursors to mental disorders, Eaton et al.63 found that 47% of those with onset of depression at the 1‐year follow‐up had sleep problems at baseline.

An estimated 65% of patients with major depression have difficulty falling asleep, frequent awakenings, or early morning awakenings.64 Three patterns of sleep architecture abnormalities have been observed in patients with major depression: 1) sleep continuity disturbances characterized by prolonged sleep‐onset, increased wake time during sleep, increased early morning wake time, and decreased TST; 2) decreased proportion and length of SWS; and 3) REM sleep abnormalities such as reduced time to REM sleep, prolonged first REM sleep episode, and increased REM sleep percentage.65 Sleep during a manic episode has been less studied than in depression, but the data suggest that abnormal sleep in mania includes disrupted sleep continuity, shortened REM latency, and increased REM density (REM eye movement activity/total REM sleep time).65

Substance use disorders are also associated with sleep problems. In a survey by Brower et al.66 of patients who were undergoing alcohol rehabilitation, 61% (n = 172) had symptoms of insomnia such as increased sleep latency during the 6 months prior to entering treatment. Approximately 45% of these patients reported using alcohol for the purpose of initiating sleep. Alcohol and illicit substance intoxication and withdrawal are known to be associated with disrupted sleep. However, sleep disturbances may persist long after withdrawal symptoms have abated. Drummond et al. found that some patients continued to have alcohol‐associated sleep problems even after 27 months of abstinence.67 Evidence also suggests that untreated insomnia and other sleep problems may increase the risk of developing substance abuse problems due to self‐medicating with alcohol and other substances to help with sleep.68

Drugs that Affect Sleep

Numerous drugs can alter sleep quantity and quality. Sedatives and opioids may initially help with sleep onset, but impair sleep architecture. Medications used to treat medical and psychiatric illnesses also disrupt sleep (Table 3). The most common agents that impair sleep include antiepileptic drugs, selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, antihypertensives, antihistamines, and corticosteroids.

Drugs that Affect Sleep, Mechanisms, and Clinical Implications
Drug Class Examples of Drugs Affect on Sleep Architecture Potential Mechanism Clinical Implications
  • Abbreviations: 5HT, serotonin, serotonergic; AED, antiepileptic drugs; BzRAs, benzodiazepines; CNS, central nervous system; DOPA, dopamine; GABA, gamma‐aminobutyric acid; GER, gastroesophageal reflux; H2, histamine2‐receptor; HCTZ, hydrochlorothiazide; MAOIs, monoamine oxidase inhibitors; NE, norepinephrine; NSAIDs, nonsteroidal anti‐inflammatory drugs; REM, rapid eye movement; SE, sleep efficiency; SNRI, serotonin norepinephrine reuptake inhibitor; SSRIs, selective serotonin reuptake inhibitors; SWS, slow‐wave sleep (stage 3 and 4, or deep sleep); TCA, tricyclic and tetracyclic antidepressants; TST, total sleep time; TWT, total wake time; , leads to or causes; , decrease or reduce; , increase.

CNS
AEDs Phenobarbital, carbamazepine, phenytoin Very sedating. AEDs tend to TST, sleep latency Inhibit neuronal calcium influx, adenosine, or 5HT activity Sedation is dose‐dependent, and tends to occur with acute use
TCAs Amoxapine, amitriptyline, imipramine, nortriptyline, desipramine, doxepin, clomipramine Very sedating. Suppresses REM sleep, TST, stage‐2 sleep Stimulate antimuscarinic‐receptor and alpha1‐receptor Suppressed REM sleep motor inhibition restlessness, psychomotor agitation during sleep subjectively sleep quality, daytime sleepiness
BzRAs Alprazolam, lorazepam, chlordiazepoxide, diazepam, oxazepam Very sedating. TST, sleep latency, SWS duration, REM, stage‐2 sleep Stimulate GABA type A receptor Minimize daytime use. Chronic BzRAs SWS long‐term sequelae unknown
MAOIs Phenylzine, tranylcypromine Very sedating. TST, REM, REM rebound if stop MAOIs Mechanism unknown Daytime sleepiness; dosing time does not affect daytime somnolence
SSRIs Sedating: paroxetine, fluvoxamine. Activating: fluoxetine, sertraline, citalopram TST, are less sedating than TCAs and MAOIs. May REM, TWT, TST, SE 5HT activity Some patients get the opposite reaction
SNRI Venlafaxine, duloxetine Activating in some patients; sedating in 12% to 31%. TST 5HT and NE activity If activating, switch to AM dosing. If sedating, switch to PM dosing
Mood stabilizer Lithium Sedating. TST, SWS, REM, REM latency daytime sedation. Dose at night
Stimulants Ephedrine, pseudoephedrine, modafinil Activating. TST, SWS, sleep latency DOPA, NE, and 5HT activity Avoid after 6 PM
Anti‐Parkinson Bromocriptine, levodopa Sedating. Nightmares, SWS DOPA Dose at night, if possible
Cardiac
Lipophilic beta‐blockers Propranolol, pindolol, metoprolol, timolol. Hydrophilic agents (atenolol and sotalol) lack these effects Activating. awakenings, TWT, REM, nightmares CNS beta‐blockade Lipophilic beta‐blockers daytime sleep when dosed in AM
CNS agents Norepinephrine, epinephrine Activating. REM, SWS Stimulate alpha1‐receptor Minimize use at night
Dopamine Activating. REM, SWS Stimulate dopamine2‐receptor and alpha1‐receptor Minimize use at night
Ca++ channel blockers Amlodipine, verapamil, nifedipine Exacerbate underlying medical condition Lower esophageal sphincter tone nocturnal GER sleep disturbance
Alpha2‐receptor agonist Clonidine Stage 1, REM, nightmares Stimulate alpha2‐receptor Alpha2‐agonists daytime sleep and sleepiness directly. Dose at night
Alpha1‐receptor blockers Doxazosin, prazosin, terazosin Inhibit alpha1‐receptor Alpha1‐receptor blockers daytime sleepiness
Diuretics HCTZ, furosemide Sedating. PM diuresis frequent awakenings
Other
Opioids Codeine, morphine Sedating. SWS, REM Stimulate mu‐receptor Minimize use at night
NSAIDs Ibuprofen, indomethcin, celecoxib TST, SE Inhibit prostaglandin synthesis Minimize use at night
Methylxanthine Theophylline Activating. stage 1, REM Causes less restful sleep
Antihistamines Diphenhydramine, promethazine Sedating H1 receptor blockade Minimize use at night
Corticosteroids Dexamethasone, prednisone Activating. REM, SWS, nightmares Melatonin secretion Can disrupt sleep, anxiety, induce mania or psychosis
H2 blockers Cimetidine, ranitidine, famotidine Sedating. TST H2 receptor blockade Sedating if >60 years old, renal impairment
Quinolone Ciprofloxacin, sparfloxacin, ofloxacin, grepafloxacin, levofloxacin Activating Stimulate GABA type A receptor Consider sleep agent after maximizing sleep hygiene. Linezolid rarely causes sleep disturbances

Lipophilic beta antagonists such as propranolol and timolol can increase total wake time, decrease REM sleep, and increase the incidence of nightmares and insomnia.69 Anabolic steroids and beta‐agonist bronchodilator therapy can cause severe anxiety, sleeplessness, and even psychosis. Vasopressor agents such as dopamine can cause cortical activation, leading to increased arousal and reduced SWS.

Hospital Environment

Environmental noise and patient care activities often interfere with sleep in the hospital. They account for about 30% of patient awakenings in ICU patients.70 Noise levels in the ICU have average sound peaks of 150 to 200 dB, and evening peaks >80 dB between midnight and 6 AM.71 By comparison, the front row seats at a rock concert have sound levels of 110 dB. The high noise level in hospitals has long been implicated as a sleep disruptor,72 but studies in the past decade have found that patient care activities probably contribute more to awakenings than does environmental noise.73 An analysis of critical care nursing routines found that activities such as taking vital signs and giving baths occurred a mean 42.6 times a night per patient.74 Tamburri et al.74 found that patients experienced 2 to 3 hours without interruption on only 6% of the 147 nights studied. Routine daily baths were provided on 55 of the 147 study nights between 2 AM and 5 AM, which is unlikely to be an opportune time for most patients.

CONCLUSION

Hospitalization often prevents patients from achieving adequate sleep and can affect recovery from illness. Understanding the major factors that impair sleep during hospitalization allows clinicians to systemically evaluate and treat sleep problems. More than just prescribing sedative/hypnotic agents, the treatment for sleep disruption includes addressing multiple medical, behavioral, and environmental factors, which will be discussed in Part 2 of this article.

Hospitalized patients often have difficulty initiating and maintaining sleep, or complain of early awakening and nonrestorative sleep.1 The etiology of sleep disruption is multifactorial and includes the patient's underlying illness(es), medical treatments, and the hospital environment. Often unrecognized and untreated during hospitalization, sleep disruption may lead to sleep deprivation, or a chronic lack of restorative sleep.

Even in healthy individuals, sleep deprivation can result in numerous physical and psychological consequences. Sleep deprivation is associated with hypertension,2, 3 impaired postural control,4 decreased ventilatory drive,5 increased sympathetic cardiovascular activation,6 blunted hypothalamic‐pituitary‐adrenal axis,7 impaired host defenses, and possibly diabetes mellitus and obesity.810 The lack of restorative sleep increases the risk of developing anxiety and mood disorders and delirium, especially in acutely ill older patients.11 In the presence of acute physical infirmity, inadequate sleep may further compound illness and impair recovery. We provide an overview of normal sleep architecture and discuss factors that lead to sleep disruption in hospitalized medical patients.

NORMAL SLEEP ARCHITECTURE AND REGULATION

Normal sleep architecture refers to a characteristic pattern of sleep, and consists of two major stages: nonrapid eye movement (NREM, pronounced non‐rem) and rapid eye movement (REM). (For a table of pertinent abbreviations and terms, see Table 1) Sleep is quantified by polysomnography (PSG), which includes an electroencephalogram (EEG), electromyogram (EMG), and electrooculogram (EOG). A PSG also includes an electrocardiogram (ECG), and measures of airflow, oxygen saturation, and body position. NREM sleep comprises 75% to 80% of total sleep time (TST), and is characterized by relatively quiescent brain activity and decreased metabolic rate.12 NREM sleep consists of four stages (S1‐S4), with each stage leading to a progressively deeper sleep (Figure 1). REM sleep follows slow wave sleep (SWS), or deep sleep, and increases over the night, comprising 20% to 25% of TST. REM sleep is characterized by an activated EEG pattern, muscle atonia, and episodic bursts of rapid eye movements.

Figure 1
Normal sleep architecture includes cycles of 2 main stages, non‐REM and REM sleep, as depicted in this hypnogram.
Pertinent Abbreviations and Terms
Acronym Term
BiPAP Bilevel positive airway pressure
CHF Congestive heart failure
CPAP Continuous positive airway pressure
COPD Chronic obstructive pulmonary disease
EEG Electroencephalogram
EOG Electroculogram
EMG Electromyogram
ESRD End‐stage renal disease
NPPV Noninvasive positive pressure ventilation
NREM Nonrapid eye movement
OSA Obstructive sleep apnea
PLMD Periodic limb movement disorder
PSG Polysomnography
RBD REM sleep behavior disorder
REM Rapid eye movement
RLS Restless leg syndrome
S1‐S4 4 Stages of sleep in NREM
SE Sleep efficiency; TST divided by total time in bed
SWS Slow wave sleep
TBI Traumatic brain injury
TST Total sleep time

Normal sleep provides a period of physiologic and mental rest. During sleep, sympathetic tone decreases and parasympathetic tone increases, leading to a reduction in heart rate, arterial blood pressure, and cardiac output.13 Deep sleep is theorized to be necessary for physiologic restoration. REM sleep is associated with dreaming, and is essential for maintaining emotional and cognitive well‐being. Sleep architecture undergoes characteristic changes as people age.14 The duration of SWS peaks in childhood and decreases with age. Consequently, people >60 years old tend to have lower arousal thresholds and to have more frequent awakenings. The results of the Sleep Heart Health Study found that increased age was associated with decreased percentage of REM sleep, worse sleep efficiency (SE, which is TST divided by total time in bed), and lower arousal thresholds.14 With the reduction of SE, older people need to spend more hours in bed to achieve the same amount of restorative sleep as when they were younger. Although sleep tends to become more disrupted as people age, insomnia should not be considered a normal part of aging, and needs to be addressed clinically.15 The results of a National Sleep Foundation telephone survey of subjects between the ages of 55 and 84 years old (n = 1,506) suggested that sleep complaints in older adults are frequently secondary to comorbid medical conditions.16

Multiple anatomic structures, pathways, and neurotransmitter systems are involved in controlling wakefulness and sleep. Neurotransmitters that promote wakefulness include acetylcholine, histamine, noradrenaline (norepinephrine), serotonin, dopamine, and hypocretin (orexin). Sleep‐promoting neurotransmitters include gamma aminobutyric acid (GABA), adenosine, and melatonin. Specific stages of sleep are regulated by the turning on and off of various neurons. REM on cells use GABA, acetylcholine, and glutamine, whereas REM off cells use norepinephrine and serotonin. SWS is promoted by GABA and serotonin.17

Sleep regulation is a balance between a homeostatic sleep need and an intrinsic body clock, or circadian pacemaker. Located in the suprachiasmic nucleus, the circadian pacemaker determines the onset and termination of sleep, and is partially regulated by environmental cues such as light and ambient temperature. Melatonin, a physiologic sleep promoter, is inhibited by ambient light, and its circulation is decreased during daylight hours. The adrenal secretion of cortisol, which is associated with wakefulness, follows a circadian pattern. Regulated by the hypothalamic‐pituitary axis, cortisol levels peak in the early morning hours in preparation for the increased metabolic demands during wakefulness.

SLEEP PROBLEMS IN HOSPITALIZED PATIENTS

Insomnia, which is characterized by difficulty initiating or maintaining sleep, is the most common sleep disorder in the United States. About one‐third of the adult population in the United States experiences insomnia at some point in their lives,18 and it is a persistent problem in approximately 10% of U.S. adults.19 Insomnia can be exacerbated during hospitalization.

Studies investigating sleep in hospitalized patients using PSG have been limited primarily to the setting of the intensive care unit (ICU). Critically ill patients, particularly those requiring mechanical ventilation, are prone to sleep disturbances and an associated delirium.2022 Critically ill patients have fragmented sleep, with decreased SE and SWS, and increased S1 and S2.23 Physician awareness of the impact of sleep disturbance in hospitalized patients is vital. Surveys reveal that approximately one‐half of patients admitted on general medical wards complain of sleep disruption.24, 25 Meissner et al.25 examined the prevalence of sleep complaints and physician recognition of these complaints among general medical patients admitted to a Veterans Affairs tertiary care center. Results showed that 47% (n = 222) of patients had complaints of either insomnia and/or excessive daytime sleepiness.

FACTORS AFFECTING SLEEP DURING HOSPITALIZATION

Many medical and neurologic illnesses, psychiatric disorders, pain, medication therapy and the hospital environment may impair sleep, and hinder recovery from illness.

General Medical Disorders

Primary sleep disorders, such as obstructive sleep apnea (OSA) and numerous other medical illnesses, can directly impair sleep physiology, leading to a cyclical interaction (Figure 2). Other conditions that disrupt sleep include congestive heart failure (CHF), diabetes mellitus, chronic obstructive pulmonary disease (COPD), gastroesophageal reflux, cardiovascular disease, thyroid disorders, renal disease, and severe liver disease.26 Table 2 lists selected medical and neurological conditions, their associated sleep‐related problems, and suggestions on how to ameliorate these problems.

Figure 2
Cyclical interaction: sleep and common medical illnesses. Abbreviations: CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CRF, chronic renal failure; CVA, cerebrovascular accident (stroke); GER, gastroesophageal reflux; HTN, hypertension; OSA, obstructive sleep apnea; PLMD, periodic limb movement disorder; PND, paroxysmal nocturnal dyspnea; RLS, restless leg syndrome.
Selected Medical and Neurological Conditions Associated with Sleep Problems and Recommended Interventions
Disease Problem Clinical Implications and Strategies to Improve Sleep
  • Abbreviations: BiPAP, bilevel positive airway pressure; CHF, congestive heart failure; CNS, central nervous system; COPD, chronic obstructive pulmonary disease; CPAP, continuous positive airway pressure; GER, gastroesophageal reflux; O2, oxygen; OSA, obstructive sleep apnea; PLMD, periodic limb movement disorder; RLS, restless leg syndrome.

Asthma Nocturnal exacerbation, nocturnal GER Inhaled corticosteroids and/or long‐acting inhaled beta‐adrenergic agents
CHF Orthopnea, paroxysmal nocturnal dyspnea, sleep‐disordered breathing, increased sympathetic tone, nighttime diuresis, Cheyne‐Stokes respiration Keep the head of bed elevated 30 degrees. Nocturnal O2 to keep O2 saturation >88%. Daytime diuresis. Optimize cardiac function to treat Cheyne‐Stokes respiration. Consider CPAP for CHF
COPD Persistent nocturnal hypoxemia with complications (e.g., cor pulmonale, polycythemia) O2 for COPD and persistent hypoxemia (PaO2 55‐60 mm Hg)
Sporadic nighttime desaturations PaO2 55 mm Hg monitor O2 saturation by pulse oximetry. If patient desaturates to 88% at night consistently, start nocturnal O2. For hypercapnia, adjust O2 to maintain O2 saturation at 88% to 90%
Early‐morning airflow obstruction Consider bedtime tiotropium and inhaled long‐acting beta‐adrenergic agonist agents
Inhibition of respiratory muscles in REM Avoid sedative‐hypnotics that cause respiratory depression
Decreased functional residual capacity from recumbent position during sleep Minimize recumbancy by keeping the head of bed up at 30 degrees
End‐stage renal disease Pruritus, nausea; increased risk of RLS and PLMD Ambulation may help with RLS. Consider ropinirole and pramipexole. Correct hyperphosphatemia and uremia. Consider antipruritic and antiemetic agents
Nocturnal GER Nocturnal GER decreased sleep, heartburn, coughing, asthma Avoid eating or drinking 2 hours before bedtime, especially those that delay gastric emptying, increase acid secretion, or decrease lower esophageal sphincter pressure; e.g., high‐fat foods, ethanol, chocolate, peppers, peppermint. Keep head of bed 30 degrees. Minimize medications that could worsen nocturnal GER; e.g., theophylline, calcium channel blockers, prostaglandins, bisphosphonates
OSA Snoring with upper airway obstruction No ethanol 2 hours before bedtime. Minimize CNS depressants. Avoid supine position. Consider CPAP, oral mandibular advancement device, and/or surgical correction. Long‐term plan should include weight loss
Stroke Focal neurologic deficits (e.g., dysphagia, weakness or paralysis) Keep head of bed 30 degrees. Regularly suction secretions. Post‐stroke patients have an increased risk of hypersomnia, insomnia, and/or OSA

Affecting approximately 24% of men and 9% of women in the United States, OSA is the most common primary sleep disorder,27, 28 and causes significant mental and physical morbidity. Risk factors for OSA include obesity, hypothyroidism‐induced muscle weakness, and structural abnormalities in the oropharynx region such as acromegaly, micrognathia, or retrognathia. OSA is characterized by episodes of complete or partial pharyngeal obstruction during sleep that cause snoring, apneic episodes, choking, dyspnea, and restlessness.28 These episodes are associated with intermittent nocturnal sympathetic activation leading to nocturnal awakenings and cortical arousals, all of which lead to daytime symptoms of fatigue, sleepiness, and cognitive impairment (Figure 2). In addition, chronic sympathetic activation causes numerous derangements in the vascular endothelium and platelet activation.29, 30 Sleep‐disordered breathing has been independently associated with cardiovascular diseases such as hypertension, CHF, ischemic heart disease, atrial fibrillation, and cerebrovascular disease.31, 32

OSA is also associated with sleep‐related gastroesophageal reflux, which is characterized by pain and nocturnal cough, and can induce nocturnal asthma attacks and laryngospasm.33 Green et al.29 found that OSA patients treated with continuous positive airway pressure (CPAP) had a 48% improvement in nocturnal reflux symptoms. Although the pathophysiology connecting OSA to the renal system is unknown, OSA has been found in up to 60% of patients with end‐stage renal disease and chronic renal failure.34

Patients with pulmonary disorders can be profoundly affected by the normal physiologic changes during sleep, particularly in REM sleep. During REM sleep, all respiratory muscles except the diaphragm become paralyzed. Thus, episodes of marked oxygen desaturation can occur in patients who rely on their accessory muscles for respiration. COPD patients have decreased TST, SWS, and REM sleep. Shortness of breath, nocturnal cough, and wheezing worsen sleep.35 The resulting fatigue and sleep deprivation negatively impact the work of breathing and impair gas exchange. Airflow obstruction tends to worsen in the early morning hours in patients with COPD and asthma, and may be related to the effect of REM on the accessory muscles for respiration. Although used to target CO2 retention, investigations using bilevel positive airway pressure ventilators (BiPAP) for improving sleep in COPD patients have been limited. Noninvasive positive pressure ventilation (NPPV) appears to acutely improve SE and TST in patients with hypercapnic COPD without significantly improving gas exchange. Other sleep parameters such as sleep architecture and the number of arousals during the night, remain unchanged during NPPV.36

CPAP has several side effects that could worsen sleep, which may explain its poor adherence rate among ambulatory patients.37 Side effects include nasal bridge discomfort, nasal congestion, swallowing air, dry nose, dry or red eyes, noise, ear pain, and rhinitis.38 During hospitalization, efforts should be made to improve patient comfort by resizing ill‐fitting masks, adding heated humidification or nasal steroids to alleviate nasal congestion, or adding a chin strap to reduce air leak and ingestion of air.

Endocrine disorders have also been associated with sleep disruption. Studies suggest that patients with diabetes mellitus have decreased TST and impaired sleep quality due to nocturia and neuropathic pain.39 Inadequate sleep may also affect glucose control. Inadequate quality or quantity of sleep has been shown to be a risk factor for developing Type 2 diabetes mellitus in large prospective studies.40 Sleep duration and quality were significant predictors of increased levels of glycosylated hemoglobin (HbA1c) in patients with Type 2 diabetes mellitus. Thyroid diseases often coexist with diabetes mellitus. Both hypo‐ and hyperthyroidism have been associated with sleep disruption. Hypothyroidism is associated with daytime somnolence and fatigue. Patients with hypothyroidism tend to have reduced SWS. Hyperthyroid patients often complain of insomnia, which has been attributed to a hypermetabolic state.

Approximately 50% of patients with chronic end‐stage renal disease (ESRD) have insomnia and other sleep disorders.41 Patients often complain of restless leg syndrome (RLS), periodic limb movement disorder (PLMD), bone pain, nausea, and pruritus. The etiology of sleep disorders appears to be related to metabolic derangements associated with ESRD or from coexisting diabetes mellitus.

RLS and PLMD are distinct problems that affect sleep differently. RLS is characterized by an unpleasant crampy, creeping or crawling sensation in the lower extremities that is relieved by movement of the legs.42 RLS symptoms typically occur soon after going to bed, and therefore tend to disrupt sleep onset. The requisite bed rest during hospitalization can worsen RLS, further exacerbating sleep problems.43 Since RLS may partially be caused by disrupted iron metabolism, serum ferritin levels should be evaluated.44 Other conditions associated with RLS include pregnancy, rheumatoid arthritis, fibromyalgia, multiple sclerosis, ESRD, and Parkinson's disease. The differential diagnosis for RLS and PLMD includes neuroleptic‐induced akathisia, peripheral neuropathy, and positional or nocturnal leg cramps. PLMD occurs in about 80% of those with RLS, and is characterized by involuntary limb movements that occur every 20 to 40 seconds during NREM sleep. Unaware of these movements, patients often experience frequent arousals throughout the night, and complain of daytime somnolence and fatigue.42

A pilot study of 35 patients with minimal hepatic encephalopathy found that nearly 50% complained of sleep difficulties.45 Hypothesizing that a dysregulation of histaminergic neurotransmission in cirrhosis alters the sleep‐wake cycle, Spahr et al.46 found that 40% of their patients reported subjective improvement in sleep when administered 25 mg of hydroxyzine, compared to none who received placebo.

Neurologic Disorders

Since the brain and its various neurotransmitter systems are critical in regulating sleep and wakefulness, patients with neurologic disorders have an increased risk of developing sleep disorders. Patients with dementia, other neurodegenerative disorders, epilepsy, and traumatic brain injury (TBI) have a higher prevalence of sleep disturbance and sleep disorders.47 Poststroke patients can develop insomnia or hypersomnia, a reduction in sleep latency, increased sleep, or excessive daytime sleepiness, and are at higher risk for OSA during the first several months after a stroke.48 Specific neurologic lesions may lead to uncommon problems such as inversion of the sleep‐wake cycle, parasomnias, and hallucinatory dream‐like states.

Both Parkinson's disease and Alzheimer's disease are associated with multiple sleep disturbances, which tend to worsen with disease progression.14 Common problems include increased sleep fragmentation and wakefulness, with increases of stage 1 sleep and reductions of SWS and REM. Patients with neurodegenerative disorders also have an increased risk of REM sleep behavior disorder, or RBD.49 RBD is characterized by vivid and unusual dreams, and physically vigorous sleep behaviors that may result in ecchymoses, lacerations, and fractures.50 Fifty percent of patients with TBI reported insomnia symptoms.51 Disorders in initiating and maintaining sleep were the most common complaints among hospitalized patients with TBI. Some patients with TBI may develop circadian rhythm disturbances.52

Pain

A majority of patients with chronic pain, 50% to 70%, complain of impaired sleep.53 Sleep disruption is so common in fibromyalgia (75%) that it is considered to be a key diagnostic symptom.54 In a study investigating the affect of pain on sleep in burn patients, pain was associated with increased intermittent awakenings and prolonged periods of wake time during the night.55 The following day, these patients had poorer pain tolerance and greater pain intensity. Pain causes sleep fragmentation by increasing cortical arousals. Recent evidence suggests that sleep deprivation can increase pain sensitivity by inhibiting opioid protein synthesis or reducing opioid receptor affinity.56

Psychiatric Disorders

Sleep problems are so common in psychiatric conditions that the Diagnostic and Statistical Manual of Mental Disorders (DMS‐IV‐TR) includes sleep disturbance as a diagnostic criterion for a manic episode, and for various depressive, anxiety, and substance abuse disorders.57 The presence of sleep disturbance in hospitalized patients may suggest the presence of an underlying psychiatric disorder that would otherwise go unrecognized. In a survey of 200 general medical patients in a Brazilian hospital, Rocha et al.58 found that 112 (56.5%) complained of insomnia, and 100 (50%) met criteria for at least 1 psychiatric disorder. However, only 3 out of the total number of 200 surveyed (1.5%) were identified as having psychiatric diagnoses in the medical record, and sleep history was not noted in the clinical evaluation. An episode of major depressive disorder was the most common psychiatric diagnosis (35%). In this study, hospitalized patients with insomnia had a 3.6 times higher risk of having major depressive disorder than inpatients without insomnia.

Insomnia has a profound effect on mental health by worsening health‐related quality of life. In a study of outpatients at family medicine, internal medicine, endocrinology, cardiology, and psychiatry clinics in 3 U.S. cities (n = 3,445), insomnia worsened health‐related quality of life nearly as much as CHF or major depressive disorder did.59 Another survey of outpatients found that those with chronic insomnia were nearly 40 times more likely to have major depression and 6 times more likely to have an anxiety disorder compared to those without insomnia.60 Longitudinal studies have found that prior insomnia was associated with 2‐ to 5‐fold increase in the odds of mood and anxiety disorders and suicide.61, 62 Examining prodromes and precursors to mental disorders, Eaton et al.63 found that 47% of those with onset of depression at the 1‐year follow‐up had sleep problems at baseline.

An estimated 65% of patients with major depression have difficulty falling asleep, frequent awakenings, or early morning awakenings.64 Three patterns of sleep architecture abnormalities have been observed in patients with major depression: 1) sleep continuity disturbances characterized by prolonged sleep‐onset, increased wake time during sleep, increased early morning wake time, and decreased TST; 2) decreased proportion and length of SWS; and 3) REM sleep abnormalities such as reduced time to REM sleep, prolonged first REM sleep episode, and increased REM sleep percentage.65 Sleep during a manic episode has been less studied than in depression, but the data suggest that abnormal sleep in mania includes disrupted sleep continuity, shortened REM latency, and increased REM density (REM eye movement activity/total REM sleep time).65

Substance use disorders are also associated with sleep problems. In a survey by Brower et al.66 of patients who were undergoing alcohol rehabilitation, 61% (n = 172) had symptoms of insomnia such as increased sleep latency during the 6 months prior to entering treatment. Approximately 45% of these patients reported using alcohol for the purpose of initiating sleep. Alcohol and illicit substance intoxication and withdrawal are known to be associated with disrupted sleep. However, sleep disturbances may persist long after withdrawal symptoms have abated. Drummond et al. found that some patients continued to have alcohol‐associated sleep problems even after 27 months of abstinence.67 Evidence also suggests that untreated insomnia and other sleep problems may increase the risk of developing substance abuse problems due to self‐medicating with alcohol and other substances to help with sleep.68

Drugs that Affect Sleep

Numerous drugs can alter sleep quantity and quality. Sedatives and opioids may initially help with sleep onset, but impair sleep architecture. Medications used to treat medical and psychiatric illnesses also disrupt sleep (Table 3). The most common agents that impair sleep include antiepileptic drugs, selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, antihypertensives, antihistamines, and corticosteroids.

Drugs that Affect Sleep, Mechanisms, and Clinical Implications
Drug Class Examples of Drugs Affect on Sleep Architecture Potential Mechanism Clinical Implications
  • Abbreviations: 5HT, serotonin, serotonergic; AED, antiepileptic drugs; BzRAs, benzodiazepines; CNS, central nervous system; DOPA, dopamine; GABA, gamma‐aminobutyric acid; GER, gastroesophageal reflux; H2, histamine2‐receptor; HCTZ, hydrochlorothiazide; MAOIs, monoamine oxidase inhibitors; NE, norepinephrine; NSAIDs, nonsteroidal anti‐inflammatory drugs; REM, rapid eye movement; SE, sleep efficiency; SNRI, serotonin norepinephrine reuptake inhibitor; SSRIs, selective serotonin reuptake inhibitors; SWS, slow‐wave sleep (stage 3 and 4, or deep sleep); TCA, tricyclic and tetracyclic antidepressants; TST, total sleep time; TWT, total wake time; , leads to or causes; , decrease or reduce; , increase.

CNS
AEDs Phenobarbital, carbamazepine, phenytoin Very sedating. AEDs tend to TST, sleep latency Inhibit neuronal calcium influx, adenosine, or 5HT activity Sedation is dose‐dependent, and tends to occur with acute use
TCAs Amoxapine, amitriptyline, imipramine, nortriptyline, desipramine, doxepin, clomipramine Very sedating. Suppresses REM sleep, TST, stage‐2 sleep Stimulate antimuscarinic‐receptor and alpha1‐receptor Suppressed REM sleep motor inhibition restlessness, psychomotor agitation during sleep subjectively sleep quality, daytime sleepiness
BzRAs Alprazolam, lorazepam, chlordiazepoxide, diazepam, oxazepam Very sedating. TST, sleep latency, SWS duration, REM, stage‐2 sleep Stimulate GABA type A receptor Minimize daytime use. Chronic BzRAs SWS long‐term sequelae unknown
MAOIs Phenylzine, tranylcypromine Very sedating. TST, REM, REM rebound if stop MAOIs Mechanism unknown Daytime sleepiness; dosing time does not affect daytime somnolence
SSRIs Sedating: paroxetine, fluvoxamine. Activating: fluoxetine, sertraline, citalopram TST, are less sedating than TCAs and MAOIs. May REM, TWT, TST, SE 5HT activity Some patients get the opposite reaction
SNRI Venlafaxine, duloxetine Activating in some patients; sedating in 12% to 31%. TST 5HT and NE activity If activating, switch to AM dosing. If sedating, switch to PM dosing
Mood stabilizer Lithium Sedating. TST, SWS, REM, REM latency daytime sedation. Dose at night
Stimulants Ephedrine, pseudoephedrine, modafinil Activating. TST, SWS, sleep latency DOPA, NE, and 5HT activity Avoid after 6 PM
Anti‐Parkinson Bromocriptine, levodopa Sedating. Nightmares, SWS DOPA Dose at night, if possible
Cardiac
Lipophilic beta‐blockers Propranolol, pindolol, metoprolol, timolol. Hydrophilic agents (atenolol and sotalol) lack these effects Activating. awakenings, TWT, REM, nightmares CNS beta‐blockade Lipophilic beta‐blockers daytime sleep when dosed in AM
CNS agents Norepinephrine, epinephrine Activating. REM, SWS Stimulate alpha1‐receptor Minimize use at night
Dopamine Activating. REM, SWS Stimulate dopamine2‐receptor and alpha1‐receptor Minimize use at night
Ca++ channel blockers Amlodipine, verapamil, nifedipine Exacerbate underlying medical condition Lower esophageal sphincter tone nocturnal GER sleep disturbance
Alpha2‐receptor agonist Clonidine Stage 1, REM, nightmares Stimulate alpha2‐receptor Alpha2‐agonists daytime sleep and sleepiness directly. Dose at night
Alpha1‐receptor blockers Doxazosin, prazosin, terazosin Inhibit alpha1‐receptor Alpha1‐receptor blockers daytime sleepiness
Diuretics HCTZ, furosemide Sedating. PM diuresis frequent awakenings
Other
Opioids Codeine, morphine Sedating. SWS, REM Stimulate mu‐receptor Minimize use at night
NSAIDs Ibuprofen, indomethcin, celecoxib TST, SE Inhibit prostaglandin synthesis Minimize use at night
Methylxanthine Theophylline Activating. stage 1, REM Causes less restful sleep
Antihistamines Diphenhydramine, promethazine Sedating H1 receptor blockade Minimize use at night
Corticosteroids Dexamethasone, prednisone Activating. REM, SWS, nightmares Melatonin secretion Can disrupt sleep, anxiety, induce mania or psychosis
H2 blockers Cimetidine, ranitidine, famotidine Sedating. TST H2 receptor blockade Sedating if >60 years old, renal impairment
Quinolone Ciprofloxacin, sparfloxacin, ofloxacin, grepafloxacin, levofloxacin Activating Stimulate GABA type A receptor Consider sleep agent after maximizing sleep hygiene. Linezolid rarely causes sleep disturbances

Lipophilic beta antagonists such as propranolol and timolol can increase total wake time, decrease REM sleep, and increase the incidence of nightmares and insomnia.69 Anabolic steroids and beta‐agonist bronchodilator therapy can cause severe anxiety, sleeplessness, and even psychosis. Vasopressor agents such as dopamine can cause cortical activation, leading to increased arousal and reduced SWS.

Hospital Environment

Environmental noise and patient care activities often interfere with sleep in the hospital. They account for about 30% of patient awakenings in ICU patients.70 Noise levels in the ICU have average sound peaks of 150 to 200 dB, and evening peaks >80 dB between midnight and 6 AM.71 By comparison, the front row seats at a rock concert have sound levels of 110 dB. The high noise level in hospitals has long been implicated as a sleep disruptor,72 but studies in the past decade have found that patient care activities probably contribute more to awakenings than does environmental noise.73 An analysis of critical care nursing routines found that activities such as taking vital signs and giving baths occurred a mean 42.6 times a night per patient.74 Tamburri et al.74 found that patients experienced 2 to 3 hours without interruption on only 6% of the 147 nights studied. Routine daily baths were provided on 55 of the 147 study nights between 2 AM and 5 AM, which is unlikely to be an opportune time for most patients.

CONCLUSION

Hospitalization often prevents patients from achieving adequate sleep and can affect recovery from illness. Understanding the major factors that impair sleep during hospitalization allows clinicians to systemically evaluate and treat sleep problems. More than just prescribing sedative/hypnotic agents, the treatment for sleep disruption includes addressing multiple medical, behavioral, and environmental factors, which will be discussed in Part 2 of this article.

References
  1. NIH State‐of‐the Science Conference Statement on Manifestations and Management of Chronic Insomnia in Adults.NIH Consens Sci Statements.2005;22(2):130.
  2. Gangwisch JE,Heymsfield SB,Boden‐Albala B, et al.Short sleep duration as a risk factor for hypertension: analyses of the first National Health and Nutrition Examination Survey.Hypertension.2006;47(5):833839.
  3. Ogawa Y,Kanbayashi T,Saito Y, et al.Total sleep deprivation elevates blood pressure through arterial baroreflex resetting: a study with microneurographic technique.Sleep.2003;26(8):986989.
  4. Fabbri M,Martoni M,Esposito MJ,Gianni B,Natale V.Postural control after a night without sleep.Neuropsychologia.2006;44(12):25202525.
  5. Schiffman PL.Sleep deprivation decreases ventilatory responses to CO2 but not load compensation.Chest.1983;84(6):695698.
  6. Zhong X,Hilton HJ,Gates GJ, et al.Increased sympathetic and decreased parasympathetic cardiovascular modulation in normal humans with acute sleep deprivation.J Appl Physiol.2005;98(6):20242032.
  7. Everson CA.Reductions in circulating anabolic hormones induced by sustained sleep deprivation in rats.Am J Physiol Endocrinol Metab.2004;286(6):E1060E1070.
  8. Knutson KL,Spiegel K,Penev P,Van Cauter E.The metabolic consequences of sleep deprivation.Sleep Med Rev.2007;11(3):163178.
  9. Irwin MR,Wang M,Campomayor CO,Collado‐Hidalgo A,Cole S.Sleep deprivation and activation of morning levels of cellular and genomic markers of inflammation.Arch Int Med.2006;166:17561752.
  10. Hui L,Hua F,Diandong H,Hong Y.Effects of sleep and sleep deprivation on immunoglobulins and complement in humans.Brain Behav Immun.2007;21:308310.
  11. Kahn‐Green ET,Killgore DB,Kamimori GH,Balkin TJ,Killgore WDS.The effects of sleep deprivation on symptoms of psychopathology in healthy adults.Sleep Med.2007;8:215221.
  12. Carskadon MA,Dement WC.Normal human sleep. In:Kryger MH,Roth T,Dement WC, editors.Principles and Practice of Sleep Medicine.3rd ed.Philadelphia:W.B. Saunders;2000:1516.
  13. Richardson G.Update on the Science, Diagnosis and Management of Insomnia.International Congress and Symposium Series 262.London:Royal Society of Medicine Press Ltd;2006.
  14. Redline S,Kirchner HL,Quan SF,Gottlieb DJ,Kapur V,Newman A.The effects of age, sex, ethnicity, and sleep‐disordered breathing on sleep architecture.Arch Intern Med.2004;164:40618.
  15. Cole C,Richards K.Sleep disruption in older adults.Am J Nurs.2007;107(5):4049.
  16. Foley D,Ancoli‐Israel S,Britz P,Walsh J.Sleep disturbances and chronic disease in older adults: results of the 2003 National Sleep Foundation Sleep in America Survey.J Psychosom Res.2004;56(5):497502.
  17. Hoyt BD.Sleep in patients with neurologic and psychiatric disorders.Prim Care.2005;32:535548.
  18. Mellinger GD,Balter MB,Uhlenhuth EH.Insomnia and its treatment: prevalence and correlates.Arch Gen Psychiatry.1985;42(3):225232.
  19. Ford DE,Kamerow DB.Epidemiologic study of sleep disturbances and psychiatric disorders: an opportunity for prevention?JAMA.1989;262:14791484.
  20. Cooper AB,Thornley KS,Young GB,Slutsky AS,Stewart TE,Hanly PJ.Sleep in critically ill patients requiring mechanical ventilation.Chest.2000;117:809818.
  21. Pandharipande P,Ely EW.Sedative and analgesic medications: risk factors for delirium and sleep disturbances in the critically ill.Crit Care Med.2006;22:313327.
  22. Friese RS,Diaz‐Arrastia R,McBride D,Frankel H,Gentilello LM.Quantity and quality of sleep in the surgical intensive care unit: are our patients sleeping?J Trauma.2007;63:12101214.
  23. BaHamman A.Sleep in acute care units.Sleep Breath.2006;10:615.
  24. Frighetto L,Marra C,Bandali S,Wilbur K,Naumann T,Jewesson P.An assessment of quality of sleep and the use of drugs with sedating properties in hospitalized adult patients.Health Qual Life Outcomes.2004;2:17.
  25. Meissner HH,Riemer A,Santiago SM,Stein M,Goldman MD,Williams AJ.Failure of physician documentation of sleep complaints in hospitalized patients.West J Med.1998;169:146149.
  26. Ballard RD.Sleep and medical disorders.Prim Care.2005;35:511533.
  27. Young T,Palta M,Dempsey J,Skatrud J,Weber S,Badr S.The occurrence of sleep‐disordered breathing among middle‐aged adults.N Engl J Med.1993;328:12301235.
  28. Bassiri AG,Guilleminault .Clinical features and evaluation of obstructive sleep apnea‐hypopnea syndrome. In:Kryger MH,Roth T,Dement WC, editors.Principles and Practice of Sleep Medicine.3rd ed.Philadelphia:W.B. Saunders;2000:869872.
  29. Green BT,Broughton WA,O'Connor JB.Marked improvement in nocturnal gastroesophageal reflux in a large cohort of patients with obstructive sleep apnea.Arch Intern Med.2003;163:4145.
  30. Berry RB,Harding SM.Sleep and medical disorders.Med Clin North Am.2004;88:679703.
  31. Wattanakit K,Boland L,Punjabi NM,Shahar E.Relation of sleep‐disordered breathing to carotid plaque and intima‐media thickness.Atherosclerosis.2008;197(1):125131.
  32. Shahar E,Whitney CW,Redline S, et al.Sleep‐disordered breathing and cardiovascular disease: cross‐sectional results of the Sleep Heart Health Study.Am J Respir Crit Care Med.2001;163:1925.
  33. Harding SM.Gastroesophageal reflux during sleep.Sleep Med Clin.2007;2:4150.
  34. Krause MA,Hamburger RJ.Sleep apnea in renal failure.Adv Perit Dial.1997;13:8892.
  35. Mohsenin V.Sleep in chronic obstructive pulmonary disease.Sleep Med Clin.2007;2:18.
  36. Krachman SL,Quaranta AJ,Berger TJ,Criner GJ.Effects of non‐invasive positive pressure ventilation on gas exchange and sleep in COPD patients.Chest.1997;112:623628.
  37. Weaver TE,Kribbs NB,Pack AI, et al.Night‐to‐night variability in CPAP use over the first three months of treatment.Sleep.1997;20(4):278283.
  38. Engleman HM,Wild MR.Improving CPAP use by patients with the sleep apnoea/hypopnoea syndrome (SAHS).Sleep Med Rev.2003;7(1):8199.
  39. Lamond N,Tiggermann M,Dawson D.Factors predicting sleep disruption in type II diabetes.Sleep.2000;23:415416.
  40. Yaggi Hk,Araujo AB,McKinlay JB.Sleep duration as a risk factor for the development of type 2 diabetes.Diabetes Care.2006;29:657661.
  41. Hanly P.Sleep disorders and end‐stage renal disease.Sleep Med Clin.2007;2:5966.
  42. Wolkove N,Elkholy O,Batzan M,Palayew M.Sleep and aging: 1. Sleep disorders commonly found in older people.CMAJ.2007;176(9):12991304.
  43. Hening W,Walters AS,Allen RP,Montplaisir J,Myers A,Ferini‐Strambi L.Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: The REST (RLS Epidemiology, Symptoms, and Treatment) primary care study.Sleep Med.2004;5(3):237246.
  44. Succoni M,Ferini‐Strambi L.Epidemiology and clinical findings of restless leg syndrome.Sleep Med.2004;5(3):293299.
  45. Cordoba J,Cabrera J,Lataif L,Peney P,Zee P,Blei AT.High prevalence of sleep disturbance in cirrhosis.Hepatology.1998;27:339345.
  46. Spahr L,Coeytaux A,Giostra E,Hadengue A,Annoni J‐M.Histamine H1 blocker hydroxyzine improves sleep in patients with cirrhosis and minimal hepatic encephalopathy: a randomized controlled pilot trial.Am J Gastroenterol.2007;102:744753.
  47. Hoyt BD.Sleep in patients with neurologic and psychiatric disorders.Prim Care.2005;32:535548.
  48. Shamsuzzaman AS,Gersh BJ,Somers VK.Obstructive sleep apnea: implications for cardiac and vascular disease.JAMA.2003;290(14):19061914.
  49. Boeve BF,Silber MH,Saper CB, et al.Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease.Brain.2007;130(Pt 11):27702788.
  50. Mahowald MW,Schenck CH.REM sleep parasomnias. In:Kryger MH,Roth T,Dement WC, editors.Principles and Practice of Sleep Medicine.3rd ed.Philadelphia:W.B. Saunders;2000:724725.
  51. Ouellet M‐C,Beaulieu‐Bonneau S,Morin CM.Insomnia in patients with traumatic brain injury.J Head Trauma Rehabil.2006;21(3):199212.
  52. Ayalon L,Borodkkin K,Dishon L,Kanety H,Dagan Y.Circadian rhythm sleep disorders following mild traumatic brain injury.Neurology.2007;68(14):11361140.
  53. Barczi SR,Juergens TM.Comorbidities: psychiatric, medical, medications, and substances.Sleep Med Clin.2006;231245.
  54. Lineberger MD,Means JK,Edinger JD.Sleep disturbance and fibromyalgia.Sleep Med Clin.2007;2:3139.
  55. Raymond I,Ancoli‐Israel S,Choiniere M.Sleep disturbances, pain and analgesia in adults hospitalized for burn injuries.Sleep Med.2004;5:551559.
  56. Lautenbader S,Kundermann B,Krieg J‐C.Sleep deprivation and pain perception.Sleep Med Rev.2006;10:357369.
  57. American Psychiatric Association.Diagnostic and Statistical Manual of Mental Disorders.4th ed. Text Revision.Washington, DC:American Psychiatric Association;2000.
  58. Rocha FL,Hara C,Rodriguez CV, et al.Is insomnia a marker for psychiatric disorders in general hospitals?Sleep Med.2005;6:549553.
  59. Katz DA,McHorney CA.The relationship between insomnia and health‐related quality of life in patients with chronic illness.J Fam Pract.2002;51(3):229235.
  60. Ford DE,Kamerow DB.Epidemiologic study of sleep disturbances and psychiatric disorders: an opportunity for prevention?JAMA.1989;262:14791484.
  61. Breslau N,Roth T,Rosenthal L,Andreski P.Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults.Biol Psychiatry.1996;39:411418.
  62. Weissman MM,Greenwald S,Nino‐Murcia G,Dement WC.The morbidity of insomnia uncomplicated by psychiatric disorders.Gen Hosp Psychiatry.1997;19:245250.
  63. Eaton WW,Badawi M,Melton B.Prodromes and precursors: epidemiologic data for primary prevention of disorders with slow onset.Am J Psychiatry.1995;152:967972.
  64. Perlis ML,Giles DE,Buysse DJ,Thase ME,Tu X,Kupfer DJ.Which depressive symptoms are related to which sleep electroencephalographic variables?Biol Psychol.1997;42:904913.
  65. Peterson MJ,Benca RM.Sleep in mood disorders.Psychiatr Clin North Am.2006;29:10091032.
  66. Brower KJ,Aldrich MS,Robinson EAR,Zucker RA,Greden JF.Insomnia, self‐medication, and relapse to alcoholism.Am J Psychiatry.2001;158:399404.
  67. Drummond SPA,Gillin JC,Smith TL,DeModena A.The sleep of abstinent pure primary alcoholic patients: natural course and relationship to relapse.Alcohol Clin Exp Res.1998;22:17961802.
  68. Teplin D,Raz B,Daiter J,Varenbut M,Tyrrell M.Screening for substance use patterns among patients referred for a variety of sleep complaints.Am J Drug Alcohol Abuse.2006;32:111120.
  69. Schweitzer PK.Drugs that disturb sleep and wakefulness. In:Kryger MH,Roth T,Dement WC, editors.Principles and Practice of Sleep Medicine.3rd ed.Philadelphia:W.B. Saunders;2000:441462.
  70. Gabor JY,Cooper AB,Crombach SA, et al.Contribution of the intensive care unit environment to sleep disruption in mechanically ventilated patients and healthy subjects.Am J Respir Crit Care Med.2003;167(5):708715.
  71. Meyer T,Eveloff S,Bauer M.Adverse environmental conditions in the respiratory and medical ICU settings.Chest.1994;105:12111216.
  72. Busch‐Vishniac IJ,West JE,Barnhill C,Hunter T,Orellana D,Chivukula R.Noise levels in Johns Hopkins Hospital.J Acoust Soc Am.2005;118(6):36293645.
  73. Freedman NS,Kotzer N,Schwab RJ.Patient perception of sleep quality and etiology of sleep disruption in the intensive care unit.Am J Respir Crit Care Med.1999;159:11551162.
  74. Tamburri LM,di Brienza R,Zozula R,Redeker NS.Nocturnal care interactions with patients in critical care units.Am J Crit Care.2004;13(2):102115.
References
  1. NIH State‐of‐the Science Conference Statement on Manifestations and Management of Chronic Insomnia in Adults.NIH Consens Sci Statements.2005;22(2):130.
  2. Gangwisch JE,Heymsfield SB,Boden‐Albala B, et al.Short sleep duration as a risk factor for hypertension: analyses of the first National Health and Nutrition Examination Survey.Hypertension.2006;47(5):833839.
  3. Ogawa Y,Kanbayashi T,Saito Y, et al.Total sleep deprivation elevates blood pressure through arterial baroreflex resetting: a study with microneurographic technique.Sleep.2003;26(8):986989.
  4. Fabbri M,Martoni M,Esposito MJ,Gianni B,Natale V.Postural control after a night without sleep.Neuropsychologia.2006;44(12):25202525.
  5. Schiffman PL.Sleep deprivation decreases ventilatory responses to CO2 but not load compensation.Chest.1983;84(6):695698.
  6. Zhong X,Hilton HJ,Gates GJ, et al.Increased sympathetic and decreased parasympathetic cardiovascular modulation in normal humans with acute sleep deprivation.J Appl Physiol.2005;98(6):20242032.
  7. Everson CA.Reductions in circulating anabolic hormones induced by sustained sleep deprivation in rats.Am J Physiol Endocrinol Metab.2004;286(6):E1060E1070.
  8. Knutson KL,Spiegel K,Penev P,Van Cauter E.The metabolic consequences of sleep deprivation.Sleep Med Rev.2007;11(3):163178.
  9. Irwin MR,Wang M,Campomayor CO,Collado‐Hidalgo A,Cole S.Sleep deprivation and activation of morning levels of cellular and genomic markers of inflammation.Arch Int Med.2006;166:17561752.
  10. Hui L,Hua F,Diandong H,Hong Y.Effects of sleep and sleep deprivation on immunoglobulins and complement in humans.Brain Behav Immun.2007;21:308310.
  11. Kahn‐Green ET,Killgore DB,Kamimori GH,Balkin TJ,Killgore WDS.The effects of sleep deprivation on symptoms of psychopathology in healthy adults.Sleep Med.2007;8:215221.
  12. Carskadon MA,Dement WC.Normal human sleep. In:Kryger MH,Roth T,Dement WC, editors.Principles and Practice of Sleep Medicine.3rd ed.Philadelphia:W.B. Saunders;2000:1516.
  13. Richardson G.Update on the Science, Diagnosis and Management of Insomnia.International Congress and Symposium Series 262.London:Royal Society of Medicine Press Ltd;2006.
  14. Redline S,Kirchner HL,Quan SF,Gottlieb DJ,Kapur V,Newman A.The effects of age, sex, ethnicity, and sleep‐disordered breathing on sleep architecture.Arch Intern Med.2004;164:40618.
  15. Cole C,Richards K.Sleep disruption in older adults.Am J Nurs.2007;107(5):4049.
  16. Foley D,Ancoli‐Israel S,Britz P,Walsh J.Sleep disturbances and chronic disease in older adults: results of the 2003 National Sleep Foundation Sleep in America Survey.J Psychosom Res.2004;56(5):497502.
  17. Hoyt BD.Sleep in patients with neurologic and psychiatric disorders.Prim Care.2005;32:535548.
  18. Mellinger GD,Balter MB,Uhlenhuth EH.Insomnia and its treatment: prevalence and correlates.Arch Gen Psychiatry.1985;42(3):225232.
  19. Ford DE,Kamerow DB.Epidemiologic study of sleep disturbances and psychiatric disorders: an opportunity for prevention?JAMA.1989;262:14791484.
  20. Cooper AB,Thornley KS,Young GB,Slutsky AS,Stewart TE,Hanly PJ.Sleep in critically ill patients requiring mechanical ventilation.Chest.2000;117:809818.
  21. Pandharipande P,Ely EW.Sedative and analgesic medications: risk factors for delirium and sleep disturbances in the critically ill.Crit Care Med.2006;22:313327.
  22. Friese RS,Diaz‐Arrastia R,McBride D,Frankel H,Gentilello LM.Quantity and quality of sleep in the surgical intensive care unit: are our patients sleeping?J Trauma.2007;63:12101214.
  23. BaHamman A.Sleep in acute care units.Sleep Breath.2006;10:615.
  24. Frighetto L,Marra C,Bandali S,Wilbur K,Naumann T,Jewesson P.An assessment of quality of sleep and the use of drugs with sedating properties in hospitalized adult patients.Health Qual Life Outcomes.2004;2:17.
  25. Meissner HH,Riemer A,Santiago SM,Stein M,Goldman MD,Williams AJ.Failure of physician documentation of sleep complaints in hospitalized patients.West J Med.1998;169:146149.
  26. Ballard RD.Sleep and medical disorders.Prim Care.2005;35:511533.
  27. Young T,Palta M,Dempsey J,Skatrud J,Weber S,Badr S.The occurrence of sleep‐disordered breathing among middle‐aged adults.N Engl J Med.1993;328:12301235.
  28. Bassiri AG,Guilleminault .Clinical features and evaluation of obstructive sleep apnea‐hypopnea syndrome. In:Kryger MH,Roth T,Dement WC, editors.Principles and Practice of Sleep Medicine.3rd ed.Philadelphia:W.B. Saunders;2000:869872.
  29. Green BT,Broughton WA,O'Connor JB.Marked improvement in nocturnal gastroesophageal reflux in a large cohort of patients with obstructive sleep apnea.Arch Intern Med.2003;163:4145.
  30. Berry RB,Harding SM.Sleep and medical disorders.Med Clin North Am.2004;88:679703.
  31. Wattanakit K,Boland L,Punjabi NM,Shahar E.Relation of sleep‐disordered breathing to carotid plaque and intima‐media thickness.Atherosclerosis.2008;197(1):125131.
  32. Shahar E,Whitney CW,Redline S, et al.Sleep‐disordered breathing and cardiovascular disease: cross‐sectional results of the Sleep Heart Health Study.Am J Respir Crit Care Med.2001;163:1925.
  33. Harding SM.Gastroesophageal reflux during sleep.Sleep Med Clin.2007;2:4150.
  34. Krause MA,Hamburger RJ.Sleep apnea in renal failure.Adv Perit Dial.1997;13:8892.
  35. Mohsenin V.Sleep in chronic obstructive pulmonary disease.Sleep Med Clin.2007;2:18.
  36. Krachman SL,Quaranta AJ,Berger TJ,Criner GJ.Effects of non‐invasive positive pressure ventilation on gas exchange and sleep in COPD patients.Chest.1997;112:623628.
  37. Weaver TE,Kribbs NB,Pack AI, et al.Night‐to‐night variability in CPAP use over the first three months of treatment.Sleep.1997;20(4):278283.
  38. Engleman HM,Wild MR.Improving CPAP use by patients with the sleep apnoea/hypopnoea syndrome (SAHS).Sleep Med Rev.2003;7(1):8199.
  39. Lamond N,Tiggermann M,Dawson D.Factors predicting sleep disruption in type II diabetes.Sleep.2000;23:415416.
  40. Yaggi Hk,Araujo AB,McKinlay JB.Sleep duration as a risk factor for the development of type 2 diabetes.Diabetes Care.2006;29:657661.
  41. Hanly P.Sleep disorders and end‐stage renal disease.Sleep Med Clin.2007;2:5966.
  42. Wolkove N,Elkholy O,Batzan M,Palayew M.Sleep and aging: 1. Sleep disorders commonly found in older people.CMAJ.2007;176(9):12991304.
  43. Hening W,Walters AS,Allen RP,Montplaisir J,Myers A,Ferini‐Strambi L.Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: The REST (RLS Epidemiology, Symptoms, and Treatment) primary care study.Sleep Med.2004;5(3):237246.
  44. Succoni M,Ferini‐Strambi L.Epidemiology and clinical findings of restless leg syndrome.Sleep Med.2004;5(3):293299.
  45. Cordoba J,Cabrera J,Lataif L,Peney P,Zee P,Blei AT.High prevalence of sleep disturbance in cirrhosis.Hepatology.1998;27:339345.
  46. Spahr L,Coeytaux A,Giostra E,Hadengue A,Annoni J‐M.Histamine H1 blocker hydroxyzine improves sleep in patients with cirrhosis and minimal hepatic encephalopathy: a randomized controlled pilot trial.Am J Gastroenterol.2007;102:744753.
  47. Hoyt BD.Sleep in patients with neurologic and psychiatric disorders.Prim Care.2005;32:535548.
  48. Shamsuzzaman AS,Gersh BJ,Somers VK.Obstructive sleep apnea: implications for cardiac and vascular disease.JAMA.2003;290(14):19061914.
  49. Boeve BF,Silber MH,Saper CB, et al.Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease.Brain.2007;130(Pt 11):27702788.
  50. Mahowald MW,Schenck CH.REM sleep parasomnias. In:Kryger MH,Roth T,Dement WC, editors.Principles and Practice of Sleep Medicine.3rd ed.Philadelphia:W.B. Saunders;2000:724725.
  51. Ouellet M‐C,Beaulieu‐Bonneau S,Morin CM.Insomnia in patients with traumatic brain injury.J Head Trauma Rehabil.2006;21(3):199212.
  52. Ayalon L,Borodkkin K,Dishon L,Kanety H,Dagan Y.Circadian rhythm sleep disorders following mild traumatic brain injury.Neurology.2007;68(14):11361140.
  53. Barczi SR,Juergens TM.Comorbidities: psychiatric, medical, medications, and substances.Sleep Med Clin.2006;231245.
  54. Lineberger MD,Means JK,Edinger JD.Sleep disturbance and fibromyalgia.Sleep Med Clin.2007;2:3139.
  55. Raymond I,Ancoli‐Israel S,Choiniere M.Sleep disturbances, pain and analgesia in adults hospitalized for burn injuries.Sleep Med.2004;5:551559.
  56. Lautenbader S,Kundermann B,Krieg J‐C.Sleep deprivation and pain perception.Sleep Med Rev.2006;10:357369.
  57. American Psychiatric Association.Diagnostic and Statistical Manual of Mental Disorders.4th ed. Text Revision.Washington, DC:American Psychiatric Association;2000.
  58. Rocha FL,Hara C,Rodriguez CV, et al.Is insomnia a marker for psychiatric disorders in general hospitals?Sleep Med.2005;6:549553.
  59. Katz DA,McHorney CA.The relationship between insomnia and health‐related quality of life in patients with chronic illness.J Fam Pract.2002;51(3):229235.
  60. Ford DE,Kamerow DB.Epidemiologic study of sleep disturbances and psychiatric disorders: an opportunity for prevention?JAMA.1989;262:14791484.
  61. Breslau N,Roth T,Rosenthal L,Andreski P.Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults.Biol Psychiatry.1996;39:411418.
  62. Weissman MM,Greenwald S,Nino‐Murcia G,Dement WC.The morbidity of insomnia uncomplicated by psychiatric disorders.Gen Hosp Psychiatry.1997;19:245250.
  63. Eaton WW,Badawi M,Melton B.Prodromes and precursors: epidemiologic data for primary prevention of disorders with slow onset.Am J Psychiatry.1995;152:967972.
  64. Perlis ML,Giles DE,Buysse DJ,Thase ME,Tu X,Kupfer DJ.Which depressive symptoms are related to which sleep electroencephalographic variables?Biol Psychol.1997;42:904913.
  65. Peterson MJ,Benca RM.Sleep in mood disorders.Psychiatr Clin North Am.2006;29:10091032.
  66. Brower KJ,Aldrich MS,Robinson EAR,Zucker RA,Greden JF.Insomnia, self‐medication, and relapse to alcoholism.Am J Psychiatry.2001;158:399404.
  67. Drummond SPA,Gillin JC,Smith TL,DeModena A.The sleep of abstinent pure primary alcoholic patients: natural course and relationship to relapse.Alcohol Clin Exp Res.1998;22:17961802.
  68. Teplin D,Raz B,Daiter J,Varenbut M,Tyrrell M.Screening for substance use patterns among patients referred for a variety of sleep complaints.Am J Drug Alcohol Abuse.2006;32:111120.
  69. Schweitzer PK.Drugs that disturb sleep and wakefulness. In:Kryger MH,Roth T,Dement WC, editors.Principles and Practice of Sleep Medicine.3rd ed.Philadelphia:W.B. Saunders;2000:441462.
  70. Gabor JY,Cooper AB,Crombach SA, et al.Contribution of the intensive care unit environment to sleep disruption in mechanically ventilated patients and healthy subjects.Am J Respir Crit Care Med.2003;167(5):708715.
  71. Meyer T,Eveloff S,Bauer M.Adverse environmental conditions in the respiratory and medical ICU settings.Chest.1994;105:12111216.
  72. Busch‐Vishniac IJ,West JE,Barnhill C,Hunter T,Orellana D,Chivukula R.Noise levels in Johns Hopkins Hospital.J Acoust Soc Am.2005;118(6):36293645.
  73. Freedman NS,Kotzer N,Schwab RJ.Patient perception of sleep quality and etiology of sleep disruption in the intensive care unit.Am J Respir Crit Care Med.1999;159:11551162.
  74. Tamburri LM,di Brienza R,Zozula R,Redeker NS.Nocturnal care interactions with patients in critical care units.Am J Crit Care.2004;13(2):102115.
Issue
Journal of Hospital Medicine - 3(6)
Issue
Journal of Hospital Medicine - 3(6)
Page Number
473-482
Page Number
473-482
Article Type
Display Headline
Sleep in hospitalized medical patients, Part 1: Factors affecting sleep
Display Headline
Sleep in hospitalized medical patients, Part 1: Factors affecting sleep
Legacy Keywords
acute illness, comorbid insomnia, hospitalized medical patient, insomnia, sleep deprivation
Legacy Keywords
acute illness, comorbid insomnia, hospitalized medical patient, insomnia, sleep deprivation
Sections
Article Source
Copyright © 2008 Society of Hospital Medicine
Disallow All Ads
Correspondence Location
University of California, Davis, Department of Psychiatry and Behavioral Sciences, 2230 Stockton Boulevard, Sacramento, CA 95817
Content Gating
Gated (full article locked unless allowed per User)
Gating Strategy
First Peek Free
Article PDF Media

Death is a Crafty Old Friend

Article Type
Changed
Mon, 01/02/2017 - 19:34
Display Headline
Death Is a Crafty Old Friend

I will never forget her first words to me: You mispronounced my name.

I remember stopping short, awkwardly looking down at the emergency room chart in my hands and wondering how I could have mispronounced Mrs. Wells. I'm sorry, how should I say your name? I asked her.

Kitty.

Ah. Miss Kitty? I tried. This is, after all, Virginia, and octogenarians here are renowned for their adherence to social niceties.

She shook her head, her frown showing just how hard she was working to be patient with me. Miss Kitty was a character on Gunsmoke, she told me. Well, actually, she was lecturing me. I have never had red hair, I don't own a saloon, and I sure as heck don't have Marshall Dillon to keep me company. Darn my luck.

She was my seventh admission that afternoon, with at least 2 more to follow, but I found a smile for her and started into my usual routine. So, what brings you to the hospital today, Kitty?

I was hoping to meet a cute young doctor, she told me. And I think I succeeded.

This was clearly not going to go quickly. We'll deal with your poor eyesight later. What about the shortness of breath that the nurse wrote on your chart? I did not even mention the audible wheezing or the pursed‐lip breathing I had heard from outside the curtain.

Oh, that's just a ploy, she lied. To get to the meeting the cute young doctor part.

In glancing at her fingers to look for clubbing, I noticed the golden band and the tiny diamond ring, both of which looked huge on her knobby fingers. Kitty, I gently scolded her, I don't have time to deal with jealous husbands.

She laughed as she absently twirled the rings around her finger. Carl won't mind, she told me. He's been dead 14 years now.

But you still wear his rings, I pointed out.

He brought this ring with him when he came back to me from France after the war, she told me, straightening the tiny diamond on her finger. It was all his private's salary could afford, so he gave me the ring and a magnifying glass, and he told me to never look at the ring without using the magnifying glass.

No, this was clearly not going to go quickly at all. But I was pretty sure I was not going to mind.

Over the next 4 days, Kitty and I got to know each other fairly well. Her chronic obstructive pulmonary disease exacerbation improved to the point that I could send her home, and she begrudgingly accepted my recommendation of oxygen at night.

Over the next 2 years, I admitted her 7 more times; to my frustration, this meant that she was seeing me more regularly than she was seeing her primary care physician. After her third admission, I found myself having to convince her that it was time to start using her oxygen continuously. When she came back for her fourth admission, I noticed the cane at her bedside. Are you having trouble walking now, Kitty? I naively asked her.

Of course not, she shot back quickly. This is just in case I see a man I want to get a closer look at. I just hook him around the ankle and pull him in.

That discharge was to a skilled nursing facility because she had no family and no one else to care for her. After her 3 months of skilled benefits, she transitioned to long‐term care, and the next time her emphysema acted up, she thanked me for the introduction to all those handsome gentlemen. On each day of that admission, she asked when I was going to let her out of the hospital. Each day, she made sure that I knew, meant missed opportunities for her to be able to figure out which of the male residents was meant to be Carl's successor.

Her sixth admission was for pneumonia, and we nearly lost her. I am still convinced that it was nothing more than her self‐described abundance of piss and vinegar that pulled her through.

When the emergency room called me less than a month later for her seventh admission, I knew that Kitty and I were getting awfully close to the end of our relationship. She was tired and weak and smaller even than she had been just a few weeks before.

I admitted her to the intensive care unit for the first time on that admission, and I made the mistake of telling her that it was because with her somnolence and with her wish that she not be intubated, I was flirting with the idea of bilevel positive airway pressure (BiPAP) ventilation. She managed to find enough wind to tell me that I should save all my flirting for her.

Three days of antibiotics, frequent bronchodilators, steroids, and as much BiPAP as she could stand did not net us much improvement. On hospital day 4, the intensive care unit nurse caught me before I knocked on Kitty's sliding glass door.

She wants to go home, Lucy told me.

We're working on it, I reminded her.

Lucy shook her head. No, she said. Home with a capital H. Heaven. Lucy relayed the conversation that Kitty had had with her. The one that my old friend had not had with me.

The one that I should have had with her.

I closed Kitty's door behind me and sat down at her side on the bed, noticing how she was drawing each breath as if she had to pay for it.

Lucy told me about your conversation, I said quietly, once Kitty had finally opened her eyes and found me. No more BiPAP, I understand. She nodded. I waited for her to say something more, but she did not. Why didn't you tell me, Kitty? I asked her gently.

She laughed; her laugh was a short, tired little thing that died in her throat. She reached from under the covers to pat my hand. I suppose, she said, that I didn't want to let you down. You always seem so proud of yourself when I come in here, gasping and coughing, and you get me well enough to go back home. She paused to blow off some CO2 and find a sad smile for me. Time to let me go, she told me. Let me be with Carl again.

We talked for quite a while. Well, actually, I did most of the talking. She did not have the wind for it. I admitted to her just how embarrassed I was that she had had to bring this up to me. I have for quite some time been rather comfortable with the notion that death is not the worst thing that can happen to a patient. It was Dr. Tom Smith, at the Medical College of Virginia, who first introduced what was then a wide‐eyed, idealist medical student to the concept of a good death: snatching a victory for compassion from the jaws of a medical defeat.

Therefore, at Kitty's insistence, there was no more BiPAP. When her breathing became labored, we gave her just enough morphine to take the edge off her air hunger. Rather than round on her in the mornings, I simply sat with her.

I would like to say that I was with Kitty when she died. It would bring the story full circle and give our relationship a clean beginning and a clean end. It would be good fiction.

However, it would also be a lie.

Lucy met me at her door again, just 3 days later, and told me about Kitty's quiet passing, in her sleep, just an hour before I had arrived for rounds.

I sat at Kitty's side one last time, holding her now cold hand. She was smiling.

At least, that is how I intend to remember that moment.

The bed sagged just a bit on the other side as I realized that Death had joined me. For those who have not had the pleasure, the part of Death is played by Gwyneth Paltrow.

We sat in silence for several minutes, Death showing me the patience that she had once told me she had.

I rarely see it.

How is she? I finally asked.

Better. She and Carl are catching up a bit. I nodded. He's giving her hell for losing that magnifying glass.

I could not help the smile. Carl was one lucky man.

She says thank you.

Whether it was true or not, it was nice for Death to say it.

She let me have a long stretch of silence before she felt the need to ruin our tender moment. You have any other business for me?

I growled a warning, and she smiled. That was a joke, Doctor. Lighten up a little, would you?

She turned to go, but I stopped her. Hey, I found a great quote for you. The last time that we had chatted, she had been lamenting the plethora of love lines and the paucity of good death ones:

Because I could not stop for Death,

He kindly stopped for me;

The carriage held but just ourselves

and immortality.

Emily Dickinson, I told her.

Huh, she said, frowning and doing that thing with her eyebrow for which Gwyneth gets paid millions. Wonder why she thought I was a he?

Acknowledgements

I thank the editors of the Journal of Hospital Medicine for considering this submission. This is a fictionalized account of a true patient experience. The patient in question has passed away, but while she was alive, she and I discussed many things, including my writing, and she actually asked that I write about her some day. This is the fulfillment of my promise to her.

Article PDF
Issue
Journal of Hospital Medicine - 3(6)
Page Number
495-497
Sections
Article PDF
Article PDF

I will never forget her first words to me: You mispronounced my name.

I remember stopping short, awkwardly looking down at the emergency room chart in my hands and wondering how I could have mispronounced Mrs. Wells. I'm sorry, how should I say your name? I asked her.

Kitty.

Ah. Miss Kitty? I tried. This is, after all, Virginia, and octogenarians here are renowned for their adherence to social niceties.

She shook her head, her frown showing just how hard she was working to be patient with me. Miss Kitty was a character on Gunsmoke, she told me. Well, actually, she was lecturing me. I have never had red hair, I don't own a saloon, and I sure as heck don't have Marshall Dillon to keep me company. Darn my luck.

She was my seventh admission that afternoon, with at least 2 more to follow, but I found a smile for her and started into my usual routine. So, what brings you to the hospital today, Kitty?

I was hoping to meet a cute young doctor, she told me. And I think I succeeded.

This was clearly not going to go quickly. We'll deal with your poor eyesight later. What about the shortness of breath that the nurse wrote on your chart? I did not even mention the audible wheezing or the pursed‐lip breathing I had heard from outside the curtain.

Oh, that's just a ploy, she lied. To get to the meeting the cute young doctor part.

In glancing at her fingers to look for clubbing, I noticed the golden band and the tiny diamond ring, both of which looked huge on her knobby fingers. Kitty, I gently scolded her, I don't have time to deal with jealous husbands.

She laughed as she absently twirled the rings around her finger. Carl won't mind, she told me. He's been dead 14 years now.

But you still wear his rings, I pointed out.

He brought this ring with him when he came back to me from France after the war, she told me, straightening the tiny diamond on her finger. It was all his private's salary could afford, so he gave me the ring and a magnifying glass, and he told me to never look at the ring without using the magnifying glass.

No, this was clearly not going to go quickly at all. But I was pretty sure I was not going to mind.

Over the next 4 days, Kitty and I got to know each other fairly well. Her chronic obstructive pulmonary disease exacerbation improved to the point that I could send her home, and she begrudgingly accepted my recommendation of oxygen at night.

Over the next 2 years, I admitted her 7 more times; to my frustration, this meant that she was seeing me more regularly than she was seeing her primary care physician. After her third admission, I found myself having to convince her that it was time to start using her oxygen continuously. When she came back for her fourth admission, I noticed the cane at her bedside. Are you having trouble walking now, Kitty? I naively asked her.

Of course not, she shot back quickly. This is just in case I see a man I want to get a closer look at. I just hook him around the ankle and pull him in.

That discharge was to a skilled nursing facility because she had no family and no one else to care for her. After her 3 months of skilled benefits, she transitioned to long‐term care, and the next time her emphysema acted up, she thanked me for the introduction to all those handsome gentlemen. On each day of that admission, she asked when I was going to let her out of the hospital. Each day, she made sure that I knew, meant missed opportunities for her to be able to figure out which of the male residents was meant to be Carl's successor.

Her sixth admission was for pneumonia, and we nearly lost her. I am still convinced that it was nothing more than her self‐described abundance of piss and vinegar that pulled her through.

When the emergency room called me less than a month later for her seventh admission, I knew that Kitty and I were getting awfully close to the end of our relationship. She was tired and weak and smaller even than she had been just a few weeks before.

I admitted her to the intensive care unit for the first time on that admission, and I made the mistake of telling her that it was because with her somnolence and with her wish that she not be intubated, I was flirting with the idea of bilevel positive airway pressure (BiPAP) ventilation. She managed to find enough wind to tell me that I should save all my flirting for her.

Three days of antibiotics, frequent bronchodilators, steroids, and as much BiPAP as she could stand did not net us much improvement. On hospital day 4, the intensive care unit nurse caught me before I knocked on Kitty's sliding glass door.

She wants to go home, Lucy told me.

We're working on it, I reminded her.

Lucy shook her head. No, she said. Home with a capital H. Heaven. Lucy relayed the conversation that Kitty had had with her. The one that my old friend had not had with me.

The one that I should have had with her.

I closed Kitty's door behind me and sat down at her side on the bed, noticing how she was drawing each breath as if she had to pay for it.

Lucy told me about your conversation, I said quietly, once Kitty had finally opened her eyes and found me. No more BiPAP, I understand. She nodded. I waited for her to say something more, but she did not. Why didn't you tell me, Kitty? I asked her gently.

She laughed; her laugh was a short, tired little thing that died in her throat. She reached from under the covers to pat my hand. I suppose, she said, that I didn't want to let you down. You always seem so proud of yourself when I come in here, gasping and coughing, and you get me well enough to go back home. She paused to blow off some CO2 and find a sad smile for me. Time to let me go, she told me. Let me be with Carl again.

We talked for quite a while. Well, actually, I did most of the talking. She did not have the wind for it. I admitted to her just how embarrassed I was that she had had to bring this up to me. I have for quite some time been rather comfortable with the notion that death is not the worst thing that can happen to a patient. It was Dr. Tom Smith, at the Medical College of Virginia, who first introduced what was then a wide‐eyed, idealist medical student to the concept of a good death: snatching a victory for compassion from the jaws of a medical defeat.

Therefore, at Kitty's insistence, there was no more BiPAP. When her breathing became labored, we gave her just enough morphine to take the edge off her air hunger. Rather than round on her in the mornings, I simply sat with her.

I would like to say that I was with Kitty when she died. It would bring the story full circle and give our relationship a clean beginning and a clean end. It would be good fiction.

However, it would also be a lie.

Lucy met me at her door again, just 3 days later, and told me about Kitty's quiet passing, in her sleep, just an hour before I had arrived for rounds.

I sat at Kitty's side one last time, holding her now cold hand. She was smiling.

At least, that is how I intend to remember that moment.

The bed sagged just a bit on the other side as I realized that Death had joined me. For those who have not had the pleasure, the part of Death is played by Gwyneth Paltrow.

We sat in silence for several minutes, Death showing me the patience that she had once told me she had.

I rarely see it.

How is she? I finally asked.

Better. She and Carl are catching up a bit. I nodded. He's giving her hell for losing that magnifying glass.

I could not help the smile. Carl was one lucky man.

She says thank you.

Whether it was true or not, it was nice for Death to say it.

She let me have a long stretch of silence before she felt the need to ruin our tender moment. You have any other business for me?

I growled a warning, and she smiled. That was a joke, Doctor. Lighten up a little, would you?

She turned to go, but I stopped her. Hey, I found a great quote for you. The last time that we had chatted, she had been lamenting the plethora of love lines and the paucity of good death ones:

Because I could not stop for Death,

He kindly stopped for me;

The carriage held but just ourselves

and immortality.

Emily Dickinson, I told her.

Huh, she said, frowning and doing that thing with her eyebrow for which Gwyneth gets paid millions. Wonder why she thought I was a he?

Acknowledgements

I thank the editors of the Journal of Hospital Medicine for considering this submission. This is a fictionalized account of a true patient experience. The patient in question has passed away, but while she was alive, she and I discussed many things, including my writing, and she actually asked that I write about her some day. This is the fulfillment of my promise to her.

I will never forget her first words to me: You mispronounced my name.

I remember stopping short, awkwardly looking down at the emergency room chart in my hands and wondering how I could have mispronounced Mrs. Wells. I'm sorry, how should I say your name? I asked her.

Kitty.

Ah. Miss Kitty? I tried. This is, after all, Virginia, and octogenarians here are renowned for their adherence to social niceties.

She shook her head, her frown showing just how hard she was working to be patient with me. Miss Kitty was a character on Gunsmoke, she told me. Well, actually, she was lecturing me. I have never had red hair, I don't own a saloon, and I sure as heck don't have Marshall Dillon to keep me company. Darn my luck.

She was my seventh admission that afternoon, with at least 2 more to follow, but I found a smile for her and started into my usual routine. So, what brings you to the hospital today, Kitty?

I was hoping to meet a cute young doctor, she told me. And I think I succeeded.

This was clearly not going to go quickly. We'll deal with your poor eyesight later. What about the shortness of breath that the nurse wrote on your chart? I did not even mention the audible wheezing or the pursed‐lip breathing I had heard from outside the curtain.

Oh, that's just a ploy, she lied. To get to the meeting the cute young doctor part.

In glancing at her fingers to look for clubbing, I noticed the golden band and the tiny diamond ring, both of which looked huge on her knobby fingers. Kitty, I gently scolded her, I don't have time to deal with jealous husbands.

She laughed as she absently twirled the rings around her finger. Carl won't mind, she told me. He's been dead 14 years now.

But you still wear his rings, I pointed out.

He brought this ring with him when he came back to me from France after the war, she told me, straightening the tiny diamond on her finger. It was all his private's salary could afford, so he gave me the ring and a magnifying glass, and he told me to never look at the ring without using the magnifying glass.

No, this was clearly not going to go quickly at all. But I was pretty sure I was not going to mind.

Over the next 4 days, Kitty and I got to know each other fairly well. Her chronic obstructive pulmonary disease exacerbation improved to the point that I could send her home, and she begrudgingly accepted my recommendation of oxygen at night.

Over the next 2 years, I admitted her 7 more times; to my frustration, this meant that she was seeing me more regularly than she was seeing her primary care physician. After her third admission, I found myself having to convince her that it was time to start using her oxygen continuously. When she came back for her fourth admission, I noticed the cane at her bedside. Are you having trouble walking now, Kitty? I naively asked her.

Of course not, she shot back quickly. This is just in case I see a man I want to get a closer look at. I just hook him around the ankle and pull him in.

That discharge was to a skilled nursing facility because she had no family and no one else to care for her. After her 3 months of skilled benefits, she transitioned to long‐term care, and the next time her emphysema acted up, she thanked me for the introduction to all those handsome gentlemen. On each day of that admission, she asked when I was going to let her out of the hospital. Each day, she made sure that I knew, meant missed opportunities for her to be able to figure out which of the male residents was meant to be Carl's successor.

Her sixth admission was for pneumonia, and we nearly lost her. I am still convinced that it was nothing more than her self‐described abundance of piss and vinegar that pulled her through.

When the emergency room called me less than a month later for her seventh admission, I knew that Kitty and I were getting awfully close to the end of our relationship. She was tired and weak and smaller even than she had been just a few weeks before.

I admitted her to the intensive care unit for the first time on that admission, and I made the mistake of telling her that it was because with her somnolence and with her wish that she not be intubated, I was flirting with the idea of bilevel positive airway pressure (BiPAP) ventilation. She managed to find enough wind to tell me that I should save all my flirting for her.

Three days of antibiotics, frequent bronchodilators, steroids, and as much BiPAP as she could stand did not net us much improvement. On hospital day 4, the intensive care unit nurse caught me before I knocked on Kitty's sliding glass door.

She wants to go home, Lucy told me.

We're working on it, I reminded her.

Lucy shook her head. No, she said. Home with a capital H. Heaven. Lucy relayed the conversation that Kitty had had with her. The one that my old friend had not had with me.

The one that I should have had with her.

I closed Kitty's door behind me and sat down at her side on the bed, noticing how she was drawing each breath as if she had to pay for it.

Lucy told me about your conversation, I said quietly, once Kitty had finally opened her eyes and found me. No more BiPAP, I understand. She nodded. I waited for her to say something more, but she did not. Why didn't you tell me, Kitty? I asked her gently.

She laughed; her laugh was a short, tired little thing that died in her throat. She reached from under the covers to pat my hand. I suppose, she said, that I didn't want to let you down. You always seem so proud of yourself when I come in here, gasping and coughing, and you get me well enough to go back home. She paused to blow off some CO2 and find a sad smile for me. Time to let me go, she told me. Let me be with Carl again.

We talked for quite a while. Well, actually, I did most of the talking. She did not have the wind for it. I admitted to her just how embarrassed I was that she had had to bring this up to me. I have for quite some time been rather comfortable with the notion that death is not the worst thing that can happen to a patient. It was Dr. Tom Smith, at the Medical College of Virginia, who first introduced what was then a wide‐eyed, idealist medical student to the concept of a good death: snatching a victory for compassion from the jaws of a medical defeat.

Therefore, at Kitty's insistence, there was no more BiPAP. When her breathing became labored, we gave her just enough morphine to take the edge off her air hunger. Rather than round on her in the mornings, I simply sat with her.

I would like to say that I was with Kitty when she died. It would bring the story full circle and give our relationship a clean beginning and a clean end. It would be good fiction.

However, it would also be a lie.

Lucy met me at her door again, just 3 days later, and told me about Kitty's quiet passing, in her sleep, just an hour before I had arrived for rounds.

I sat at Kitty's side one last time, holding her now cold hand. She was smiling.

At least, that is how I intend to remember that moment.

The bed sagged just a bit on the other side as I realized that Death had joined me. For those who have not had the pleasure, the part of Death is played by Gwyneth Paltrow.

We sat in silence for several minutes, Death showing me the patience that she had once told me she had.

I rarely see it.

How is she? I finally asked.

Better. She and Carl are catching up a bit. I nodded. He's giving her hell for losing that magnifying glass.

I could not help the smile. Carl was one lucky man.

She says thank you.

Whether it was true or not, it was nice for Death to say it.

She let me have a long stretch of silence before she felt the need to ruin our tender moment. You have any other business for me?

I growled a warning, and she smiled. That was a joke, Doctor. Lighten up a little, would you?

She turned to go, but I stopped her. Hey, I found a great quote for you. The last time that we had chatted, she had been lamenting the plethora of love lines and the paucity of good death ones:

Because I could not stop for Death,

He kindly stopped for me;

The carriage held but just ourselves

and immortality.

Emily Dickinson, I told her.

Huh, she said, frowning and doing that thing with her eyebrow for which Gwyneth gets paid millions. Wonder why she thought I was a he?

Acknowledgements

I thank the editors of the Journal of Hospital Medicine for considering this submission. This is a fictionalized account of a true patient experience. The patient in question has passed away, but while she was alive, she and I discussed many things, including my writing, and she actually asked that I write about her some day. This is the fulfillment of my promise to her.

Issue
Journal of Hospital Medicine - 3(6)
Issue
Journal of Hospital Medicine - 3(6)
Page Number
495-497
Page Number
495-497
Article Type
Display Headline
Death Is a Crafty Old Friend
Display Headline
Death Is a Crafty Old Friend
Sections
Article Source
Copyright © 2008 Society of Hospital Medicine
Disallow All Ads
Correspondence Location
Riverside Tappahannock Hospital, 618 Hospital Road, Tappahannock, VA 22560
Content Gating
Gated (full article locked unless allowed per User)
Gating Strategy
First Peek Free
Article PDF Media

One Hundred Years Later

Article Type
Changed
Mon, 01/02/2017 - 19:34
Display Headline
One hundred years later

The approach to clinical conundrums by an expert clinician is revealed through presentation of an actual patient's case in an approach typical of morning report. Similar to patient care, sequential pieces of information are provided to the clinician who is unfamiliar with the case. The focus is on the thought processes of both the clinical team caring for the patient and the discussant.

A 36 year‐old male physician was admitted to a Baltimore hospital in April 1907 with weight loss, weakness, arthralgias, and abdominal distension that had progressed over 5 years.

In 1907, major causes of unexplained weight loss included tuberculosis, hyperthyroidism, cancer, and diabetes. Arthralgias and weakness are not specific. The insidious progression over 5 years narrows the infectious possibilities; tuberculosis and syphilis are important considerations. Since surgical removal was the main treatment for malignancy in 1907, a history of prior surgery might point to a previously diagnosed malignancy that is now progressing.

Five years earlier, while visiting Turkey as a medical missionary, he first noted the onset of arthralgias that lasted 6 to 8 hours and occurred 3 to 4 times per week. Over time, these attacks lasted up to 24 hours and became associated with warmth, swelling, and tenderness of both small and large joints. He gradually lost weight and strength. One year prior to arrival in the hospital, he developed a cough productive of yellow sputum. Seven months prior, he returned from Turkey to Atlanta and noticed an increase in his cough, along with fevers of 100 Fahrenheit and night sweats.

The primacy of the arthralgias in this illness lead me to consider primary rheumatic diseases, and multisystem diseases (including infections) with a predominant skeletal component. In 1907, tests for lupus and the rheumatoid factor were not available. Neither skeletal remains nor works of art provide evidence that rheumatoid arthritis existed until the 19th century, whereas ankylosing spondylitis, gout, and rickets were present by then.

As a medical missionary, he might have acquired a disease endemic to the areas he visited, or the travel history may be a red herring. Familial Mediterranean fever, though prevalent in Turkey and a cause of arthralgias accompanied by recurrent attacks of abdominal pain and fever, is not an acquired disease. Behcet's disease, also known as Silk Trader's Route disease, is found in descendents of the countries that comprised the ancient Silk Route from Japan to the Middle East and may cause arthritis along with oral ulcers, genital lesions, pathergy or uveitis. I would inquire about his ancestry and fevers before dismissing these possibilities.

Although 5 years would be unusually long for tuberculosis to go unrecognized, a physician in the first half of the 20th century would place tuberculosis near the top of possible diagnoses. In 1930, a time when the population of the United States was considerably less, there were over 300,000 cases of tuberculosis. Physicians, and in particular pathologists since autopsies were more commonly performed, often died from tuberculosis since streptomycin, the first antituberculous medication, did not arrive until 1944. At the turn of the 20th century, the ability to detect tubercle bacilli was quite good. Thus, I would include tuberculous peritonitis as a cause of the progressive abdominal symptoms in this physician. In approximately one‐third of patients with tuberculous peritonitis there is evidence of pulmonary disease, and I would try to culture tuberculosis in samples of sputum, a test then so common it probably rivaled our frequent complete blood counts in popularity.

Six months prior, examinations of sputum were negative for tubercle bacilli. Four months prior to arrival, the patient moved to New Mexico. His cough improved but he continued to lose weight and had diarrhea consisting of 3 to 4 loose or semiformed bowel movements per day. Three months prior to admission, he noted an increase in abdominal girth along with right lower quadrant fullness. One month prior, he noted painful swelling and warmth in both ankles as well as dyspnea with exertion.

The increased abdominal girth in the context of chronic illness might be due to ascites, adenopathy, visceromegaly, or mass lesions such as a neoplasm or abscess. If ascites is the cause, one would need to consider primary hepatic disorders, as well as extrahepatic diseases that could progress over years. Infection with hepatitis A virus does not cause chronic liver disease. Hepatitis B, in those days, was referred to as serum hepatitis, and a serum marker for the B virusthe Australia antigenwas not identified until 1967. Cardiac causes of ascites include congestive heart failure and constrictive pericarditis, the latter an important consideration because it is potentially curable. Also, constrictive pericarditis can present as an indolent weight‐losing disease because of chronic visceral congestion. Other considerations include nephrotic syndrome, infection, and neoplasm, including mesothelioma.

Abdominal distention might also be seen with a smoldering abscess. In addition to an appendiceal process, the travel and right lower quadrant localization reminds us to consider ameboma. This patient surely was in an area where amebiasis was endemic, and amebomaa chronic inflammatory form of infection with E. histolytica not associated with diarrhea or liver cystsmay mimic cecal carcinoma. Exertional dyspnea suggests at least the possibility of cardiac disease. Despite the negative sputum cultures, tuberculosis remains high on the list as a cause of constrictive pericarditis or peritonitis, either of which may occur in the absence of active pulmonary disease.

Past medical history included measles and whooping cough as a child, mild pleurisy at age 14, mild influenza 7 years previously. The patient had a tonsillectomy as a child and had a portion of his inferior turbinate bone removed in an attempt to relieve a nasal condition.

On physical exam, the patient was thin and the skin over his face and hands was deep brown. His temperature was 101.5 Fahrenheit, the heart rate was 100, and the respiratory rate was 24. Small lymph nodes were palpable in the axillary and epitrochlear areas. His thorax moved asymmetrically, with less movement on the left apex and slight dullness to percussion in that area. The pulmonic component of the second heart sound was mildly accentuated. The abdomen displayed fullness and tympany, most pronounced in the right lower quadrant without hepatosplenomegaly. The left ankle was swollen, and the overlying skin was tense, shiny, and hot. On both lower legs, areas of discoloration and slight induration were observed, felt to be consistent with faded erythema nodosum.

Though pleurisy has numerous causes, its presence raises the specter of tuberculosis again. The nasal condition triggers thoughts of Wegener's granulomatosis or lethal midline granuloma, both unlikely diagnoses here. The pulmonary exam suggests an apical process, such as tuberculosis, and the accentuated pulmonic heart sound implies pulmonary hypertension, which could be due to a number of chronic pulmonary diseases. The epitrochlear nodes are of interest since lymphoma and Hodgkin's disease rarely involve this area; syphilis and human immunodeficiency virus (HIV) are a few of the chronic diseases that may involve this lymph node region. More helpful is the absence of hepatosplenomegaly, since many indolent malignancies and infections would be expected to enlarge these organs by this point.

Monoarticular arthritis is often due to infection, and less likely due to rheumatoid disease. When rheumatoid arthritis flares, the entire skeleton flares, not single joints. Given the indolence and this single joint involvement, tuberculosis again comes to mind.

I would next want to obtain a plain chest radiograph, looking for evidence of tuberculosis. As with any test, one should ask how this will change management. In 1907, antituberculous medications were not available, so therapy was directed at lowering oxygen tension in the primary site of infection; for example, pulmonary disease was addressed via pneumothorax. If the chest radiograph provides little hint of tuberculosis, then consideration must be given to exploratory surgery of the abdomen given the focal abnormality in the right lower quadrant.

A peripheral blood smear revealed a hypochromic microcytic anemia. The total red blood cell count was 4.468 million/mm3 (normal range for men is 4.52‐5.90 million/mm3), white blood cell count was 8180/mm3, including 80% granulocytes and 9% eosinophils. On gross inspection, the stool was clay‐colored, and stool microscopy demonstrated large numbers of neutral fat droplets, but no ova, parasites, or tubercle bacilli. Urinalysis revealed no albumin or casts, and the bones were normal on ankle radiographs. Another sample of sputum revealed no tubercle bacilli, and intradermal placement of tuberculin provoked no reaction.

His negative tuberculin skin reaction is unusual for that era, because of the prevalence of tuberculosis. Most likely, he is anergic because of his severe underlying illness, and the absent reaction is thus not all that helpful a clue. Multiple negative sputum examinations lower the possibility of pulmonary, but not extrapulmonary, tuberculosis. The absence of bony destruction on ankle radiographs lowers my suspicion for tuberculous arthritis.

The excess stool fat implies steatogenic diarrhea from malabsorption, and 2 categories here are pancreatic and luminal diseases. Of these 2, pancreatic etiologies produce more severe malabsorption. We do not hear mention of jaundice, however, and I cannot see how to link the pancreas to the arthritis. A chronic infection which may produce malabsorption and eosinophilia is strongyloidiasis, endemic in the southeastern United States. However, this patient did not manifest the most common finding of chronic strongyloidiasis, namely asthma. Adrenal insufficiency, as might result from disseminated tuberculosis, is associated with increased skin pigmentation, diarrhea, and eosinophilia. However, the diarrhea of adrenal insufficiency is not malabsorptive, and serum electrolytes and cortisol tests were not available then to confirm this diagnosis antemortem.

In an attempt to identify a unifying cause of chronic arthritis, malabsorption, and increased skin pigmentation, I must consider Whipple's disease first and foremost. Physicians then were strapped and observation was often the default mode of the day. Given the abdominal findings, an exploratory laparotomy would be warranted if his condition deteriorated.

Despite forced oral feedings, the patient continued to lose weight, from his normal of 175 pounds to a nadir of 145 pounds. Because of worsening abdominal distention, the patient underwent exploratory abdominal surgery on the twenty‐first hospital day. Intraoperatively, no ascites was seen, but his mesenteric lymph nodes were hard and markedly enlarged. The abdomen was closed without further intervention. Two days after the surgery, the patient abruptly developed dyspnea. His respirations were 40 per minute, heart rate was 120, and he had minimal rales at the lung bases without findings of consolidation. He died 2 hours later, on the twenty‐third hospital day, and an autopsy was performed.

The final event may have been a pulmonary embolism. As for the adenopathy, lymphoma and tuberculosis are possible. Heavy chain disease, an unusual lymphoproliferative disorder found in persons from the old Silk Trader's Route from the Middle East to the Orient, is a remote prospect. However, 5 years is just too indolent for most cancers and would be very unusual for tuberculosis. I think the findings support Whipple's disease, and I wonder if this was the first reported case.

On postmortem examination, the abdominal adenopathy was striking. The small intestine contained enlarged villi with thickened submucosa, and the mesenteric nodes were enlarged with fat deposits and abnormal foamy cells. Within these foamy cells, microscopy revealed numerous rod‐shaped organisms. All studies were negative for tuberculosis, and although the pathologist, Dr. George Hoyt Whipple, suspected an infectious etiology, he offered the name intestinal lipodystrophy to emphasize the striking small intestinal changes he witnessed at autopsy, and which are the hallmarks of the disease that now bears his name. Whipple also shared the 1934 Nobel Prize in Physiology or Medicine with Minot and Murphy for their discovery that a nutritional substance in liver, now known as vitamin B12, was beneficial in treating pernicious anemia.

COMMENTARY

This is the index case of Whipple's disease, summarized from the original 1907 description.1 George Hoyt Whipple, then a pathologist at Johns Hopkins, highlights the value of keen observation and a well‐done case report in describing a new disease entity. One of the roles of case reports is to detail the features of an unknown disease. In this capacity, Whipple's summary is exemplary. His achievement was having the openness of mind to realize he was witnessing something novel, and to take the first step on the road to discovery. Although Whipple suspected he was staring at a unique disease, he could not pinpoint the culprit bacteria and he had trouble squaring the extraintestinal findings with the marked intestinal anomalies. It was left to decades of input from others to confirm the association of arthralgias, eosinophilia, skin hyperpigmentation, and cardiac valve abnormalities with intestinal malabsorption, and to culture the infectious agent.

In his discussion, Whipple recognized he was confronted with a novel clinical entity. Prior to surgery, pulmonary and mesenteric tuberculosis were suspected, based on the fevers, weight loss, cough, fat malabsorption, and lymphadenopathy. However, he felt the left apical exam was more representative of retraction from prior disease than active infection. He was also bothered by the negative skin reaction and sputum tests. At surgery, the pronounced adenopathy suggested sarcoma or Hodgkin's disease but postmortem examination eliminated these possibilities. At autopsy, the abdominal findings were most striking. The small intestine demonstrated enlarged villi with thickened submucosa and markedly enlarged mesenteric lymph glands containing large fat deposits and distinctly abnormal foamy cells. These foamy macrophages contained great numbers of rod‐shaped organisms resembling the tubercle bacillus. However, all tests were negative for tuberculosis, and the lungs contained no active disease. Though he suspected an infectious etiology, Whipple offered the name intestinal lipodystrophy to emphasize the striking small intestinal pathology.

Although Whipple had surmised a novel infectious agent in 1907, it took almost a century to isolate the causative microbe. Granules within foamy macrophages of the small intestine were detected on periodic acid‐Schiff (PAS) staining in 1949.2 Similar PAS‐positive granules were soon discovered in other tissues and fluid, providing a plausible explanation for the systemic features of the disease.3 Electron microscopy confirmed the presence of infectious bacilli in 1961,4 ushering in the era of antimicrobial treatment for this disease. More recently, using polymerase chain reaction (PCR), a unique bacterial 16S ribosomal RNA gene was isolated in patients with Whipple's disease.5, 6 Phylogenetically classified with the actinobacteria, Tropheryma whipplei (fom the Greek trophe, nourishment, and eryma, barrier) was ultimately subcultured in 2000,7 and immunodetection testing became possible. Using this technique, the archived pathology specimens from the 1907 index case demonstrated numerous intracellular bacteria in the lamina propria, closing the loop started by Whipple nearly a century earlier.8

Whipple's index case report described most of the manifestations of the disease we are familiar with today. As in the original description, arthralgias are the most common initial symptom and may precede diagnosis by a mean of 8 years. Other cardinal features include weight loss, abdominal pain and steatorrhea due to small intestinal involvement. Table 1 summarizes the important signs and symptoms of Whipple's disease.9, 10 One notable manifestation missing in Whipple's report is central nervous system involvement. Central nervous system (CNS) disease ranges from cognitive deficits to encephalitis and focal defects, and may occur years after treatment and without concomitant intestinal symptoms.

Clinical Features of Whipple Disease
Clinical Feature Comment
  • Two pathognomonic involuntary muscle signs in CNS Whipple disease are oculomasticatory and oculo‐facial‐skeletal myorhythmia.10

Cardinal features (present in 60% to 90%)
Arthropathy Most common initial symptom, preceding diagnosis by a mean of 8 years. Migratory, nonerosive, mainly in the peripheral joints.
Weight loss
Diarrhea Usually steatorrhea, may be associated with pain or occult blood in the stool
Other common features (present in 20% to 45%)
Fever
Lymphadenopathy May present as a palpable mass
Increased skin pigmentation Mechanism unknown (evidence of adrenal insufficiency has not been found in Whipple's)
Cardiac disease Culture‐negative endocarditis
Hypotension
Peripheral edema
Uncommon clinical features
Central nervous system involvement May be global (dementia, personality change, sleep disturbance) or focal (cranial neuropathy, nystagmus)
Eye disease Uveitis, retinitis
Hepatosplenomegaly
Polyserositis
Ascites

A remaining mystery is why this pathogen results only rarely in clinical disease. Caucasians comprise the majority of infected patients, and men are affected 8 times more often than women. An overrepresentation of HLA‐B27 suggests a genetic predisposition, though its role in pathogenesis is unclear. T. whipplei has been identified by PCR methods in asymptomatic individuals, implying additional abnormalities must be present in susceptible hosts for symptoms to occur following colonization.11 The exact immune defects are speculative, and immunodeficiency states (such as HIV) have not been consistently identified in patients with Whipple's disease.

The cornerstone of diagnosing Whipple's disease is upper endoscopy with duodenal biopsy. Flattening of the villi and markedly increased PAS‐positive staining of lamina propria macrophages are strongly suggestive of the diagnosis. PAS‐positive staining is not unique to T. whipplei, however. In patients with profound immunodeficiency, Mycobacterium avium intracellulare may stain positive with PAS. Since Whipple's disease is only rarely associated with HIV, a negative HIV test would favor a diagnosis of Whipple's disease. Electron microscopy may distinguish T. whipplei from its mimickers by morphology. For extraintestinal disease, PCR testing on samples from infected tissue has been found to be a reliable diagnostic aid.9

Given the rarity of the disease, controlled clinical trials addressing optimal treatment are lacking. Current recommendations include initial therapy for 14 days with an agent that crosses the blood‐brain barrier (eg, ceftriaxone) to reduce the incidence of CNS disease. This is then followed by a year or more of oral antimicrobial therapy with trimethoprim‐sulfamethoxazole or a tetracycline.9 While most patients respond within 2 to 3 weeks, relapse may occur in as many as one‐third of patients.

Historical case reports reinforce the case‐based learning paradigm. As the discussant remarks, observation was all too often the only recourse for physicians a century ago. In recounting the 7‐year progression of disease in 1 individual, Whipple provides a unique window into the natural evolution of the key features of this systemic disease. Viewed through the prism of Whipple's eyes, we can recall the striking lymphoid hyperplasia and unusual organisms in the small intestine, cementing our understanding of the pathogenesis of this disorder. Revisiting past cases allows us to learn of and learn from the past.

Teaching Points

  • Whipple's disease should be considered in patients with unexplained arthralgias accompanied by weight loss, malabsorption, and abdominal pain.

  • For suspected intestinal Whipple's disease, diagnosis is best made by duodenal biopsy demonstrating PAS‐positive staining in lamina propria macrophages.

  • Systemic manifestations of Whipple's disease include culture‐negative endocarditis and CNS disease. PCR testing of involved sites for T. whipplei is recommended to confirm extraintestinal disease.

References
  1. Whipple GH.A hitherto undescribed disease characterized anatomically by deposits of fat and fatty acids in the intestinal and mesenteric lymphatic tissues.Bull Johns Hopkins Hosp.1907;18:382391.
  2. Black‐Schaffer B.The tinctoral demonstration of a glycoprotein in Whipple's disease.Proc Soc Exp Biol Med.1949;72:225227.
  3. Fleming JL,Wiesner RH,Shorter RG.Whipple's disease: clinical, biochemical, and histopathologic features and assessment of treatment in 29 patients.Mayo Clin Proc.1988;63:539551.
  4. Yardley JH,Hendrix TR.Combined electron and light microscopy in Whipple's disease: demonstration of “bacillary bodies” in the intestine.Bull Johns Hopkins Hosp.1961;109:8098.
  5. Wilson KH,Blitchington R,Frothingham R,Wilson JAP.Phylogeny of the Whipple's disease‐associated bacterium.Lancet.1991;338:474475.
  6. Relman DA,Schmidt TM,MacDermott RP,Falkow S.Identification of the uncultured bacillus of Whipple's disease.N Engl J Med.1992;327:293301.
  7. Raoult D,Birg ML,La Scola B, et al.Cultivation of the bacillus of Whipple's disease.N Engl J Med.2000;342:620625.
  8. Dumler SJ,Baisden BL,Yardley JH,Raoult D.Immunodetection of Tropheryma whipplei in intestinal tissue from Dr. Whipple's 1907 patient.N Engl J Med.2003;348:14111412.
  9. Marth T,Raoult D.Whipple's disease.Lancet.2003;361:239246.
  10. Louis ED,Lynch T,Kaufmann P, et al.Diagnostic guidelines in central nervous system Whipple's disease.Ann Neurol.1996;40:561568.
  11. Ehrbar HU,Bauerfeind P,Dutly F, et al.PCR‐positive tests for Tropheryma whippleii in patients without Whipple's disease.Lancet.1999;353:2214.
Article PDF
Issue
Journal of Hospital Medicine - 3(6)
Page Number
483-488
Sections
Article PDF
Article PDF

The approach to clinical conundrums by an expert clinician is revealed through presentation of an actual patient's case in an approach typical of morning report. Similar to patient care, sequential pieces of information are provided to the clinician who is unfamiliar with the case. The focus is on the thought processes of both the clinical team caring for the patient and the discussant.

A 36 year‐old male physician was admitted to a Baltimore hospital in April 1907 with weight loss, weakness, arthralgias, and abdominal distension that had progressed over 5 years.

In 1907, major causes of unexplained weight loss included tuberculosis, hyperthyroidism, cancer, and diabetes. Arthralgias and weakness are not specific. The insidious progression over 5 years narrows the infectious possibilities; tuberculosis and syphilis are important considerations. Since surgical removal was the main treatment for malignancy in 1907, a history of prior surgery might point to a previously diagnosed malignancy that is now progressing.

Five years earlier, while visiting Turkey as a medical missionary, he first noted the onset of arthralgias that lasted 6 to 8 hours and occurred 3 to 4 times per week. Over time, these attacks lasted up to 24 hours and became associated with warmth, swelling, and tenderness of both small and large joints. He gradually lost weight and strength. One year prior to arrival in the hospital, he developed a cough productive of yellow sputum. Seven months prior, he returned from Turkey to Atlanta and noticed an increase in his cough, along with fevers of 100 Fahrenheit and night sweats.

The primacy of the arthralgias in this illness lead me to consider primary rheumatic diseases, and multisystem diseases (including infections) with a predominant skeletal component. In 1907, tests for lupus and the rheumatoid factor were not available. Neither skeletal remains nor works of art provide evidence that rheumatoid arthritis existed until the 19th century, whereas ankylosing spondylitis, gout, and rickets were present by then.

As a medical missionary, he might have acquired a disease endemic to the areas he visited, or the travel history may be a red herring. Familial Mediterranean fever, though prevalent in Turkey and a cause of arthralgias accompanied by recurrent attacks of abdominal pain and fever, is not an acquired disease. Behcet's disease, also known as Silk Trader's Route disease, is found in descendents of the countries that comprised the ancient Silk Route from Japan to the Middle East and may cause arthritis along with oral ulcers, genital lesions, pathergy or uveitis. I would inquire about his ancestry and fevers before dismissing these possibilities.

Although 5 years would be unusually long for tuberculosis to go unrecognized, a physician in the first half of the 20th century would place tuberculosis near the top of possible diagnoses. In 1930, a time when the population of the United States was considerably less, there were over 300,000 cases of tuberculosis. Physicians, and in particular pathologists since autopsies were more commonly performed, often died from tuberculosis since streptomycin, the first antituberculous medication, did not arrive until 1944. At the turn of the 20th century, the ability to detect tubercle bacilli was quite good. Thus, I would include tuberculous peritonitis as a cause of the progressive abdominal symptoms in this physician. In approximately one‐third of patients with tuberculous peritonitis there is evidence of pulmonary disease, and I would try to culture tuberculosis in samples of sputum, a test then so common it probably rivaled our frequent complete blood counts in popularity.

Six months prior, examinations of sputum were negative for tubercle bacilli. Four months prior to arrival, the patient moved to New Mexico. His cough improved but he continued to lose weight and had diarrhea consisting of 3 to 4 loose or semiformed bowel movements per day. Three months prior to admission, he noted an increase in abdominal girth along with right lower quadrant fullness. One month prior, he noted painful swelling and warmth in both ankles as well as dyspnea with exertion.

The increased abdominal girth in the context of chronic illness might be due to ascites, adenopathy, visceromegaly, or mass lesions such as a neoplasm or abscess. If ascites is the cause, one would need to consider primary hepatic disorders, as well as extrahepatic diseases that could progress over years. Infection with hepatitis A virus does not cause chronic liver disease. Hepatitis B, in those days, was referred to as serum hepatitis, and a serum marker for the B virusthe Australia antigenwas not identified until 1967. Cardiac causes of ascites include congestive heart failure and constrictive pericarditis, the latter an important consideration because it is potentially curable. Also, constrictive pericarditis can present as an indolent weight‐losing disease because of chronic visceral congestion. Other considerations include nephrotic syndrome, infection, and neoplasm, including mesothelioma.

Abdominal distention might also be seen with a smoldering abscess. In addition to an appendiceal process, the travel and right lower quadrant localization reminds us to consider ameboma. This patient surely was in an area where amebiasis was endemic, and amebomaa chronic inflammatory form of infection with E. histolytica not associated with diarrhea or liver cystsmay mimic cecal carcinoma. Exertional dyspnea suggests at least the possibility of cardiac disease. Despite the negative sputum cultures, tuberculosis remains high on the list as a cause of constrictive pericarditis or peritonitis, either of which may occur in the absence of active pulmonary disease.

Past medical history included measles and whooping cough as a child, mild pleurisy at age 14, mild influenza 7 years previously. The patient had a tonsillectomy as a child and had a portion of his inferior turbinate bone removed in an attempt to relieve a nasal condition.

On physical exam, the patient was thin and the skin over his face and hands was deep brown. His temperature was 101.5 Fahrenheit, the heart rate was 100, and the respiratory rate was 24. Small lymph nodes were palpable in the axillary and epitrochlear areas. His thorax moved asymmetrically, with less movement on the left apex and slight dullness to percussion in that area. The pulmonic component of the second heart sound was mildly accentuated. The abdomen displayed fullness and tympany, most pronounced in the right lower quadrant without hepatosplenomegaly. The left ankle was swollen, and the overlying skin was tense, shiny, and hot. On both lower legs, areas of discoloration and slight induration were observed, felt to be consistent with faded erythema nodosum.

Though pleurisy has numerous causes, its presence raises the specter of tuberculosis again. The nasal condition triggers thoughts of Wegener's granulomatosis or lethal midline granuloma, both unlikely diagnoses here. The pulmonary exam suggests an apical process, such as tuberculosis, and the accentuated pulmonic heart sound implies pulmonary hypertension, which could be due to a number of chronic pulmonary diseases. The epitrochlear nodes are of interest since lymphoma and Hodgkin's disease rarely involve this area; syphilis and human immunodeficiency virus (HIV) are a few of the chronic diseases that may involve this lymph node region. More helpful is the absence of hepatosplenomegaly, since many indolent malignancies and infections would be expected to enlarge these organs by this point.

Monoarticular arthritis is often due to infection, and less likely due to rheumatoid disease. When rheumatoid arthritis flares, the entire skeleton flares, not single joints. Given the indolence and this single joint involvement, tuberculosis again comes to mind.

I would next want to obtain a plain chest radiograph, looking for evidence of tuberculosis. As with any test, one should ask how this will change management. In 1907, antituberculous medications were not available, so therapy was directed at lowering oxygen tension in the primary site of infection; for example, pulmonary disease was addressed via pneumothorax. If the chest radiograph provides little hint of tuberculosis, then consideration must be given to exploratory surgery of the abdomen given the focal abnormality in the right lower quadrant.

A peripheral blood smear revealed a hypochromic microcytic anemia. The total red blood cell count was 4.468 million/mm3 (normal range for men is 4.52‐5.90 million/mm3), white blood cell count was 8180/mm3, including 80% granulocytes and 9% eosinophils. On gross inspection, the stool was clay‐colored, and stool microscopy demonstrated large numbers of neutral fat droplets, but no ova, parasites, or tubercle bacilli. Urinalysis revealed no albumin or casts, and the bones were normal on ankle radiographs. Another sample of sputum revealed no tubercle bacilli, and intradermal placement of tuberculin provoked no reaction.

His negative tuberculin skin reaction is unusual for that era, because of the prevalence of tuberculosis. Most likely, he is anergic because of his severe underlying illness, and the absent reaction is thus not all that helpful a clue. Multiple negative sputum examinations lower the possibility of pulmonary, but not extrapulmonary, tuberculosis. The absence of bony destruction on ankle radiographs lowers my suspicion for tuberculous arthritis.

The excess stool fat implies steatogenic diarrhea from malabsorption, and 2 categories here are pancreatic and luminal diseases. Of these 2, pancreatic etiologies produce more severe malabsorption. We do not hear mention of jaundice, however, and I cannot see how to link the pancreas to the arthritis. A chronic infection which may produce malabsorption and eosinophilia is strongyloidiasis, endemic in the southeastern United States. However, this patient did not manifest the most common finding of chronic strongyloidiasis, namely asthma. Adrenal insufficiency, as might result from disseminated tuberculosis, is associated with increased skin pigmentation, diarrhea, and eosinophilia. However, the diarrhea of adrenal insufficiency is not malabsorptive, and serum electrolytes and cortisol tests were not available then to confirm this diagnosis antemortem.

In an attempt to identify a unifying cause of chronic arthritis, malabsorption, and increased skin pigmentation, I must consider Whipple's disease first and foremost. Physicians then were strapped and observation was often the default mode of the day. Given the abdominal findings, an exploratory laparotomy would be warranted if his condition deteriorated.

Despite forced oral feedings, the patient continued to lose weight, from his normal of 175 pounds to a nadir of 145 pounds. Because of worsening abdominal distention, the patient underwent exploratory abdominal surgery on the twenty‐first hospital day. Intraoperatively, no ascites was seen, but his mesenteric lymph nodes were hard and markedly enlarged. The abdomen was closed without further intervention. Two days after the surgery, the patient abruptly developed dyspnea. His respirations were 40 per minute, heart rate was 120, and he had minimal rales at the lung bases without findings of consolidation. He died 2 hours later, on the twenty‐third hospital day, and an autopsy was performed.

The final event may have been a pulmonary embolism. As for the adenopathy, lymphoma and tuberculosis are possible. Heavy chain disease, an unusual lymphoproliferative disorder found in persons from the old Silk Trader's Route from the Middle East to the Orient, is a remote prospect. However, 5 years is just too indolent for most cancers and would be very unusual for tuberculosis. I think the findings support Whipple's disease, and I wonder if this was the first reported case.

On postmortem examination, the abdominal adenopathy was striking. The small intestine contained enlarged villi with thickened submucosa, and the mesenteric nodes were enlarged with fat deposits and abnormal foamy cells. Within these foamy cells, microscopy revealed numerous rod‐shaped organisms. All studies were negative for tuberculosis, and although the pathologist, Dr. George Hoyt Whipple, suspected an infectious etiology, he offered the name intestinal lipodystrophy to emphasize the striking small intestinal changes he witnessed at autopsy, and which are the hallmarks of the disease that now bears his name. Whipple also shared the 1934 Nobel Prize in Physiology or Medicine with Minot and Murphy for their discovery that a nutritional substance in liver, now known as vitamin B12, was beneficial in treating pernicious anemia.

COMMENTARY

This is the index case of Whipple's disease, summarized from the original 1907 description.1 George Hoyt Whipple, then a pathologist at Johns Hopkins, highlights the value of keen observation and a well‐done case report in describing a new disease entity. One of the roles of case reports is to detail the features of an unknown disease. In this capacity, Whipple's summary is exemplary. His achievement was having the openness of mind to realize he was witnessing something novel, and to take the first step on the road to discovery. Although Whipple suspected he was staring at a unique disease, he could not pinpoint the culprit bacteria and he had trouble squaring the extraintestinal findings with the marked intestinal anomalies. It was left to decades of input from others to confirm the association of arthralgias, eosinophilia, skin hyperpigmentation, and cardiac valve abnormalities with intestinal malabsorption, and to culture the infectious agent.

In his discussion, Whipple recognized he was confronted with a novel clinical entity. Prior to surgery, pulmonary and mesenteric tuberculosis were suspected, based on the fevers, weight loss, cough, fat malabsorption, and lymphadenopathy. However, he felt the left apical exam was more representative of retraction from prior disease than active infection. He was also bothered by the negative skin reaction and sputum tests. At surgery, the pronounced adenopathy suggested sarcoma or Hodgkin's disease but postmortem examination eliminated these possibilities. At autopsy, the abdominal findings were most striking. The small intestine demonstrated enlarged villi with thickened submucosa and markedly enlarged mesenteric lymph glands containing large fat deposits and distinctly abnormal foamy cells. These foamy macrophages contained great numbers of rod‐shaped organisms resembling the tubercle bacillus. However, all tests were negative for tuberculosis, and the lungs contained no active disease. Though he suspected an infectious etiology, Whipple offered the name intestinal lipodystrophy to emphasize the striking small intestinal pathology.

Although Whipple had surmised a novel infectious agent in 1907, it took almost a century to isolate the causative microbe. Granules within foamy macrophages of the small intestine were detected on periodic acid‐Schiff (PAS) staining in 1949.2 Similar PAS‐positive granules were soon discovered in other tissues and fluid, providing a plausible explanation for the systemic features of the disease.3 Electron microscopy confirmed the presence of infectious bacilli in 1961,4 ushering in the era of antimicrobial treatment for this disease. More recently, using polymerase chain reaction (PCR), a unique bacterial 16S ribosomal RNA gene was isolated in patients with Whipple's disease.5, 6 Phylogenetically classified with the actinobacteria, Tropheryma whipplei (fom the Greek trophe, nourishment, and eryma, barrier) was ultimately subcultured in 2000,7 and immunodetection testing became possible. Using this technique, the archived pathology specimens from the 1907 index case demonstrated numerous intracellular bacteria in the lamina propria, closing the loop started by Whipple nearly a century earlier.8

Whipple's index case report described most of the manifestations of the disease we are familiar with today. As in the original description, arthralgias are the most common initial symptom and may precede diagnosis by a mean of 8 years. Other cardinal features include weight loss, abdominal pain and steatorrhea due to small intestinal involvement. Table 1 summarizes the important signs and symptoms of Whipple's disease.9, 10 One notable manifestation missing in Whipple's report is central nervous system involvement. Central nervous system (CNS) disease ranges from cognitive deficits to encephalitis and focal defects, and may occur years after treatment and without concomitant intestinal symptoms.

Clinical Features of Whipple Disease
Clinical Feature Comment
  • Two pathognomonic involuntary muscle signs in CNS Whipple disease are oculomasticatory and oculo‐facial‐skeletal myorhythmia.10

Cardinal features (present in 60% to 90%)
Arthropathy Most common initial symptom, preceding diagnosis by a mean of 8 years. Migratory, nonerosive, mainly in the peripheral joints.
Weight loss
Diarrhea Usually steatorrhea, may be associated with pain or occult blood in the stool
Other common features (present in 20% to 45%)
Fever
Lymphadenopathy May present as a palpable mass
Increased skin pigmentation Mechanism unknown (evidence of adrenal insufficiency has not been found in Whipple's)
Cardiac disease Culture‐negative endocarditis
Hypotension
Peripheral edema
Uncommon clinical features
Central nervous system involvement May be global (dementia, personality change, sleep disturbance) or focal (cranial neuropathy, nystagmus)
Eye disease Uveitis, retinitis
Hepatosplenomegaly
Polyserositis
Ascites

A remaining mystery is why this pathogen results only rarely in clinical disease. Caucasians comprise the majority of infected patients, and men are affected 8 times more often than women. An overrepresentation of HLA‐B27 suggests a genetic predisposition, though its role in pathogenesis is unclear. T. whipplei has been identified by PCR methods in asymptomatic individuals, implying additional abnormalities must be present in susceptible hosts for symptoms to occur following colonization.11 The exact immune defects are speculative, and immunodeficiency states (such as HIV) have not been consistently identified in patients with Whipple's disease.

The cornerstone of diagnosing Whipple's disease is upper endoscopy with duodenal biopsy. Flattening of the villi and markedly increased PAS‐positive staining of lamina propria macrophages are strongly suggestive of the diagnosis. PAS‐positive staining is not unique to T. whipplei, however. In patients with profound immunodeficiency, Mycobacterium avium intracellulare may stain positive with PAS. Since Whipple's disease is only rarely associated with HIV, a negative HIV test would favor a diagnosis of Whipple's disease. Electron microscopy may distinguish T. whipplei from its mimickers by morphology. For extraintestinal disease, PCR testing on samples from infected tissue has been found to be a reliable diagnostic aid.9

Given the rarity of the disease, controlled clinical trials addressing optimal treatment are lacking. Current recommendations include initial therapy for 14 days with an agent that crosses the blood‐brain barrier (eg, ceftriaxone) to reduce the incidence of CNS disease. This is then followed by a year or more of oral antimicrobial therapy with trimethoprim‐sulfamethoxazole or a tetracycline.9 While most patients respond within 2 to 3 weeks, relapse may occur in as many as one‐third of patients.

Historical case reports reinforce the case‐based learning paradigm. As the discussant remarks, observation was all too often the only recourse for physicians a century ago. In recounting the 7‐year progression of disease in 1 individual, Whipple provides a unique window into the natural evolution of the key features of this systemic disease. Viewed through the prism of Whipple's eyes, we can recall the striking lymphoid hyperplasia and unusual organisms in the small intestine, cementing our understanding of the pathogenesis of this disorder. Revisiting past cases allows us to learn of and learn from the past.

Teaching Points

  • Whipple's disease should be considered in patients with unexplained arthralgias accompanied by weight loss, malabsorption, and abdominal pain.

  • For suspected intestinal Whipple's disease, diagnosis is best made by duodenal biopsy demonstrating PAS‐positive staining in lamina propria macrophages.

  • Systemic manifestations of Whipple's disease include culture‐negative endocarditis and CNS disease. PCR testing of involved sites for T. whipplei is recommended to confirm extraintestinal disease.

The approach to clinical conundrums by an expert clinician is revealed through presentation of an actual patient's case in an approach typical of morning report. Similar to patient care, sequential pieces of information are provided to the clinician who is unfamiliar with the case. The focus is on the thought processes of both the clinical team caring for the patient and the discussant.

A 36 year‐old male physician was admitted to a Baltimore hospital in April 1907 with weight loss, weakness, arthralgias, and abdominal distension that had progressed over 5 years.

In 1907, major causes of unexplained weight loss included tuberculosis, hyperthyroidism, cancer, and diabetes. Arthralgias and weakness are not specific. The insidious progression over 5 years narrows the infectious possibilities; tuberculosis and syphilis are important considerations. Since surgical removal was the main treatment for malignancy in 1907, a history of prior surgery might point to a previously diagnosed malignancy that is now progressing.

Five years earlier, while visiting Turkey as a medical missionary, he first noted the onset of arthralgias that lasted 6 to 8 hours and occurred 3 to 4 times per week. Over time, these attacks lasted up to 24 hours and became associated with warmth, swelling, and tenderness of both small and large joints. He gradually lost weight and strength. One year prior to arrival in the hospital, he developed a cough productive of yellow sputum. Seven months prior, he returned from Turkey to Atlanta and noticed an increase in his cough, along with fevers of 100 Fahrenheit and night sweats.

The primacy of the arthralgias in this illness lead me to consider primary rheumatic diseases, and multisystem diseases (including infections) with a predominant skeletal component. In 1907, tests for lupus and the rheumatoid factor were not available. Neither skeletal remains nor works of art provide evidence that rheumatoid arthritis existed until the 19th century, whereas ankylosing spondylitis, gout, and rickets were present by then.

As a medical missionary, he might have acquired a disease endemic to the areas he visited, or the travel history may be a red herring. Familial Mediterranean fever, though prevalent in Turkey and a cause of arthralgias accompanied by recurrent attacks of abdominal pain and fever, is not an acquired disease. Behcet's disease, also known as Silk Trader's Route disease, is found in descendents of the countries that comprised the ancient Silk Route from Japan to the Middle East and may cause arthritis along with oral ulcers, genital lesions, pathergy or uveitis. I would inquire about his ancestry and fevers before dismissing these possibilities.

Although 5 years would be unusually long for tuberculosis to go unrecognized, a physician in the first half of the 20th century would place tuberculosis near the top of possible diagnoses. In 1930, a time when the population of the United States was considerably less, there were over 300,000 cases of tuberculosis. Physicians, and in particular pathologists since autopsies were more commonly performed, often died from tuberculosis since streptomycin, the first antituberculous medication, did not arrive until 1944. At the turn of the 20th century, the ability to detect tubercle bacilli was quite good. Thus, I would include tuberculous peritonitis as a cause of the progressive abdominal symptoms in this physician. In approximately one‐third of patients with tuberculous peritonitis there is evidence of pulmonary disease, and I would try to culture tuberculosis in samples of sputum, a test then so common it probably rivaled our frequent complete blood counts in popularity.

Six months prior, examinations of sputum were negative for tubercle bacilli. Four months prior to arrival, the patient moved to New Mexico. His cough improved but he continued to lose weight and had diarrhea consisting of 3 to 4 loose or semiformed bowel movements per day. Three months prior to admission, he noted an increase in abdominal girth along with right lower quadrant fullness. One month prior, he noted painful swelling and warmth in both ankles as well as dyspnea with exertion.

The increased abdominal girth in the context of chronic illness might be due to ascites, adenopathy, visceromegaly, or mass lesions such as a neoplasm or abscess. If ascites is the cause, one would need to consider primary hepatic disorders, as well as extrahepatic diseases that could progress over years. Infection with hepatitis A virus does not cause chronic liver disease. Hepatitis B, in those days, was referred to as serum hepatitis, and a serum marker for the B virusthe Australia antigenwas not identified until 1967. Cardiac causes of ascites include congestive heart failure and constrictive pericarditis, the latter an important consideration because it is potentially curable. Also, constrictive pericarditis can present as an indolent weight‐losing disease because of chronic visceral congestion. Other considerations include nephrotic syndrome, infection, and neoplasm, including mesothelioma.

Abdominal distention might also be seen with a smoldering abscess. In addition to an appendiceal process, the travel and right lower quadrant localization reminds us to consider ameboma. This patient surely was in an area where amebiasis was endemic, and amebomaa chronic inflammatory form of infection with E. histolytica not associated with diarrhea or liver cystsmay mimic cecal carcinoma. Exertional dyspnea suggests at least the possibility of cardiac disease. Despite the negative sputum cultures, tuberculosis remains high on the list as a cause of constrictive pericarditis or peritonitis, either of which may occur in the absence of active pulmonary disease.

Past medical history included measles and whooping cough as a child, mild pleurisy at age 14, mild influenza 7 years previously. The patient had a tonsillectomy as a child and had a portion of his inferior turbinate bone removed in an attempt to relieve a nasal condition.

On physical exam, the patient was thin and the skin over his face and hands was deep brown. His temperature was 101.5 Fahrenheit, the heart rate was 100, and the respiratory rate was 24. Small lymph nodes were palpable in the axillary and epitrochlear areas. His thorax moved asymmetrically, with less movement on the left apex and slight dullness to percussion in that area. The pulmonic component of the second heart sound was mildly accentuated. The abdomen displayed fullness and tympany, most pronounced in the right lower quadrant without hepatosplenomegaly. The left ankle was swollen, and the overlying skin was tense, shiny, and hot. On both lower legs, areas of discoloration and slight induration were observed, felt to be consistent with faded erythema nodosum.

Though pleurisy has numerous causes, its presence raises the specter of tuberculosis again. The nasal condition triggers thoughts of Wegener's granulomatosis or lethal midline granuloma, both unlikely diagnoses here. The pulmonary exam suggests an apical process, such as tuberculosis, and the accentuated pulmonic heart sound implies pulmonary hypertension, which could be due to a number of chronic pulmonary diseases. The epitrochlear nodes are of interest since lymphoma and Hodgkin's disease rarely involve this area; syphilis and human immunodeficiency virus (HIV) are a few of the chronic diseases that may involve this lymph node region. More helpful is the absence of hepatosplenomegaly, since many indolent malignancies and infections would be expected to enlarge these organs by this point.

Monoarticular arthritis is often due to infection, and less likely due to rheumatoid disease. When rheumatoid arthritis flares, the entire skeleton flares, not single joints. Given the indolence and this single joint involvement, tuberculosis again comes to mind.

I would next want to obtain a plain chest radiograph, looking for evidence of tuberculosis. As with any test, one should ask how this will change management. In 1907, antituberculous medications were not available, so therapy was directed at lowering oxygen tension in the primary site of infection; for example, pulmonary disease was addressed via pneumothorax. If the chest radiograph provides little hint of tuberculosis, then consideration must be given to exploratory surgery of the abdomen given the focal abnormality in the right lower quadrant.

A peripheral blood smear revealed a hypochromic microcytic anemia. The total red blood cell count was 4.468 million/mm3 (normal range for men is 4.52‐5.90 million/mm3), white blood cell count was 8180/mm3, including 80% granulocytes and 9% eosinophils. On gross inspection, the stool was clay‐colored, and stool microscopy demonstrated large numbers of neutral fat droplets, but no ova, parasites, or tubercle bacilli. Urinalysis revealed no albumin or casts, and the bones were normal on ankle radiographs. Another sample of sputum revealed no tubercle bacilli, and intradermal placement of tuberculin provoked no reaction.

His negative tuberculin skin reaction is unusual for that era, because of the prevalence of tuberculosis. Most likely, he is anergic because of his severe underlying illness, and the absent reaction is thus not all that helpful a clue. Multiple negative sputum examinations lower the possibility of pulmonary, but not extrapulmonary, tuberculosis. The absence of bony destruction on ankle radiographs lowers my suspicion for tuberculous arthritis.

The excess stool fat implies steatogenic diarrhea from malabsorption, and 2 categories here are pancreatic and luminal diseases. Of these 2, pancreatic etiologies produce more severe malabsorption. We do not hear mention of jaundice, however, and I cannot see how to link the pancreas to the arthritis. A chronic infection which may produce malabsorption and eosinophilia is strongyloidiasis, endemic in the southeastern United States. However, this patient did not manifest the most common finding of chronic strongyloidiasis, namely asthma. Adrenal insufficiency, as might result from disseminated tuberculosis, is associated with increased skin pigmentation, diarrhea, and eosinophilia. However, the diarrhea of adrenal insufficiency is not malabsorptive, and serum electrolytes and cortisol tests were not available then to confirm this diagnosis antemortem.

In an attempt to identify a unifying cause of chronic arthritis, malabsorption, and increased skin pigmentation, I must consider Whipple's disease first and foremost. Physicians then were strapped and observation was often the default mode of the day. Given the abdominal findings, an exploratory laparotomy would be warranted if his condition deteriorated.

Despite forced oral feedings, the patient continued to lose weight, from his normal of 175 pounds to a nadir of 145 pounds. Because of worsening abdominal distention, the patient underwent exploratory abdominal surgery on the twenty‐first hospital day. Intraoperatively, no ascites was seen, but his mesenteric lymph nodes were hard and markedly enlarged. The abdomen was closed without further intervention. Two days after the surgery, the patient abruptly developed dyspnea. His respirations were 40 per minute, heart rate was 120, and he had minimal rales at the lung bases without findings of consolidation. He died 2 hours later, on the twenty‐third hospital day, and an autopsy was performed.

The final event may have been a pulmonary embolism. As for the adenopathy, lymphoma and tuberculosis are possible. Heavy chain disease, an unusual lymphoproliferative disorder found in persons from the old Silk Trader's Route from the Middle East to the Orient, is a remote prospect. However, 5 years is just too indolent for most cancers and would be very unusual for tuberculosis. I think the findings support Whipple's disease, and I wonder if this was the first reported case.

On postmortem examination, the abdominal adenopathy was striking. The small intestine contained enlarged villi with thickened submucosa, and the mesenteric nodes were enlarged with fat deposits and abnormal foamy cells. Within these foamy cells, microscopy revealed numerous rod‐shaped organisms. All studies were negative for tuberculosis, and although the pathologist, Dr. George Hoyt Whipple, suspected an infectious etiology, he offered the name intestinal lipodystrophy to emphasize the striking small intestinal changes he witnessed at autopsy, and which are the hallmarks of the disease that now bears his name. Whipple also shared the 1934 Nobel Prize in Physiology or Medicine with Minot and Murphy for their discovery that a nutritional substance in liver, now known as vitamin B12, was beneficial in treating pernicious anemia.

COMMENTARY

This is the index case of Whipple's disease, summarized from the original 1907 description.1 George Hoyt Whipple, then a pathologist at Johns Hopkins, highlights the value of keen observation and a well‐done case report in describing a new disease entity. One of the roles of case reports is to detail the features of an unknown disease. In this capacity, Whipple's summary is exemplary. His achievement was having the openness of mind to realize he was witnessing something novel, and to take the first step on the road to discovery. Although Whipple suspected he was staring at a unique disease, he could not pinpoint the culprit bacteria and he had trouble squaring the extraintestinal findings with the marked intestinal anomalies. It was left to decades of input from others to confirm the association of arthralgias, eosinophilia, skin hyperpigmentation, and cardiac valve abnormalities with intestinal malabsorption, and to culture the infectious agent.

In his discussion, Whipple recognized he was confronted with a novel clinical entity. Prior to surgery, pulmonary and mesenteric tuberculosis were suspected, based on the fevers, weight loss, cough, fat malabsorption, and lymphadenopathy. However, he felt the left apical exam was more representative of retraction from prior disease than active infection. He was also bothered by the negative skin reaction and sputum tests. At surgery, the pronounced adenopathy suggested sarcoma or Hodgkin's disease but postmortem examination eliminated these possibilities. At autopsy, the abdominal findings were most striking. The small intestine demonstrated enlarged villi with thickened submucosa and markedly enlarged mesenteric lymph glands containing large fat deposits and distinctly abnormal foamy cells. These foamy macrophages contained great numbers of rod‐shaped organisms resembling the tubercle bacillus. However, all tests were negative for tuberculosis, and the lungs contained no active disease. Though he suspected an infectious etiology, Whipple offered the name intestinal lipodystrophy to emphasize the striking small intestinal pathology.

Although Whipple had surmised a novel infectious agent in 1907, it took almost a century to isolate the causative microbe. Granules within foamy macrophages of the small intestine were detected on periodic acid‐Schiff (PAS) staining in 1949.2 Similar PAS‐positive granules were soon discovered in other tissues and fluid, providing a plausible explanation for the systemic features of the disease.3 Electron microscopy confirmed the presence of infectious bacilli in 1961,4 ushering in the era of antimicrobial treatment for this disease. More recently, using polymerase chain reaction (PCR), a unique bacterial 16S ribosomal RNA gene was isolated in patients with Whipple's disease.5, 6 Phylogenetically classified with the actinobacteria, Tropheryma whipplei (fom the Greek trophe, nourishment, and eryma, barrier) was ultimately subcultured in 2000,7 and immunodetection testing became possible. Using this technique, the archived pathology specimens from the 1907 index case demonstrated numerous intracellular bacteria in the lamina propria, closing the loop started by Whipple nearly a century earlier.8

Whipple's index case report described most of the manifestations of the disease we are familiar with today. As in the original description, arthralgias are the most common initial symptom and may precede diagnosis by a mean of 8 years. Other cardinal features include weight loss, abdominal pain and steatorrhea due to small intestinal involvement. Table 1 summarizes the important signs and symptoms of Whipple's disease.9, 10 One notable manifestation missing in Whipple's report is central nervous system involvement. Central nervous system (CNS) disease ranges from cognitive deficits to encephalitis and focal defects, and may occur years after treatment and without concomitant intestinal symptoms.

Clinical Features of Whipple Disease
Clinical Feature Comment
  • Two pathognomonic involuntary muscle signs in CNS Whipple disease are oculomasticatory and oculo‐facial‐skeletal myorhythmia.10

Cardinal features (present in 60% to 90%)
Arthropathy Most common initial symptom, preceding diagnosis by a mean of 8 years. Migratory, nonerosive, mainly in the peripheral joints.
Weight loss
Diarrhea Usually steatorrhea, may be associated with pain or occult blood in the stool
Other common features (present in 20% to 45%)
Fever
Lymphadenopathy May present as a palpable mass
Increased skin pigmentation Mechanism unknown (evidence of adrenal insufficiency has not been found in Whipple's)
Cardiac disease Culture‐negative endocarditis
Hypotension
Peripheral edema
Uncommon clinical features
Central nervous system involvement May be global (dementia, personality change, sleep disturbance) or focal (cranial neuropathy, nystagmus)
Eye disease Uveitis, retinitis
Hepatosplenomegaly
Polyserositis
Ascites

A remaining mystery is why this pathogen results only rarely in clinical disease. Caucasians comprise the majority of infected patients, and men are affected 8 times more often than women. An overrepresentation of HLA‐B27 suggests a genetic predisposition, though its role in pathogenesis is unclear. T. whipplei has been identified by PCR methods in asymptomatic individuals, implying additional abnormalities must be present in susceptible hosts for symptoms to occur following colonization.11 The exact immune defects are speculative, and immunodeficiency states (such as HIV) have not been consistently identified in patients with Whipple's disease.

The cornerstone of diagnosing Whipple's disease is upper endoscopy with duodenal biopsy. Flattening of the villi and markedly increased PAS‐positive staining of lamina propria macrophages are strongly suggestive of the diagnosis. PAS‐positive staining is not unique to T. whipplei, however. In patients with profound immunodeficiency, Mycobacterium avium intracellulare may stain positive with PAS. Since Whipple's disease is only rarely associated with HIV, a negative HIV test would favor a diagnosis of Whipple's disease. Electron microscopy may distinguish T. whipplei from its mimickers by morphology. For extraintestinal disease, PCR testing on samples from infected tissue has been found to be a reliable diagnostic aid.9

Given the rarity of the disease, controlled clinical trials addressing optimal treatment are lacking. Current recommendations include initial therapy for 14 days with an agent that crosses the blood‐brain barrier (eg, ceftriaxone) to reduce the incidence of CNS disease. This is then followed by a year or more of oral antimicrobial therapy with trimethoprim‐sulfamethoxazole or a tetracycline.9 While most patients respond within 2 to 3 weeks, relapse may occur in as many as one‐third of patients.

Historical case reports reinforce the case‐based learning paradigm. As the discussant remarks, observation was all too often the only recourse for physicians a century ago. In recounting the 7‐year progression of disease in 1 individual, Whipple provides a unique window into the natural evolution of the key features of this systemic disease. Viewed through the prism of Whipple's eyes, we can recall the striking lymphoid hyperplasia and unusual organisms in the small intestine, cementing our understanding of the pathogenesis of this disorder. Revisiting past cases allows us to learn of and learn from the past.

Teaching Points

  • Whipple's disease should be considered in patients with unexplained arthralgias accompanied by weight loss, malabsorption, and abdominal pain.

  • For suspected intestinal Whipple's disease, diagnosis is best made by duodenal biopsy demonstrating PAS‐positive staining in lamina propria macrophages.

  • Systemic manifestations of Whipple's disease include culture‐negative endocarditis and CNS disease. PCR testing of involved sites for T. whipplei is recommended to confirm extraintestinal disease.

References
  1. Whipple GH.A hitherto undescribed disease characterized anatomically by deposits of fat and fatty acids in the intestinal and mesenteric lymphatic tissues.Bull Johns Hopkins Hosp.1907;18:382391.
  2. Black‐Schaffer B.The tinctoral demonstration of a glycoprotein in Whipple's disease.Proc Soc Exp Biol Med.1949;72:225227.
  3. Fleming JL,Wiesner RH,Shorter RG.Whipple's disease: clinical, biochemical, and histopathologic features and assessment of treatment in 29 patients.Mayo Clin Proc.1988;63:539551.
  4. Yardley JH,Hendrix TR.Combined electron and light microscopy in Whipple's disease: demonstration of “bacillary bodies” in the intestine.Bull Johns Hopkins Hosp.1961;109:8098.
  5. Wilson KH,Blitchington R,Frothingham R,Wilson JAP.Phylogeny of the Whipple's disease‐associated bacterium.Lancet.1991;338:474475.
  6. Relman DA,Schmidt TM,MacDermott RP,Falkow S.Identification of the uncultured bacillus of Whipple's disease.N Engl J Med.1992;327:293301.
  7. Raoult D,Birg ML,La Scola B, et al.Cultivation of the bacillus of Whipple's disease.N Engl J Med.2000;342:620625.
  8. Dumler SJ,Baisden BL,Yardley JH,Raoult D.Immunodetection of Tropheryma whipplei in intestinal tissue from Dr. Whipple's 1907 patient.N Engl J Med.2003;348:14111412.
  9. Marth T,Raoult D.Whipple's disease.Lancet.2003;361:239246.
  10. Louis ED,Lynch T,Kaufmann P, et al.Diagnostic guidelines in central nervous system Whipple's disease.Ann Neurol.1996;40:561568.
  11. Ehrbar HU,Bauerfeind P,Dutly F, et al.PCR‐positive tests for Tropheryma whippleii in patients without Whipple's disease.Lancet.1999;353:2214.
References
  1. Whipple GH.A hitherto undescribed disease characterized anatomically by deposits of fat and fatty acids in the intestinal and mesenteric lymphatic tissues.Bull Johns Hopkins Hosp.1907;18:382391.
  2. Black‐Schaffer B.The tinctoral demonstration of a glycoprotein in Whipple's disease.Proc Soc Exp Biol Med.1949;72:225227.
  3. Fleming JL,Wiesner RH,Shorter RG.Whipple's disease: clinical, biochemical, and histopathologic features and assessment of treatment in 29 patients.Mayo Clin Proc.1988;63:539551.
  4. Yardley JH,Hendrix TR.Combined electron and light microscopy in Whipple's disease: demonstration of “bacillary bodies” in the intestine.Bull Johns Hopkins Hosp.1961;109:8098.
  5. Wilson KH,Blitchington R,Frothingham R,Wilson JAP.Phylogeny of the Whipple's disease‐associated bacterium.Lancet.1991;338:474475.
  6. Relman DA,Schmidt TM,MacDermott RP,Falkow S.Identification of the uncultured bacillus of Whipple's disease.N Engl J Med.1992;327:293301.
  7. Raoult D,Birg ML,La Scola B, et al.Cultivation of the bacillus of Whipple's disease.N Engl J Med.2000;342:620625.
  8. Dumler SJ,Baisden BL,Yardley JH,Raoult D.Immunodetection of Tropheryma whipplei in intestinal tissue from Dr. Whipple's 1907 patient.N Engl J Med.2003;348:14111412.
  9. Marth T,Raoult D.Whipple's disease.Lancet.2003;361:239246.
  10. Louis ED,Lynch T,Kaufmann P, et al.Diagnostic guidelines in central nervous system Whipple's disease.Ann Neurol.1996;40:561568.
  11. Ehrbar HU,Bauerfeind P,Dutly F, et al.PCR‐positive tests for Tropheryma whippleii in patients without Whipple's disease.Lancet.1999;353:2214.
Issue
Journal of Hospital Medicine - 3(6)
Issue
Journal of Hospital Medicine - 3(6)
Page Number
483-488
Page Number
483-488
Article Type
Display Headline
One hundred years later
Display Headline
One hundred years later
Sections
Article Source
Copyright © 2008 Society of Hospital Medicine
Disallow All Ads
Correspondence Location
Department of Medicine, California Pacific Medical Center, 2351 Clay Street, Suite 380, San Francisco, CA 94115
Content Gating
Gated (full article locked unless allowed per User)
Gating Strategy
First Peek Free
Article PDF Media

Recognition, Risk, and Treatment of ADHF

Article Type
Changed
Mon, 01/02/2017 - 19:34
Display Headline
Hospitalized patients with acute decompensated heart failure: Recognition, risk stratification, and treatment review

Currently, acute decompensated heart failure (ADHF) accounts for 3% of all hospitalizations in the United States and is the second most common indication for hospitalization in individuals 65 years of age.1 These hospitalizations are costly and frequently have limited sustained benefits. The total direct medical cost attributable to ADHF hospitalization in the United States is estimated to be $18.8 billion annually.2 Furthermore, 50% of all patients hospitalized for ADHF are readmitted within 6 months of discharge.3 Clearly, the hospital management of these patients requires reevaluation.

The purpose of this article is to review the recognition, risk stratification, and treatment of ADHF and to discuss the role hospitalists can play in improving this treatment.

RECOGNITION OF ADHF

The American College of Cardiology/American Heart Association guidelines classify patients with heart failure into 1 of 4 stages, A through D.4 Patients with heart failure risk factors who do not have evidence of structural heart disease are classified as Stage A. Patients with evidence of structural heart disease who have never been symptomatic are classified as Stage B. Patients who are presently or previously symptomatic and responsive to standard therapies are classified as Stage C. Finally, patients are classified as Stage D if they are refractory to standard therapies and require specialized advanced treatment such as mechanical circulatory support, continuous inotropic infusions, or cardiac transplantation. By definition, patients with ADHF have either Stage C or Stage D heart failure.

Early recognition and appropriate treatment are key components in improving the management of these patients.57 Hospitalization is recommended for patients with evidence of severely decompensated heart failure, dyspnea at rest, hemodynamically significant arrhythmias, and acute coronary syndromes and should be considered in patients with worsening congestion, major electrolyte abnormalities, associated comorbid conditions, and repeated implantable cardioverter‐defibrillator firings.8 However, correctly identifying ADHF at the time of hospital presentation can be challenging.9 The diagnosis of ADHF is based on signs and symptoms, supported by radiographic findings, biomarkers, and echocardiography.8, 10 Unfortunately, the typical signs and symptoms of ADHFfor example, rales, peripheral edema, dyspnea at rest, and fatiguemay be missing at hospital presentation. In an early evaluation, rales, edema, and elevated mean jugular venous pressure were absent in 18 of 43 patients with documented pulmonary capillary wedge pressures (PCWP) 22 mm Hg.11 These findings have recently been confirmed using data from 2 large registries, the Acute Decompensated Heart Failure National Registry (ADHERE) and the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE‐HF) registry. In these registries, 32%36% of patients admitted with ADHF did not have rales, 33%35% did not have peripheral edema, 56%64% did not have dyspnea at rest, and approximately 67% did not have fatigue (Figure 1).12, 13 Furthermore, even when these signs and symptoms are present, they are nondiagnostic, because they can be produced by a variety of disorders, including hepatic, renal, and pulmonary dysfunction.8, 14

Figure 1
Prevalence of rales, peripheral edema, dyspnea at rest, and fatigue in patients admitted for acute decompensated heart failure in the Acute Decompensated Heart Failure National Registry (ADHERE; N = 67,966) and the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure registry (OPTIMIZE‐HF; N = 48,612). Derived from Abraham et al12 and Gheorghiade et al.13

Similarly, radiographic and echocardiographic features of ADHF are not always present. Overall, 26% of patients in ADHERE did not have evidence of pulmonary congestion on their initial chest radiograph, and 50%55% of patients in both registries had preserved systolic function.13, 1517 Consequently, attention has turned to biomarkers as a means of rapidly and accurately identifying ADHF. Serum Btype natriuretic peptide (BNP) and its N‐terminal prohormone (NT‐proBNP) have proven to be both diagnostic and prognostic indicators in ADHF.14, 1825 In the Breathing Not Properly Multinational Study, a BNP level 100 pg/mL was found to have a 90% sensitivity (95% confidence interval [CI]: 88%92%) and a 76% specificity (95% CI: 73%79%) for heart failure in patients presenting to the emergency department with dyspnea.21 In addition, BNP levels have been shown to correlate with heart failure severity18 and to be a more accurate reflection of this severity than clinical judgment.23 In a prospective randomized evaluation, the addition of BNP assessment to a standard diagnostic evaluation resulted in fewer patients being hospitalized (75% vs. 85%; P = .008), more rapid initiation of appropriate therapy (63 vs. 90 minutes; P = .03), and a shorter median duration of hospitalization (8 vs. 11 days; P = .001).26 As a result, the American College of Emergency Physicians guidelines now state that measurement of BNP or NT‐proBNP can improve diagnostic accuracy in acute heart failure syndrome when compared with standard clinical judgment alone.27

It is important to remember, however, that BNP levels cannot be interpreted in isolation; clinical judgment still plays a vital role. Obesity decreases BNP levels due to the expression of natriuretic peptide clearance receptors in adipose tissue.9, 28, 29 In contrast, BNP levels increase with age and are higher in women than in men.29 In addition, pulmonary embolism, an important diagnostic consideration in patients presenting with dyspnea, has been shown to increase serum BNP levels above the diagnostic threshold for ADHF.9, 29 Likewise, renal dysfunction, a common comorbidity in patients with heart failure (cardiorenal syndrome), increases serum BNP levels.30 As a result, the BNP threshold value for the diagnosis of ADHF rises from 100 pg/mL in patients with normal renal function to 200 pg/mL in patients with an estimated glomerular filtration rate <60 mL/min/1.73 m2.30 Finally, it is now well recognized that BNP production is up‐regulated by numerous physiologic conditions in addition to heart failure, including cardiac hypertrophy, endothelial dysfunction, and arrhythmia.31 Consequently, an elevated BNP level may indicate one of these conditions instead of ADHF. For example, recent data demonstrate that BNP levels are increased in patients with acute coronary syndromes and also serve as a significant prognostic factor in these patients.32, 33

RISK STRATIFICATION

Risk stratification, another important component in improving the management of patients with ADHF, helps determine the appropriate location (eg, outpatient, hospital ward, intensive care unit) for and intensity of initial monitoring and treatment.13, 25, 3452 Univariate analyses have identified several morbidity and/or mortality risk factors, including age,3540 blood pressure,13, 34, 37, 3941 respiratory rate,37 left ventricular ejection fraction (LVEF),36, 41, 48 renal function,34, 36, 37, 39, 40, 42, 43 anemia,25, 44, 45 hyponatremia,37, 39, 46 BNP level,36, 49, 50 cardiac troponin level,48 diuretic dose,36, 49, 50 previous heart failure hospitalization,44, 51, 52 and comorbid conditions.35, 37, 39 Unfortunately, these univariate factors are not very helpful in and of themselves, as they regularly occur in conjunction with each other. True risk assessment requires multivariate analyses of large datasets.

Multivariate risk factors for short‐term mortality in patients admitted for ADHF have been evaluated in 3 separate studies. Lee et al used multiple logistic regression to analyze data from 4031 hospitalization episodes at 34 centers in Canada,37 Fonarow et al used both classification and regression tree and multivariate regression models to analyze data from 65,275 hospitalization episodes at 263 centers in the United States,34 and Rohde et al used stepwise logistic regression to analyze data from 779 consecutive hospitalization episodes at a single center in Brazil.39 Despite these differences in statistical methodology and geographic location, the findings of these 3 analyses are remarkably similar. All 3 evaluations identified advanced age, lower systolic blood pressure, and renal dysfunction (cardiorenal syndrome) as significant and independent risk factors for short‐term mortality, and 2 of the 3 identified hyponatremia and comorbid cancer as additional risk factors (Table 1).34 Of note, lower systolic blood pressure did not mean hypotension in these evaluations. Mortality risk was significantly increased in patients with systolic blood pressure <115‐124 mm Hg. In the largest of these studies, a simple risk tree utilizing admission blood pressure, serum creatinine concentration, and blood urea nitrogen level stratified patients into groups with in‐hospital mortality risk ranging from 2.1%21.9% in the derivation and 2.3%19.8% in the validation cohorts (Figure 2).34 Taken together, these studies underscore the substantial role age, blood pressure, renal function, serum sodium concentration, and comorbidities play in increasing mortality risk, and these factors should always be considered in determining the intensity and location of ADHF treatment and degree of monitoring employed therein.

Figure 2
Risk of in‐hospital mortality based on Classification and Regression Tree Analysis (CART) of data from the Acute Decompensated Heart Failure National Registry (ADHERE). The model was developed using data from the initial 33,046 hospitalizations in the registry (Derivation cohort) and validated using data from the subsequent 32,229 hospitalizations (Validation cohort). Abbreviations: BUN, blood urea nitrogen; SBP, systolic blood pressure; SCr, serum creatinine. Adapted from Fonarow et al.34
Multivariate Risk Factors in Patients Admitted for Acute Decompensated Heart Failure
Parameter Study
Lee et al37 Fonarow et al34 Rohde et al39
  • Abbreviations: BUN, blood urea nitrogen; COPD, chronic obstructive pulmonary disease; SBP, systolic blood pressure.

Data source 34 Hospitals 263 Hospitals Single center
Admissions evaluated 4031 65,275 779
Outcome parameter 30‐Day mortality In‐hospital mortality In‐hospital mortality
Independent risk factors
Older age Yes Yes Yes (>70 years)
Lower SBP Yes Yes (<115 mm Hg) Yes (124 mm Hg)
Renal dysfunction Yes Yes Yes
Elevated BUN Yes Yes (>43 mg/dL) Yes (>37 mg/dL)
Elevated serum creatinine Yes (>2.75 mg/dL) Yes (>1.4 mg/dL)
Hyponatremia Yes Yes (<136 mEq/L)
Elevated heart rate Yes
Elevated respiratory rate Yes
Comorbid conditions Yes Yes
Cancer Yes Yes
Cerebrovascular disease Yes
COPD Yes
Dementia Yes

Although BNP and cardiac troponin level were not significant risk factors in the multivariate models, these levels were not routinely assessed in patients admitted for ADHF 5 to 10 years ago. For example, admission BNP was available in only 18% of patients in the Fonarow analysis,34 and this lack of data may explain the absence of these parameters in these multivariate analyses. In a recent analysis limited to patients with admission BNP and cardiac troponin data, in‐hospital mortality was significantly increased when BNP was 840 pg/mL (odds ratio [OR]: 1.60; 95% CI: 1.431.80; P < .001), cardiac troponin was positive (OR: 1.85; 95% CI: 1.572.18; P < .001) or both (OR: 3.00; 95% CI: 2.473.66; P < .001) even after adjusting for differences in age, gender, blood urea nitrogen, systolic blood pressure, serum creatinine concentration, serum sodium concentration, heart rate, and dyspnea at rest.4

THERAPY

Ideally, treatment should be rooted in evidence‐based guidelines. However, relatively few randomized, controlled clinical trials have been completed in patients with ADHF, and consequently there are minimal data available to construct these guidelines. The American College of Cardiology and the American Heart Association have jointly published guidelines since 1995 on the management of heart failure.4, 53 However, these guidelines, which were last updated in 2005, discuss only the management of chronic heart failure, not the management of ADHF.4 In fact, the most recent version of these guidelines specifically states, The committee elected to focus this document on the diagnosis and management of chronic heart failure It specifically did not consider acute heart failure, which might merit a separate set of guidelines.4

The first guideline to specifically address the management of ADHF was published in 2004.5 These guidelines, a consensus statement based on expert panel review of the available literature, were created to improve treatment at member hospitals of a national group purchasing organization and focused only on the initial 24 hours of care. They had 2 important components. The first was a timeline emphasizing rapid assessment and institution of therapy, followed by serial reevaluations every couple of hours thereafter.5 The second was a flow chart detailing recommended initial therapies based on the current clinical findings and the patient's chronic outpatient pharmacotherapy, followed by modifications to this initial therapy based on the response observed during the serial reevaluations. Treatment recommendations were as follows: for patients with mild volume overload, an intravenous diuretic; for patients with moderate to severe volume overload, an intravenous diuretic plus an intravenous vasodilator (nitroglycerin or nesiritide); and for patients with low cardiac output, an inotropic agent with or without a subsequent intravenous vasodilator.

In 2005, the European Society of Cardiology published its guidelines for the treatment of ADHF.10 These guidelines state that the immediate goal of ADHF therapy is to improve symptoms and stabilize hemodynamics, but these short‐term benefits must be accompanied by favorable effects on long‐term outcomes.10 Recommended treatment consists of fluid loading, diuretics, vasodilators (glyceryl trinitrate, isosorbide dinitrate, nitroprusside, or nesiritide), and/or inotropic agents (dopamine, dobutamine, milrinone, enoximone, levosimendan, norepinephrine, or epinephrine), depending on the patient's clinical status and hemodynamics.10 In general, the guidelines recommend fluid loading in patients with low cardiac output and low PCWP; a vasodilator or inotropic agent, depending on systolic blood pressure, in patients with low cardiac output and normal to high PCWP; and an intravenous diuretic in patients with normal cardiac output and high PCWP pressure. Finally, respiratory support, eg, continuous positive airway pressure (CPAP), noninvasive positive pressure ventilation, or endotracheal intubation and mechanical ventilation, may be necessary in some patients with left‐heart failure.

In 2006, the Heart Failure Society of America published comprehensive heart failure practice guidelines.8 These guidelines expand the goals of ADHF therapy to include improving symptoms, optimizing volume status, identifying precipitating factors, enhancing chronic oral therapy, and minimizing side effects. They provide the most detailed recommendations yet with respect to monitoring patents admitted for ADHF.8 According to these guidelines, this monitoring should include more than daily assessment of vital signs, including orthostatic blood pressure, and at least daily assessment of heart failure signs and symptoms, fluid intake and output, weight, electrolytes, and renal function. Treatment recommendations are similar to those in preceding guidelines. Intravenous loop diuretics are recommended as first‐line therapy in patients with volume overload.8 In the absence of systemic hypotension, the addition of an intravenous vasodilator (nitroglycerin, nitroprusside, or nesiritide) should be considered to achieve rapid symptomatic improvement.8 Intravenous inotropic therapy may be considered to improve symptoms and end‐organ function in patients with low‐output syndrome (left ventricular dilation, reduced LVEF, and diminished peripheral perfusion), especially if systolic blood pressure is <90 mm Hg or there is symptomatic hypotension despite adequate filling pressures.54 Outside of this small select group of patients, there is no rationale for the use of inotropic agents.8 Patients with ADHF who received an inotropic agent in the absence of a clearly defined clinical indication had an increased risk of adverse events without any evidence of clinical benefit in the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME‐CHF) trial.54 Ultrafiltration may be considered in patients who fail to respond adequately to diuretic therapy,6, 8 and an implantable left ventricular assist device (LVAD) should be considered as a bridge to cardiac transplantation in patients with severe heart failure (Stage D) who have become refractory to all means of medical circulatory support and may be considered in highly selected nontransplantation candidates who cannot be weaned from intravenous inotropic support.8, 52

Whether to continue or temporarily stop chronic oral heart failure medications during treatment of an acute decompensation is not addressed in any of the evidence‐based guidelines and ultimately, this decision must be based on the patient's clinical status. In general, guideline‐recommended intravenous diuretic therapy temporarily replaces the patient's chronic oral diuretic regimen. Oral ‐blocker therapy should be continued whenever possible, as long as the patient's blood pressure and clinical status can tolerate it. In an analysis of data from the OPTIMIZE‐HF registry, patients with ADHF who had withdrawal of ‐blocker had significantly greater risk‐adjusted mortality compared to those in whom this therapy was continued (hazard ratio: 2.3; 95% CI: 1.2‐4.6; P = .013).55, 56 Finally, it is recommended that patients receiving an angiotensin‐converting enzyme inhibitor be continued on this agent as long as they are not in cardiogenic shock and do not have significantly deteriorating renal function.8

ROLE OF THE HOSPITALIST

Despite the presence of treatment guidelines, significant variation in the treatment of patients with ADHF persists.8, 58 Treatment of these patients is frequently contrary to the recommendations in published guidelines and can adversely impact both the cost of hospitalization and the ultimate clinical outcome. Low adherence to accepted standards of medical care has been shown to be a significant and independent risk factor for early hospital readmission.58 Furthermore, the main determinant of inotrope use in the ESCAPE trial was not the patient's cardiac output, blood pressure, or PCWP, but instead was the hospital to which the patient was admitted.59

Hospitalists are positioned to play a key role in improving both inpatient care of ADHF patients and the transition to long‐term patient management.60, 61 However, specific core competencies are required before hospitalists can effectively undertake this role. Table 2 highlights some of these core competencies.57

Selected Core Competencies for Hospitalists in Management of Heart Failure
Domain Competencies
  • Adapted from the Journal of Hospital Medicine.57

Knowledge Underlying causes of heart failure (eg, ischemia, cardiomyopathy, arrhythmia, drugs, alcohol)
Precipitating factors leading to exacerbation (eg, fluid overload)
Indicated tests to evaluate heart failure (eg, chest x‐ray, echocardiography, B‐type natriuretic peptide levels)
Risk factors for the development of heart failure (eg, hypertension, hyperlipidemia, coronary artery disease, diabetes, obesity)
Risk stratification in patients admitted with heart failure
Evidence‐based therapeutic options for management of both acute and chronic heart failure
Indications, contraindications, and mechanisms of action of drugs used to treat heart failure
Skills Identify signs of low perfusion (eg, capillary refill, end‐organ dysfunction)
Attitudes Recognize indications for cardiac consultation (eg, ischemia, atypical presentation, unresponsive to usual therapy)
Recognize indications for transplantation evaluation (eg, uncontrollable severe heart failure)
System organization and improvement Advocate establishment and support of outpatient heart failure management teams

Data indicate that hospitalists are more likely than nonhospitalists to implement evidence‐based assessments and treatment.62 Lindenauer et al conducted a retrospective review of medical records from patients admitted for ADHF at a community‐based teaching hospital who were not managed by cardiologists and found that the assessment of left ventricular function was significantly greater when the patient's care was managed by a hospitalist (94%) compared to a nonhospitalist (87%; P = .04).61 Similarly, Roytman et al performed a retrospective review of medical records from another community‐based teaching hospital and found that patients admitted for ADHF who were managed by hospitalists were more likely than patients managed by community physicians (55% cardiologists) to receive intravenous diuretics (90% vs. 73%; P < .001) and to have angiotensin‐converting enzyme inhibitor or angiotensin receptor blocker therapy initiated or resumed within 24 hours of hospital admission (86% vs. 72%; P = .003).62

Hospitalist care has also been shown to significantly reduce the duration of hospitalization. In the evaluation by Lindenauer et al, the risk‐adjusted length of stay was significantly shorter in patients whose care was managed by a hospitalist (P = .03). This benefit was greatest for patients in the major severity category.61 Similarly, in the review by Roytman et al, hospitalist care was associated with a 13%40% reduction in adjusted length of stay (P = .002), depending on disease severity.62 These reductions appear to be directly related to the greater experience of hospitalists in managing this and other acute disorders. In a retrospective review of data from an urban teaching hospital, care by a hospitalist, when compared with that by a nonhospitalist, was associated with a 15% reduction in overall length of stay (5.0 vs. 5.9 days; P < .02), with the greatest benefit observed in those patients whose disorders required close clinical monitoring (ie, heart failure, stroke, asthma, or pneumonia) or complex discharge planning.63 Moreover, there was a significant inverse correlation between the mean duration of hospitalization and the number of months of inpatient care provided by the attending physician each year ( = 0.19 day per month of inpatient care; P < .002).63

Finally, hospitalists are uniquely situated to influence medical care. Hospitalists have the ability to closely interact with patients over the course of several days. This exposure enhances opportunities to provide and reinforce patient education and information on lifestyle modifications, which have been shown to reduce the frequency of rehospitalization.60 In one evaluation, initiation of a care‐management program that included increased patient education reduced rehospitalizations for heart failure by 85% (P < .001).64 In another, an intensive, targeted education program significantly decreased the 1‐year risk‐adjusted probability of readmission or death (hazard ratio: 0.56; 95% CI: 0.32‐0.96; P = .03).65 Finally, it is important to remember that hospitalists also play a key role in the education of medical students and residents.60 This opportunity permits hospitalists to promote the adoption of standardized treatment algorithms that hopefully will be retained and propagated by these students long after their initial exposure to the hospitalist, thereby magnifying the effects of this education.

References
  1. DeFrances CJ,Cullen KA,Kozak LJ.National Hospital Discharge Survey: 2005 annual summary with detailed diagnosis and procedure data.Vital Health Stat 13.2007; (165):1209.
  2. Rosamond W,Flegal K,Furie K, et al.Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.Circulation.2008;117(4):e25e146.
  3. Aghababian RV.Acutely decompensated heart failure: opportunities to improve care and outcomes in the emergency department.Rev Cardiovasc Med.2002;3(suppl 4):S3S9.
  4. Hunt SA,Abraham WT,Chin MH, et al.ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult—summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure).Circulation.2005;112(12):18251852.
  5. DiDomenico RJ,Park HY,Southworth MR, et al.Guidelines for acute decompensated heart failure treatment.Ann Pharmacother.2004;38(4):649660.
  6. Costanzo MR,Saltzberg M,O'Sullivan J,Sobotka P.Early ultrafiltration in patients with decompensated heart failure and diuretic resistance.J Am Coll Cardiol.2005;46(11):20472051.
  7. Peacock WF,Fonarow GC,Emerman CL,Mills RM,Wynne J.Impact of early initiation of intravenous therapy for acute decompensated heart failure on outcomes in ADHERE.Cardiology.2007;107(1):4451.
  8. Heart Failure Society of America.Executive Summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline.J Card Fail.2006;12(1):1038.
  9. Silver MA,Maisel A,Yancy CW, et al.BNP Consensus Panel 2004: a clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases.Congest Heart Fail.2004;10(5 suppl 3):130.
  10. Nieminen MS,Böhm M,Cowie MR, et al.Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology.Eur Heart J.2005;26(4):384416.
  11. Stevenson LW,Perloff JK.The limited reliability of physical signs for estimating hemodynamics in chronic heart failure.JAMA.1989;261(6):884888.
  12. Abraham WT,Adams KF,Fonarow GC, et al.In‐hospital mortality in patients with acute decompensated heart failure treated with intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).J Am Coll Cardiol.2005;46(1):5764.
  13. Gheorghiade M,Abraham WT,Albert NM, et al.Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure.JAMA.2006;296(18):22172226.
  14. Morrison LK,Harrison A,Krishnaswamy P,Kazanegra R,Clopton P,Maisel A.Utility of a rapid B‐natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea.J Am Coll Cardiol.2002;39(2):202209.
  15. Fonarow GC.Overview of acutely decompensated congestive heart failure (ADHF): a report from the ADHERE registry.Heart Fail Rev.2004;9(3):179185.
  16. Costanzo MR,Johannes RS,Pine M, et al.The safety of intravenous diuretics alone versus diuretics plus parenteral vasoactive therapies in hospitalized patients with acutely decompensated heart failure: a propensity score and instrumental variable analysis using the Acutely Decompensated Heart Failure National Registry (ADHERE) database.Am Heart J.2007;154(2):267277.
  17. Fonarow GC,Stough WG,Abraham WT, et al.Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE‐HF registry.J Am Coll Cardiol.2007;50(8):768777.
  18. Dao Q,Krishnaswamy P,Kazanegra R, et al.Utility of B‐type natriuretic peptide in the diagnosis of congestive heart failure in an urgent‐care setting.J Am Coll Cardiol.2001;37(2):379385.
  19. Harrison A,Morrison LK,Krishnaswamy P, et al.B‐type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea.Ann Emerg Med.2002;39(2):131138.
  20. Maisel A.B‐type natriuretic peptide levels: diagnostic and prognostic in congestive heart failure: what's next?Circulation.2002;105(20):23282331.
  21. Maisel AS,Krishnaswamy P,Nowak RM, et al.Rapid measurement of B‐type natriuretic peptide in the emergency diagnosis of heart failure.N Engl J Med.2002;347(3):161167.
  22. Maisel AS,McCord J,Nowak RM, et al.Bedside B‐type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction: results from the Breathing Not Properly Multinational Study.J Am Coll Cardiol.2003;41(11):20102017.
  23. Maisel A,Hollander JE,Guss D, et al.Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT): a multicenter study of B‐type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath.J Am Coll Cardiol.2004;44(6):13281333.
  24. Seino Y,Ogawa A,Yamashita T, et al.Application of NT‐proBNP and BNP measurements in cardiac care: a more discerning marker for the detection and evaluation of heart failure.Eur J Heart Fail.2004;6(3):295300.
  25. Baggish AL,van Kimmenade R,Bayes‐Genis A, et al.Hemoglobin and N‐terminal pro‐brain natriuretic peptide: independent and synergistic predictors of mortality in patients with acute heart failure. Results from the International Collaborative of NT‐proBNP (ICON) Study.Clin Chim Acta.2007;381(2):145150.
  26. Mueller C,Scholer A,Laule‐Kilian K, et al.Use of B‐type natriuretic peptide in the evaluation and management of acute dyspnea.N Engl J Med.2004;350(7):647654.
  27. American College of Emergency Physicians Clinical Policies Subcommittee (Writing Committee) on Acute Heart Failure Syndromes,Silvers SM,Howell JM,Kosowsky JM,Rokos IC,Jagoda AS.Clinical policy: critical issues in the evaluation and management of adult patients presenting to the emergency department with acute heart failure syndromes.Ann Emerg Med.2007;49(5):627669.
  28. Sarzani R,Dessi‐Fulgheri P,Paci VM,Espinosa E,Rappelli A.Expression of natriuretic peptide receptors in human adipose and other tissues.J Endocrinol Invest.1996;19(9):581585.
  29. Cowie MR,Jourdain P,Maisel A, et al.Clinical applications of B‐type natriuretic peptide (BNP) testing.Eur Heart J.2003;24(19):17101718.
  30. McCullough PA,Duc P,Omland T, et al.B‐type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study.Am J Kidney Dis.2003;41(3):571579.
  31. McKie PM,Burnett JC.B‐type natriuretic peptide as a biomarker beyond heart failure: speculations and opportunities.Mayo Clin Proc.2005;80(8):10291036.
  32. Galvani M,Ferrini D,Ottani F.Natriuretic peptides for risk stratification of patients with acute coronary syndromes.Eur J Heart Fail.2004;6(3):327333.
  33. Sinclair H,Paterson M,Walker S,Beckett G,Fox KA.Predicting outcome in patients with acute coronary syndrome: evaluation of B‐type natriuretic peptide and the global registry of acute coronary events (GRACE) risk score.Scott Med J.2007;52(3):813.
  34. Fonarow GC,Adams KFJ,Abraham WT,Yancy CW,Boscardin WJ.Risk stratification for in‐hospital mortality in acutely decompensated heart failure: classification and regression tree analysis.JAMA.2005;293(5):572580.
  35. Blackledge HM,Tomlinson J,Squire IB.Prognosis for patients newly admitted to hospital with heart failure: survival trends in 12 220 index admissions in Leicestershire 1993–2001.Heart.2003;89(6):615620.
  36. Kerzner R,Gage BF,Freedland KE,Rich MW.Predictors of mortality in younger and older patients with heart failure and preserved or reduced left ventricular ejection fraction.Am Heart J.2003;146(2):286290.
  37. Lee DS,Austin PC,Rouleau JL,Liu PP,Naimark D,Tu JV.Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model.JAMA.2003;290(19):25812587.
  38. Clinical Quality Improvement Network Investigators.Mortality risk and patterns of practice in 4606 acute care patients with congestive heart failure: the relative importance of age, sex, and medical therapy.Arch Intern Med.1996;156(15):16691673.
  39. Rohde LE,Goldraich L,Polanczyk CA, et al.A simple clinically based predictive rule for heart failure in‐hospital mortality.J Card Fail.2006;12(8):587593.
  40. Siirilä‐Waris K,Lassus J,Melin J,Peuhkurinen K,Nieminen MS,Harjola V‐P.Characteristics, outcomes, and predictors of 1‐year mortality in patients hospitalized for acute heart failure.Eur Heart J.2006;27(24):30113017.
  41. Adamopoulos C,Zannad F,Fay R, et al.Ejection fraction and blood pressure are important and interactive predictors of 4‐week mortality in severe acute heart failure.Eur J Heart Fail.2007;9(9):935941.
  42. Smith GL,Vaccarino V,Kosiborod M, et al.Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure?J Card Fail.2003;9(1):1325.
  43. Forman DE,Butler J,Wang Y, et al.Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure.J Am Coll Cardiol.2004;43(1):6167.
  44. Felker GM,Gattis WA,Leimberger JD, et al.Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure.Am J Cardiol.2003;92(5):625628.
  45. Young JB,Abraham WT,Albert NM, et al.Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE‐HF registry).Am J Cardiol.2008;101(2):223230.
  46. Gheorghiade M,Abraham WT,Albert NM, et al.Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE‐HF registry.Eur Heart J.2007;28(8):980988.
  47. Ishii J,Cui W,Kitagawa F, et al.Prognostic value of combination of cardiac troponin T and B‐type natriuretic peptide after initiation of treatment in patients with chronic heart failure.Clin Chem.2003;49(12):20202026.
  48. Fonarow GC,Peacock WF,Horwich TB, et al.Usefulness of B‐type natriuretic peptide and cardiac troponin levels to predict in‐hospital mortality from ADHERE.Am J Cardiol.2008;101(2):231237.
  49. Eshaghian S,Horwich TB,Fonarow GC.Relation of loop diuretic dose to mortality in advanced heart failure.Am J Cardiol.2006;97(12):17591764.
  50. Hasselblad V,Gattis Stough W,Shah MR, et al.Relation between diuretic dose and outcome in a heart failure population: results of the ESCAPE trial [Abstract 250].J Card Fail.2005;11(6 Suppl):S157.
  51. Setoguchi S,Stevenson LW,Schneeweiss S.Repeated hospitalizations predict mortality in the community population with heart failure.Am Heart J.2007;154(2):260266.
  52. Costanzo MR,Mills RM,Wynne J.Characteristics of “Stage D” heart failure: insights from the Acute Decompensated Heart Failure National Registry Longitudinal Module (ADHERE LM).Am Heart J.2008;155(2):339347.
  53. American College of Cardiology/American Heart Association Task Force on Practice Guidelines.Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure).J Am Coll Cardiol.1995;26(5):13761398.
  54. Cuffe MS,Califf RM,Adams KFJ, et al.Short‐term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.JAMA.2002;287(12):15411547.
  55. Fonarow GC,Abraham WT,Albert NM, et al.Influence of beta‐blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE‐HF program.J Am Coll Cardiol.2008;52(3):190199.
  56. Fonarow GC,Abraham WT,Albert NM, et al.Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE‐HF): rationale and design.Am Heart J.2004;148(1):4351.
  57. Pistoria MJ,Amin AN,Dressler DD,McKean SCW,Budnitz TL, eds.The core competencies in hospital medicine: a framework for curriculum development by the Society of Hospital Medicine.J Hosp Med.2006;1(Suppl 1):295.
  58. Ashton CM,Kuykendall DH,Johnson ML,Wray NP,Wu L.The association between the quality of inpatient care and early readmission.Ann Intern Med.1995;122(6):415421.
  59. Elkayam U,Tasissa G,Binanay C, et al.Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure.Am Heart J.2007;153(1):98104.
  60. Amin A.Improving the management of patients after myocardial infarction, from admission to discharge.Clin Ther.2006;28(10):15091539.
  61. Lindenauer PK,Chehabeddine R,Pekow P,Fitzgerald J,Benjamin EM.Quality of care for patients hospitalized with heart failure: assessing the impact of hospitalists.Arch Intern Med.2002;162(11):12511256.
  62. Roytman MM,Thomas SM,Jiang CS.Comparison of practice patterns of hospitalists and community physicians in the care of patients with congestive heart failure.J Hosp Med.2008;3(1):3541.
  63. Southern WN,Berger MA,Bellin EY,Hailpern SM,Arnsten JH.Hospitalist care and length of stay in patients requiring complex discharge planning and close clinical monitoring.Arch Intern Med.2007;167(17):18691874.
  64. Fonarow GC,Stevenson LW,Walden JA, et al.Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure.J Am Coll Cardiol.1997;30(3):725732.
  65. Krumholz HM,Amatruda J,Smith GL, et al.Randomized trial of an education and support intervention to prevent readmission of patients with heart failure.J Am Coll Cardiol.2002;39(1):8389.
Article PDF
Issue
Journal of Hospital Medicine - 3(6)
Page Number
S16-S24
Legacy Keywords
Acute decompensated heart failure, diagnosis, guidelines, outcomes, treatment
Sections
Article PDF
Article PDF

Currently, acute decompensated heart failure (ADHF) accounts for 3% of all hospitalizations in the United States and is the second most common indication for hospitalization in individuals 65 years of age.1 These hospitalizations are costly and frequently have limited sustained benefits. The total direct medical cost attributable to ADHF hospitalization in the United States is estimated to be $18.8 billion annually.2 Furthermore, 50% of all patients hospitalized for ADHF are readmitted within 6 months of discharge.3 Clearly, the hospital management of these patients requires reevaluation.

The purpose of this article is to review the recognition, risk stratification, and treatment of ADHF and to discuss the role hospitalists can play in improving this treatment.

RECOGNITION OF ADHF

The American College of Cardiology/American Heart Association guidelines classify patients with heart failure into 1 of 4 stages, A through D.4 Patients with heart failure risk factors who do not have evidence of structural heart disease are classified as Stage A. Patients with evidence of structural heart disease who have never been symptomatic are classified as Stage B. Patients who are presently or previously symptomatic and responsive to standard therapies are classified as Stage C. Finally, patients are classified as Stage D if they are refractory to standard therapies and require specialized advanced treatment such as mechanical circulatory support, continuous inotropic infusions, or cardiac transplantation. By definition, patients with ADHF have either Stage C or Stage D heart failure.

Early recognition and appropriate treatment are key components in improving the management of these patients.57 Hospitalization is recommended for patients with evidence of severely decompensated heart failure, dyspnea at rest, hemodynamically significant arrhythmias, and acute coronary syndromes and should be considered in patients with worsening congestion, major electrolyte abnormalities, associated comorbid conditions, and repeated implantable cardioverter‐defibrillator firings.8 However, correctly identifying ADHF at the time of hospital presentation can be challenging.9 The diagnosis of ADHF is based on signs and symptoms, supported by radiographic findings, biomarkers, and echocardiography.8, 10 Unfortunately, the typical signs and symptoms of ADHFfor example, rales, peripheral edema, dyspnea at rest, and fatiguemay be missing at hospital presentation. In an early evaluation, rales, edema, and elevated mean jugular venous pressure were absent in 18 of 43 patients with documented pulmonary capillary wedge pressures (PCWP) 22 mm Hg.11 These findings have recently been confirmed using data from 2 large registries, the Acute Decompensated Heart Failure National Registry (ADHERE) and the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE‐HF) registry. In these registries, 32%36% of patients admitted with ADHF did not have rales, 33%35% did not have peripheral edema, 56%64% did not have dyspnea at rest, and approximately 67% did not have fatigue (Figure 1).12, 13 Furthermore, even when these signs and symptoms are present, they are nondiagnostic, because they can be produced by a variety of disorders, including hepatic, renal, and pulmonary dysfunction.8, 14

Figure 1
Prevalence of rales, peripheral edema, dyspnea at rest, and fatigue in patients admitted for acute decompensated heart failure in the Acute Decompensated Heart Failure National Registry (ADHERE; N = 67,966) and the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure registry (OPTIMIZE‐HF; N = 48,612). Derived from Abraham et al12 and Gheorghiade et al.13

Similarly, radiographic and echocardiographic features of ADHF are not always present. Overall, 26% of patients in ADHERE did not have evidence of pulmonary congestion on their initial chest radiograph, and 50%55% of patients in both registries had preserved systolic function.13, 1517 Consequently, attention has turned to biomarkers as a means of rapidly and accurately identifying ADHF. Serum Btype natriuretic peptide (BNP) and its N‐terminal prohormone (NT‐proBNP) have proven to be both diagnostic and prognostic indicators in ADHF.14, 1825 In the Breathing Not Properly Multinational Study, a BNP level 100 pg/mL was found to have a 90% sensitivity (95% confidence interval [CI]: 88%92%) and a 76% specificity (95% CI: 73%79%) for heart failure in patients presenting to the emergency department with dyspnea.21 In addition, BNP levels have been shown to correlate with heart failure severity18 and to be a more accurate reflection of this severity than clinical judgment.23 In a prospective randomized evaluation, the addition of BNP assessment to a standard diagnostic evaluation resulted in fewer patients being hospitalized (75% vs. 85%; P = .008), more rapid initiation of appropriate therapy (63 vs. 90 minutes; P = .03), and a shorter median duration of hospitalization (8 vs. 11 days; P = .001).26 As a result, the American College of Emergency Physicians guidelines now state that measurement of BNP or NT‐proBNP can improve diagnostic accuracy in acute heart failure syndrome when compared with standard clinical judgment alone.27

It is important to remember, however, that BNP levels cannot be interpreted in isolation; clinical judgment still plays a vital role. Obesity decreases BNP levels due to the expression of natriuretic peptide clearance receptors in adipose tissue.9, 28, 29 In contrast, BNP levels increase with age and are higher in women than in men.29 In addition, pulmonary embolism, an important diagnostic consideration in patients presenting with dyspnea, has been shown to increase serum BNP levels above the diagnostic threshold for ADHF.9, 29 Likewise, renal dysfunction, a common comorbidity in patients with heart failure (cardiorenal syndrome), increases serum BNP levels.30 As a result, the BNP threshold value for the diagnosis of ADHF rises from 100 pg/mL in patients with normal renal function to 200 pg/mL in patients with an estimated glomerular filtration rate <60 mL/min/1.73 m2.30 Finally, it is now well recognized that BNP production is up‐regulated by numerous physiologic conditions in addition to heart failure, including cardiac hypertrophy, endothelial dysfunction, and arrhythmia.31 Consequently, an elevated BNP level may indicate one of these conditions instead of ADHF. For example, recent data demonstrate that BNP levels are increased in patients with acute coronary syndromes and also serve as a significant prognostic factor in these patients.32, 33

RISK STRATIFICATION

Risk stratification, another important component in improving the management of patients with ADHF, helps determine the appropriate location (eg, outpatient, hospital ward, intensive care unit) for and intensity of initial monitoring and treatment.13, 25, 3452 Univariate analyses have identified several morbidity and/or mortality risk factors, including age,3540 blood pressure,13, 34, 37, 3941 respiratory rate,37 left ventricular ejection fraction (LVEF),36, 41, 48 renal function,34, 36, 37, 39, 40, 42, 43 anemia,25, 44, 45 hyponatremia,37, 39, 46 BNP level,36, 49, 50 cardiac troponin level,48 diuretic dose,36, 49, 50 previous heart failure hospitalization,44, 51, 52 and comorbid conditions.35, 37, 39 Unfortunately, these univariate factors are not very helpful in and of themselves, as they regularly occur in conjunction with each other. True risk assessment requires multivariate analyses of large datasets.

Multivariate risk factors for short‐term mortality in patients admitted for ADHF have been evaluated in 3 separate studies. Lee et al used multiple logistic regression to analyze data from 4031 hospitalization episodes at 34 centers in Canada,37 Fonarow et al used both classification and regression tree and multivariate regression models to analyze data from 65,275 hospitalization episodes at 263 centers in the United States,34 and Rohde et al used stepwise logistic regression to analyze data from 779 consecutive hospitalization episodes at a single center in Brazil.39 Despite these differences in statistical methodology and geographic location, the findings of these 3 analyses are remarkably similar. All 3 evaluations identified advanced age, lower systolic blood pressure, and renal dysfunction (cardiorenal syndrome) as significant and independent risk factors for short‐term mortality, and 2 of the 3 identified hyponatremia and comorbid cancer as additional risk factors (Table 1).34 Of note, lower systolic blood pressure did not mean hypotension in these evaluations. Mortality risk was significantly increased in patients with systolic blood pressure <115‐124 mm Hg. In the largest of these studies, a simple risk tree utilizing admission blood pressure, serum creatinine concentration, and blood urea nitrogen level stratified patients into groups with in‐hospital mortality risk ranging from 2.1%21.9% in the derivation and 2.3%19.8% in the validation cohorts (Figure 2).34 Taken together, these studies underscore the substantial role age, blood pressure, renal function, serum sodium concentration, and comorbidities play in increasing mortality risk, and these factors should always be considered in determining the intensity and location of ADHF treatment and degree of monitoring employed therein.

Figure 2
Risk of in‐hospital mortality based on Classification and Regression Tree Analysis (CART) of data from the Acute Decompensated Heart Failure National Registry (ADHERE). The model was developed using data from the initial 33,046 hospitalizations in the registry (Derivation cohort) and validated using data from the subsequent 32,229 hospitalizations (Validation cohort). Abbreviations: BUN, blood urea nitrogen; SBP, systolic blood pressure; SCr, serum creatinine. Adapted from Fonarow et al.34
Multivariate Risk Factors in Patients Admitted for Acute Decompensated Heart Failure
Parameter Study
Lee et al37 Fonarow et al34 Rohde et al39
  • Abbreviations: BUN, blood urea nitrogen; COPD, chronic obstructive pulmonary disease; SBP, systolic blood pressure.

Data source 34 Hospitals 263 Hospitals Single center
Admissions evaluated 4031 65,275 779
Outcome parameter 30‐Day mortality In‐hospital mortality In‐hospital mortality
Independent risk factors
Older age Yes Yes Yes (>70 years)
Lower SBP Yes Yes (<115 mm Hg) Yes (124 mm Hg)
Renal dysfunction Yes Yes Yes
Elevated BUN Yes Yes (>43 mg/dL) Yes (>37 mg/dL)
Elevated serum creatinine Yes (>2.75 mg/dL) Yes (>1.4 mg/dL)
Hyponatremia Yes Yes (<136 mEq/L)
Elevated heart rate Yes
Elevated respiratory rate Yes
Comorbid conditions Yes Yes
Cancer Yes Yes
Cerebrovascular disease Yes
COPD Yes
Dementia Yes

Although BNP and cardiac troponin level were not significant risk factors in the multivariate models, these levels were not routinely assessed in patients admitted for ADHF 5 to 10 years ago. For example, admission BNP was available in only 18% of patients in the Fonarow analysis,34 and this lack of data may explain the absence of these parameters in these multivariate analyses. In a recent analysis limited to patients with admission BNP and cardiac troponin data, in‐hospital mortality was significantly increased when BNP was 840 pg/mL (odds ratio [OR]: 1.60; 95% CI: 1.431.80; P < .001), cardiac troponin was positive (OR: 1.85; 95% CI: 1.572.18; P < .001) or both (OR: 3.00; 95% CI: 2.473.66; P < .001) even after adjusting for differences in age, gender, blood urea nitrogen, systolic blood pressure, serum creatinine concentration, serum sodium concentration, heart rate, and dyspnea at rest.4

THERAPY

Ideally, treatment should be rooted in evidence‐based guidelines. However, relatively few randomized, controlled clinical trials have been completed in patients with ADHF, and consequently there are minimal data available to construct these guidelines. The American College of Cardiology and the American Heart Association have jointly published guidelines since 1995 on the management of heart failure.4, 53 However, these guidelines, which were last updated in 2005, discuss only the management of chronic heart failure, not the management of ADHF.4 In fact, the most recent version of these guidelines specifically states, The committee elected to focus this document on the diagnosis and management of chronic heart failure It specifically did not consider acute heart failure, which might merit a separate set of guidelines.4

The first guideline to specifically address the management of ADHF was published in 2004.5 These guidelines, a consensus statement based on expert panel review of the available literature, were created to improve treatment at member hospitals of a national group purchasing organization and focused only on the initial 24 hours of care. They had 2 important components. The first was a timeline emphasizing rapid assessment and institution of therapy, followed by serial reevaluations every couple of hours thereafter.5 The second was a flow chart detailing recommended initial therapies based on the current clinical findings and the patient's chronic outpatient pharmacotherapy, followed by modifications to this initial therapy based on the response observed during the serial reevaluations. Treatment recommendations were as follows: for patients with mild volume overload, an intravenous diuretic; for patients with moderate to severe volume overload, an intravenous diuretic plus an intravenous vasodilator (nitroglycerin or nesiritide); and for patients with low cardiac output, an inotropic agent with or without a subsequent intravenous vasodilator.

In 2005, the European Society of Cardiology published its guidelines for the treatment of ADHF.10 These guidelines state that the immediate goal of ADHF therapy is to improve symptoms and stabilize hemodynamics, but these short‐term benefits must be accompanied by favorable effects on long‐term outcomes.10 Recommended treatment consists of fluid loading, diuretics, vasodilators (glyceryl trinitrate, isosorbide dinitrate, nitroprusside, or nesiritide), and/or inotropic agents (dopamine, dobutamine, milrinone, enoximone, levosimendan, norepinephrine, or epinephrine), depending on the patient's clinical status and hemodynamics.10 In general, the guidelines recommend fluid loading in patients with low cardiac output and low PCWP; a vasodilator or inotropic agent, depending on systolic blood pressure, in patients with low cardiac output and normal to high PCWP; and an intravenous diuretic in patients with normal cardiac output and high PCWP pressure. Finally, respiratory support, eg, continuous positive airway pressure (CPAP), noninvasive positive pressure ventilation, or endotracheal intubation and mechanical ventilation, may be necessary in some patients with left‐heart failure.

In 2006, the Heart Failure Society of America published comprehensive heart failure practice guidelines.8 These guidelines expand the goals of ADHF therapy to include improving symptoms, optimizing volume status, identifying precipitating factors, enhancing chronic oral therapy, and minimizing side effects. They provide the most detailed recommendations yet with respect to monitoring patents admitted for ADHF.8 According to these guidelines, this monitoring should include more than daily assessment of vital signs, including orthostatic blood pressure, and at least daily assessment of heart failure signs and symptoms, fluid intake and output, weight, electrolytes, and renal function. Treatment recommendations are similar to those in preceding guidelines. Intravenous loop diuretics are recommended as first‐line therapy in patients with volume overload.8 In the absence of systemic hypotension, the addition of an intravenous vasodilator (nitroglycerin, nitroprusside, or nesiritide) should be considered to achieve rapid symptomatic improvement.8 Intravenous inotropic therapy may be considered to improve symptoms and end‐organ function in patients with low‐output syndrome (left ventricular dilation, reduced LVEF, and diminished peripheral perfusion), especially if systolic blood pressure is <90 mm Hg or there is symptomatic hypotension despite adequate filling pressures.54 Outside of this small select group of patients, there is no rationale for the use of inotropic agents.8 Patients with ADHF who received an inotropic agent in the absence of a clearly defined clinical indication had an increased risk of adverse events without any evidence of clinical benefit in the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME‐CHF) trial.54 Ultrafiltration may be considered in patients who fail to respond adequately to diuretic therapy,6, 8 and an implantable left ventricular assist device (LVAD) should be considered as a bridge to cardiac transplantation in patients with severe heart failure (Stage D) who have become refractory to all means of medical circulatory support and may be considered in highly selected nontransplantation candidates who cannot be weaned from intravenous inotropic support.8, 52

Whether to continue or temporarily stop chronic oral heart failure medications during treatment of an acute decompensation is not addressed in any of the evidence‐based guidelines and ultimately, this decision must be based on the patient's clinical status. In general, guideline‐recommended intravenous diuretic therapy temporarily replaces the patient's chronic oral diuretic regimen. Oral ‐blocker therapy should be continued whenever possible, as long as the patient's blood pressure and clinical status can tolerate it. In an analysis of data from the OPTIMIZE‐HF registry, patients with ADHF who had withdrawal of ‐blocker had significantly greater risk‐adjusted mortality compared to those in whom this therapy was continued (hazard ratio: 2.3; 95% CI: 1.2‐4.6; P = .013).55, 56 Finally, it is recommended that patients receiving an angiotensin‐converting enzyme inhibitor be continued on this agent as long as they are not in cardiogenic shock and do not have significantly deteriorating renal function.8

ROLE OF THE HOSPITALIST

Despite the presence of treatment guidelines, significant variation in the treatment of patients with ADHF persists.8, 58 Treatment of these patients is frequently contrary to the recommendations in published guidelines and can adversely impact both the cost of hospitalization and the ultimate clinical outcome. Low adherence to accepted standards of medical care has been shown to be a significant and independent risk factor for early hospital readmission.58 Furthermore, the main determinant of inotrope use in the ESCAPE trial was not the patient's cardiac output, blood pressure, or PCWP, but instead was the hospital to which the patient was admitted.59

Hospitalists are positioned to play a key role in improving both inpatient care of ADHF patients and the transition to long‐term patient management.60, 61 However, specific core competencies are required before hospitalists can effectively undertake this role. Table 2 highlights some of these core competencies.57

Selected Core Competencies for Hospitalists in Management of Heart Failure
Domain Competencies
  • Adapted from the Journal of Hospital Medicine.57

Knowledge Underlying causes of heart failure (eg, ischemia, cardiomyopathy, arrhythmia, drugs, alcohol)
Precipitating factors leading to exacerbation (eg, fluid overload)
Indicated tests to evaluate heart failure (eg, chest x‐ray, echocardiography, B‐type natriuretic peptide levels)
Risk factors for the development of heart failure (eg, hypertension, hyperlipidemia, coronary artery disease, diabetes, obesity)
Risk stratification in patients admitted with heart failure
Evidence‐based therapeutic options for management of both acute and chronic heart failure
Indications, contraindications, and mechanisms of action of drugs used to treat heart failure
Skills Identify signs of low perfusion (eg, capillary refill, end‐organ dysfunction)
Attitudes Recognize indications for cardiac consultation (eg, ischemia, atypical presentation, unresponsive to usual therapy)
Recognize indications for transplantation evaluation (eg, uncontrollable severe heart failure)
System organization and improvement Advocate establishment and support of outpatient heart failure management teams

Data indicate that hospitalists are more likely than nonhospitalists to implement evidence‐based assessments and treatment.62 Lindenauer et al conducted a retrospective review of medical records from patients admitted for ADHF at a community‐based teaching hospital who were not managed by cardiologists and found that the assessment of left ventricular function was significantly greater when the patient's care was managed by a hospitalist (94%) compared to a nonhospitalist (87%; P = .04).61 Similarly, Roytman et al performed a retrospective review of medical records from another community‐based teaching hospital and found that patients admitted for ADHF who were managed by hospitalists were more likely than patients managed by community physicians (55% cardiologists) to receive intravenous diuretics (90% vs. 73%; P < .001) and to have angiotensin‐converting enzyme inhibitor or angiotensin receptor blocker therapy initiated or resumed within 24 hours of hospital admission (86% vs. 72%; P = .003).62

Hospitalist care has also been shown to significantly reduce the duration of hospitalization. In the evaluation by Lindenauer et al, the risk‐adjusted length of stay was significantly shorter in patients whose care was managed by a hospitalist (P = .03). This benefit was greatest for patients in the major severity category.61 Similarly, in the review by Roytman et al, hospitalist care was associated with a 13%40% reduction in adjusted length of stay (P = .002), depending on disease severity.62 These reductions appear to be directly related to the greater experience of hospitalists in managing this and other acute disorders. In a retrospective review of data from an urban teaching hospital, care by a hospitalist, when compared with that by a nonhospitalist, was associated with a 15% reduction in overall length of stay (5.0 vs. 5.9 days; P < .02), with the greatest benefit observed in those patients whose disorders required close clinical monitoring (ie, heart failure, stroke, asthma, or pneumonia) or complex discharge planning.63 Moreover, there was a significant inverse correlation between the mean duration of hospitalization and the number of months of inpatient care provided by the attending physician each year ( = 0.19 day per month of inpatient care; P < .002).63

Finally, hospitalists are uniquely situated to influence medical care. Hospitalists have the ability to closely interact with patients over the course of several days. This exposure enhances opportunities to provide and reinforce patient education and information on lifestyle modifications, which have been shown to reduce the frequency of rehospitalization.60 In one evaluation, initiation of a care‐management program that included increased patient education reduced rehospitalizations for heart failure by 85% (P < .001).64 In another, an intensive, targeted education program significantly decreased the 1‐year risk‐adjusted probability of readmission or death (hazard ratio: 0.56; 95% CI: 0.32‐0.96; P = .03).65 Finally, it is important to remember that hospitalists also play a key role in the education of medical students and residents.60 This opportunity permits hospitalists to promote the adoption of standardized treatment algorithms that hopefully will be retained and propagated by these students long after their initial exposure to the hospitalist, thereby magnifying the effects of this education.

Currently, acute decompensated heart failure (ADHF) accounts for 3% of all hospitalizations in the United States and is the second most common indication for hospitalization in individuals 65 years of age.1 These hospitalizations are costly and frequently have limited sustained benefits. The total direct medical cost attributable to ADHF hospitalization in the United States is estimated to be $18.8 billion annually.2 Furthermore, 50% of all patients hospitalized for ADHF are readmitted within 6 months of discharge.3 Clearly, the hospital management of these patients requires reevaluation.

The purpose of this article is to review the recognition, risk stratification, and treatment of ADHF and to discuss the role hospitalists can play in improving this treatment.

RECOGNITION OF ADHF

The American College of Cardiology/American Heart Association guidelines classify patients with heart failure into 1 of 4 stages, A through D.4 Patients with heart failure risk factors who do not have evidence of structural heart disease are classified as Stage A. Patients with evidence of structural heart disease who have never been symptomatic are classified as Stage B. Patients who are presently or previously symptomatic and responsive to standard therapies are classified as Stage C. Finally, patients are classified as Stage D if they are refractory to standard therapies and require specialized advanced treatment such as mechanical circulatory support, continuous inotropic infusions, or cardiac transplantation. By definition, patients with ADHF have either Stage C or Stage D heart failure.

Early recognition and appropriate treatment are key components in improving the management of these patients.57 Hospitalization is recommended for patients with evidence of severely decompensated heart failure, dyspnea at rest, hemodynamically significant arrhythmias, and acute coronary syndromes and should be considered in patients with worsening congestion, major electrolyte abnormalities, associated comorbid conditions, and repeated implantable cardioverter‐defibrillator firings.8 However, correctly identifying ADHF at the time of hospital presentation can be challenging.9 The diagnosis of ADHF is based on signs and symptoms, supported by radiographic findings, biomarkers, and echocardiography.8, 10 Unfortunately, the typical signs and symptoms of ADHFfor example, rales, peripheral edema, dyspnea at rest, and fatiguemay be missing at hospital presentation. In an early evaluation, rales, edema, and elevated mean jugular venous pressure were absent in 18 of 43 patients with documented pulmonary capillary wedge pressures (PCWP) 22 mm Hg.11 These findings have recently been confirmed using data from 2 large registries, the Acute Decompensated Heart Failure National Registry (ADHERE) and the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE‐HF) registry. In these registries, 32%36% of patients admitted with ADHF did not have rales, 33%35% did not have peripheral edema, 56%64% did not have dyspnea at rest, and approximately 67% did not have fatigue (Figure 1).12, 13 Furthermore, even when these signs and symptoms are present, they are nondiagnostic, because they can be produced by a variety of disorders, including hepatic, renal, and pulmonary dysfunction.8, 14

Figure 1
Prevalence of rales, peripheral edema, dyspnea at rest, and fatigue in patients admitted for acute decompensated heart failure in the Acute Decompensated Heart Failure National Registry (ADHERE; N = 67,966) and the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure registry (OPTIMIZE‐HF; N = 48,612). Derived from Abraham et al12 and Gheorghiade et al.13

Similarly, radiographic and echocardiographic features of ADHF are not always present. Overall, 26% of patients in ADHERE did not have evidence of pulmonary congestion on their initial chest radiograph, and 50%55% of patients in both registries had preserved systolic function.13, 1517 Consequently, attention has turned to biomarkers as a means of rapidly and accurately identifying ADHF. Serum Btype natriuretic peptide (BNP) and its N‐terminal prohormone (NT‐proBNP) have proven to be both diagnostic and prognostic indicators in ADHF.14, 1825 In the Breathing Not Properly Multinational Study, a BNP level 100 pg/mL was found to have a 90% sensitivity (95% confidence interval [CI]: 88%92%) and a 76% specificity (95% CI: 73%79%) for heart failure in patients presenting to the emergency department with dyspnea.21 In addition, BNP levels have been shown to correlate with heart failure severity18 and to be a more accurate reflection of this severity than clinical judgment.23 In a prospective randomized evaluation, the addition of BNP assessment to a standard diagnostic evaluation resulted in fewer patients being hospitalized (75% vs. 85%; P = .008), more rapid initiation of appropriate therapy (63 vs. 90 minutes; P = .03), and a shorter median duration of hospitalization (8 vs. 11 days; P = .001).26 As a result, the American College of Emergency Physicians guidelines now state that measurement of BNP or NT‐proBNP can improve diagnostic accuracy in acute heart failure syndrome when compared with standard clinical judgment alone.27

It is important to remember, however, that BNP levels cannot be interpreted in isolation; clinical judgment still plays a vital role. Obesity decreases BNP levels due to the expression of natriuretic peptide clearance receptors in adipose tissue.9, 28, 29 In contrast, BNP levels increase with age and are higher in women than in men.29 In addition, pulmonary embolism, an important diagnostic consideration in patients presenting with dyspnea, has been shown to increase serum BNP levels above the diagnostic threshold for ADHF.9, 29 Likewise, renal dysfunction, a common comorbidity in patients with heart failure (cardiorenal syndrome), increases serum BNP levels.30 As a result, the BNP threshold value for the diagnosis of ADHF rises from 100 pg/mL in patients with normal renal function to 200 pg/mL in patients with an estimated glomerular filtration rate <60 mL/min/1.73 m2.30 Finally, it is now well recognized that BNP production is up‐regulated by numerous physiologic conditions in addition to heart failure, including cardiac hypertrophy, endothelial dysfunction, and arrhythmia.31 Consequently, an elevated BNP level may indicate one of these conditions instead of ADHF. For example, recent data demonstrate that BNP levels are increased in patients with acute coronary syndromes and also serve as a significant prognostic factor in these patients.32, 33

RISK STRATIFICATION

Risk stratification, another important component in improving the management of patients with ADHF, helps determine the appropriate location (eg, outpatient, hospital ward, intensive care unit) for and intensity of initial monitoring and treatment.13, 25, 3452 Univariate analyses have identified several morbidity and/or mortality risk factors, including age,3540 blood pressure,13, 34, 37, 3941 respiratory rate,37 left ventricular ejection fraction (LVEF),36, 41, 48 renal function,34, 36, 37, 39, 40, 42, 43 anemia,25, 44, 45 hyponatremia,37, 39, 46 BNP level,36, 49, 50 cardiac troponin level,48 diuretic dose,36, 49, 50 previous heart failure hospitalization,44, 51, 52 and comorbid conditions.35, 37, 39 Unfortunately, these univariate factors are not very helpful in and of themselves, as they regularly occur in conjunction with each other. True risk assessment requires multivariate analyses of large datasets.

Multivariate risk factors for short‐term mortality in patients admitted for ADHF have been evaluated in 3 separate studies. Lee et al used multiple logistic regression to analyze data from 4031 hospitalization episodes at 34 centers in Canada,37 Fonarow et al used both classification and regression tree and multivariate regression models to analyze data from 65,275 hospitalization episodes at 263 centers in the United States,34 and Rohde et al used stepwise logistic regression to analyze data from 779 consecutive hospitalization episodes at a single center in Brazil.39 Despite these differences in statistical methodology and geographic location, the findings of these 3 analyses are remarkably similar. All 3 evaluations identified advanced age, lower systolic blood pressure, and renal dysfunction (cardiorenal syndrome) as significant and independent risk factors for short‐term mortality, and 2 of the 3 identified hyponatremia and comorbid cancer as additional risk factors (Table 1).34 Of note, lower systolic blood pressure did not mean hypotension in these evaluations. Mortality risk was significantly increased in patients with systolic blood pressure <115‐124 mm Hg. In the largest of these studies, a simple risk tree utilizing admission blood pressure, serum creatinine concentration, and blood urea nitrogen level stratified patients into groups with in‐hospital mortality risk ranging from 2.1%21.9% in the derivation and 2.3%19.8% in the validation cohorts (Figure 2).34 Taken together, these studies underscore the substantial role age, blood pressure, renal function, serum sodium concentration, and comorbidities play in increasing mortality risk, and these factors should always be considered in determining the intensity and location of ADHF treatment and degree of monitoring employed therein.

Figure 2
Risk of in‐hospital mortality based on Classification and Regression Tree Analysis (CART) of data from the Acute Decompensated Heart Failure National Registry (ADHERE). The model was developed using data from the initial 33,046 hospitalizations in the registry (Derivation cohort) and validated using data from the subsequent 32,229 hospitalizations (Validation cohort). Abbreviations: BUN, blood urea nitrogen; SBP, systolic blood pressure; SCr, serum creatinine. Adapted from Fonarow et al.34
Multivariate Risk Factors in Patients Admitted for Acute Decompensated Heart Failure
Parameter Study
Lee et al37 Fonarow et al34 Rohde et al39
  • Abbreviations: BUN, blood urea nitrogen; COPD, chronic obstructive pulmonary disease; SBP, systolic blood pressure.

Data source 34 Hospitals 263 Hospitals Single center
Admissions evaluated 4031 65,275 779
Outcome parameter 30‐Day mortality In‐hospital mortality In‐hospital mortality
Independent risk factors
Older age Yes Yes Yes (>70 years)
Lower SBP Yes Yes (<115 mm Hg) Yes (124 mm Hg)
Renal dysfunction Yes Yes Yes
Elevated BUN Yes Yes (>43 mg/dL) Yes (>37 mg/dL)
Elevated serum creatinine Yes (>2.75 mg/dL) Yes (>1.4 mg/dL)
Hyponatremia Yes Yes (<136 mEq/L)
Elevated heart rate Yes
Elevated respiratory rate Yes
Comorbid conditions Yes Yes
Cancer Yes Yes
Cerebrovascular disease Yes
COPD Yes
Dementia Yes

Although BNP and cardiac troponin level were not significant risk factors in the multivariate models, these levels were not routinely assessed in patients admitted for ADHF 5 to 10 years ago. For example, admission BNP was available in only 18% of patients in the Fonarow analysis,34 and this lack of data may explain the absence of these parameters in these multivariate analyses. In a recent analysis limited to patients with admission BNP and cardiac troponin data, in‐hospital mortality was significantly increased when BNP was 840 pg/mL (odds ratio [OR]: 1.60; 95% CI: 1.431.80; P < .001), cardiac troponin was positive (OR: 1.85; 95% CI: 1.572.18; P < .001) or both (OR: 3.00; 95% CI: 2.473.66; P < .001) even after adjusting for differences in age, gender, blood urea nitrogen, systolic blood pressure, serum creatinine concentration, serum sodium concentration, heart rate, and dyspnea at rest.4

THERAPY

Ideally, treatment should be rooted in evidence‐based guidelines. However, relatively few randomized, controlled clinical trials have been completed in patients with ADHF, and consequently there are minimal data available to construct these guidelines. The American College of Cardiology and the American Heart Association have jointly published guidelines since 1995 on the management of heart failure.4, 53 However, these guidelines, which were last updated in 2005, discuss only the management of chronic heart failure, not the management of ADHF.4 In fact, the most recent version of these guidelines specifically states, The committee elected to focus this document on the diagnosis and management of chronic heart failure It specifically did not consider acute heart failure, which might merit a separate set of guidelines.4

The first guideline to specifically address the management of ADHF was published in 2004.5 These guidelines, a consensus statement based on expert panel review of the available literature, were created to improve treatment at member hospitals of a national group purchasing organization and focused only on the initial 24 hours of care. They had 2 important components. The first was a timeline emphasizing rapid assessment and institution of therapy, followed by serial reevaluations every couple of hours thereafter.5 The second was a flow chart detailing recommended initial therapies based on the current clinical findings and the patient's chronic outpatient pharmacotherapy, followed by modifications to this initial therapy based on the response observed during the serial reevaluations. Treatment recommendations were as follows: for patients with mild volume overload, an intravenous diuretic; for patients with moderate to severe volume overload, an intravenous diuretic plus an intravenous vasodilator (nitroglycerin or nesiritide); and for patients with low cardiac output, an inotropic agent with or without a subsequent intravenous vasodilator.

In 2005, the European Society of Cardiology published its guidelines for the treatment of ADHF.10 These guidelines state that the immediate goal of ADHF therapy is to improve symptoms and stabilize hemodynamics, but these short‐term benefits must be accompanied by favorable effects on long‐term outcomes.10 Recommended treatment consists of fluid loading, diuretics, vasodilators (glyceryl trinitrate, isosorbide dinitrate, nitroprusside, or nesiritide), and/or inotropic agents (dopamine, dobutamine, milrinone, enoximone, levosimendan, norepinephrine, or epinephrine), depending on the patient's clinical status and hemodynamics.10 In general, the guidelines recommend fluid loading in patients with low cardiac output and low PCWP; a vasodilator or inotropic agent, depending on systolic blood pressure, in patients with low cardiac output and normal to high PCWP; and an intravenous diuretic in patients with normal cardiac output and high PCWP pressure. Finally, respiratory support, eg, continuous positive airway pressure (CPAP), noninvasive positive pressure ventilation, or endotracheal intubation and mechanical ventilation, may be necessary in some patients with left‐heart failure.

In 2006, the Heart Failure Society of America published comprehensive heart failure practice guidelines.8 These guidelines expand the goals of ADHF therapy to include improving symptoms, optimizing volume status, identifying precipitating factors, enhancing chronic oral therapy, and minimizing side effects. They provide the most detailed recommendations yet with respect to monitoring patents admitted for ADHF.8 According to these guidelines, this monitoring should include more than daily assessment of vital signs, including orthostatic blood pressure, and at least daily assessment of heart failure signs and symptoms, fluid intake and output, weight, electrolytes, and renal function. Treatment recommendations are similar to those in preceding guidelines. Intravenous loop diuretics are recommended as first‐line therapy in patients with volume overload.8 In the absence of systemic hypotension, the addition of an intravenous vasodilator (nitroglycerin, nitroprusside, or nesiritide) should be considered to achieve rapid symptomatic improvement.8 Intravenous inotropic therapy may be considered to improve symptoms and end‐organ function in patients with low‐output syndrome (left ventricular dilation, reduced LVEF, and diminished peripheral perfusion), especially if systolic blood pressure is <90 mm Hg or there is symptomatic hypotension despite adequate filling pressures.54 Outside of this small select group of patients, there is no rationale for the use of inotropic agents.8 Patients with ADHF who received an inotropic agent in the absence of a clearly defined clinical indication had an increased risk of adverse events without any evidence of clinical benefit in the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME‐CHF) trial.54 Ultrafiltration may be considered in patients who fail to respond adequately to diuretic therapy,6, 8 and an implantable left ventricular assist device (LVAD) should be considered as a bridge to cardiac transplantation in patients with severe heart failure (Stage D) who have become refractory to all means of medical circulatory support and may be considered in highly selected nontransplantation candidates who cannot be weaned from intravenous inotropic support.8, 52

Whether to continue or temporarily stop chronic oral heart failure medications during treatment of an acute decompensation is not addressed in any of the evidence‐based guidelines and ultimately, this decision must be based on the patient's clinical status. In general, guideline‐recommended intravenous diuretic therapy temporarily replaces the patient's chronic oral diuretic regimen. Oral ‐blocker therapy should be continued whenever possible, as long as the patient's blood pressure and clinical status can tolerate it. In an analysis of data from the OPTIMIZE‐HF registry, patients with ADHF who had withdrawal of ‐blocker had significantly greater risk‐adjusted mortality compared to those in whom this therapy was continued (hazard ratio: 2.3; 95% CI: 1.2‐4.6; P = .013).55, 56 Finally, it is recommended that patients receiving an angiotensin‐converting enzyme inhibitor be continued on this agent as long as they are not in cardiogenic shock and do not have significantly deteriorating renal function.8

ROLE OF THE HOSPITALIST

Despite the presence of treatment guidelines, significant variation in the treatment of patients with ADHF persists.8, 58 Treatment of these patients is frequently contrary to the recommendations in published guidelines and can adversely impact both the cost of hospitalization and the ultimate clinical outcome. Low adherence to accepted standards of medical care has been shown to be a significant and independent risk factor for early hospital readmission.58 Furthermore, the main determinant of inotrope use in the ESCAPE trial was not the patient's cardiac output, blood pressure, or PCWP, but instead was the hospital to which the patient was admitted.59

Hospitalists are positioned to play a key role in improving both inpatient care of ADHF patients and the transition to long‐term patient management.60, 61 However, specific core competencies are required before hospitalists can effectively undertake this role. Table 2 highlights some of these core competencies.57

Selected Core Competencies for Hospitalists in Management of Heart Failure
Domain Competencies
  • Adapted from the Journal of Hospital Medicine.57

Knowledge Underlying causes of heart failure (eg, ischemia, cardiomyopathy, arrhythmia, drugs, alcohol)
Precipitating factors leading to exacerbation (eg, fluid overload)
Indicated tests to evaluate heart failure (eg, chest x‐ray, echocardiography, B‐type natriuretic peptide levels)
Risk factors for the development of heart failure (eg, hypertension, hyperlipidemia, coronary artery disease, diabetes, obesity)
Risk stratification in patients admitted with heart failure
Evidence‐based therapeutic options for management of both acute and chronic heart failure
Indications, contraindications, and mechanisms of action of drugs used to treat heart failure
Skills Identify signs of low perfusion (eg, capillary refill, end‐organ dysfunction)
Attitudes Recognize indications for cardiac consultation (eg, ischemia, atypical presentation, unresponsive to usual therapy)
Recognize indications for transplantation evaluation (eg, uncontrollable severe heart failure)
System organization and improvement Advocate establishment and support of outpatient heart failure management teams

Data indicate that hospitalists are more likely than nonhospitalists to implement evidence‐based assessments and treatment.62 Lindenauer et al conducted a retrospective review of medical records from patients admitted for ADHF at a community‐based teaching hospital who were not managed by cardiologists and found that the assessment of left ventricular function was significantly greater when the patient's care was managed by a hospitalist (94%) compared to a nonhospitalist (87%; P = .04).61 Similarly, Roytman et al performed a retrospective review of medical records from another community‐based teaching hospital and found that patients admitted for ADHF who were managed by hospitalists were more likely than patients managed by community physicians (55% cardiologists) to receive intravenous diuretics (90% vs. 73%; P < .001) and to have angiotensin‐converting enzyme inhibitor or angiotensin receptor blocker therapy initiated or resumed within 24 hours of hospital admission (86% vs. 72%; P = .003).62

Hospitalist care has also been shown to significantly reduce the duration of hospitalization. In the evaluation by Lindenauer et al, the risk‐adjusted length of stay was significantly shorter in patients whose care was managed by a hospitalist (P = .03). This benefit was greatest for patients in the major severity category.61 Similarly, in the review by Roytman et al, hospitalist care was associated with a 13%40% reduction in adjusted length of stay (P = .002), depending on disease severity.62 These reductions appear to be directly related to the greater experience of hospitalists in managing this and other acute disorders. In a retrospective review of data from an urban teaching hospital, care by a hospitalist, when compared with that by a nonhospitalist, was associated with a 15% reduction in overall length of stay (5.0 vs. 5.9 days; P < .02), with the greatest benefit observed in those patients whose disorders required close clinical monitoring (ie, heart failure, stroke, asthma, or pneumonia) or complex discharge planning.63 Moreover, there was a significant inverse correlation between the mean duration of hospitalization and the number of months of inpatient care provided by the attending physician each year ( = 0.19 day per month of inpatient care; P < .002).63

Finally, hospitalists are uniquely situated to influence medical care. Hospitalists have the ability to closely interact with patients over the course of several days. This exposure enhances opportunities to provide and reinforce patient education and information on lifestyle modifications, which have been shown to reduce the frequency of rehospitalization.60 In one evaluation, initiation of a care‐management program that included increased patient education reduced rehospitalizations for heart failure by 85% (P < .001).64 In another, an intensive, targeted education program significantly decreased the 1‐year risk‐adjusted probability of readmission or death (hazard ratio: 0.56; 95% CI: 0.32‐0.96; P = .03).65 Finally, it is important to remember that hospitalists also play a key role in the education of medical students and residents.60 This opportunity permits hospitalists to promote the adoption of standardized treatment algorithms that hopefully will be retained and propagated by these students long after their initial exposure to the hospitalist, thereby magnifying the effects of this education.

References
  1. DeFrances CJ,Cullen KA,Kozak LJ.National Hospital Discharge Survey: 2005 annual summary with detailed diagnosis and procedure data.Vital Health Stat 13.2007; (165):1209.
  2. Rosamond W,Flegal K,Furie K, et al.Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.Circulation.2008;117(4):e25e146.
  3. Aghababian RV.Acutely decompensated heart failure: opportunities to improve care and outcomes in the emergency department.Rev Cardiovasc Med.2002;3(suppl 4):S3S9.
  4. Hunt SA,Abraham WT,Chin MH, et al.ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult—summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure).Circulation.2005;112(12):18251852.
  5. DiDomenico RJ,Park HY,Southworth MR, et al.Guidelines for acute decompensated heart failure treatment.Ann Pharmacother.2004;38(4):649660.
  6. Costanzo MR,Saltzberg M,O'Sullivan J,Sobotka P.Early ultrafiltration in patients with decompensated heart failure and diuretic resistance.J Am Coll Cardiol.2005;46(11):20472051.
  7. Peacock WF,Fonarow GC,Emerman CL,Mills RM,Wynne J.Impact of early initiation of intravenous therapy for acute decompensated heart failure on outcomes in ADHERE.Cardiology.2007;107(1):4451.
  8. Heart Failure Society of America.Executive Summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline.J Card Fail.2006;12(1):1038.
  9. Silver MA,Maisel A,Yancy CW, et al.BNP Consensus Panel 2004: a clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases.Congest Heart Fail.2004;10(5 suppl 3):130.
  10. Nieminen MS,Böhm M,Cowie MR, et al.Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology.Eur Heart J.2005;26(4):384416.
  11. Stevenson LW,Perloff JK.The limited reliability of physical signs for estimating hemodynamics in chronic heart failure.JAMA.1989;261(6):884888.
  12. Abraham WT,Adams KF,Fonarow GC, et al.In‐hospital mortality in patients with acute decompensated heart failure treated with intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).J Am Coll Cardiol.2005;46(1):5764.
  13. Gheorghiade M,Abraham WT,Albert NM, et al.Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure.JAMA.2006;296(18):22172226.
  14. Morrison LK,Harrison A,Krishnaswamy P,Kazanegra R,Clopton P,Maisel A.Utility of a rapid B‐natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea.J Am Coll Cardiol.2002;39(2):202209.
  15. Fonarow GC.Overview of acutely decompensated congestive heart failure (ADHF): a report from the ADHERE registry.Heart Fail Rev.2004;9(3):179185.
  16. Costanzo MR,Johannes RS,Pine M, et al.The safety of intravenous diuretics alone versus diuretics plus parenteral vasoactive therapies in hospitalized patients with acutely decompensated heart failure: a propensity score and instrumental variable analysis using the Acutely Decompensated Heart Failure National Registry (ADHERE) database.Am Heart J.2007;154(2):267277.
  17. Fonarow GC,Stough WG,Abraham WT, et al.Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE‐HF registry.J Am Coll Cardiol.2007;50(8):768777.
  18. Dao Q,Krishnaswamy P,Kazanegra R, et al.Utility of B‐type natriuretic peptide in the diagnosis of congestive heart failure in an urgent‐care setting.J Am Coll Cardiol.2001;37(2):379385.
  19. Harrison A,Morrison LK,Krishnaswamy P, et al.B‐type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea.Ann Emerg Med.2002;39(2):131138.
  20. Maisel A.B‐type natriuretic peptide levels: diagnostic and prognostic in congestive heart failure: what's next?Circulation.2002;105(20):23282331.
  21. Maisel AS,Krishnaswamy P,Nowak RM, et al.Rapid measurement of B‐type natriuretic peptide in the emergency diagnosis of heart failure.N Engl J Med.2002;347(3):161167.
  22. Maisel AS,McCord J,Nowak RM, et al.Bedside B‐type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction: results from the Breathing Not Properly Multinational Study.J Am Coll Cardiol.2003;41(11):20102017.
  23. Maisel A,Hollander JE,Guss D, et al.Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT): a multicenter study of B‐type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath.J Am Coll Cardiol.2004;44(6):13281333.
  24. Seino Y,Ogawa A,Yamashita T, et al.Application of NT‐proBNP and BNP measurements in cardiac care: a more discerning marker for the detection and evaluation of heart failure.Eur J Heart Fail.2004;6(3):295300.
  25. Baggish AL,van Kimmenade R,Bayes‐Genis A, et al.Hemoglobin and N‐terminal pro‐brain natriuretic peptide: independent and synergistic predictors of mortality in patients with acute heart failure. Results from the International Collaborative of NT‐proBNP (ICON) Study.Clin Chim Acta.2007;381(2):145150.
  26. Mueller C,Scholer A,Laule‐Kilian K, et al.Use of B‐type natriuretic peptide in the evaluation and management of acute dyspnea.N Engl J Med.2004;350(7):647654.
  27. American College of Emergency Physicians Clinical Policies Subcommittee (Writing Committee) on Acute Heart Failure Syndromes,Silvers SM,Howell JM,Kosowsky JM,Rokos IC,Jagoda AS.Clinical policy: critical issues in the evaluation and management of adult patients presenting to the emergency department with acute heart failure syndromes.Ann Emerg Med.2007;49(5):627669.
  28. Sarzani R,Dessi‐Fulgheri P,Paci VM,Espinosa E,Rappelli A.Expression of natriuretic peptide receptors in human adipose and other tissues.J Endocrinol Invest.1996;19(9):581585.
  29. Cowie MR,Jourdain P,Maisel A, et al.Clinical applications of B‐type natriuretic peptide (BNP) testing.Eur Heart J.2003;24(19):17101718.
  30. McCullough PA,Duc P,Omland T, et al.B‐type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study.Am J Kidney Dis.2003;41(3):571579.
  31. McKie PM,Burnett JC.B‐type natriuretic peptide as a biomarker beyond heart failure: speculations and opportunities.Mayo Clin Proc.2005;80(8):10291036.
  32. Galvani M,Ferrini D,Ottani F.Natriuretic peptides for risk stratification of patients with acute coronary syndromes.Eur J Heart Fail.2004;6(3):327333.
  33. Sinclair H,Paterson M,Walker S,Beckett G,Fox KA.Predicting outcome in patients with acute coronary syndrome: evaluation of B‐type natriuretic peptide and the global registry of acute coronary events (GRACE) risk score.Scott Med J.2007;52(3):813.
  34. Fonarow GC,Adams KFJ,Abraham WT,Yancy CW,Boscardin WJ.Risk stratification for in‐hospital mortality in acutely decompensated heart failure: classification and regression tree analysis.JAMA.2005;293(5):572580.
  35. Blackledge HM,Tomlinson J,Squire IB.Prognosis for patients newly admitted to hospital with heart failure: survival trends in 12 220 index admissions in Leicestershire 1993–2001.Heart.2003;89(6):615620.
  36. Kerzner R,Gage BF,Freedland KE,Rich MW.Predictors of mortality in younger and older patients with heart failure and preserved or reduced left ventricular ejection fraction.Am Heart J.2003;146(2):286290.
  37. Lee DS,Austin PC,Rouleau JL,Liu PP,Naimark D,Tu JV.Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model.JAMA.2003;290(19):25812587.
  38. Clinical Quality Improvement Network Investigators.Mortality risk and patterns of practice in 4606 acute care patients with congestive heart failure: the relative importance of age, sex, and medical therapy.Arch Intern Med.1996;156(15):16691673.
  39. Rohde LE,Goldraich L,Polanczyk CA, et al.A simple clinically based predictive rule for heart failure in‐hospital mortality.J Card Fail.2006;12(8):587593.
  40. Siirilä‐Waris K,Lassus J,Melin J,Peuhkurinen K,Nieminen MS,Harjola V‐P.Characteristics, outcomes, and predictors of 1‐year mortality in patients hospitalized for acute heart failure.Eur Heart J.2006;27(24):30113017.
  41. Adamopoulos C,Zannad F,Fay R, et al.Ejection fraction and blood pressure are important and interactive predictors of 4‐week mortality in severe acute heart failure.Eur J Heart Fail.2007;9(9):935941.
  42. Smith GL,Vaccarino V,Kosiborod M, et al.Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure?J Card Fail.2003;9(1):1325.
  43. Forman DE,Butler J,Wang Y, et al.Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure.J Am Coll Cardiol.2004;43(1):6167.
  44. Felker GM,Gattis WA,Leimberger JD, et al.Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure.Am J Cardiol.2003;92(5):625628.
  45. Young JB,Abraham WT,Albert NM, et al.Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE‐HF registry).Am J Cardiol.2008;101(2):223230.
  46. Gheorghiade M,Abraham WT,Albert NM, et al.Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE‐HF registry.Eur Heart J.2007;28(8):980988.
  47. Ishii J,Cui W,Kitagawa F, et al.Prognostic value of combination of cardiac troponin T and B‐type natriuretic peptide after initiation of treatment in patients with chronic heart failure.Clin Chem.2003;49(12):20202026.
  48. Fonarow GC,Peacock WF,Horwich TB, et al.Usefulness of B‐type natriuretic peptide and cardiac troponin levels to predict in‐hospital mortality from ADHERE.Am J Cardiol.2008;101(2):231237.
  49. Eshaghian S,Horwich TB,Fonarow GC.Relation of loop diuretic dose to mortality in advanced heart failure.Am J Cardiol.2006;97(12):17591764.
  50. Hasselblad V,Gattis Stough W,Shah MR, et al.Relation between diuretic dose and outcome in a heart failure population: results of the ESCAPE trial [Abstract 250].J Card Fail.2005;11(6 Suppl):S157.
  51. Setoguchi S,Stevenson LW,Schneeweiss S.Repeated hospitalizations predict mortality in the community population with heart failure.Am Heart J.2007;154(2):260266.
  52. Costanzo MR,Mills RM,Wynne J.Characteristics of “Stage D” heart failure: insights from the Acute Decompensated Heart Failure National Registry Longitudinal Module (ADHERE LM).Am Heart J.2008;155(2):339347.
  53. American College of Cardiology/American Heart Association Task Force on Practice Guidelines.Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure).J Am Coll Cardiol.1995;26(5):13761398.
  54. Cuffe MS,Califf RM,Adams KFJ, et al.Short‐term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.JAMA.2002;287(12):15411547.
  55. Fonarow GC,Abraham WT,Albert NM, et al.Influence of beta‐blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE‐HF program.J Am Coll Cardiol.2008;52(3):190199.
  56. Fonarow GC,Abraham WT,Albert NM, et al.Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE‐HF): rationale and design.Am Heart J.2004;148(1):4351.
  57. Pistoria MJ,Amin AN,Dressler DD,McKean SCW,Budnitz TL, eds.The core competencies in hospital medicine: a framework for curriculum development by the Society of Hospital Medicine.J Hosp Med.2006;1(Suppl 1):295.
  58. Ashton CM,Kuykendall DH,Johnson ML,Wray NP,Wu L.The association between the quality of inpatient care and early readmission.Ann Intern Med.1995;122(6):415421.
  59. Elkayam U,Tasissa G,Binanay C, et al.Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure.Am Heart J.2007;153(1):98104.
  60. Amin A.Improving the management of patients after myocardial infarction, from admission to discharge.Clin Ther.2006;28(10):15091539.
  61. Lindenauer PK,Chehabeddine R,Pekow P,Fitzgerald J,Benjamin EM.Quality of care for patients hospitalized with heart failure: assessing the impact of hospitalists.Arch Intern Med.2002;162(11):12511256.
  62. Roytman MM,Thomas SM,Jiang CS.Comparison of practice patterns of hospitalists and community physicians in the care of patients with congestive heart failure.J Hosp Med.2008;3(1):3541.
  63. Southern WN,Berger MA,Bellin EY,Hailpern SM,Arnsten JH.Hospitalist care and length of stay in patients requiring complex discharge planning and close clinical monitoring.Arch Intern Med.2007;167(17):18691874.
  64. Fonarow GC,Stevenson LW,Walden JA, et al.Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure.J Am Coll Cardiol.1997;30(3):725732.
  65. Krumholz HM,Amatruda J,Smith GL, et al.Randomized trial of an education and support intervention to prevent readmission of patients with heart failure.J Am Coll Cardiol.2002;39(1):8389.
References
  1. DeFrances CJ,Cullen KA,Kozak LJ.National Hospital Discharge Survey: 2005 annual summary with detailed diagnosis and procedure data.Vital Health Stat 13.2007; (165):1209.
  2. Rosamond W,Flegal K,Furie K, et al.Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.Circulation.2008;117(4):e25e146.
  3. Aghababian RV.Acutely decompensated heart failure: opportunities to improve care and outcomes in the emergency department.Rev Cardiovasc Med.2002;3(suppl 4):S3S9.
  4. Hunt SA,Abraham WT,Chin MH, et al.ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult—summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure).Circulation.2005;112(12):18251852.
  5. DiDomenico RJ,Park HY,Southworth MR, et al.Guidelines for acute decompensated heart failure treatment.Ann Pharmacother.2004;38(4):649660.
  6. Costanzo MR,Saltzberg M,O'Sullivan J,Sobotka P.Early ultrafiltration in patients with decompensated heart failure and diuretic resistance.J Am Coll Cardiol.2005;46(11):20472051.
  7. Peacock WF,Fonarow GC,Emerman CL,Mills RM,Wynne J.Impact of early initiation of intravenous therapy for acute decompensated heart failure on outcomes in ADHERE.Cardiology.2007;107(1):4451.
  8. Heart Failure Society of America.Executive Summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline.J Card Fail.2006;12(1):1038.
  9. Silver MA,Maisel A,Yancy CW, et al.BNP Consensus Panel 2004: a clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases.Congest Heart Fail.2004;10(5 suppl 3):130.
  10. Nieminen MS,Böhm M,Cowie MR, et al.Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology.Eur Heart J.2005;26(4):384416.
  11. Stevenson LW,Perloff JK.The limited reliability of physical signs for estimating hemodynamics in chronic heart failure.JAMA.1989;261(6):884888.
  12. Abraham WT,Adams KF,Fonarow GC, et al.In‐hospital mortality in patients with acute decompensated heart failure treated with intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).J Am Coll Cardiol.2005;46(1):5764.
  13. Gheorghiade M,Abraham WT,Albert NM, et al.Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure.JAMA.2006;296(18):22172226.
  14. Morrison LK,Harrison A,Krishnaswamy P,Kazanegra R,Clopton P,Maisel A.Utility of a rapid B‐natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea.J Am Coll Cardiol.2002;39(2):202209.
  15. Fonarow GC.Overview of acutely decompensated congestive heart failure (ADHF): a report from the ADHERE registry.Heart Fail Rev.2004;9(3):179185.
  16. Costanzo MR,Johannes RS,Pine M, et al.The safety of intravenous diuretics alone versus diuretics plus parenteral vasoactive therapies in hospitalized patients with acutely decompensated heart failure: a propensity score and instrumental variable analysis using the Acutely Decompensated Heart Failure National Registry (ADHERE) database.Am Heart J.2007;154(2):267277.
  17. Fonarow GC,Stough WG,Abraham WT, et al.Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE‐HF registry.J Am Coll Cardiol.2007;50(8):768777.
  18. Dao Q,Krishnaswamy P,Kazanegra R, et al.Utility of B‐type natriuretic peptide in the diagnosis of congestive heart failure in an urgent‐care setting.J Am Coll Cardiol.2001;37(2):379385.
  19. Harrison A,Morrison LK,Krishnaswamy P, et al.B‐type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea.Ann Emerg Med.2002;39(2):131138.
  20. Maisel A.B‐type natriuretic peptide levels: diagnostic and prognostic in congestive heart failure: what's next?Circulation.2002;105(20):23282331.
  21. Maisel AS,Krishnaswamy P,Nowak RM, et al.Rapid measurement of B‐type natriuretic peptide in the emergency diagnosis of heart failure.N Engl J Med.2002;347(3):161167.
  22. Maisel AS,McCord J,Nowak RM, et al.Bedside B‐type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction: results from the Breathing Not Properly Multinational Study.J Am Coll Cardiol.2003;41(11):20102017.
  23. Maisel A,Hollander JE,Guss D, et al.Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT): a multicenter study of B‐type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath.J Am Coll Cardiol.2004;44(6):13281333.
  24. Seino Y,Ogawa A,Yamashita T, et al.Application of NT‐proBNP and BNP measurements in cardiac care: a more discerning marker for the detection and evaluation of heart failure.Eur J Heart Fail.2004;6(3):295300.
  25. Baggish AL,van Kimmenade R,Bayes‐Genis A, et al.Hemoglobin and N‐terminal pro‐brain natriuretic peptide: independent and synergistic predictors of mortality in patients with acute heart failure. Results from the International Collaborative of NT‐proBNP (ICON) Study.Clin Chim Acta.2007;381(2):145150.
  26. Mueller C,Scholer A,Laule‐Kilian K, et al.Use of B‐type natriuretic peptide in the evaluation and management of acute dyspnea.N Engl J Med.2004;350(7):647654.
  27. American College of Emergency Physicians Clinical Policies Subcommittee (Writing Committee) on Acute Heart Failure Syndromes,Silvers SM,Howell JM,Kosowsky JM,Rokos IC,Jagoda AS.Clinical policy: critical issues in the evaluation and management of adult patients presenting to the emergency department with acute heart failure syndromes.Ann Emerg Med.2007;49(5):627669.
  28. Sarzani R,Dessi‐Fulgheri P,Paci VM,Espinosa E,Rappelli A.Expression of natriuretic peptide receptors in human adipose and other tissues.J Endocrinol Invest.1996;19(9):581585.
  29. Cowie MR,Jourdain P,Maisel A, et al.Clinical applications of B‐type natriuretic peptide (BNP) testing.Eur Heart J.2003;24(19):17101718.
  30. McCullough PA,Duc P,Omland T, et al.B‐type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study.Am J Kidney Dis.2003;41(3):571579.
  31. McKie PM,Burnett JC.B‐type natriuretic peptide as a biomarker beyond heart failure: speculations and opportunities.Mayo Clin Proc.2005;80(8):10291036.
  32. Galvani M,Ferrini D,Ottani F.Natriuretic peptides for risk stratification of patients with acute coronary syndromes.Eur J Heart Fail.2004;6(3):327333.
  33. Sinclair H,Paterson M,Walker S,Beckett G,Fox KA.Predicting outcome in patients with acute coronary syndrome: evaluation of B‐type natriuretic peptide and the global registry of acute coronary events (GRACE) risk score.Scott Med J.2007;52(3):813.
  34. Fonarow GC,Adams KFJ,Abraham WT,Yancy CW,Boscardin WJ.Risk stratification for in‐hospital mortality in acutely decompensated heart failure: classification and regression tree analysis.JAMA.2005;293(5):572580.
  35. Blackledge HM,Tomlinson J,Squire IB.Prognosis for patients newly admitted to hospital with heart failure: survival trends in 12 220 index admissions in Leicestershire 1993–2001.Heart.2003;89(6):615620.
  36. Kerzner R,Gage BF,Freedland KE,Rich MW.Predictors of mortality in younger and older patients with heart failure and preserved or reduced left ventricular ejection fraction.Am Heart J.2003;146(2):286290.
  37. Lee DS,Austin PC,Rouleau JL,Liu PP,Naimark D,Tu JV.Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model.JAMA.2003;290(19):25812587.
  38. Clinical Quality Improvement Network Investigators.Mortality risk and patterns of practice in 4606 acute care patients with congestive heart failure: the relative importance of age, sex, and medical therapy.Arch Intern Med.1996;156(15):16691673.
  39. Rohde LE,Goldraich L,Polanczyk CA, et al.A simple clinically based predictive rule for heart failure in‐hospital mortality.J Card Fail.2006;12(8):587593.
  40. Siirilä‐Waris K,Lassus J,Melin J,Peuhkurinen K,Nieminen MS,Harjola V‐P.Characteristics, outcomes, and predictors of 1‐year mortality in patients hospitalized for acute heart failure.Eur Heart J.2006;27(24):30113017.
  41. Adamopoulos C,Zannad F,Fay R, et al.Ejection fraction and blood pressure are important and interactive predictors of 4‐week mortality in severe acute heart failure.Eur J Heart Fail.2007;9(9):935941.
  42. Smith GL,Vaccarino V,Kosiborod M, et al.Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure?J Card Fail.2003;9(1):1325.
  43. Forman DE,Butler J,Wang Y, et al.Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure.J Am Coll Cardiol.2004;43(1):6167.
  44. Felker GM,Gattis WA,Leimberger JD, et al.Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure.Am J Cardiol.2003;92(5):625628.
  45. Young JB,Abraham WT,Albert NM, et al.Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE‐HF registry).Am J Cardiol.2008;101(2):223230.
  46. Gheorghiade M,Abraham WT,Albert NM, et al.Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE‐HF registry.Eur Heart J.2007;28(8):980988.
  47. Ishii J,Cui W,Kitagawa F, et al.Prognostic value of combination of cardiac troponin T and B‐type natriuretic peptide after initiation of treatment in patients with chronic heart failure.Clin Chem.2003;49(12):20202026.
  48. Fonarow GC,Peacock WF,Horwich TB, et al.Usefulness of B‐type natriuretic peptide and cardiac troponin levels to predict in‐hospital mortality from ADHERE.Am J Cardiol.2008;101(2):231237.
  49. Eshaghian S,Horwich TB,Fonarow GC.Relation of loop diuretic dose to mortality in advanced heart failure.Am J Cardiol.2006;97(12):17591764.
  50. Hasselblad V,Gattis Stough W,Shah MR, et al.Relation between diuretic dose and outcome in a heart failure population: results of the ESCAPE trial [Abstract 250].J Card Fail.2005;11(6 Suppl):S157.
  51. Setoguchi S,Stevenson LW,Schneeweiss S.Repeated hospitalizations predict mortality in the community population with heart failure.Am Heart J.2007;154(2):260266.
  52. Costanzo MR,Mills RM,Wynne J.Characteristics of “Stage D” heart failure: insights from the Acute Decompensated Heart Failure National Registry Longitudinal Module (ADHERE LM).Am Heart J.2008;155(2):339347.
  53. American College of Cardiology/American Heart Association Task Force on Practice Guidelines.Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure).J Am Coll Cardiol.1995;26(5):13761398.
  54. Cuffe MS,Califf RM,Adams KFJ, et al.Short‐term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.JAMA.2002;287(12):15411547.
  55. Fonarow GC,Abraham WT,Albert NM, et al.Influence of beta‐blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE‐HF program.J Am Coll Cardiol.2008;52(3):190199.
  56. Fonarow GC,Abraham WT,Albert NM, et al.Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE‐HF): rationale and design.Am Heart J.2004;148(1):4351.
  57. Pistoria MJ,Amin AN,Dressler DD,McKean SCW,Budnitz TL, eds.The core competencies in hospital medicine: a framework for curriculum development by the Society of Hospital Medicine.J Hosp Med.2006;1(Suppl 1):295.
  58. Ashton CM,Kuykendall DH,Johnson ML,Wray NP,Wu L.The association between the quality of inpatient care and early readmission.Ann Intern Med.1995;122(6):415421.
  59. Elkayam U,Tasissa G,Binanay C, et al.Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure.Am Heart J.2007;153(1):98104.
  60. Amin A.Improving the management of patients after myocardial infarction, from admission to discharge.Clin Ther.2006;28(10):15091539.
  61. Lindenauer PK,Chehabeddine R,Pekow P,Fitzgerald J,Benjamin EM.Quality of care for patients hospitalized with heart failure: assessing the impact of hospitalists.Arch Intern Med.2002;162(11):12511256.
  62. Roytman MM,Thomas SM,Jiang CS.Comparison of practice patterns of hospitalists and community physicians in the care of patients with congestive heart failure.J Hosp Med.2008;3(1):3541.
  63. Southern WN,Berger MA,Bellin EY,Hailpern SM,Arnsten JH.Hospitalist care and length of stay in patients requiring complex discharge planning and close clinical monitoring.Arch Intern Med.2007;167(17):18691874.
  64. Fonarow GC,Stevenson LW,Walden JA, et al.Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure.J Am Coll Cardiol.1997;30(3):725732.
  65. Krumholz HM,Amatruda J,Smith GL, et al.Randomized trial of an education and support intervention to prevent readmission of patients with heart failure.J Am Coll Cardiol.2002;39(1):8389.
Issue
Journal of Hospital Medicine - 3(6)
Issue
Journal of Hospital Medicine - 3(6)
Page Number
S16-S24
Page Number
S16-S24
Article Type
Display Headline
Hospitalized patients with acute decompensated heart failure: Recognition, risk stratification, and treatment review
Display Headline
Hospitalized patients with acute decompensated heart failure: Recognition, risk stratification, and treatment review
Legacy Keywords
Acute decompensated heart failure, diagnosis, guidelines, outcomes, treatment
Legacy Keywords
Acute decompensated heart failure, diagnosis, guidelines, outcomes, treatment
Sections
Article Source
Copyright © 2008 Society of Hospital Medicine
Disallow All Ads
Correspondence Location
Department of Medicine, Executive Director, Hospitalist Program, University of California, Irvine, 101 The City Drive South, Building 26, Room 1005 ZC‐4076H Orange, CA 92868
Content Gating
Gated (full article locked unless allowed per User)
Gating Strategy
First Peek Free
Article PDF Media

Management of Volume Overload

Article Type
Changed
Mon, 01/02/2017 - 19:34
Display Headline
Inpatient management of patients with volume overload and high filling pressures

Although patients with left ventricular dysfunction may present with low‐output syndrome and even cardiogenic shock, the majority are admitted with symptoms of congestion.1 The classic symptoms of congestive heart failure reflect fluid overload, that is, orthopnea, paroxysmal nocturnal dyspnea, and peripheral edema; these symptoms can be so dramatic that it is not surprising that patients seek hospitalization.2 Activation of the renin angiotensin system coupled with sympathetic hyperactivity results in marked sodium retention and increased filling pressures in the right and left ventricle that ultimately bring about these congestive symptoms of dyspnea and orthopnea.3 Increased filling pressure precedes admission to the hospital, and filling pressure falls during successful therapy.4, 5 Indeed, normalization of the left ventricular filling pressure much better predicts survival than improved cardiac output.6 However, despite the many advances in the evidence‐based armamentarium for heart failure, the one great deficiency in the evidence base is the lack of data on modalities that can reduce or normalize left ventricular filling pressures. This is not as unexpected as it seems because the symptoms of congestion are so dramatic and, until recently, the tools to mitigate were so few that randomized trials were difficult to conceive. However, the treatment paradigms for acute decompensated heart failure (ADHF) management are changing, and evidence‐based mortality trials for filling pressure reduction and congestion relief continue to evolve.710

DIURETICS

Mercurial diuretics were introduced in the 1920s as the mainstay of therapy for ADHF; the loop diuretics became the foundation of therapy in the 1960s.11, 12 In the Acute Decompensated Heart Failure National Registry database (ADHERE), 88% of patients received intravenous loop diuretics during their hospitalization.13 Loop diuretics act in the thick ascending limb of the loop of Henle to inhibit reabsorption of sodium and chloride by inhibiting the sodium, potassium, and chloride (Na+/K+/2Cl) pump. This blockade causes increased delivery of these solutes to the distal convoluted tubule and collecting duct, resulting in a shift in the balance of osmotic forces toward fluid secretion into the collecting system. Through this mechanism, loop diuretics increase natriuresis and diuresis (Figure 1).14

Figure 1
Single juxtamedullary nephron. Adapted with permission from Patel et al.14

Less commonly used are the thiazide diuretics, which act on the distal convoluted tubule to block Na+, K+‐ATPase and thereby NaCl transport in the distal convoluted tubule.15 Thiazide diuretics are much less powerful than loop diuretics and are rarely used intravenously in the hospital. These do possess a synergistic effect when used with loop diuretics in that sodium reabsorption is blocked in 2 sections of the nephron.16 Extreme care must be taken to avoid overdiuresis, but this combination can be helpful to treat diuretic resistance.17

The third class of agents are the so‐called potassium‐sparing diuretics, which block sodium reuptake in the final portion of the nephron (the collecting ducts), resulting in an obligatory reuptake of potassium. These agents include the aldosterone receptor blocker spironolactone and eplerenone, which act primarily through competitive binding of receptors at the aldosterone‐dependent sodium‐potassium exchange site in the distal convoluted renal tubule. Although weak diuretics, they are the only class of diuretics shown to improve mortality in moderate to severe heart failure,18, 19 presumably by modulating the abnormal neurohormonal activation of the sympathetic nervous system and the renin‐angiotensin‐aldosterone axis.20 Unfortunately, severe hyperkalemia remains a significant side effect and can limit their use.21

Despite the obvious beneficial effects of loop diuretics in the treatment of ADHF, we lack key fundamental information about these most frequently used drugs. For example, what is the correct dose? Escalating the dose of diuretics has been associated with increased mortality in heart failure even when corrected for the severity of the illness.22, 23 Proposed explanations for the increased morality in patients with heart failure include activation of the renin‐angiotensin‐aldosterone system and sympathetic nervous system, decreases in the glomerular filtration rate (GFR) contributing to cardiorenal syndrome, and intravascular volume contraction and decreased left ventricular filling pressure worsening cardiac performance in patients without significant fluid retention.22, 23 It is now recognized that kidney dysfunction plays a vital role in the progress of patients with heart failure, and increases in serum creatinine or blood urea nitrogen are known predictors of mortality.24 Thus, larger doses of diuretics may result in unfavorable outcomes in heart failure patients because of adverse effects on renal function. In the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE), there was a clear increase in mortality with escalating loop diuretic doses, especially above 300 mg/day of furosemide (or an equivalent dose of another loop diuretic).25 Although patients with renal dysfunction may require higher doses, prudence would dictate using the lowest dose to gain a reasonable urine output.

How should loop diuretics be given: as a bolus or continuous infusion? Although diuretics have been typically given as a bolus, there are significant theoretical concerns about this method. Furosemide, for example, has a half‐life of approximately 2 hours; when it is given once or twice a day, a breaking phenomenon is seen in which the kidneys start to retain sodium and the effectiveness of the bolus is reduced.26 A Cochrane review has found evidence that a continuous infusion of diuretics produces more diuresis, although the same article suggests that more titration is needed to support this observation.27

Several loop diuretics are used clinically, including furosemide, torsemide, and bumetanide. Which one should be chosen? Furosemide is the least expensive and most widely used, but 2 animal models suggest more favorable cardiac effects (less fibrosis) with torsemide and even mortality benefit.28, 29 There are no comparable human data to guide the clinician, unfortunately. On a milligram per milligram basis, bumetanide produces more natriuresis than either torsemide or furosemide, but again, the clinical significance of this is not known.

VASODILATORS

Nitrates

Nitrates, including nitroglycerin and nitroprusside, have been used in therapy for ADHF primarily as venodilators.30 Thus, they have been shown to reduce right and left ventricular filling pressures, systemic and pulmonary vascular resistance, and, to a lesser extent, systemic blood pressure.31 A serious drawback to the continued use of nitrates is the development of tolerance that can become apparent within hours of their initial use.32 In addition, there have not been large outcome trials to define the duration of benefit or the proper dose.

Nesiritide

A potential role for the natriuretic peptides in heart failure dates back to the 1980s when extracts of the right atrial tissue of rats was shown to produce a brisk natriuresis when given intravenously to a second animal.33 Nesiritide, as the commercially prepared B‐type natriuretic peptide is called, consistently reduced preload and afterload and caused natriuresis in some studies.34, 35 Natriuresis and augmentation of diuresis has not been consistently demonstrated in published reports, however.36, 37 In addition, B‐type natriuretic peptide, when given therapeutically, does suppress aldosterone.38

The largest clinical experience to date with nesiritide came in the Vasodilation in the Management of Acute Congestive Heart Failure (VMAC) trial.39 In this study, nesiritide was compared with intravenous nitroglycerin and placebo when added to standard care for 3 hours in a double‐blind, randomized protocol. Nesiritide reduced filling pressures in comparison with nitroglycerin and placebo and provided greater symptomatic relief in comparison with placebo but not in comparison with nitroglycerin.39 In a retrospective review of consecutive patients, the addition of nesiritide resulted in a decreased length of stay without compromising renal function.40

In 2005, 2 meta‐analyses were published that raised questions about the safety of nesiritide.41, 42 In the first, a review of 5 nesiritide/placebo trials found an increased risk for worsening renal function (specifically, a rise in serum creatinine of 0.5 mg/dL or more).41 This increase occurred in 21% of nesiritide‐treated patients versus 15% of those on placebo (P = .001). Some of these trials in the meta‐analysis employed dosages of nesiritide greater than the currently recommended 0.01 g/kg/minute. When only those patients in the VMAC group that received the recommended 0.01 g/kg/minute dose were analyzed, there was not a significant rise in creatinine.43 Riter et al44 reported a retrospective analysis finding that half or even quarter doses of nesiritide actually produced improvement in renal function compared with the standard dose or no nesiritide use. Higher doses of diuretics, >160 mg of furosemide or its equivalent in conjunction with nesiritide, did increase the risk of renal dysfunction.45 In the Nesiritide Administered Perianesthesia (NAPA) trial, 0.01 g/kg/minute of nesiritide was given as a defined 24‐hour infusion without bolus to high‐risk patients with left ventricular dysfunction undergoing bypass and mitral valve surgery.46 Although serum creatinine increased in both groups following surgery, it increased more so with placebo than nesiritide (P < 0.001), despite increased urine output (P < 0.001) and shorter length of hospital stay (P = 0.043) in the nesiritide group.46 A smaller study of similar design also noted preservation of renal function with nesiritide compared with placebo in bypass patients.47 Therefore, the current recommendation for nesiritide use is to use no more than 0.01 g/kg/minute. Reduction of diuretic doses would be prudent when nesiritide is used.

Sackner‐Bernstein et al42 combined the results of 3 placebo‐controlled trials and reported an increase in mortality with nesiritide at 30 days. In this study, significant differences were found between the placebo and nesiritide groups in terms of baseline renal function,48 blood pressure, and inotrope use, and this may explain the observed mortality difference.42 Mortality was the same at 180 days. Abraham49 analyzed the 7 available trials and risk‐adjusted the patient populations to avoid group inequalities; with this method, no significant effect of nesiritide use on mortality was seen. The 2 most recent large trialsFollow‐Up Serial Infusions of Nesiritide II (FUSION II) (no effect of nesiritide on mortality) and NAPA (mortality decreased in nesiritide‐treated patients)have provided more safety data concerning the use of nesiritide.46, 50 The most definitive answer will come with the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND‐HF) trial, which will recruit 7000 patients, the largest trial in ADHF to date.

ULTRAFILTRATION (UF)

UF removes water and nonprotein‐bound smallmolecular‐weight and mediummolecular‐weight solutes through the semipermeable membrane when hydrostatic pressure, generated by blood pressure or an external blood pump, exceeds oncotic pressure. The fluid removal rate can be adjusted between 100 and 500 mL/hour. The Ultrafiltration Versus Intravenous Diuretics for Patients Hospitalized for Acute Decompensated Congestive Heart Failure (UNLOAD) trial randomized UF with intravenous diuretic therapy in patients with ADHF and showed that UF produced greater weight and fluid loss at 48 hours versus diuretics and reduced the 90‐day readmission rate for heart failure.51 There was no statistically significant difference noted between the overall mortality and serum creatinine between the 2 groups. Rogers et al52 found in a small, randomized trial that during a 48‐hour period, UF showed no significant difference in the renal hemodynamics (GFR and renal plasma flow in patients with ADHF) versus the standard treatment with intravenous diuretics. The Heart Failure Society of America treatment guidelines for the evaluation and management of patients with ADHF suggest that when congestion fails to improve in response to diuretic therapy, UF may be considered (strength of evidence = C).53

Perhaps the most vexing issue surrounding the use of diuretics, vasodilators, and UF is when to stop intravenous therapy in the hospitalized patient. There are no clear guidelines about this, and perhaps clinical experience is of paramount importance. Theoretically, vasodilator and fluid removal therapy should be continued until the patient is euvolemic, that is, has normal filling pressures (usually associated with normalization of the neck veins and loss of S3) with improvement in symptoms. This was clearly seen in the ESCAPE trial, in which use of either hemodynamic guidance or clinical evaluation of jugular venous pressure resulted in more normal filling pressures.5 This is an extremely important issue because continued fluid removal beyond the point at which the patient is euvolemic may result in renal dysfunction; the latter is a strong predictor of prolonged hospitalization and mortality.54, 55

Initial fluid removal can be rapid with either diuretics or UF, and filling pressures fall within minutes with nesiritide. This is beneficial to the patient as long as extracellular sodium and water reenter the vascular bed to maintain preload. Boyle and Sobotka56 emphasized the importance of this plasma refill rate and proposed monitoring the hematocrit as is done in dialysis to prevent excessive fluid removal. As can be seen in Figure 2, the plasma compartment is easily refilled when extracellular volume is increased in edematous patients early in their therapy. However, the plasma refill rate can fall precipitously when this compartment is depleted. Hence, clinicians must be ever alert to this transition period when continued fluid removal or vasodilator therapy results in depletion of vascular, not interstitial, volume with rapid declines in preload and cardiac output. Therefore, these therapies should be stopped when the patient becomes euvolemic, not later when the patient has become hypovolemic with the attendant problems. In the ESCAPE trial, the jugular venous pressure was the best indicator of a normal filling pressure,5, 54 although this is not an infallible guide. Our practice is to stop diuretics and vasodilators when edema has resolved and jugular venous pressure is below 8 cm. In addition, checking blood urea nitrogen and creatinine twice a day can give an early warning of hypovolemia when these rise 25% above baseline.57 Volume status should be carefully evaluated by changes in the physical examination, including postural blood pressure changes and increases in blood urea nitrogen and creatinine. When worsening renal function occurs, judicious fluid replacement with 500 to 1000 mL of normal saline given over 2 to 4 hours can quickly restore euvolemia and may improve renal function in the hypovolemic patient.

Figure 2
The importance of the plasma refill rate in the management of acute decompensated heart failure (ADHF). (A) The patient with ADHF and significant fluid overload. The extracellular compartment contains more volume than normal. The removal of fluid from the vascular compartment as well as reduction in venous pressure by vasodilators reduces vascular venous pressure and thus increases fluid movement from the extracellular compartment. This is termed the plasma refill rate, as fluid removed by the kidneys is replaced from the extracellular compartment. Homeostasis is maintained as long as urine output or ultrafiltrate removal does not exceed the plasma refill rate. Vasodilators can increase the plasma refill rate by reducing venous tone and hence venous pressure. (B) As long as the plasma refill rate equals or exceeds fluid loss, volume in the vascular bed is maintained along with ventricular preload. Diuretics, ultrafiltration, and vasodilators should be stopped at this point. (C) When diuretics and/or vasodilators are continued beyond the point of depletion of already removed extracellular fluid, then the plasma refill rate no longer keeps up with fluid removal, and vascular volume is reduced below normal. This results in decreased preload and reduced cardiac output, blood pressure, and renal perfusion. The transition from euvolemia to hypovolemia may be very subtle and abrupt. This accounts for the frequency of worsening renal function in heart failure and its untoward consequences.

INVESTIGATIONAL THERAPIES

Oral Vasopressin Antagonist

Elevation of arginine vasopressin contributes to fluid retention and hyponatremia and is directly proportional to the severity of heart failure.58 Tolvaptan is an oral, nonpeptide, selective vasopressin V2 receptor antagonist whose action on the distal nephron causes loss of electrolyte‐free water (aquaresis).59 The efficacy of tolvaptan was tested in a double‐blind, prospective, randomized international trial, the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST), with a 30 mg/day oral dosage of tolvaptan versus placebo within 48 hours of admission with ADHF.7, 9 Patients receiving tolvaptan showed improvement in dyspnea on day 1 along with body weight and edema reduction on day 7 or discharge in comparison with placebo. The improvement in global clinical assessment was not different between the 2 groups. The serious adverse event frequencies were similar between the groups without excess renal failure or hypotension in the tolvaptan group.7, 9 Unfortunately, this small beneficial effect in the hospital did not result in positive survival benefit.

Adenosine A1‐Receptor (AA1R) Antagonists

The kidney is the only organ in which adenosine is a paracrine vasoconstrictor.60 Dittrich et al61 did a randomized, double‐blind, placebo‐controlled, 2‐way crossover study in patients with heart failure and renal impairment (median GFR = 50 mL/minute) and tested the effectiveness of the AA1R antagonist rolofylline as a renal vasodilator in an outpatient setting. Blockade of these receptors increased vasodilation and GFR. Givertz et al62 evaluated the effect of AA1R antagonists on diuresis and renal function in patients with ADHF and renal impairment or diuretic resistance. A paired, randomized, double‐blind, placebo‐controlled, proof‐of‐concept trial in patients with ADHF and volume overload found that the AA1R antagonist KW‐3092 enhances the response of loop diuretics and may have a renal protective effect. Prophylaxis for Thromboembolism in Critical Care Trials 1 and 2 (PROTECT 1,2) studies investigating KW‐3092 to assess the effects on heart failure and renal function, are currently under way.10

CONCLUSION

The goals in the management of ADHF are deceptively simple: improve symptoms by normalizing filling pressure and volume status efficiently without worsening renal function. Powerful tools, including diuretics, vasodilators, and UF, exist to accomplish these goals, but determining which tools to use in which patients and the precise manner in which to use the tools (alone or in combination and duration) remains more of an art than a science. The concept of euvolemia needs to be more carefully defined and conceptualized in a way that is useful for clinicians. Frequent monitoring of clinical signs, electrolytes, and renal function are our current best guides to assess volume status during therapy. Newer modalities hold promise that early detection of fluid overload may prevent hospitalization and reduce costs. Similarly, new pharmacologic therapies hold promise that their use may improve cardiac function and reduce renal abnormalities, thereby improving outcomes in patients with ADHF.

References
  1. Stevenson L.Tailored therapy to hemodynamic goals for advanced heart failure.Eur J Heart Fail.1999;1(3):251257.
  2. Kannel WB,D'Agostino RB,Silbershatz H,Belanger AJ,Wilson PWF,Levy D.Profile for estimating risk of heart failure.Arch Intern Med.1999;159(11):11971204.
  3. Packer M.The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure [editorial].J Am Coll Cardiol.1992;20(1):248254.
  4. Adamson PB,Magalski A,Braunschweig F, et al.Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system.J Am Coll Cardiol.2003;41(4):565571.
  5. Binanay C,Califf RM,Hasselblad V, et al.Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial.JAMA.2005;294(13):16251633.
  6. Fonarow GC,Stevenson LW,Steimle AE, et al.Persistently high left ventricular filling pressures predict mortality despite angiotensin converting enzyme inhibition in advanced heart failure [abstract 2624].Circulation.1994;90(4 pt 2):I‐488.
  7. Konstam MA,Gheorghiade M,Burnett JC, et al.Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.JAMA.2007;297(12):13191331.
  8. Califf RM. Considerations in designing acute decompensated heart failure clinical trials. Available at:http://www.medscape.com/viewarticle/557964. Accessed September 2008.
  9. Gheorghiade M,Konstam MA,Burnett JC, et al.Short‐term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.JAMA.2007;297(12):13321343.
  10. Chaparro S,Dittrich HC,Tang WHW.Rolofylline (KW‐3902): a new adenosine A1‐receptor antagonist for acute congestive heart failure.Future Cardiol.2008;4(2):117123.
  11. Lal S,Murtagh JG,Pollock AM,Fletcher E,Binnion PF.Acute haemodynamic effects of frusemide in patients with normal and raised left atrial pressures.Br Heart J.1969;31(6):711717.
  12. Saxl R,Heilig R.The diuretic effect of Novasurol and other mercury injections.Wien Klin Wochenschr.2002;33:943944.
  13. Fonarow GC,Heywood JT,Heidenreich PA,Lopatin M,Yancy CW.Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE).Am Heart J.2007;153(6):10211028.
  14. Patel J,Smith M,Heywood JT.Optimal use of diuretics in patients with heart failure.Curr Treat Options Cardiovasc Med.2007;9(4):332342.
  15. Monroy A,Plata C,Hebert SC,Gamba G.Characterization of the thiazide‐sensitive Na(+)‐Cl(−) cotransporter: a new model for ions and diuretics interaction.Am J Physiol Renal Physiol.2000;279(1):F161F169.
  16. Ellison DH.Diuretic therapy and resistance in congestive heart failure.Cardiology.2001;96(3–4):132143.
  17. Dormans TPJ,Gerlag PGG.Combination of high‐dose furosemide and hydrochlorothiazide in the treatment of refractory congestive heart failure.Eur Heart J.1996;17(12):18671874.
  18. Pitt B,Zannad F,Remme WJ, et al.The effect of spironolactone on morbidity and mortality in patients with severe heart failure.N Engl J Med.1999;341(10):709717.
  19. Pitt B,Remme W,Zannad F, et al.Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.N Engl J Med.2003;348(14):13091321.
  20. Adams KF.Pathophysiologic role of the renin‐angiotensin‐aldosterone and sympathetic nervous systems in heart failure.Am J Health Syst Pharm.2004;61(suppl 2):S4S13.
  21. Hauben M,Reich L,Gerrits CM,Madigan D.Detection of spironolactone‐associated hyperkalaemia following the Randomized Aldactone Evaluation Study (RALES).Drug Saf.2007;30(12):11431149.
  22. Eshaghian S,Horwich TB,Fonarow GC.Relation of loop diuretic dose to mortality in advanced heart failure.Am J Cardiol.2006;97(12):17591764.
  23. Chuen MJNK,MacFadyen RJ.Dose‐dependent association between use of loop diuretics and mortality in advanced systolic heart failure.Am J Cardiol.2006;98(10):14161417.
  24. Fonarow GC,Adams KFJ,Abraham WT,Yancy CW,Boscardin WJ.Risk stratification for in‐hospital mortality in acutely decompensated heart failure: classification and regression tree analysis.JAMA.2005;293(5):572580.
  25. Hasselblad V,Gattis Stough W,Shah MR, et al.Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial.Eur J Heart Fail.2007;9(10):10641069.
  26. Loon NR,Wilcox CS,Unwin RJ.Mechanism of impaired natriuretic response to furosemide during prolonged therapy.Kidney Int.1989;36(4):682689.
  27. Salvador DRK,Rey NR,Ramos GC,Punzalan FER.Continuous infusion versus bolus injection of loop diuretics in congestive heart failure.Cochrane Database Syst Rev.2004; (1):CD003178.
  28. López B,Querejeta R,González A,Sánchez E,Larman M,Díez J.Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure.J Am Coll Cardiol.2004;43(11):20282035.
  29. Veeraveedu PT,Watanabe K,Ma M, et al.Comparative effects of torasemide and furosemide in rats with heart failure.Biochem Pharmacol.2008;75(3):649659.
  30. Elkayam U,Janmohamed M,Habib M,Hatamizadeh P.Vasodilators in the management of acute heart failure.Crit Care Med.2008;36(suppl 1):S95S105.
  31. Hollenberg SM.Vasodilators in acute heart failure.Heart Fail Rev.2007;12(2):143147.
  32. Elkayam U,Kulick D,McIntosh N,Roth A,Hsueh W,Rahimtoola SH.Incidence of early tolerance to hemodynamic effects of continuous infusion of nitroglycerin in patients with coronary artery disease and heart failure.Circulation.1987;76(3):577584.
  33. Baines AD,DeBold AJ,Sonnenberg H.Natriuretic effect of atrial extract on isolated perfused rat kidney.Can J Physiol Pharmacol.1983;61(12):14621466.
  34. Abraham WT,Lowes BD,Ferguson DA, et al.Systemic hemodynamic, neurohormonal, and renal effects of a steady‐state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure.J Card Fail.1998;4(1):3744.
  35. Yoshimura M,Yasue H,Morita E, et al.Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure.Circulation.1991;84(4):15811588.
  36. Wang DJ,Dowling TC,Meadows D, et al.Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine.Circulation.2004;110(12):16201625.
  37. Witteles RM,Kao D,Christopherson D, et al.Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre‐existing renal dysfunction: a randomized, double‐blind, placebo‐controlled clinical trial.J Am Coll Cardiol.2007;50(19):18351840.
  38. Colucci WS,Elkayam U,Horton DP, et al.Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure.N Engl J Med.2000;343(4):246253.
  39. Publication Committee for the VMAC Investigators.Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial.JAMA.2002;287(12):15311540.
  40. Chang R,Elatre WA,Heywood JT.Effect of nesiritide on length of hospital stay in patients with decompensated heart failure.J Cardiovasc Pharmacol Ther.2004;9(3):173177.
  41. Sackner‐Bernstein JD,Skopicki HA,Aaronson KD.Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure.Circulation.2005;111(12):14871491.
  42. Sackner‐Bernstein JD,Kowalski M,Fox M,Aaronson K.Short‐term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials.JAMA.2005;293(15):19001905.
  43. Abraham WT.Serum creatinine elevations in patients receiving nesiritide are related to starting dose [abstract 248].J Card Fail.2005;11(suppl 6):S156.
  44. Riter HG,Redfield MM,Burnett JC,Chen HH.Nonhypotensive low‐dose nesiritide has differential renal effects compared with standard‐dose nesiritide in patients with acute decompensated heart failure and renal dysfunction.JAm Coll Cardiol.2006;47(11):23342335.
  45. Heywood JT.Combining nesiritide with high‐dose diuretics may increase the risk of increased serum creatinine [abstract 2180].Circulation.2005;112(17 suppl II):II‐451II‐452.
  46. Mentzer RMJ,Oz MC,Sladen RN, et al.Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: the NAPA trial.J Am Coll Cardiol.2007;49(6):716726.
  47. Chen HH,Sundt TM,Cook DJ,Heublein DM,Burnett JC.Low dose nesiritide and the preservation of renal function in patients with renal dysfunction undergoing cardiopulmonary‐bypass surgery: a double‐blind placebo‐controlled pilot study.Circulation.2007;116(suppl 11):I‐134I‐138.
  48. Heywood JT.Temporal characteristics of serum creatinine elevations in patients receiving nesiritide and nitroglycerin [abstract 2793].Circulation.2008;112(17 suppl II):II‐590.
  49. Abraham WT.Nesiritide does not increase 30‐day or 6‐month mortality risk [abstract 3169].Circulation.2005;112(17 suppl II):II‐676.
  50. Yancy CW,Drum H,Massie BM, et al.Safety and efficacy of outpatient nesiritide in patients with advanced heart failure.Circ Heart Fail.2008;1:916.
  51. Costanzo MR,Guglin ME,Saltzberg MT, et al.Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure.J Am Coll Cardiol.2007;49(6):675683.
  52. Rogers HL,Marshall J,Bock J, et al.A randomized, controlled trial of the renal effects of ultrafiltration as compared to furosemide in patients with acute decompensated heart failure.J Card Fail.2008;14(1):15.
  53. Heart Failure Society of America. Evaluation and management of patients with acute decompensated heart failure.J Card Fail.2006;12(1):e86e103.
  54. Nohria A,Hasselblad V,Stebbins A, et al.Cardiorenal interactions: insights from the ESCAPE trial.J Am Coll Cardiol.2008;51(13):12681274.
  55. Forman DE,Butler J,Wang Y, et al.Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure.J Am Coll Cardiol.2004;43(1):6167.
  56. Boyle A,Sobotka PA.Redefining the therapeutic objective in decompensated heart failure: hemoconcentration as a surrogate for plasma refill rate.J Card Fail.2006;12(4):247249.
  57. Heywood JT.The cardiorenal syndrome: lessons from the ADHERE database and treatment options.Heart Fail Rev.2004;9(3):195201.
  58. Kumar S,Rubin S,Mather PJ,Whellan DJ.Hyponatremia and vasopressin antagonism in congestive heart failure.Clin Cardiol.2007;30(11):546551.
  59. Goldsmith SR,Gheorghiade M.Vasopressin antagonism in heart failure.J Am Coll Cardiol.2005;46(10):17851791.
  60. Gottlieb SS,Brater DC,Thomas I, et al.BG9719 (CVT‐124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy.Circulation.2002;105(11):13481353.
  61. Dittrich HC,Gupta DK,Hack TC,Dowling T,Callahan J,Thomson S.The effect of KW‐3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment.J Card Fail.2007;13(8):609617.
  62. Givertz MM,Massie BM,Fields TK,Pearson LL,Dittrich HC;CKI‐201 and CKI‐202 Investigators.The effects of KW‐3902, an adenosine A1‐receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance.J Am Coll Cardiol.2007;50(16):15511560.
Article PDF
Issue
Journal of Hospital Medicine - 3(6)
Page Number
S25-S32
Legacy Keywords
acute decompensated heart failure, ADHF, filling pressure, renal function, volume overload
Sections
Article PDF
Article PDF

Although patients with left ventricular dysfunction may present with low‐output syndrome and even cardiogenic shock, the majority are admitted with symptoms of congestion.1 The classic symptoms of congestive heart failure reflect fluid overload, that is, orthopnea, paroxysmal nocturnal dyspnea, and peripheral edema; these symptoms can be so dramatic that it is not surprising that patients seek hospitalization.2 Activation of the renin angiotensin system coupled with sympathetic hyperactivity results in marked sodium retention and increased filling pressures in the right and left ventricle that ultimately bring about these congestive symptoms of dyspnea and orthopnea.3 Increased filling pressure precedes admission to the hospital, and filling pressure falls during successful therapy.4, 5 Indeed, normalization of the left ventricular filling pressure much better predicts survival than improved cardiac output.6 However, despite the many advances in the evidence‐based armamentarium for heart failure, the one great deficiency in the evidence base is the lack of data on modalities that can reduce or normalize left ventricular filling pressures. This is not as unexpected as it seems because the symptoms of congestion are so dramatic and, until recently, the tools to mitigate were so few that randomized trials were difficult to conceive. However, the treatment paradigms for acute decompensated heart failure (ADHF) management are changing, and evidence‐based mortality trials for filling pressure reduction and congestion relief continue to evolve.710

DIURETICS

Mercurial diuretics were introduced in the 1920s as the mainstay of therapy for ADHF; the loop diuretics became the foundation of therapy in the 1960s.11, 12 In the Acute Decompensated Heart Failure National Registry database (ADHERE), 88% of patients received intravenous loop diuretics during their hospitalization.13 Loop diuretics act in the thick ascending limb of the loop of Henle to inhibit reabsorption of sodium and chloride by inhibiting the sodium, potassium, and chloride (Na+/K+/2Cl) pump. This blockade causes increased delivery of these solutes to the distal convoluted tubule and collecting duct, resulting in a shift in the balance of osmotic forces toward fluid secretion into the collecting system. Through this mechanism, loop diuretics increase natriuresis and diuresis (Figure 1).14

Figure 1
Single juxtamedullary nephron. Adapted with permission from Patel et al.14

Less commonly used are the thiazide diuretics, which act on the distal convoluted tubule to block Na+, K+‐ATPase and thereby NaCl transport in the distal convoluted tubule.15 Thiazide diuretics are much less powerful than loop diuretics and are rarely used intravenously in the hospital. These do possess a synergistic effect when used with loop diuretics in that sodium reabsorption is blocked in 2 sections of the nephron.16 Extreme care must be taken to avoid overdiuresis, but this combination can be helpful to treat diuretic resistance.17

The third class of agents are the so‐called potassium‐sparing diuretics, which block sodium reuptake in the final portion of the nephron (the collecting ducts), resulting in an obligatory reuptake of potassium. These agents include the aldosterone receptor blocker spironolactone and eplerenone, which act primarily through competitive binding of receptors at the aldosterone‐dependent sodium‐potassium exchange site in the distal convoluted renal tubule. Although weak diuretics, they are the only class of diuretics shown to improve mortality in moderate to severe heart failure,18, 19 presumably by modulating the abnormal neurohormonal activation of the sympathetic nervous system and the renin‐angiotensin‐aldosterone axis.20 Unfortunately, severe hyperkalemia remains a significant side effect and can limit their use.21

Despite the obvious beneficial effects of loop diuretics in the treatment of ADHF, we lack key fundamental information about these most frequently used drugs. For example, what is the correct dose? Escalating the dose of diuretics has been associated with increased mortality in heart failure even when corrected for the severity of the illness.22, 23 Proposed explanations for the increased morality in patients with heart failure include activation of the renin‐angiotensin‐aldosterone system and sympathetic nervous system, decreases in the glomerular filtration rate (GFR) contributing to cardiorenal syndrome, and intravascular volume contraction and decreased left ventricular filling pressure worsening cardiac performance in patients without significant fluid retention.22, 23 It is now recognized that kidney dysfunction plays a vital role in the progress of patients with heart failure, and increases in serum creatinine or blood urea nitrogen are known predictors of mortality.24 Thus, larger doses of diuretics may result in unfavorable outcomes in heart failure patients because of adverse effects on renal function. In the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE), there was a clear increase in mortality with escalating loop diuretic doses, especially above 300 mg/day of furosemide (or an equivalent dose of another loop diuretic).25 Although patients with renal dysfunction may require higher doses, prudence would dictate using the lowest dose to gain a reasonable urine output.

How should loop diuretics be given: as a bolus or continuous infusion? Although diuretics have been typically given as a bolus, there are significant theoretical concerns about this method. Furosemide, for example, has a half‐life of approximately 2 hours; when it is given once or twice a day, a breaking phenomenon is seen in which the kidneys start to retain sodium and the effectiveness of the bolus is reduced.26 A Cochrane review has found evidence that a continuous infusion of diuretics produces more diuresis, although the same article suggests that more titration is needed to support this observation.27

Several loop diuretics are used clinically, including furosemide, torsemide, and bumetanide. Which one should be chosen? Furosemide is the least expensive and most widely used, but 2 animal models suggest more favorable cardiac effects (less fibrosis) with torsemide and even mortality benefit.28, 29 There are no comparable human data to guide the clinician, unfortunately. On a milligram per milligram basis, bumetanide produces more natriuresis than either torsemide or furosemide, but again, the clinical significance of this is not known.

VASODILATORS

Nitrates

Nitrates, including nitroglycerin and nitroprusside, have been used in therapy for ADHF primarily as venodilators.30 Thus, they have been shown to reduce right and left ventricular filling pressures, systemic and pulmonary vascular resistance, and, to a lesser extent, systemic blood pressure.31 A serious drawback to the continued use of nitrates is the development of tolerance that can become apparent within hours of their initial use.32 In addition, there have not been large outcome trials to define the duration of benefit or the proper dose.

Nesiritide

A potential role for the natriuretic peptides in heart failure dates back to the 1980s when extracts of the right atrial tissue of rats was shown to produce a brisk natriuresis when given intravenously to a second animal.33 Nesiritide, as the commercially prepared B‐type natriuretic peptide is called, consistently reduced preload and afterload and caused natriuresis in some studies.34, 35 Natriuresis and augmentation of diuresis has not been consistently demonstrated in published reports, however.36, 37 In addition, B‐type natriuretic peptide, when given therapeutically, does suppress aldosterone.38

The largest clinical experience to date with nesiritide came in the Vasodilation in the Management of Acute Congestive Heart Failure (VMAC) trial.39 In this study, nesiritide was compared with intravenous nitroglycerin and placebo when added to standard care for 3 hours in a double‐blind, randomized protocol. Nesiritide reduced filling pressures in comparison with nitroglycerin and placebo and provided greater symptomatic relief in comparison with placebo but not in comparison with nitroglycerin.39 In a retrospective review of consecutive patients, the addition of nesiritide resulted in a decreased length of stay without compromising renal function.40

In 2005, 2 meta‐analyses were published that raised questions about the safety of nesiritide.41, 42 In the first, a review of 5 nesiritide/placebo trials found an increased risk for worsening renal function (specifically, a rise in serum creatinine of 0.5 mg/dL or more).41 This increase occurred in 21% of nesiritide‐treated patients versus 15% of those on placebo (P = .001). Some of these trials in the meta‐analysis employed dosages of nesiritide greater than the currently recommended 0.01 g/kg/minute. When only those patients in the VMAC group that received the recommended 0.01 g/kg/minute dose were analyzed, there was not a significant rise in creatinine.43 Riter et al44 reported a retrospective analysis finding that half or even quarter doses of nesiritide actually produced improvement in renal function compared with the standard dose or no nesiritide use. Higher doses of diuretics, >160 mg of furosemide or its equivalent in conjunction with nesiritide, did increase the risk of renal dysfunction.45 In the Nesiritide Administered Perianesthesia (NAPA) trial, 0.01 g/kg/minute of nesiritide was given as a defined 24‐hour infusion without bolus to high‐risk patients with left ventricular dysfunction undergoing bypass and mitral valve surgery.46 Although serum creatinine increased in both groups following surgery, it increased more so with placebo than nesiritide (P < 0.001), despite increased urine output (P < 0.001) and shorter length of hospital stay (P = 0.043) in the nesiritide group.46 A smaller study of similar design also noted preservation of renal function with nesiritide compared with placebo in bypass patients.47 Therefore, the current recommendation for nesiritide use is to use no more than 0.01 g/kg/minute. Reduction of diuretic doses would be prudent when nesiritide is used.

Sackner‐Bernstein et al42 combined the results of 3 placebo‐controlled trials and reported an increase in mortality with nesiritide at 30 days. In this study, significant differences were found between the placebo and nesiritide groups in terms of baseline renal function,48 blood pressure, and inotrope use, and this may explain the observed mortality difference.42 Mortality was the same at 180 days. Abraham49 analyzed the 7 available trials and risk‐adjusted the patient populations to avoid group inequalities; with this method, no significant effect of nesiritide use on mortality was seen. The 2 most recent large trialsFollow‐Up Serial Infusions of Nesiritide II (FUSION II) (no effect of nesiritide on mortality) and NAPA (mortality decreased in nesiritide‐treated patients)have provided more safety data concerning the use of nesiritide.46, 50 The most definitive answer will come with the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND‐HF) trial, which will recruit 7000 patients, the largest trial in ADHF to date.

ULTRAFILTRATION (UF)

UF removes water and nonprotein‐bound smallmolecular‐weight and mediummolecular‐weight solutes through the semipermeable membrane when hydrostatic pressure, generated by blood pressure or an external blood pump, exceeds oncotic pressure. The fluid removal rate can be adjusted between 100 and 500 mL/hour. The Ultrafiltration Versus Intravenous Diuretics for Patients Hospitalized for Acute Decompensated Congestive Heart Failure (UNLOAD) trial randomized UF with intravenous diuretic therapy in patients with ADHF and showed that UF produced greater weight and fluid loss at 48 hours versus diuretics and reduced the 90‐day readmission rate for heart failure.51 There was no statistically significant difference noted between the overall mortality and serum creatinine between the 2 groups. Rogers et al52 found in a small, randomized trial that during a 48‐hour period, UF showed no significant difference in the renal hemodynamics (GFR and renal plasma flow in patients with ADHF) versus the standard treatment with intravenous diuretics. The Heart Failure Society of America treatment guidelines for the evaluation and management of patients with ADHF suggest that when congestion fails to improve in response to diuretic therapy, UF may be considered (strength of evidence = C).53

Perhaps the most vexing issue surrounding the use of diuretics, vasodilators, and UF is when to stop intravenous therapy in the hospitalized patient. There are no clear guidelines about this, and perhaps clinical experience is of paramount importance. Theoretically, vasodilator and fluid removal therapy should be continued until the patient is euvolemic, that is, has normal filling pressures (usually associated with normalization of the neck veins and loss of S3) with improvement in symptoms. This was clearly seen in the ESCAPE trial, in which use of either hemodynamic guidance or clinical evaluation of jugular venous pressure resulted in more normal filling pressures.5 This is an extremely important issue because continued fluid removal beyond the point at which the patient is euvolemic may result in renal dysfunction; the latter is a strong predictor of prolonged hospitalization and mortality.54, 55

Initial fluid removal can be rapid with either diuretics or UF, and filling pressures fall within minutes with nesiritide. This is beneficial to the patient as long as extracellular sodium and water reenter the vascular bed to maintain preload. Boyle and Sobotka56 emphasized the importance of this plasma refill rate and proposed monitoring the hematocrit as is done in dialysis to prevent excessive fluid removal. As can be seen in Figure 2, the plasma compartment is easily refilled when extracellular volume is increased in edematous patients early in their therapy. However, the plasma refill rate can fall precipitously when this compartment is depleted. Hence, clinicians must be ever alert to this transition period when continued fluid removal or vasodilator therapy results in depletion of vascular, not interstitial, volume with rapid declines in preload and cardiac output. Therefore, these therapies should be stopped when the patient becomes euvolemic, not later when the patient has become hypovolemic with the attendant problems. In the ESCAPE trial, the jugular venous pressure was the best indicator of a normal filling pressure,5, 54 although this is not an infallible guide. Our practice is to stop diuretics and vasodilators when edema has resolved and jugular venous pressure is below 8 cm. In addition, checking blood urea nitrogen and creatinine twice a day can give an early warning of hypovolemia when these rise 25% above baseline.57 Volume status should be carefully evaluated by changes in the physical examination, including postural blood pressure changes and increases in blood urea nitrogen and creatinine. When worsening renal function occurs, judicious fluid replacement with 500 to 1000 mL of normal saline given over 2 to 4 hours can quickly restore euvolemia and may improve renal function in the hypovolemic patient.

Figure 2
The importance of the plasma refill rate in the management of acute decompensated heart failure (ADHF). (A) The patient with ADHF and significant fluid overload. The extracellular compartment contains more volume than normal. The removal of fluid from the vascular compartment as well as reduction in venous pressure by vasodilators reduces vascular venous pressure and thus increases fluid movement from the extracellular compartment. This is termed the plasma refill rate, as fluid removed by the kidneys is replaced from the extracellular compartment. Homeostasis is maintained as long as urine output or ultrafiltrate removal does not exceed the plasma refill rate. Vasodilators can increase the plasma refill rate by reducing venous tone and hence venous pressure. (B) As long as the plasma refill rate equals or exceeds fluid loss, volume in the vascular bed is maintained along with ventricular preload. Diuretics, ultrafiltration, and vasodilators should be stopped at this point. (C) When diuretics and/or vasodilators are continued beyond the point of depletion of already removed extracellular fluid, then the plasma refill rate no longer keeps up with fluid removal, and vascular volume is reduced below normal. This results in decreased preload and reduced cardiac output, blood pressure, and renal perfusion. The transition from euvolemia to hypovolemia may be very subtle and abrupt. This accounts for the frequency of worsening renal function in heart failure and its untoward consequences.

INVESTIGATIONAL THERAPIES

Oral Vasopressin Antagonist

Elevation of arginine vasopressin contributes to fluid retention and hyponatremia and is directly proportional to the severity of heart failure.58 Tolvaptan is an oral, nonpeptide, selective vasopressin V2 receptor antagonist whose action on the distal nephron causes loss of electrolyte‐free water (aquaresis).59 The efficacy of tolvaptan was tested in a double‐blind, prospective, randomized international trial, the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST), with a 30 mg/day oral dosage of tolvaptan versus placebo within 48 hours of admission with ADHF.7, 9 Patients receiving tolvaptan showed improvement in dyspnea on day 1 along with body weight and edema reduction on day 7 or discharge in comparison with placebo. The improvement in global clinical assessment was not different between the 2 groups. The serious adverse event frequencies were similar between the groups without excess renal failure or hypotension in the tolvaptan group.7, 9 Unfortunately, this small beneficial effect in the hospital did not result in positive survival benefit.

Adenosine A1‐Receptor (AA1R) Antagonists

The kidney is the only organ in which adenosine is a paracrine vasoconstrictor.60 Dittrich et al61 did a randomized, double‐blind, placebo‐controlled, 2‐way crossover study in patients with heart failure and renal impairment (median GFR = 50 mL/minute) and tested the effectiveness of the AA1R antagonist rolofylline as a renal vasodilator in an outpatient setting. Blockade of these receptors increased vasodilation and GFR. Givertz et al62 evaluated the effect of AA1R antagonists on diuresis and renal function in patients with ADHF and renal impairment or diuretic resistance. A paired, randomized, double‐blind, placebo‐controlled, proof‐of‐concept trial in patients with ADHF and volume overload found that the AA1R antagonist KW‐3092 enhances the response of loop diuretics and may have a renal protective effect. Prophylaxis for Thromboembolism in Critical Care Trials 1 and 2 (PROTECT 1,2) studies investigating KW‐3092 to assess the effects on heart failure and renal function, are currently under way.10

CONCLUSION

The goals in the management of ADHF are deceptively simple: improve symptoms by normalizing filling pressure and volume status efficiently without worsening renal function. Powerful tools, including diuretics, vasodilators, and UF, exist to accomplish these goals, but determining which tools to use in which patients and the precise manner in which to use the tools (alone or in combination and duration) remains more of an art than a science. The concept of euvolemia needs to be more carefully defined and conceptualized in a way that is useful for clinicians. Frequent monitoring of clinical signs, electrolytes, and renal function are our current best guides to assess volume status during therapy. Newer modalities hold promise that early detection of fluid overload may prevent hospitalization and reduce costs. Similarly, new pharmacologic therapies hold promise that their use may improve cardiac function and reduce renal abnormalities, thereby improving outcomes in patients with ADHF.

Although patients with left ventricular dysfunction may present with low‐output syndrome and even cardiogenic shock, the majority are admitted with symptoms of congestion.1 The classic symptoms of congestive heart failure reflect fluid overload, that is, orthopnea, paroxysmal nocturnal dyspnea, and peripheral edema; these symptoms can be so dramatic that it is not surprising that patients seek hospitalization.2 Activation of the renin angiotensin system coupled with sympathetic hyperactivity results in marked sodium retention and increased filling pressures in the right and left ventricle that ultimately bring about these congestive symptoms of dyspnea and orthopnea.3 Increased filling pressure precedes admission to the hospital, and filling pressure falls during successful therapy.4, 5 Indeed, normalization of the left ventricular filling pressure much better predicts survival than improved cardiac output.6 However, despite the many advances in the evidence‐based armamentarium for heart failure, the one great deficiency in the evidence base is the lack of data on modalities that can reduce or normalize left ventricular filling pressures. This is not as unexpected as it seems because the symptoms of congestion are so dramatic and, until recently, the tools to mitigate were so few that randomized trials were difficult to conceive. However, the treatment paradigms for acute decompensated heart failure (ADHF) management are changing, and evidence‐based mortality trials for filling pressure reduction and congestion relief continue to evolve.710

DIURETICS

Mercurial diuretics were introduced in the 1920s as the mainstay of therapy for ADHF; the loop diuretics became the foundation of therapy in the 1960s.11, 12 In the Acute Decompensated Heart Failure National Registry database (ADHERE), 88% of patients received intravenous loop diuretics during their hospitalization.13 Loop diuretics act in the thick ascending limb of the loop of Henle to inhibit reabsorption of sodium and chloride by inhibiting the sodium, potassium, and chloride (Na+/K+/2Cl) pump. This blockade causes increased delivery of these solutes to the distal convoluted tubule and collecting duct, resulting in a shift in the balance of osmotic forces toward fluid secretion into the collecting system. Through this mechanism, loop diuretics increase natriuresis and diuresis (Figure 1).14

Figure 1
Single juxtamedullary nephron. Adapted with permission from Patel et al.14

Less commonly used are the thiazide diuretics, which act on the distal convoluted tubule to block Na+, K+‐ATPase and thereby NaCl transport in the distal convoluted tubule.15 Thiazide diuretics are much less powerful than loop diuretics and are rarely used intravenously in the hospital. These do possess a synergistic effect when used with loop diuretics in that sodium reabsorption is blocked in 2 sections of the nephron.16 Extreme care must be taken to avoid overdiuresis, but this combination can be helpful to treat diuretic resistance.17

The third class of agents are the so‐called potassium‐sparing diuretics, which block sodium reuptake in the final portion of the nephron (the collecting ducts), resulting in an obligatory reuptake of potassium. These agents include the aldosterone receptor blocker spironolactone and eplerenone, which act primarily through competitive binding of receptors at the aldosterone‐dependent sodium‐potassium exchange site in the distal convoluted renal tubule. Although weak diuretics, they are the only class of diuretics shown to improve mortality in moderate to severe heart failure,18, 19 presumably by modulating the abnormal neurohormonal activation of the sympathetic nervous system and the renin‐angiotensin‐aldosterone axis.20 Unfortunately, severe hyperkalemia remains a significant side effect and can limit their use.21

Despite the obvious beneficial effects of loop diuretics in the treatment of ADHF, we lack key fundamental information about these most frequently used drugs. For example, what is the correct dose? Escalating the dose of diuretics has been associated with increased mortality in heart failure even when corrected for the severity of the illness.22, 23 Proposed explanations for the increased morality in patients with heart failure include activation of the renin‐angiotensin‐aldosterone system and sympathetic nervous system, decreases in the glomerular filtration rate (GFR) contributing to cardiorenal syndrome, and intravascular volume contraction and decreased left ventricular filling pressure worsening cardiac performance in patients without significant fluid retention.22, 23 It is now recognized that kidney dysfunction plays a vital role in the progress of patients with heart failure, and increases in serum creatinine or blood urea nitrogen are known predictors of mortality.24 Thus, larger doses of diuretics may result in unfavorable outcomes in heart failure patients because of adverse effects on renal function. In the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE), there was a clear increase in mortality with escalating loop diuretic doses, especially above 300 mg/day of furosemide (or an equivalent dose of another loop diuretic).25 Although patients with renal dysfunction may require higher doses, prudence would dictate using the lowest dose to gain a reasonable urine output.

How should loop diuretics be given: as a bolus or continuous infusion? Although diuretics have been typically given as a bolus, there are significant theoretical concerns about this method. Furosemide, for example, has a half‐life of approximately 2 hours; when it is given once or twice a day, a breaking phenomenon is seen in which the kidneys start to retain sodium and the effectiveness of the bolus is reduced.26 A Cochrane review has found evidence that a continuous infusion of diuretics produces more diuresis, although the same article suggests that more titration is needed to support this observation.27

Several loop diuretics are used clinically, including furosemide, torsemide, and bumetanide. Which one should be chosen? Furosemide is the least expensive and most widely used, but 2 animal models suggest more favorable cardiac effects (less fibrosis) with torsemide and even mortality benefit.28, 29 There are no comparable human data to guide the clinician, unfortunately. On a milligram per milligram basis, bumetanide produces more natriuresis than either torsemide or furosemide, but again, the clinical significance of this is not known.

VASODILATORS

Nitrates

Nitrates, including nitroglycerin and nitroprusside, have been used in therapy for ADHF primarily as venodilators.30 Thus, they have been shown to reduce right and left ventricular filling pressures, systemic and pulmonary vascular resistance, and, to a lesser extent, systemic blood pressure.31 A serious drawback to the continued use of nitrates is the development of tolerance that can become apparent within hours of their initial use.32 In addition, there have not been large outcome trials to define the duration of benefit or the proper dose.

Nesiritide

A potential role for the natriuretic peptides in heart failure dates back to the 1980s when extracts of the right atrial tissue of rats was shown to produce a brisk natriuresis when given intravenously to a second animal.33 Nesiritide, as the commercially prepared B‐type natriuretic peptide is called, consistently reduced preload and afterload and caused natriuresis in some studies.34, 35 Natriuresis and augmentation of diuresis has not been consistently demonstrated in published reports, however.36, 37 In addition, B‐type natriuretic peptide, when given therapeutically, does suppress aldosterone.38

The largest clinical experience to date with nesiritide came in the Vasodilation in the Management of Acute Congestive Heart Failure (VMAC) trial.39 In this study, nesiritide was compared with intravenous nitroglycerin and placebo when added to standard care for 3 hours in a double‐blind, randomized protocol. Nesiritide reduced filling pressures in comparison with nitroglycerin and placebo and provided greater symptomatic relief in comparison with placebo but not in comparison with nitroglycerin.39 In a retrospective review of consecutive patients, the addition of nesiritide resulted in a decreased length of stay without compromising renal function.40

In 2005, 2 meta‐analyses were published that raised questions about the safety of nesiritide.41, 42 In the first, a review of 5 nesiritide/placebo trials found an increased risk for worsening renal function (specifically, a rise in serum creatinine of 0.5 mg/dL or more).41 This increase occurred in 21% of nesiritide‐treated patients versus 15% of those on placebo (P = .001). Some of these trials in the meta‐analysis employed dosages of nesiritide greater than the currently recommended 0.01 g/kg/minute. When only those patients in the VMAC group that received the recommended 0.01 g/kg/minute dose were analyzed, there was not a significant rise in creatinine.43 Riter et al44 reported a retrospective analysis finding that half or even quarter doses of nesiritide actually produced improvement in renal function compared with the standard dose or no nesiritide use. Higher doses of diuretics, >160 mg of furosemide or its equivalent in conjunction with nesiritide, did increase the risk of renal dysfunction.45 In the Nesiritide Administered Perianesthesia (NAPA) trial, 0.01 g/kg/minute of nesiritide was given as a defined 24‐hour infusion without bolus to high‐risk patients with left ventricular dysfunction undergoing bypass and mitral valve surgery.46 Although serum creatinine increased in both groups following surgery, it increased more so with placebo than nesiritide (P < 0.001), despite increased urine output (P < 0.001) and shorter length of hospital stay (P = 0.043) in the nesiritide group.46 A smaller study of similar design also noted preservation of renal function with nesiritide compared with placebo in bypass patients.47 Therefore, the current recommendation for nesiritide use is to use no more than 0.01 g/kg/minute. Reduction of diuretic doses would be prudent when nesiritide is used.

Sackner‐Bernstein et al42 combined the results of 3 placebo‐controlled trials and reported an increase in mortality with nesiritide at 30 days. In this study, significant differences were found between the placebo and nesiritide groups in terms of baseline renal function,48 blood pressure, and inotrope use, and this may explain the observed mortality difference.42 Mortality was the same at 180 days. Abraham49 analyzed the 7 available trials and risk‐adjusted the patient populations to avoid group inequalities; with this method, no significant effect of nesiritide use on mortality was seen. The 2 most recent large trialsFollow‐Up Serial Infusions of Nesiritide II (FUSION II) (no effect of nesiritide on mortality) and NAPA (mortality decreased in nesiritide‐treated patients)have provided more safety data concerning the use of nesiritide.46, 50 The most definitive answer will come with the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND‐HF) trial, which will recruit 7000 patients, the largest trial in ADHF to date.

ULTRAFILTRATION (UF)

UF removes water and nonprotein‐bound smallmolecular‐weight and mediummolecular‐weight solutes through the semipermeable membrane when hydrostatic pressure, generated by blood pressure or an external blood pump, exceeds oncotic pressure. The fluid removal rate can be adjusted between 100 and 500 mL/hour. The Ultrafiltration Versus Intravenous Diuretics for Patients Hospitalized for Acute Decompensated Congestive Heart Failure (UNLOAD) trial randomized UF with intravenous diuretic therapy in patients with ADHF and showed that UF produced greater weight and fluid loss at 48 hours versus diuretics and reduced the 90‐day readmission rate for heart failure.51 There was no statistically significant difference noted between the overall mortality and serum creatinine between the 2 groups. Rogers et al52 found in a small, randomized trial that during a 48‐hour period, UF showed no significant difference in the renal hemodynamics (GFR and renal plasma flow in patients with ADHF) versus the standard treatment with intravenous diuretics. The Heart Failure Society of America treatment guidelines for the evaluation and management of patients with ADHF suggest that when congestion fails to improve in response to diuretic therapy, UF may be considered (strength of evidence = C).53

Perhaps the most vexing issue surrounding the use of diuretics, vasodilators, and UF is when to stop intravenous therapy in the hospitalized patient. There are no clear guidelines about this, and perhaps clinical experience is of paramount importance. Theoretically, vasodilator and fluid removal therapy should be continued until the patient is euvolemic, that is, has normal filling pressures (usually associated with normalization of the neck veins and loss of S3) with improvement in symptoms. This was clearly seen in the ESCAPE trial, in which use of either hemodynamic guidance or clinical evaluation of jugular venous pressure resulted in more normal filling pressures.5 This is an extremely important issue because continued fluid removal beyond the point at which the patient is euvolemic may result in renal dysfunction; the latter is a strong predictor of prolonged hospitalization and mortality.54, 55

Initial fluid removal can be rapid with either diuretics or UF, and filling pressures fall within minutes with nesiritide. This is beneficial to the patient as long as extracellular sodium and water reenter the vascular bed to maintain preload. Boyle and Sobotka56 emphasized the importance of this plasma refill rate and proposed monitoring the hematocrit as is done in dialysis to prevent excessive fluid removal. As can be seen in Figure 2, the plasma compartment is easily refilled when extracellular volume is increased in edematous patients early in their therapy. However, the plasma refill rate can fall precipitously when this compartment is depleted. Hence, clinicians must be ever alert to this transition period when continued fluid removal or vasodilator therapy results in depletion of vascular, not interstitial, volume with rapid declines in preload and cardiac output. Therefore, these therapies should be stopped when the patient becomes euvolemic, not later when the patient has become hypovolemic with the attendant problems. In the ESCAPE trial, the jugular venous pressure was the best indicator of a normal filling pressure,5, 54 although this is not an infallible guide. Our practice is to stop diuretics and vasodilators when edema has resolved and jugular venous pressure is below 8 cm. In addition, checking blood urea nitrogen and creatinine twice a day can give an early warning of hypovolemia when these rise 25% above baseline.57 Volume status should be carefully evaluated by changes in the physical examination, including postural blood pressure changes and increases in blood urea nitrogen and creatinine. When worsening renal function occurs, judicious fluid replacement with 500 to 1000 mL of normal saline given over 2 to 4 hours can quickly restore euvolemia and may improve renal function in the hypovolemic patient.

Figure 2
The importance of the plasma refill rate in the management of acute decompensated heart failure (ADHF). (A) The patient with ADHF and significant fluid overload. The extracellular compartment contains more volume than normal. The removal of fluid from the vascular compartment as well as reduction in venous pressure by vasodilators reduces vascular venous pressure and thus increases fluid movement from the extracellular compartment. This is termed the plasma refill rate, as fluid removed by the kidneys is replaced from the extracellular compartment. Homeostasis is maintained as long as urine output or ultrafiltrate removal does not exceed the plasma refill rate. Vasodilators can increase the plasma refill rate by reducing venous tone and hence venous pressure. (B) As long as the plasma refill rate equals or exceeds fluid loss, volume in the vascular bed is maintained along with ventricular preload. Diuretics, ultrafiltration, and vasodilators should be stopped at this point. (C) When diuretics and/or vasodilators are continued beyond the point of depletion of already removed extracellular fluid, then the plasma refill rate no longer keeps up with fluid removal, and vascular volume is reduced below normal. This results in decreased preload and reduced cardiac output, blood pressure, and renal perfusion. The transition from euvolemia to hypovolemia may be very subtle and abrupt. This accounts for the frequency of worsening renal function in heart failure and its untoward consequences.

INVESTIGATIONAL THERAPIES

Oral Vasopressin Antagonist

Elevation of arginine vasopressin contributes to fluid retention and hyponatremia and is directly proportional to the severity of heart failure.58 Tolvaptan is an oral, nonpeptide, selective vasopressin V2 receptor antagonist whose action on the distal nephron causes loss of electrolyte‐free water (aquaresis).59 The efficacy of tolvaptan was tested in a double‐blind, prospective, randomized international trial, the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST), with a 30 mg/day oral dosage of tolvaptan versus placebo within 48 hours of admission with ADHF.7, 9 Patients receiving tolvaptan showed improvement in dyspnea on day 1 along with body weight and edema reduction on day 7 or discharge in comparison with placebo. The improvement in global clinical assessment was not different between the 2 groups. The serious adverse event frequencies were similar between the groups without excess renal failure or hypotension in the tolvaptan group.7, 9 Unfortunately, this small beneficial effect in the hospital did not result in positive survival benefit.

Adenosine A1‐Receptor (AA1R) Antagonists

The kidney is the only organ in which adenosine is a paracrine vasoconstrictor.60 Dittrich et al61 did a randomized, double‐blind, placebo‐controlled, 2‐way crossover study in patients with heart failure and renal impairment (median GFR = 50 mL/minute) and tested the effectiveness of the AA1R antagonist rolofylline as a renal vasodilator in an outpatient setting. Blockade of these receptors increased vasodilation and GFR. Givertz et al62 evaluated the effect of AA1R antagonists on diuresis and renal function in patients with ADHF and renal impairment or diuretic resistance. A paired, randomized, double‐blind, placebo‐controlled, proof‐of‐concept trial in patients with ADHF and volume overload found that the AA1R antagonist KW‐3092 enhances the response of loop diuretics and may have a renal protective effect. Prophylaxis for Thromboembolism in Critical Care Trials 1 and 2 (PROTECT 1,2) studies investigating KW‐3092 to assess the effects on heart failure and renal function, are currently under way.10

CONCLUSION

The goals in the management of ADHF are deceptively simple: improve symptoms by normalizing filling pressure and volume status efficiently without worsening renal function. Powerful tools, including diuretics, vasodilators, and UF, exist to accomplish these goals, but determining which tools to use in which patients and the precise manner in which to use the tools (alone or in combination and duration) remains more of an art than a science. The concept of euvolemia needs to be more carefully defined and conceptualized in a way that is useful for clinicians. Frequent monitoring of clinical signs, electrolytes, and renal function are our current best guides to assess volume status during therapy. Newer modalities hold promise that early detection of fluid overload may prevent hospitalization and reduce costs. Similarly, new pharmacologic therapies hold promise that their use may improve cardiac function and reduce renal abnormalities, thereby improving outcomes in patients with ADHF.

References
  1. Stevenson L.Tailored therapy to hemodynamic goals for advanced heart failure.Eur J Heart Fail.1999;1(3):251257.
  2. Kannel WB,D'Agostino RB,Silbershatz H,Belanger AJ,Wilson PWF,Levy D.Profile for estimating risk of heart failure.Arch Intern Med.1999;159(11):11971204.
  3. Packer M.The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure [editorial].J Am Coll Cardiol.1992;20(1):248254.
  4. Adamson PB,Magalski A,Braunschweig F, et al.Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system.J Am Coll Cardiol.2003;41(4):565571.
  5. Binanay C,Califf RM,Hasselblad V, et al.Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial.JAMA.2005;294(13):16251633.
  6. Fonarow GC,Stevenson LW,Steimle AE, et al.Persistently high left ventricular filling pressures predict mortality despite angiotensin converting enzyme inhibition in advanced heart failure [abstract 2624].Circulation.1994;90(4 pt 2):I‐488.
  7. Konstam MA,Gheorghiade M,Burnett JC, et al.Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.JAMA.2007;297(12):13191331.
  8. Califf RM. Considerations in designing acute decompensated heart failure clinical trials. Available at:http://www.medscape.com/viewarticle/557964. Accessed September 2008.
  9. Gheorghiade M,Konstam MA,Burnett JC, et al.Short‐term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.JAMA.2007;297(12):13321343.
  10. Chaparro S,Dittrich HC,Tang WHW.Rolofylline (KW‐3902): a new adenosine A1‐receptor antagonist for acute congestive heart failure.Future Cardiol.2008;4(2):117123.
  11. Lal S,Murtagh JG,Pollock AM,Fletcher E,Binnion PF.Acute haemodynamic effects of frusemide in patients with normal and raised left atrial pressures.Br Heart J.1969;31(6):711717.
  12. Saxl R,Heilig R.The diuretic effect of Novasurol and other mercury injections.Wien Klin Wochenschr.2002;33:943944.
  13. Fonarow GC,Heywood JT,Heidenreich PA,Lopatin M,Yancy CW.Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE).Am Heart J.2007;153(6):10211028.
  14. Patel J,Smith M,Heywood JT.Optimal use of diuretics in patients with heart failure.Curr Treat Options Cardiovasc Med.2007;9(4):332342.
  15. Monroy A,Plata C,Hebert SC,Gamba G.Characterization of the thiazide‐sensitive Na(+)‐Cl(−) cotransporter: a new model for ions and diuretics interaction.Am J Physiol Renal Physiol.2000;279(1):F161F169.
  16. Ellison DH.Diuretic therapy and resistance in congestive heart failure.Cardiology.2001;96(3–4):132143.
  17. Dormans TPJ,Gerlag PGG.Combination of high‐dose furosemide and hydrochlorothiazide in the treatment of refractory congestive heart failure.Eur Heart J.1996;17(12):18671874.
  18. Pitt B,Zannad F,Remme WJ, et al.The effect of spironolactone on morbidity and mortality in patients with severe heart failure.N Engl J Med.1999;341(10):709717.
  19. Pitt B,Remme W,Zannad F, et al.Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.N Engl J Med.2003;348(14):13091321.
  20. Adams KF.Pathophysiologic role of the renin‐angiotensin‐aldosterone and sympathetic nervous systems in heart failure.Am J Health Syst Pharm.2004;61(suppl 2):S4S13.
  21. Hauben M,Reich L,Gerrits CM,Madigan D.Detection of spironolactone‐associated hyperkalaemia following the Randomized Aldactone Evaluation Study (RALES).Drug Saf.2007;30(12):11431149.
  22. Eshaghian S,Horwich TB,Fonarow GC.Relation of loop diuretic dose to mortality in advanced heart failure.Am J Cardiol.2006;97(12):17591764.
  23. Chuen MJNK,MacFadyen RJ.Dose‐dependent association between use of loop diuretics and mortality in advanced systolic heart failure.Am J Cardiol.2006;98(10):14161417.
  24. Fonarow GC,Adams KFJ,Abraham WT,Yancy CW,Boscardin WJ.Risk stratification for in‐hospital mortality in acutely decompensated heart failure: classification and regression tree analysis.JAMA.2005;293(5):572580.
  25. Hasselblad V,Gattis Stough W,Shah MR, et al.Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial.Eur J Heart Fail.2007;9(10):10641069.
  26. Loon NR,Wilcox CS,Unwin RJ.Mechanism of impaired natriuretic response to furosemide during prolonged therapy.Kidney Int.1989;36(4):682689.
  27. Salvador DRK,Rey NR,Ramos GC,Punzalan FER.Continuous infusion versus bolus injection of loop diuretics in congestive heart failure.Cochrane Database Syst Rev.2004; (1):CD003178.
  28. López B,Querejeta R,González A,Sánchez E,Larman M,Díez J.Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure.J Am Coll Cardiol.2004;43(11):20282035.
  29. Veeraveedu PT,Watanabe K,Ma M, et al.Comparative effects of torasemide and furosemide in rats with heart failure.Biochem Pharmacol.2008;75(3):649659.
  30. Elkayam U,Janmohamed M,Habib M,Hatamizadeh P.Vasodilators in the management of acute heart failure.Crit Care Med.2008;36(suppl 1):S95S105.
  31. Hollenberg SM.Vasodilators in acute heart failure.Heart Fail Rev.2007;12(2):143147.
  32. Elkayam U,Kulick D,McIntosh N,Roth A,Hsueh W,Rahimtoola SH.Incidence of early tolerance to hemodynamic effects of continuous infusion of nitroglycerin in patients with coronary artery disease and heart failure.Circulation.1987;76(3):577584.
  33. Baines AD,DeBold AJ,Sonnenberg H.Natriuretic effect of atrial extract on isolated perfused rat kidney.Can J Physiol Pharmacol.1983;61(12):14621466.
  34. Abraham WT,Lowes BD,Ferguson DA, et al.Systemic hemodynamic, neurohormonal, and renal effects of a steady‐state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure.J Card Fail.1998;4(1):3744.
  35. Yoshimura M,Yasue H,Morita E, et al.Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure.Circulation.1991;84(4):15811588.
  36. Wang DJ,Dowling TC,Meadows D, et al.Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine.Circulation.2004;110(12):16201625.
  37. Witteles RM,Kao D,Christopherson D, et al.Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre‐existing renal dysfunction: a randomized, double‐blind, placebo‐controlled clinical trial.J Am Coll Cardiol.2007;50(19):18351840.
  38. Colucci WS,Elkayam U,Horton DP, et al.Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure.N Engl J Med.2000;343(4):246253.
  39. Publication Committee for the VMAC Investigators.Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial.JAMA.2002;287(12):15311540.
  40. Chang R,Elatre WA,Heywood JT.Effect of nesiritide on length of hospital stay in patients with decompensated heart failure.J Cardiovasc Pharmacol Ther.2004;9(3):173177.
  41. Sackner‐Bernstein JD,Skopicki HA,Aaronson KD.Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure.Circulation.2005;111(12):14871491.
  42. Sackner‐Bernstein JD,Kowalski M,Fox M,Aaronson K.Short‐term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials.JAMA.2005;293(15):19001905.
  43. Abraham WT.Serum creatinine elevations in patients receiving nesiritide are related to starting dose [abstract 248].J Card Fail.2005;11(suppl 6):S156.
  44. Riter HG,Redfield MM,Burnett JC,Chen HH.Nonhypotensive low‐dose nesiritide has differential renal effects compared with standard‐dose nesiritide in patients with acute decompensated heart failure and renal dysfunction.JAm Coll Cardiol.2006;47(11):23342335.
  45. Heywood JT.Combining nesiritide with high‐dose diuretics may increase the risk of increased serum creatinine [abstract 2180].Circulation.2005;112(17 suppl II):II‐451II‐452.
  46. Mentzer RMJ,Oz MC,Sladen RN, et al.Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: the NAPA trial.J Am Coll Cardiol.2007;49(6):716726.
  47. Chen HH,Sundt TM,Cook DJ,Heublein DM,Burnett JC.Low dose nesiritide and the preservation of renal function in patients with renal dysfunction undergoing cardiopulmonary‐bypass surgery: a double‐blind placebo‐controlled pilot study.Circulation.2007;116(suppl 11):I‐134I‐138.
  48. Heywood JT.Temporal characteristics of serum creatinine elevations in patients receiving nesiritide and nitroglycerin [abstract 2793].Circulation.2008;112(17 suppl II):II‐590.
  49. Abraham WT.Nesiritide does not increase 30‐day or 6‐month mortality risk [abstract 3169].Circulation.2005;112(17 suppl II):II‐676.
  50. Yancy CW,Drum H,Massie BM, et al.Safety and efficacy of outpatient nesiritide in patients with advanced heart failure.Circ Heart Fail.2008;1:916.
  51. Costanzo MR,Guglin ME,Saltzberg MT, et al.Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure.J Am Coll Cardiol.2007;49(6):675683.
  52. Rogers HL,Marshall J,Bock J, et al.A randomized, controlled trial of the renal effects of ultrafiltration as compared to furosemide in patients with acute decompensated heart failure.J Card Fail.2008;14(1):15.
  53. Heart Failure Society of America. Evaluation and management of patients with acute decompensated heart failure.J Card Fail.2006;12(1):e86e103.
  54. Nohria A,Hasselblad V,Stebbins A, et al.Cardiorenal interactions: insights from the ESCAPE trial.J Am Coll Cardiol.2008;51(13):12681274.
  55. Forman DE,Butler J,Wang Y, et al.Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure.J Am Coll Cardiol.2004;43(1):6167.
  56. Boyle A,Sobotka PA.Redefining the therapeutic objective in decompensated heart failure: hemoconcentration as a surrogate for plasma refill rate.J Card Fail.2006;12(4):247249.
  57. Heywood JT.The cardiorenal syndrome: lessons from the ADHERE database and treatment options.Heart Fail Rev.2004;9(3):195201.
  58. Kumar S,Rubin S,Mather PJ,Whellan DJ.Hyponatremia and vasopressin antagonism in congestive heart failure.Clin Cardiol.2007;30(11):546551.
  59. Goldsmith SR,Gheorghiade M.Vasopressin antagonism in heart failure.J Am Coll Cardiol.2005;46(10):17851791.
  60. Gottlieb SS,Brater DC,Thomas I, et al.BG9719 (CVT‐124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy.Circulation.2002;105(11):13481353.
  61. Dittrich HC,Gupta DK,Hack TC,Dowling T,Callahan J,Thomson S.The effect of KW‐3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment.J Card Fail.2007;13(8):609617.
  62. Givertz MM,Massie BM,Fields TK,Pearson LL,Dittrich HC;CKI‐201 and CKI‐202 Investigators.The effects of KW‐3902, an adenosine A1‐receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance.J Am Coll Cardiol.2007;50(16):15511560.
References
  1. Stevenson L.Tailored therapy to hemodynamic goals for advanced heart failure.Eur J Heart Fail.1999;1(3):251257.
  2. Kannel WB,D'Agostino RB,Silbershatz H,Belanger AJ,Wilson PWF,Levy D.Profile for estimating risk of heart failure.Arch Intern Med.1999;159(11):11971204.
  3. Packer M.The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure [editorial].J Am Coll Cardiol.1992;20(1):248254.
  4. Adamson PB,Magalski A,Braunschweig F, et al.Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system.J Am Coll Cardiol.2003;41(4):565571.
  5. Binanay C,Califf RM,Hasselblad V, et al.Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial.JAMA.2005;294(13):16251633.
  6. Fonarow GC,Stevenson LW,Steimle AE, et al.Persistently high left ventricular filling pressures predict mortality despite angiotensin converting enzyme inhibition in advanced heart failure [abstract 2624].Circulation.1994;90(4 pt 2):I‐488.
  7. Konstam MA,Gheorghiade M,Burnett JC, et al.Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.JAMA.2007;297(12):13191331.
  8. Califf RM. Considerations in designing acute decompensated heart failure clinical trials. Available at:http://www.medscape.com/viewarticle/557964. Accessed September 2008.
  9. Gheorghiade M,Konstam MA,Burnett JC, et al.Short‐term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.JAMA.2007;297(12):13321343.
  10. Chaparro S,Dittrich HC,Tang WHW.Rolofylline (KW‐3902): a new adenosine A1‐receptor antagonist for acute congestive heart failure.Future Cardiol.2008;4(2):117123.
  11. Lal S,Murtagh JG,Pollock AM,Fletcher E,Binnion PF.Acute haemodynamic effects of frusemide in patients with normal and raised left atrial pressures.Br Heart J.1969;31(6):711717.
  12. Saxl R,Heilig R.The diuretic effect of Novasurol and other mercury injections.Wien Klin Wochenschr.2002;33:943944.
  13. Fonarow GC,Heywood JT,Heidenreich PA,Lopatin M,Yancy CW.Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE).Am Heart J.2007;153(6):10211028.
  14. Patel J,Smith M,Heywood JT.Optimal use of diuretics in patients with heart failure.Curr Treat Options Cardiovasc Med.2007;9(4):332342.
  15. Monroy A,Plata C,Hebert SC,Gamba G.Characterization of the thiazide‐sensitive Na(+)‐Cl(−) cotransporter: a new model for ions and diuretics interaction.Am J Physiol Renal Physiol.2000;279(1):F161F169.
  16. Ellison DH.Diuretic therapy and resistance in congestive heart failure.Cardiology.2001;96(3–4):132143.
  17. Dormans TPJ,Gerlag PGG.Combination of high‐dose furosemide and hydrochlorothiazide in the treatment of refractory congestive heart failure.Eur Heart J.1996;17(12):18671874.
  18. Pitt B,Zannad F,Remme WJ, et al.The effect of spironolactone on morbidity and mortality in patients with severe heart failure.N Engl J Med.1999;341(10):709717.
  19. Pitt B,Remme W,Zannad F, et al.Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.N Engl J Med.2003;348(14):13091321.
  20. Adams KF.Pathophysiologic role of the renin‐angiotensin‐aldosterone and sympathetic nervous systems in heart failure.Am J Health Syst Pharm.2004;61(suppl 2):S4S13.
  21. Hauben M,Reich L,Gerrits CM,Madigan D.Detection of spironolactone‐associated hyperkalaemia following the Randomized Aldactone Evaluation Study (RALES).Drug Saf.2007;30(12):11431149.
  22. Eshaghian S,Horwich TB,Fonarow GC.Relation of loop diuretic dose to mortality in advanced heart failure.Am J Cardiol.2006;97(12):17591764.
  23. Chuen MJNK,MacFadyen RJ.Dose‐dependent association between use of loop diuretics and mortality in advanced systolic heart failure.Am J Cardiol.2006;98(10):14161417.
  24. Fonarow GC,Adams KFJ,Abraham WT,Yancy CW,Boscardin WJ.Risk stratification for in‐hospital mortality in acutely decompensated heart failure: classification and regression tree analysis.JAMA.2005;293(5):572580.
  25. Hasselblad V,Gattis Stough W,Shah MR, et al.Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial.Eur J Heart Fail.2007;9(10):10641069.
  26. Loon NR,Wilcox CS,Unwin RJ.Mechanism of impaired natriuretic response to furosemide during prolonged therapy.Kidney Int.1989;36(4):682689.
  27. Salvador DRK,Rey NR,Ramos GC,Punzalan FER.Continuous infusion versus bolus injection of loop diuretics in congestive heart failure.Cochrane Database Syst Rev.2004; (1):CD003178.
  28. López B,Querejeta R,González A,Sánchez E,Larman M,Díez J.Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure.J Am Coll Cardiol.2004;43(11):20282035.
  29. Veeraveedu PT,Watanabe K,Ma M, et al.Comparative effects of torasemide and furosemide in rats with heart failure.Biochem Pharmacol.2008;75(3):649659.
  30. Elkayam U,Janmohamed M,Habib M,Hatamizadeh P.Vasodilators in the management of acute heart failure.Crit Care Med.2008;36(suppl 1):S95S105.
  31. Hollenberg SM.Vasodilators in acute heart failure.Heart Fail Rev.2007;12(2):143147.
  32. Elkayam U,Kulick D,McIntosh N,Roth A,Hsueh W,Rahimtoola SH.Incidence of early tolerance to hemodynamic effects of continuous infusion of nitroglycerin in patients with coronary artery disease and heart failure.Circulation.1987;76(3):577584.
  33. Baines AD,DeBold AJ,Sonnenberg H.Natriuretic effect of atrial extract on isolated perfused rat kidney.Can J Physiol Pharmacol.1983;61(12):14621466.
  34. Abraham WT,Lowes BD,Ferguson DA, et al.Systemic hemodynamic, neurohormonal, and renal effects of a steady‐state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure.J Card Fail.1998;4(1):3744.
  35. Yoshimura M,Yasue H,Morita E, et al.Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure.Circulation.1991;84(4):15811588.
  36. Wang DJ,Dowling TC,Meadows D, et al.Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine.Circulation.2004;110(12):16201625.
  37. Witteles RM,Kao D,Christopherson D, et al.Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre‐existing renal dysfunction: a randomized, double‐blind, placebo‐controlled clinical trial.J Am Coll Cardiol.2007;50(19):18351840.
  38. Colucci WS,Elkayam U,Horton DP, et al.Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure.N Engl J Med.2000;343(4):246253.
  39. Publication Committee for the VMAC Investigators.Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial.JAMA.2002;287(12):15311540.
  40. Chang R,Elatre WA,Heywood JT.Effect of nesiritide on length of hospital stay in patients with decompensated heart failure.J Cardiovasc Pharmacol Ther.2004;9(3):173177.
  41. Sackner‐Bernstein JD,Skopicki HA,Aaronson KD.Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure.Circulation.2005;111(12):14871491.
  42. Sackner‐Bernstein JD,Kowalski M,Fox M,Aaronson K.Short‐term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials.JAMA.2005;293(15):19001905.
  43. Abraham WT.Serum creatinine elevations in patients receiving nesiritide are related to starting dose [abstract 248].J Card Fail.2005;11(suppl 6):S156.
  44. Riter HG,Redfield MM,Burnett JC,Chen HH.Nonhypotensive low‐dose nesiritide has differential renal effects compared with standard‐dose nesiritide in patients with acute decompensated heart failure and renal dysfunction.JAm Coll Cardiol.2006;47(11):23342335.
  45. Heywood JT.Combining nesiritide with high‐dose diuretics may increase the risk of increased serum creatinine [abstract 2180].Circulation.2005;112(17 suppl II):II‐451II‐452.
  46. Mentzer RMJ,Oz MC,Sladen RN, et al.Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: the NAPA trial.J Am Coll Cardiol.2007;49(6):716726.
  47. Chen HH,Sundt TM,Cook DJ,Heublein DM,Burnett JC.Low dose nesiritide and the preservation of renal function in patients with renal dysfunction undergoing cardiopulmonary‐bypass surgery: a double‐blind placebo‐controlled pilot study.Circulation.2007;116(suppl 11):I‐134I‐138.
  48. Heywood JT.Temporal characteristics of serum creatinine elevations in patients receiving nesiritide and nitroglycerin [abstract 2793].Circulation.2008;112(17 suppl II):II‐590.
  49. Abraham WT.Nesiritide does not increase 30‐day or 6‐month mortality risk [abstract 3169].Circulation.2005;112(17 suppl II):II‐676.
  50. Yancy CW,Drum H,Massie BM, et al.Safety and efficacy of outpatient nesiritide in patients with advanced heart failure.Circ Heart Fail.2008;1:916.
  51. Costanzo MR,Guglin ME,Saltzberg MT, et al.Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure.J Am Coll Cardiol.2007;49(6):675683.
  52. Rogers HL,Marshall J,Bock J, et al.A randomized, controlled trial of the renal effects of ultrafiltration as compared to furosemide in patients with acute decompensated heart failure.J Card Fail.2008;14(1):15.
  53. Heart Failure Society of America. Evaluation and management of patients with acute decompensated heart failure.J Card Fail.2006;12(1):e86e103.
  54. Nohria A,Hasselblad V,Stebbins A, et al.Cardiorenal interactions: insights from the ESCAPE trial.J Am Coll Cardiol.2008;51(13):12681274.
  55. Forman DE,Butler J,Wang Y, et al.Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure.J Am Coll Cardiol.2004;43(1):6167.
  56. Boyle A,Sobotka PA.Redefining the therapeutic objective in decompensated heart failure: hemoconcentration as a surrogate for plasma refill rate.J Card Fail.2006;12(4):247249.
  57. Heywood JT.The cardiorenal syndrome: lessons from the ADHERE database and treatment options.Heart Fail Rev.2004;9(3):195201.
  58. Kumar S,Rubin S,Mather PJ,Whellan DJ.Hyponatremia and vasopressin antagonism in congestive heart failure.Clin Cardiol.2007;30(11):546551.
  59. Goldsmith SR,Gheorghiade M.Vasopressin antagonism in heart failure.J Am Coll Cardiol.2005;46(10):17851791.
  60. Gottlieb SS,Brater DC,Thomas I, et al.BG9719 (CVT‐124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy.Circulation.2002;105(11):13481353.
  61. Dittrich HC,Gupta DK,Hack TC,Dowling T,Callahan J,Thomson S.The effect of KW‐3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment.J Card Fail.2007;13(8):609617.
  62. Givertz MM,Massie BM,Fields TK,Pearson LL,Dittrich HC;CKI‐201 and CKI‐202 Investigators.The effects of KW‐3902, an adenosine A1‐receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance.J Am Coll Cardiol.2007;50(16):15511560.
Issue
Journal of Hospital Medicine - 3(6)
Issue
Journal of Hospital Medicine - 3(6)
Page Number
S25-S32
Page Number
S25-S32
Article Type
Display Headline
Inpatient management of patients with volume overload and high filling pressures
Display Headline
Inpatient management of patients with volume overload and high filling pressures
Legacy Keywords
acute decompensated heart failure, ADHF, filling pressure, renal function, volume overload
Legacy Keywords
acute decompensated heart failure, ADHF, filling pressure, renal function, volume overload
Sections
Article Source
Copyright © 2008 Society of Hospital Medicine
Disallow All Ads
Correspondence Location
Heart Failure Recovery and Research Program, Scripps Clinic, 10666 North Torrey Pines Road, La Jolla, CA 92037
Content Gating
Gated (full article locked unless allowed per User)
Gating Strategy
First Peek Free
Article PDF Media

Multidisciplinary Management of ADHF

Article Type
Changed
Mon, 01/02/2017 - 19:34
Display Headline
Who is managing acute decompensated heart failure? The need for a multidisciplinary approach

Acute decompensated heart failure (ADHF) is a common disorder that is frequently managed by hospitalists. This management is expected to expand over the next several years because of a continuing increase in the number of ADHF admissions coupled with a plateau or possible decline in the number of practicing cardiologists (Figure 1).114 In addition, 12% of fellowship training positions in cardiology were eliminated between 1995 and 2001, and the fact that the current number of training positions is inadequate to meet future demands is not recognized.15, 16 Given the severity of this disorder, the limited data from randomized, controlled clinical trials,17 and the limitations of current treatment, this management can be both challenging and rewarding. The goal of this special supplement of the Journal of Hospital Medicine is to assist hospitalists in this endeavor by summarizing the currently available data and treatment options and presenting a rational evidence‐based algorithm for the management of ADHF.

Figure 1
(—) Actual number of admissions and (‐ ‐ ‐) estimated number of admissions for acute decompensated heart failure (AHDF) in the United States and the number of specialists available to handle this workload. Actual numbers for ADHF admissions over time were extracted from National Hospital Discharge Summary publications,1–7 and the estimated number of ADHF admissions in 2010 was calculated by multiplication of the prevalence of ADHF admission in various age groups from 2004 National Hospital Discharge Summary data8 by the estimated number of individuals in each of these age groups in 2010 according to US Census estimates.9 Actual numbers of cardiologists were extracted from Foot et al.10 and the 35th Bethesda Conference.11 The estimated number of cardiologists in 2010 was calculated on the basis of the statement in the Bethesda Conference report that the number of cardiologists is expected to fall to 5 per 100,000 individuals in 2020 and the estimated population in 2020 according to US Census estimates. This number was then extrapolated back to 2010 with linear interpolation. Actual and estimated numbers of hospitalists were extracted from Baudendistel and Wachter,12 Wachter,13 and Amin.14

A multidisciplinary approach to heart failure has been shown to reduce cost, decrease length of stay, curtail readmissions, and improve compliance.1820 By leading and coordinating teams of physicians, pharmacists, nurses, nutritionists, physical therapists, and case managers and by developing and implementing indications for cardiology consultation, hospitalists can facilitate this multidisciplinary approach.21, 22 However, it is important to remember that hospitalists do not replace cardiologists, who remain a valuable and key component of this multidisciplinary team. Their input is vital in developing care pathways and criteria for consultation, and they, along with primary care physicians, will be the primary source of patient care following hospital discharge. Good communication between hospitalists and cardiologists is essential to optimize the care of patients with ADHF.

Maximizing the efficacy of ADHF care requires a thorough understanding of (1) the causes and potential treatments for the patient's acute decompensation, (2) the management of the patient's chronic heart failure, and (3) potential future therapies. Strategies to improve the continuum of heart failure care have been employed to help improve patient outcomes.23 For example, hospital‐based disease management programs have consistently been shown to optimize care and reduce rehospitalization rates in patients with heart failure.24 These programs involve a multidisciplinary, multifaceted approach to care in order to provide a continuum of care extending from hospitalization and into a patient's home environment.

Because of their practice location and experience, hospitalists are uniquely suited to influence acute inpatient care.25 They see patients in a variety of hospital settings and consequently tend to think of the entire system and not just an isolated component or patient.14 In addition, they have a vested interest in hospital quality improvement measures and are frequently involved in evaluating policies and procedures and developing and implementing clinical pathways, guidelines, and decision‐support tools.26 Data demonstrate that compliance is greater with evidence‐based guidelines and core performance measures when inpatient care is directed by a hospitalist.2730 Improved compliance with selected quality measures in patients with acute myocardial infarction and congestive heart failure has been observed when hospitals implement standardized admission and discharge orders.31, 32

Numerous transitions, such as outpatient to inpatient, intensive care unit to ward, and ward to home, occur during hospitalization, and these transitions are frequently associated with changes in the patient's medication regimen. During an acute illness, chronic medications may be held or discontinued, long‐acting medications may be changed to short‐acting ones to better titrate dose and achieve tighter control, and closed formularies may necessitate substituting 1 medication for another.33 A breakdown in communication during hospitalization‐associated transitions commonly affects medication regimens and can adversely impact patient care.3436 In a prospective evaluation, 53.6% [95% confidence interval (CI): 45.7%61.6%] of patients admitted to the hospital had at least 1 unintended discrepancy between their admission medication orders and their chronic outpatient regimen; 38.6% of these discrepancies were considered a potential threat to the patient.34 Likewise, 49% of patients being discharged from the hospital in another evaluation had an unexplained discrepancy between their preadmission and discharge medications.36 As a result, the Joint Commission on Accreditation of Healthcare Organizations now requires accredited facilities to perform medication reconciliation whenever a patient changes service, setting, provider, or level of care and new medication orders are written.37 This reconciliation is especially important in patients with heart failure, for whom polypharmacy is common and noncompliance with appropriate treatment regimens substantially increases readmission rates.3842

During these transition periods, hospitalists can play an important role in bridging the communication gap and providing this medication reconciliation.33 For example, actively involving hospitalists in all aspects of the reconciliation process at 1 institution resulted in a 4‐fold increase in consistency with preadmission medications.43 Similarly, because of the number of discharge summaries that they write, hospitalists are well suited to lead implementation of new policies and procedures to ensure compliance with recent changes in the Joint Commission on Accreditation of Healthcare Organizations requirements regarding these summaries.

In addition to playing an active role in acute patient management, hospitalists can substantially influence long‐term care and outcomes. Consequently, hospitalists must be well versed in the management of chronic heart failure. Patients are intensely focused on their illness during the hospitalization period, and this focus enhances opportunities for meaningful education and behavior modification. Numerous studies have demonstrated that adherence to long‐term therapy is improved when this therapy is initiated before or at hospital discharge.4446 In an evaluation of data from the Organized Program To Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure Registry (OPTIMIZE‐HF), the prescription of a ‐blocker at discharge was associated with a significant reduction in 60‐ to 90‐day mortality [hazard ratio (HR): 0.48; 95% CI: 0.30‐0.79], and prescription of an angiotensin‐converting enzyme inhibitor or angiotensin receptor blocker at discharge was associated with a significant reduction in 60‐ to 90‐day mortality and/or rehospitalization (HR: 0.51; 95% CI: 0.34‐0.78).47 In the Cardiac Hospitalization Atherosclerosis Management Program (CHAMP), emphasizing initiation of chronic therapy prior to hospital discharge was associated with 3.0‐fold greater angiotensin‐converting enzyme inhibitor use and 3.2‐fold greater ‐blocker use at 1 year (both P < 0.01).46 Similarly, in patients surviving acute myocardial infarction, the strongest predictor of ‐blocker use at 30 days following discharge was receipt of a ‐blocker prescription at the time of discharge (HR: 15.8; 95% CI: 10.8‐23.3), and this beneficial effect was sustained for up to a year (Figure 2).44 Likewise, in patients with ADHF, the prevalence of ‐blocker therapy at 60 days was significantly increased when this therapy was initiated before discharge (91%) versus after discharge (73%; P < 0.001).45 This predischarge initiation of chronic therapy has been shown to reduce morbidity and mortality.

Figure 2
The percent of β‐blocker use over the first year following acute myocardial infarction in patients who were or were not prescribed a β‐blocker at the time of hospital discharge. Reprinted with permission from the Journal of the American College of Cardiology.44 Copyright 2002, American College of Cardiology Foundation.

An awareness of new therapies for ADHF that are in late stages of clinical development can improve understanding of the complex pathophysiology of ADHF and enhance appropriate adaptation of these therapies once they become clinically available. These new therapies represent an attempt to improve on existing therapies, and consequently, they fall into the same 3 general categories as current therapies: diuretics, vasodilators, and inotropic agents.48, 49 Vasopressin receptor antagonists and adenosine receptor antagonists represent an attempt to stimulate aquaresis without inducing hyponatremia, hypokalemia, diminished glomerular filtration, or adverse neurohormonal activation;4854 endothelin receptor antagonists and newer natriuretic peptides represent an attempt to stimulate vasodilation and improve cardiac output without diminishing renal function;49, 55 and myosin activators and sodium‐potassium adenosine triphosphatase inhibitors represent an attempt to enhance contractility without inducing arrhythmogenicity or increasing mortality risk4859 (Table 1).

Investigational Therapies for Acute Decompensated Heart Failure
Class/MOA Agent(s) Advantages/Disadvantages References
  • Abbreviations: ATPase, adenosine triphosphatase; MOA, mechanism of action.

Vasopressin receptor antagonists Tolvaptan Induce aquaresis without natriuresis deGoma et al.48
Conivaptan Potentially avoid hyponatremia and hypokalemia Tang and Hobbs49
Lixivaptan Konstam et al.50
SR‐121463b Schrier et al.51
Schweiger and Zdanowicz52
Adenosine A1 receptor antagonists Rolofylline Increase renal blood flow Tang and Hobbs49
BG‐9719 Increase intraglomerular hydraulic pressure deGoma et al.48
BG‐9928 May produce diuresis without adversely affecting glomerular filtration and renal function Givertz et al.53 Greenberg et al.54
Endothelin receptor antagonists Tezosentan Potent vasodilator Tang and Hobbs49
Improves cardiac output McMurray et al.55
Hemodynamic effects have not translated into an improvement in heart failure symptoms or risk of death.
Natriuretic peptides Ularitide Resists inactivation by neutral endopeptidase deGoma et al.48
Improves filling pressures and dyspnea scores Mitrovic et al.59
No apparent deleterious effect on short‐term renal function
Myosin activators CK‐1827452 Tries to dissociate inotropy from arrhythmogenicity deGoma et al.48
Enhances contractility by targeting myocardial myosin, the force generating cardiac enzymes Cytokinetics56
Still very early in clinical development (just entered phase 2)
Sodium‐potassium ATPase inhibitors Istaroxime Tries to dissociate inotropy from arrhythmogenicity deGoma et al.48
Enhances contractility by stimulating calcium entry into the sarcolemmal Na/Ca exchanger Blair et al.57
Lusitropic Cleland et al.58
Still very early in clinical development (just completed first phase 2 trial)

Finally, although major advancements in the medical therapy of heart failure patients have substantially improved outcomes,60 technological advances in mechanical devices,61 including automatic implantable cardioverter defibrillators, cardiac resynchronization therapy, and ventricular assist devices, as well as advances in the surgical treatment of heart failure,62 have also been used to support the failing heart. Heart failure patients being treated with mechanical devices, as well as those following cardiac transplant, require unique care. As more mechanical and surgical innovations emerge, nonpharmacologic therapy will continue to evolve as a cornerstone of the management strategy in heart failure patients. Hospitalists will need to rely on care pathways, criteria for consultation, and good communication with cardiologists to optimize the care of these patients. Hospitalists should work with their cardiology colleagues in their local institution to develop appropriate criteria for cardiology consultation, and everyone should be educated on these criteria.

The subsequent discussions in this supplement expand on these topics. First, I review the presentation and early recognition, risk stratification, and treatment of patients with ADHF and the role of the hospitalist in this assessment and treatment process. Next, Dr. Khan and Dr. Heywood review the role of diuretics, vasodilators, and ultrafiltration in the management of patients with volume overload and high filling pressures and conclude with a discussion of potential future pharmacologic treatment options, such as tolvaptan and rolofylline, and nonpharmacologic modalities, such as wireless hemodynamic monitoring through implanted devices. Finally, Dr. Michota and I discuss bridging the gap between evidence and practice in the management of patients with ADHF. We review the evidence‐based guidelines that are currently available; discuss the appropriate location for treatment based on the patient's initial history and physical, radiographic, and laboratory findings; provide a practical algorithm for this treatment; and discuss means to transition care from the inpatient setting to the outpatient setting in a manner that enhances compliance with long‐term therapy and reduces recidivism. Given the anticipated growth in ADHF and the need for hospitalists to manage this disease together with cardiologists and others, we believe that the provided information will be helpful in the management of ADHF.

References
  1. Graves EJ,Kozak LJ.National Hospital Discharge Survey: annual summary, 1996.Vital Health Stat.1999;13(140):146.
  2. Haldeman GA,Croft JB,Giles WH,Rashidee A.Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995.Am Heart J.1999;137(2):352360.
  3. Kozak LJ,Owings MF,Hall MJ.National Hospital Discharge Survey: 2001 annual summary with detailed diagnosis and procedure data.Vital Health Stat.2004;13(156):1198.
  4. Kozak LJ,Owings MF,Hall MJ.National Hospital Discharge Survey: 2002 annual summary with detailed diagnosis and procedure data.Vital Health Stat.2005;13(158):1199.
  5. DeFrances CJ,Cullen KA,Kozak LJ.National Hospital Discharge Survey: 2005 annual summary with detailed diagnosis and procedure data.Vital Health Stat.2007;13(165):1209.
  6. Kozak LJ,DeFrances CJ,Hall MJ.National Hospital Discharge Survey: 2004 annual summary with detailed diagnosis and procedure data.Vital Health Stat.2006;13(162):1209.
  7. Kozak LJ,Lees KA,DeFrances CJ.National Hospital Discharge Survey: 2003 annual summary with detailed diagnosis and procedure data.Vital Health Stat.2006;13(160):1206.
  8. Division for Heart Disease and Stroke Prevention. Heart failure fact sheet. Available at: http://www.cdc.gov/dhdsp/library/fs_heart_failure_longdesc.htm. Accessed September2008.
  9. US Census Bureau. Projected population of the United States, by age and sex: 2000 to 2050. Available at: http://www.census.gov/population/www/projections/usinterimproj/natprojtab02a.pdf. Accessed September2008.
  10. Foot DK,Lewis RP,Pearson TA,Beller GA.Demographics and cardiology, 1950–2050.J Am Coll Cardiol.2000;35(4):10671081.
  11. 35th Bethesda Conference.Cardiology's workforce crisis: a pragmatic approach. Bethesda, Maryland, 17–18 October 2003.J Am Coll Cardiol.2004;44(2):216275.
  12. Baudendistel TE,Wachter RM.The evolution of the hospitalist movement in the USA.Clin Med.2002;2(4):327330.
  13. Wachter RM.Hospitalists in the United States—mission accomplished or work in progress?N Engl J Med.2004;350(19):19351936.
  14. Amin AN.Identifying strategies to improve outcomes and reduce costs—a role for the hospitalist.Curr Opin Pulm Med.2004;10(suppl):S19S22.
  15. Bonow RO,Smith SC.Cardiovascular manpower: the looming crisis.Circulation.2004;109(7):817820.
  16. Kereiakes DJ,Willerson JT.The United States cardiovascular care deficit.Circulation.2004;109(7):821823.
  17. Heart Failure Society of America.Evaluation and management of patients with acute decompensated heart failure.J Card Fail.2006;12(1):e86e103.
  18. Gattis WA,Hasselblad V,Whellan DJ,O'Connor CM.Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team. Results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) study.Arch Intern Med.1999;159(16):19391945.
  19. Ducharme A,Doyon O,White M,Rouleau JL,Brophy JM.Impact of care at a multidisciplinary congestive heart failure clinic: a randomized trial.CMAJ.2005;173(1):4045.
  20. Knox D,Mischke L.Implementing a congestive heart failure disease management program to decrease length of stay and cost.J Cardiovasc Nurs.1999;14(1):5574.
  21. Pistoria MJ,Amin AN,Dressler DD,McKean SCW,Budnitz TL.The core competencies in hospital medicine: a framework for curriculum development by the Society of Hospital Medicine.J Hosp Med.2006;1(suppl 1):295.
  22. Cobaugh DJ,Amin A,Brookwalter T, et al.ASHP‐SHM joint statement on hospitalist‐pharmacist collaboration.J Hosp Med.2008;3(suppl 3). doi://10.1002/jhm.315. Available at: http://www3.interscience.wiley.com.
  23. Kay D,Blue A,Pye P,Lacy A,Gray C,Moore S.Heart failure: improving the continuum of care.Care Manag J.2006;7(2):5863.
  24. Berkowitz R,Blank LJ,Powell SK.Strategies to reduce hospitalization in the management of heart failure.Lippincotts Case Manag.2005;10(6 suppl):S1S15.
  25. Amin A.Improving the management of patients after myocardial infarction, from admission to discharge.Clin Ther.2006;28(10):15091539.
  26. Amin AN.The role of hospitalists in the management of acute decompensated heart failure.Am Heart Hosp J.2005;3(2):111117.
  27. Lindenauer PK,Chehabeddine R,Pekow P,Fitzgerald J,Benjamin EM.Quality of care for patients hospitalized with heart failure: assessing the impact of hospitalists.Arch Intern Med.2002;162(11):12511256.
  28. Amin AN,Owen MM.Productive interdisciplinary team relationships: the hospitalist and the case manager.Lippincotts Case Manag.2006;11(3):160164.
  29. Collier VU.Use of pay for performance in a community hospital private hospitalist group: a preliminary report.Trans Am Clin Climatol Assoc.2007;118:263272.
  30. Roytman MM,Thomas SM,Jiang CS.Comparison of practice patterns of hospitalists and community physicians in the care of patients with congestive heart failure.J Hosp Med.2008;3(1):3541.
  31. Ozdas A,Speroff T,Waitman LR,Ozbolt J,Butler J,Miller RA.Integrating “best of care” protocols into clinicians' workflow via care provider order entry: impact on quality‐of‐care indicators for acute myocardial infarction.J Am Med Inform Assoc.2006;13(2):188196.
  32. Butler J,Speroff T,Arbogast PG, et al.Improved compliance with quality measures at hospital discharge with a computerized physician order entry system.Am Heart J.2006;151(3):643653.
  33. Kripalani S,Jackson AT,Schnipper JL,Coleman EA.Promoting effective transitions of care at hospital discharge: a review of key issues for hospitalists.J Hosp Med.2007;2(5):314323.
  34. Cornish PL,Knowles SR,Marchesano R, et al.Unintended medication discrepancies at the time of hospital admission.Arch Intern Med.2005;165(4):424429.
  35. Gleason KM,Groszek JM,Sullivan C,Rooney D,Barnard C,Noskin GA.Reconciliation of discrepancies in medication histories and admission orders of newly hospitalized patients.Am J Health Syst Pharm.2004;61(16):16891695.
  36. Schnipper JL,Kirwin JL,Cotugno MC, et al.Role of pharmacist counseling in preventing adverse drug events after hospitalization.Arch Intern Med.2006;166(5):565571.
  37. Joint Commission on Accreditation of Healthcare Organizations. Using medication reconciliation to prevent errors. Sentinel Event Alert #35. Available at: http://www.jointcommission.org/sentinelevents/sentineleventalert/sea_35.htm. Accessed September2008.
  38. Ghali JK,Kadakia S,Cooper R,Ferlinz J.Precipitating factors leading to decompensation of heart failure: traits among urban blacks.Arch Intern Med.1988;148(9):20132016.
  39. Vinson JM,Rich MW,Sperry JC,Shah AS,McNamara T.Early readmission of elderly patients with congestive heart failure.J Am Geriatr Soc.1990;38(12):12901295.
  40. Peacock WF,Albert NM.Observation unit management of heart failure.Emerg Med Clin North Am.2001;19(1):209232.
  41. Adams KF,Fonarow GC,Emerman CL, et al.Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Failure National Registry (ADHERE).Am Heart J.2005;149(2):209216.
  42. Gheorghiade M,Abraham WT,Albert NM, et al.Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure.JAMA.2006;296(18):22172226.
  43. Katz PS. Eliminating drug errors: hospitals adopt medication reconciliation to improve patient safety. Available at: http://www.acponline.org/clinical_information/journals_publications/acp_hospitalist/may07/drug_errors.htm. Accessed September2008.
  44. Butler J,Arbogast PG,BeLue R, et al.Outpatient adherence to beta‐blocker therapy after acute myocardial infarction.JAm Coll Cardiol.2002;40(9):15891595.
  45. Gattis WA,O'Connor CM.Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure.Am J Cardiol.2004;93(9A):74B76B.
  46. Fonarow GC,Gawlinski A,Moughrabi S,Tillisch JH.Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP).Am J Cardiol.2001;87(7):819822.
  47. Fonarow GC,Abraham WT,Albert NM, et al.Association between performance measures and clinical outcomes for patients hospitalized with heart failure.JAMA.2007;297(1):6170.
  48. deGoma EM,Vagelos RH,Fowler MB,Ashley EA.Emerging therapies for the management of decompensated heart failure: from bench to bedside.J Am Coll Cardiol.2006;48(12):23972409.
  49. Tang WHW,Hobbs RE.Novel strategies for the management of acute decompensated heart failure.Curr Cardiol Rev.2005;1(1):15.
  50. Konstam MA,Gheorghiade M,Burnett JC, et al.Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial.JAMA.2007;297(12):13191331.
  51. Schrier RW,Gross P,Gheorghiade M, et al.Tolvaptan, a selective oral vasopressin V2‐receptor antagonist, for hyponatremia.N Engl J Med.2006;355(20):20992112.
  52. Schweiger TA,Zdanowicz MM.Vasopressin‐receptor antagonists in heart failure.Am J Health Syst Pharm.2008;65(9):807817.
  53. Givertz MM,Massie BM,Fields TK,Pearson LL,Dittrich HC.The effects of KW‐3902, an adenosine A1‐receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance.J Am Coll Cardiol.2007;50(16):15511560.
  54. Greenberg B,Thomas I,Banish D, et al.Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure: results of a placebo‐controlled, dose‐escalation study.J Am Coll Cardiol.2007;50(7):600606.
  55. McMurray JJ,Teerlink JR,Cotter G, et al.Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials.JAMA.2007;298(17):20092019.
  56. CK‐1827452. Cytokinetics Web site. Available at: http://www.cytokinetics.com/ck_1827452. Accessed September2008.
  57. Blair JE,Macarie C,Ruzyllo W, et al.Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON‐HF) trial.Am J Ther.2008;15(3):231240.
  58. Cleland JG,Coletta AP,Yassin A, et al.Clinical trials update from the American College of Cardiology 2008: CARISMA, TRENDS, meta‐analysis of Cox‐2 studies, HAT, ON‐TARGET, HYVET, ACCOMPLISH, MOMENTUM, PROTECT, HORIZON‐HF and REVERSE.Eur J Heart Fail.2008;10(6):614620.
  59. Mitrovic V,Seferovic PM,Simeunovic D, et al.Haemodynamic and clinical effects of ularitide in decompensated heart failure.Eur Heart J.2006;27(23):28232832.
  60. Brieke A,Cleveland J,Lindenfeld J.Mechanical support in acute and chronic heart failure.Curr Cardiol Rep.2008;10(3):168175.
  61. Kale P,Fang JC.Devices in acute heart failure.Crit Care Med.2008;36(1 suppl):S121S128.
  62. Allen LA,Felker GM.Advances in the surgical treatment of heart failure.Curr Opin Cardiol.2008;23(3):249253.
Article PDF
Issue
Journal of Hospital Medicine - 3(6)
Page Number
S1-S6
Sections
Article PDF
Article PDF

Acute decompensated heart failure (ADHF) is a common disorder that is frequently managed by hospitalists. This management is expected to expand over the next several years because of a continuing increase in the number of ADHF admissions coupled with a plateau or possible decline in the number of practicing cardiologists (Figure 1).114 In addition, 12% of fellowship training positions in cardiology were eliminated between 1995 and 2001, and the fact that the current number of training positions is inadequate to meet future demands is not recognized.15, 16 Given the severity of this disorder, the limited data from randomized, controlled clinical trials,17 and the limitations of current treatment, this management can be both challenging and rewarding. The goal of this special supplement of the Journal of Hospital Medicine is to assist hospitalists in this endeavor by summarizing the currently available data and treatment options and presenting a rational evidence‐based algorithm for the management of ADHF.

Figure 1
(—) Actual number of admissions and (‐ ‐ ‐) estimated number of admissions for acute decompensated heart failure (AHDF) in the United States and the number of specialists available to handle this workload. Actual numbers for ADHF admissions over time were extracted from National Hospital Discharge Summary publications,1–7 and the estimated number of ADHF admissions in 2010 was calculated by multiplication of the prevalence of ADHF admission in various age groups from 2004 National Hospital Discharge Summary data8 by the estimated number of individuals in each of these age groups in 2010 according to US Census estimates.9 Actual numbers of cardiologists were extracted from Foot et al.10 and the 35th Bethesda Conference.11 The estimated number of cardiologists in 2010 was calculated on the basis of the statement in the Bethesda Conference report that the number of cardiologists is expected to fall to 5 per 100,000 individuals in 2020 and the estimated population in 2020 according to US Census estimates. This number was then extrapolated back to 2010 with linear interpolation. Actual and estimated numbers of hospitalists were extracted from Baudendistel and Wachter,12 Wachter,13 and Amin.14

A multidisciplinary approach to heart failure has been shown to reduce cost, decrease length of stay, curtail readmissions, and improve compliance.1820 By leading and coordinating teams of physicians, pharmacists, nurses, nutritionists, physical therapists, and case managers and by developing and implementing indications for cardiology consultation, hospitalists can facilitate this multidisciplinary approach.21, 22 However, it is important to remember that hospitalists do not replace cardiologists, who remain a valuable and key component of this multidisciplinary team. Their input is vital in developing care pathways and criteria for consultation, and they, along with primary care physicians, will be the primary source of patient care following hospital discharge. Good communication between hospitalists and cardiologists is essential to optimize the care of patients with ADHF.

Maximizing the efficacy of ADHF care requires a thorough understanding of (1) the causes and potential treatments for the patient's acute decompensation, (2) the management of the patient's chronic heart failure, and (3) potential future therapies. Strategies to improve the continuum of heart failure care have been employed to help improve patient outcomes.23 For example, hospital‐based disease management programs have consistently been shown to optimize care and reduce rehospitalization rates in patients with heart failure.24 These programs involve a multidisciplinary, multifaceted approach to care in order to provide a continuum of care extending from hospitalization and into a patient's home environment.

Because of their practice location and experience, hospitalists are uniquely suited to influence acute inpatient care.25 They see patients in a variety of hospital settings and consequently tend to think of the entire system and not just an isolated component or patient.14 In addition, they have a vested interest in hospital quality improvement measures and are frequently involved in evaluating policies and procedures and developing and implementing clinical pathways, guidelines, and decision‐support tools.26 Data demonstrate that compliance is greater with evidence‐based guidelines and core performance measures when inpatient care is directed by a hospitalist.2730 Improved compliance with selected quality measures in patients with acute myocardial infarction and congestive heart failure has been observed when hospitals implement standardized admission and discharge orders.31, 32

Numerous transitions, such as outpatient to inpatient, intensive care unit to ward, and ward to home, occur during hospitalization, and these transitions are frequently associated with changes in the patient's medication regimen. During an acute illness, chronic medications may be held or discontinued, long‐acting medications may be changed to short‐acting ones to better titrate dose and achieve tighter control, and closed formularies may necessitate substituting 1 medication for another.33 A breakdown in communication during hospitalization‐associated transitions commonly affects medication regimens and can adversely impact patient care.3436 In a prospective evaluation, 53.6% [95% confidence interval (CI): 45.7%61.6%] of patients admitted to the hospital had at least 1 unintended discrepancy between their admission medication orders and their chronic outpatient regimen; 38.6% of these discrepancies were considered a potential threat to the patient.34 Likewise, 49% of patients being discharged from the hospital in another evaluation had an unexplained discrepancy between their preadmission and discharge medications.36 As a result, the Joint Commission on Accreditation of Healthcare Organizations now requires accredited facilities to perform medication reconciliation whenever a patient changes service, setting, provider, or level of care and new medication orders are written.37 This reconciliation is especially important in patients with heart failure, for whom polypharmacy is common and noncompliance with appropriate treatment regimens substantially increases readmission rates.3842

During these transition periods, hospitalists can play an important role in bridging the communication gap and providing this medication reconciliation.33 For example, actively involving hospitalists in all aspects of the reconciliation process at 1 institution resulted in a 4‐fold increase in consistency with preadmission medications.43 Similarly, because of the number of discharge summaries that they write, hospitalists are well suited to lead implementation of new policies and procedures to ensure compliance with recent changes in the Joint Commission on Accreditation of Healthcare Organizations requirements regarding these summaries.

In addition to playing an active role in acute patient management, hospitalists can substantially influence long‐term care and outcomes. Consequently, hospitalists must be well versed in the management of chronic heart failure. Patients are intensely focused on their illness during the hospitalization period, and this focus enhances opportunities for meaningful education and behavior modification. Numerous studies have demonstrated that adherence to long‐term therapy is improved when this therapy is initiated before or at hospital discharge.4446 In an evaluation of data from the Organized Program To Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure Registry (OPTIMIZE‐HF), the prescription of a ‐blocker at discharge was associated with a significant reduction in 60‐ to 90‐day mortality [hazard ratio (HR): 0.48; 95% CI: 0.30‐0.79], and prescription of an angiotensin‐converting enzyme inhibitor or angiotensin receptor blocker at discharge was associated with a significant reduction in 60‐ to 90‐day mortality and/or rehospitalization (HR: 0.51; 95% CI: 0.34‐0.78).47 In the Cardiac Hospitalization Atherosclerosis Management Program (CHAMP), emphasizing initiation of chronic therapy prior to hospital discharge was associated with 3.0‐fold greater angiotensin‐converting enzyme inhibitor use and 3.2‐fold greater ‐blocker use at 1 year (both P < 0.01).46 Similarly, in patients surviving acute myocardial infarction, the strongest predictor of ‐blocker use at 30 days following discharge was receipt of a ‐blocker prescription at the time of discharge (HR: 15.8; 95% CI: 10.8‐23.3), and this beneficial effect was sustained for up to a year (Figure 2).44 Likewise, in patients with ADHF, the prevalence of ‐blocker therapy at 60 days was significantly increased when this therapy was initiated before discharge (91%) versus after discharge (73%; P < 0.001).45 This predischarge initiation of chronic therapy has been shown to reduce morbidity and mortality.

Figure 2
The percent of β‐blocker use over the first year following acute myocardial infarction in patients who were or were not prescribed a β‐blocker at the time of hospital discharge. Reprinted with permission from the Journal of the American College of Cardiology.44 Copyright 2002, American College of Cardiology Foundation.

An awareness of new therapies for ADHF that are in late stages of clinical development can improve understanding of the complex pathophysiology of ADHF and enhance appropriate adaptation of these therapies once they become clinically available. These new therapies represent an attempt to improve on existing therapies, and consequently, they fall into the same 3 general categories as current therapies: diuretics, vasodilators, and inotropic agents.48, 49 Vasopressin receptor antagonists and adenosine receptor antagonists represent an attempt to stimulate aquaresis without inducing hyponatremia, hypokalemia, diminished glomerular filtration, or adverse neurohormonal activation;4854 endothelin receptor antagonists and newer natriuretic peptides represent an attempt to stimulate vasodilation and improve cardiac output without diminishing renal function;49, 55 and myosin activators and sodium‐potassium adenosine triphosphatase inhibitors represent an attempt to enhance contractility without inducing arrhythmogenicity or increasing mortality risk4859 (Table 1).

Investigational Therapies for Acute Decompensated Heart Failure
Class/MOA Agent(s) Advantages/Disadvantages References
  • Abbreviations: ATPase, adenosine triphosphatase; MOA, mechanism of action.

Vasopressin receptor antagonists Tolvaptan Induce aquaresis without natriuresis deGoma et al.48
Conivaptan Potentially avoid hyponatremia and hypokalemia Tang and Hobbs49
Lixivaptan Konstam et al.50
SR‐121463b Schrier et al.51
Schweiger and Zdanowicz52
Adenosine A1 receptor antagonists Rolofylline Increase renal blood flow Tang and Hobbs49
BG‐9719 Increase intraglomerular hydraulic pressure deGoma et al.48
BG‐9928 May produce diuresis without adversely affecting glomerular filtration and renal function Givertz et al.53 Greenberg et al.54
Endothelin receptor antagonists Tezosentan Potent vasodilator Tang and Hobbs49
Improves cardiac output McMurray et al.55
Hemodynamic effects have not translated into an improvement in heart failure symptoms or risk of death.
Natriuretic peptides Ularitide Resists inactivation by neutral endopeptidase deGoma et al.48
Improves filling pressures and dyspnea scores Mitrovic et al.59
No apparent deleterious effect on short‐term renal function
Myosin activators CK‐1827452 Tries to dissociate inotropy from arrhythmogenicity deGoma et al.48
Enhances contractility by targeting myocardial myosin, the force generating cardiac enzymes Cytokinetics56
Still very early in clinical development (just entered phase 2)
Sodium‐potassium ATPase inhibitors Istaroxime Tries to dissociate inotropy from arrhythmogenicity deGoma et al.48
Enhances contractility by stimulating calcium entry into the sarcolemmal Na/Ca exchanger Blair et al.57
Lusitropic Cleland et al.58
Still very early in clinical development (just completed first phase 2 trial)

Finally, although major advancements in the medical therapy of heart failure patients have substantially improved outcomes,60 technological advances in mechanical devices,61 including automatic implantable cardioverter defibrillators, cardiac resynchronization therapy, and ventricular assist devices, as well as advances in the surgical treatment of heart failure,62 have also been used to support the failing heart. Heart failure patients being treated with mechanical devices, as well as those following cardiac transplant, require unique care. As more mechanical and surgical innovations emerge, nonpharmacologic therapy will continue to evolve as a cornerstone of the management strategy in heart failure patients. Hospitalists will need to rely on care pathways, criteria for consultation, and good communication with cardiologists to optimize the care of these patients. Hospitalists should work with their cardiology colleagues in their local institution to develop appropriate criteria for cardiology consultation, and everyone should be educated on these criteria.

The subsequent discussions in this supplement expand on these topics. First, I review the presentation and early recognition, risk stratification, and treatment of patients with ADHF and the role of the hospitalist in this assessment and treatment process. Next, Dr. Khan and Dr. Heywood review the role of diuretics, vasodilators, and ultrafiltration in the management of patients with volume overload and high filling pressures and conclude with a discussion of potential future pharmacologic treatment options, such as tolvaptan and rolofylline, and nonpharmacologic modalities, such as wireless hemodynamic monitoring through implanted devices. Finally, Dr. Michota and I discuss bridging the gap between evidence and practice in the management of patients with ADHF. We review the evidence‐based guidelines that are currently available; discuss the appropriate location for treatment based on the patient's initial history and physical, radiographic, and laboratory findings; provide a practical algorithm for this treatment; and discuss means to transition care from the inpatient setting to the outpatient setting in a manner that enhances compliance with long‐term therapy and reduces recidivism. Given the anticipated growth in ADHF and the need for hospitalists to manage this disease together with cardiologists and others, we believe that the provided information will be helpful in the management of ADHF.

Acute decompensated heart failure (ADHF) is a common disorder that is frequently managed by hospitalists. This management is expected to expand over the next several years because of a continuing increase in the number of ADHF admissions coupled with a plateau or possible decline in the number of practicing cardiologists (Figure 1).114 In addition, 12% of fellowship training positions in cardiology were eliminated between 1995 and 2001, and the fact that the current number of training positions is inadequate to meet future demands is not recognized.15, 16 Given the severity of this disorder, the limited data from randomized, controlled clinical trials,17 and the limitations of current treatment, this management can be both challenging and rewarding. The goal of this special supplement of the Journal of Hospital Medicine is to assist hospitalists in this endeavor by summarizing the currently available data and treatment options and presenting a rational evidence‐based algorithm for the management of ADHF.

Figure 1
(—) Actual number of admissions and (‐ ‐ ‐) estimated number of admissions for acute decompensated heart failure (AHDF) in the United States and the number of specialists available to handle this workload. Actual numbers for ADHF admissions over time were extracted from National Hospital Discharge Summary publications,1–7 and the estimated number of ADHF admissions in 2010 was calculated by multiplication of the prevalence of ADHF admission in various age groups from 2004 National Hospital Discharge Summary data8 by the estimated number of individuals in each of these age groups in 2010 according to US Census estimates.9 Actual numbers of cardiologists were extracted from Foot et al.10 and the 35th Bethesda Conference.11 The estimated number of cardiologists in 2010 was calculated on the basis of the statement in the Bethesda Conference report that the number of cardiologists is expected to fall to 5 per 100,000 individuals in 2020 and the estimated population in 2020 according to US Census estimates. This number was then extrapolated back to 2010 with linear interpolation. Actual and estimated numbers of hospitalists were extracted from Baudendistel and Wachter,12 Wachter,13 and Amin.14

A multidisciplinary approach to heart failure has been shown to reduce cost, decrease length of stay, curtail readmissions, and improve compliance.1820 By leading and coordinating teams of physicians, pharmacists, nurses, nutritionists, physical therapists, and case managers and by developing and implementing indications for cardiology consultation, hospitalists can facilitate this multidisciplinary approach.21, 22 However, it is important to remember that hospitalists do not replace cardiologists, who remain a valuable and key component of this multidisciplinary team. Their input is vital in developing care pathways and criteria for consultation, and they, along with primary care physicians, will be the primary source of patient care following hospital discharge. Good communication between hospitalists and cardiologists is essential to optimize the care of patients with ADHF.

Maximizing the efficacy of ADHF care requires a thorough understanding of (1) the causes and potential treatments for the patient's acute decompensation, (2) the management of the patient's chronic heart failure, and (3) potential future therapies. Strategies to improve the continuum of heart failure care have been employed to help improve patient outcomes.23 For example, hospital‐based disease management programs have consistently been shown to optimize care and reduce rehospitalization rates in patients with heart failure.24 These programs involve a multidisciplinary, multifaceted approach to care in order to provide a continuum of care extending from hospitalization and into a patient's home environment.

Because of their practice location and experience, hospitalists are uniquely suited to influence acute inpatient care.25 They see patients in a variety of hospital settings and consequently tend to think of the entire system and not just an isolated component or patient.14 In addition, they have a vested interest in hospital quality improvement measures and are frequently involved in evaluating policies and procedures and developing and implementing clinical pathways, guidelines, and decision‐support tools.26 Data demonstrate that compliance is greater with evidence‐based guidelines and core performance measures when inpatient care is directed by a hospitalist.2730 Improved compliance with selected quality measures in patients with acute myocardial infarction and congestive heart failure has been observed when hospitals implement standardized admission and discharge orders.31, 32

Numerous transitions, such as outpatient to inpatient, intensive care unit to ward, and ward to home, occur during hospitalization, and these transitions are frequently associated with changes in the patient's medication regimen. During an acute illness, chronic medications may be held or discontinued, long‐acting medications may be changed to short‐acting ones to better titrate dose and achieve tighter control, and closed formularies may necessitate substituting 1 medication for another.33 A breakdown in communication during hospitalization‐associated transitions commonly affects medication regimens and can adversely impact patient care.3436 In a prospective evaluation, 53.6% [95% confidence interval (CI): 45.7%61.6%] of patients admitted to the hospital had at least 1 unintended discrepancy between their admission medication orders and their chronic outpatient regimen; 38.6% of these discrepancies were considered a potential threat to the patient.34 Likewise, 49% of patients being discharged from the hospital in another evaluation had an unexplained discrepancy between their preadmission and discharge medications.36 As a result, the Joint Commission on Accreditation of Healthcare Organizations now requires accredited facilities to perform medication reconciliation whenever a patient changes service, setting, provider, or level of care and new medication orders are written.37 This reconciliation is especially important in patients with heart failure, for whom polypharmacy is common and noncompliance with appropriate treatment regimens substantially increases readmission rates.3842

During these transition periods, hospitalists can play an important role in bridging the communication gap and providing this medication reconciliation.33 For example, actively involving hospitalists in all aspects of the reconciliation process at 1 institution resulted in a 4‐fold increase in consistency with preadmission medications.43 Similarly, because of the number of discharge summaries that they write, hospitalists are well suited to lead implementation of new policies and procedures to ensure compliance with recent changes in the Joint Commission on Accreditation of Healthcare Organizations requirements regarding these summaries.

In addition to playing an active role in acute patient management, hospitalists can substantially influence long‐term care and outcomes. Consequently, hospitalists must be well versed in the management of chronic heart failure. Patients are intensely focused on their illness during the hospitalization period, and this focus enhances opportunities for meaningful education and behavior modification. Numerous studies have demonstrated that adherence to long‐term therapy is improved when this therapy is initiated before or at hospital discharge.4446 In an evaluation of data from the Organized Program To Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure Registry (OPTIMIZE‐HF), the prescription of a ‐blocker at discharge was associated with a significant reduction in 60‐ to 90‐day mortality [hazard ratio (HR): 0.48; 95% CI: 0.30‐0.79], and prescription of an angiotensin‐converting enzyme inhibitor or angiotensin receptor blocker at discharge was associated with a significant reduction in 60‐ to 90‐day mortality and/or rehospitalization (HR: 0.51; 95% CI: 0.34‐0.78).47 In the Cardiac Hospitalization Atherosclerosis Management Program (CHAMP), emphasizing initiation of chronic therapy prior to hospital discharge was associated with 3.0‐fold greater angiotensin‐converting enzyme inhibitor use and 3.2‐fold greater ‐blocker use at 1 year (both P < 0.01).46 Similarly, in patients surviving acute myocardial infarction, the strongest predictor of ‐blocker use at 30 days following discharge was receipt of a ‐blocker prescription at the time of discharge (HR: 15.8; 95% CI: 10.8‐23.3), and this beneficial effect was sustained for up to a year (Figure 2).44 Likewise, in patients with ADHF, the prevalence of ‐blocker therapy at 60 days was significantly increased when this therapy was initiated before discharge (91%) versus after discharge (73%; P < 0.001).45 This predischarge initiation of chronic therapy has been shown to reduce morbidity and mortality.

Figure 2
The percent of β‐blocker use over the first year following acute myocardial infarction in patients who were or were not prescribed a β‐blocker at the time of hospital discharge. Reprinted with permission from the Journal of the American College of Cardiology.44 Copyright 2002, American College of Cardiology Foundation.

An awareness of new therapies for ADHF that are in late stages of clinical development can improve understanding of the complex pathophysiology of ADHF and enhance appropriate adaptation of these therapies once they become clinically available. These new therapies represent an attempt to improve on existing therapies, and consequently, they fall into the same 3 general categories as current therapies: diuretics, vasodilators, and inotropic agents.48, 49 Vasopressin receptor antagonists and adenosine receptor antagonists represent an attempt to stimulate aquaresis without inducing hyponatremia, hypokalemia, diminished glomerular filtration, or adverse neurohormonal activation;4854 endothelin receptor antagonists and newer natriuretic peptides represent an attempt to stimulate vasodilation and improve cardiac output without diminishing renal function;49, 55 and myosin activators and sodium‐potassium adenosine triphosphatase inhibitors represent an attempt to enhance contractility without inducing arrhythmogenicity or increasing mortality risk4859 (Table 1).

Investigational Therapies for Acute Decompensated Heart Failure
Class/MOA Agent(s) Advantages/Disadvantages References
  • Abbreviations: ATPase, adenosine triphosphatase; MOA, mechanism of action.

Vasopressin receptor antagonists Tolvaptan Induce aquaresis without natriuresis deGoma et al.48
Conivaptan Potentially avoid hyponatremia and hypokalemia Tang and Hobbs49
Lixivaptan Konstam et al.50
SR‐121463b Schrier et al.51
Schweiger and Zdanowicz52
Adenosine A1 receptor antagonists Rolofylline Increase renal blood flow Tang and Hobbs49
BG‐9719 Increase intraglomerular hydraulic pressure deGoma et al.48
BG‐9928 May produce diuresis without adversely affecting glomerular filtration and renal function Givertz et al.53 Greenberg et al.54
Endothelin receptor antagonists Tezosentan Potent vasodilator Tang and Hobbs49
Improves cardiac output McMurray et al.55
Hemodynamic effects have not translated into an improvement in heart failure symptoms or risk of death.
Natriuretic peptides Ularitide Resists inactivation by neutral endopeptidase deGoma et al.48
Improves filling pressures and dyspnea scores Mitrovic et al.59
No apparent deleterious effect on short‐term renal function
Myosin activators CK‐1827452 Tries to dissociate inotropy from arrhythmogenicity deGoma et al.48
Enhances contractility by targeting myocardial myosin, the force generating cardiac enzymes Cytokinetics56
Still very early in clinical development (just entered phase 2)
Sodium‐potassium ATPase inhibitors Istaroxime Tries to dissociate inotropy from arrhythmogenicity deGoma et al.48
Enhances contractility by stimulating calcium entry into the sarcolemmal Na/Ca exchanger Blair et al.57
Lusitropic Cleland et al.58
Still very early in clinical development (just completed first phase 2 trial)

Finally, although major advancements in the medical therapy of heart failure patients have substantially improved outcomes,60 technological advances in mechanical devices,61 including automatic implantable cardioverter defibrillators, cardiac resynchronization therapy, and ventricular assist devices, as well as advances in the surgical treatment of heart failure,62 have also been used to support the failing heart. Heart failure patients being treated with mechanical devices, as well as those following cardiac transplant, require unique care. As more mechanical and surgical innovations emerge, nonpharmacologic therapy will continue to evolve as a cornerstone of the management strategy in heart failure patients. Hospitalists will need to rely on care pathways, criteria for consultation, and good communication with cardiologists to optimize the care of these patients. Hospitalists should work with their cardiology colleagues in their local institution to develop appropriate criteria for cardiology consultation, and everyone should be educated on these criteria.

The subsequent discussions in this supplement expand on these topics. First, I review the presentation and early recognition, risk stratification, and treatment of patients with ADHF and the role of the hospitalist in this assessment and treatment process. Next, Dr. Khan and Dr. Heywood review the role of diuretics, vasodilators, and ultrafiltration in the management of patients with volume overload and high filling pressures and conclude with a discussion of potential future pharmacologic treatment options, such as tolvaptan and rolofylline, and nonpharmacologic modalities, such as wireless hemodynamic monitoring through implanted devices. Finally, Dr. Michota and I discuss bridging the gap between evidence and practice in the management of patients with ADHF. We review the evidence‐based guidelines that are currently available; discuss the appropriate location for treatment based on the patient's initial history and physical, radiographic, and laboratory findings; provide a practical algorithm for this treatment; and discuss means to transition care from the inpatient setting to the outpatient setting in a manner that enhances compliance with long‐term therapy and reduces recidivism. Given the anticipated growth in ADHF and the need for hospitalists to manage this disease together with cardiologists and others, we believe that the provided information will be helpful in the management of ADHF.

References
  1. Graves EJ,Kozak LJ.National Hospital Discharge Survey: annual summary, 1996.Vital Health Stat.1999;13(140):146.
  2. Haldeman GA,Croft JB,Giles WH,Rashidee A.Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995.Am Heart J.1999;137(2):352360.
  3. Kozak LJ,Owings MF,Hall MJ.National Hospital Discharge Survey: 2001 annual summary with detailed diagnosis and procedure data.Vital Health Stat.2004;13(156):1198.
  4. Kozak LJ,Owings MF,Hall MJ.National Hospital Discharge Survey: 2002 annual summary with detailed diagnosis and procedure data.Vital Health Stat.2005;13(158):1199.
  5. DeFrances CJ,Cullen KA,Kozak LJ.National Hospital Discharge Survey: 2005 annual summary with detailed diagnosis and procedure data.Vital Health Stat.2007;13(165):1209.
  6. Kozak LJ,DeFrances CJ,Hall MJ.National Hospital Discharge Survey: 2004 annual summary with detailed diagnosis and procedure data.Vital Health Stat.2006;13(162):1209.
  7. Kozak LJ,Lees KA,DeFrances CJ.National Hospital Discharge Survey: 2003 annual summary with detailed diagnosis and procedure data.Vital Health Stat.2006;13(160):1206.
  8. Division for Heart Disease and Stroke Prevention. Heart failure fact sheet. Available at: http://www.cdc.gov/dhdsp/library/fs_heart_failure_longdesc.htm. Accessed September2008.
  9. US Census Bureau. Projected population of the United States, by age and sex: 2000 to 2050. Available at: http://www.census.gov/population/www/projections/usinterimproj/natprojtab02a.pdf. Accessed September2008.
  10. Foot DK,Lewis RP,Pearson TA,Beller GA.Demographics and cardiology, 1950–2050.J Am Coll Cardiol.2000;35(4):10671081.
  11. 35th Bethesda Conference.Cardiology's workforce crisis: a pragmatic approach. Bethesda, Maryland, 17–18 October 2003.J Am Coll Cardiol.2004;44(2):216275.
  12. Baudendistel TE,Wachter RM.The evolution of the hospitalist movement in the USA.Clin Med.2002;2(4):327330.
  13. Wachter RM.Hospitalists in the United States—mission accomplished or work in progress?N Engl J Med.2004;350(19):19351936.
  14. Amin AN.Identifying strategies to improve outcomes and reduce costs—a role for the hospitalist.Curr Opin Pulm Med.2004;10(suppl):S19S22.
  15. Bonow RO,Smith SC.Cardiovascular manpower: the looming crisis.Circulation.2004;109(7):817820.
  16. Kereiakes DJ,Willerson JT.The United States cardiovascular care deficit.Circulation.2004;109(7):821823.
  17. Heart Failure Society of America.Evaluation and management of patients with acute decompensated heart failure.J Card Fail.2006;12(1):e86e103.
  18. Gattis WA,Hasselblad V,Whellan DJ,O'Connor CM.Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team. Results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) study.Arch Intern Med.1999;159(16):19391945.
  19. Ducharme A,Doyon O,White M,Rouleau JL,Brophy JM.Impact of care at a multidisciplinary congestive heart failure clinic: a randomized trial.CMAJ.2005;173(1):4045.
  20. Knox D,Mischke L.Implementing a congestive heart failure disease management program to decrease length of stay and cost.J Cardiovasc Nurs.1999;14(1):5574.
  21. Pistoria MJ,Amin AN,Dressler DD,McKean SCW,Budnitz TL.The core competencies in hospital medicine: a framework for curriculum development by the Society of Hospital Medicine.J Hosp Med.2006;1(suppl 1):295.
  22. Cobaugh DJ,Amin A,Brookwalter T, et al.ASHP‐SHM joint statement on hospitalist‐pharmacist collaboration.J Hosp Med.2008;3(suppl 3). doi://10.1002/jhm.315. Available at: http://www3.interscience.wiley.com.
  23. Kay D,Blue A,Pye P,Lacy A,Gray C,Moore S.Heart failure: improving the continuum of care.Care Manag J.2006;7(2):5863.
  24. Berkowitz R,Blank LJ,Powell SK.Strategies to reduce hospitalization in the management of heart failure.Lippincotts Case Manag.2005;10(6 suppl):S1S15.
  25. Amin A.Improving the management of patients after myocardial infarction, from admission to discharge.Clin Ther.2006;28(10):15091539.
  26. Amin AN.The role of hospitalists in the management of acute decompensated heart failure.Am Heart Hosp J.2005;3(2):111117.
  27. Lindenauer PK,Chehabeddine R,Pekow P,Fitzgerald J,Benjamin EM.Quality of care for patients hospitalized with heart failure: assessing the impact of hospitalists.Arch Intern Med.2002;162(11):12511256.
  28. Amin AN,Owen MM.Productive interdisciplinary team relationships: the hospitalist and the case manager.Lippincotts Case Manag.2006;11(3):160164.
  29. Collier VU.Use of pay for performance in a community hospital private hospitalist group: a preliminary report.Trans Am Clin Climatol Assoc.2007;118:263272.
  30. Roytman MM,Thomas SM,Jiang CS.Comparison of practice patterns of hospitalists and community physicians in the care of patients with congestive heart failure.J Hosp Med.2008;3(1):3541.
  31. Ozdas A,Speroff T,Waitman LR,Ozbolt J,Butler J,Miller RA.Integrating “best of care” protocols into clinicians' workflow via care provider order entry: impact on quality‐of‐care indicators for acute myocardial infarction.J Am Med Inform Assoc.2006;13(2):188196.
  32. Butler J,Speroff T,Arbogast PG, et al.Improved compliance with quality measures at hospital discharge with a computerized physician order entry system.Am Heart J.2006;151(3):643653.
  33. Kripalani S,Jackson AT,Schnipper JL,Coleman EA.Promoting effective transitions of care at hospital discharge: a review of key issues for hospitalists.J Hosp Med.2007;2(5):314323.
  34. Cornish PL,Knowles SR,Marchesano R, et al.Unintended medication discrepancies at the time of hospital admission.Arch Intern Med.2005;165(4):424429.
  35. Gleason KM,Groszek JM,Sullivan C,Rooney D,Barnard C,Noskin GA.Reconciliation of discrepancies in medication histories and admission orders of newly hospitalized patients.Am J Health Syst Pharm.2004;61(16):16891695.
  36. Schnipper JL,Kirwin JL,Cotugno MC, et al.Role of pharmacist counseling in preventing adverse drug events after hospitalization.Arch Intern Med.2006;166(5):565571.
  37. Joint Commission on Accreditation of Healthcare Organizations. Using medication reconciliation to prevent errors. Sentinel Event Alert #35. Available at: http://www.jointcommission.org/sentinelevents/sentineleventalert/sea_35.htm. Accessed September2008.
  38. Ghali JK,Kadakia S,Cooper R,Ferlinz J.Precipitating factors leading to decompensation of heart failure: traits among urban blacks.Arch Intern Med.1988;148(9):20132016.
  39. Vinson JM,Rich MW,Sperry JC,Shah AS,McNamara T.Early readmission of elderly patients with congestive heart failure.J Am Geriatr Soc.1990;38(12):12901295.
  40. Peacock WF,Albert NM.Observation unit management of heart failure.Emerg Med Clin North Am.2001;19(1):209232.
  41. Adams KF,Fonarow GC,Emerman CL, et al.Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Failure National Registry (ADHERE).Am Heart J.2005;149(2):209216.
  42. Gheorghiade M,Abraham WT,Albert NM, et al.Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure.JAMA.2006;296(18):22172226.
  43. Katz PS. Eliminating drug errors: hospitals adopt medication reconciliation to improve patient safety. Available at: http://www.acponline.org/clinical_information/journals_publications/acp_hospitalist/may07/drug_errors.htm. Accessed September2008.
  44. Butler J,Arbogast PG,BeLue R, et al.Outpatient adherence to beta‐blocker therapy after acute myocardial infarction.JAm Coll Cardiol.2002;40(9):15891595.
  45. Gattis WA,O'Connor CM.Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure.Am J Cardiol.2004;93(9A):74B76B.
  46. Fonarow GC,Gawlinski A,Moughrabi S,Tillisch JH.Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP).Am J Cardiol.2001;87(7):819822.
  47. Fonarow GC,Abraham WT,Albert NM, et al.Association between performance measures and clinical outcomes for patients hospitalized with heart failure.JAMA.2007;297(1):6170.
  48. deGoma EM,Vagelos RH,Fowler MB,Ashley EA.Emerging therapies for the management of decompensated heart failure: from bench to bedside.J Am Coll Cardiol.2006;48(12):23972409.
  49. Tang WHW,Hobbs RE.Novel strategies for the management of acute decompensated heart failure.Curr Cardiol Rev.2005;1(1):15.
  50. Konstam MA,Gheorghiade M,Burnett JC, et al.Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial.JAMA.2007;297(12):13191331.
  51. Schrier RW,Gross P,Gheorghiade M, et al.Tolvaptan, a selective oral vasopressin V2‐receptor antagonist, for hyponatremia.N Engl J Med.2006;355(20):20992112.
  52. Schweiger TA,Zdanowicz MM.Vasopressin‐receptor antagonists in heart failure.Am J Health Syst Pharm.2008;65(9):807817.
  53. Givertz MM,Massie BM,Fields TK,Pearson LL,Dittrich HC.The effects of KW‐3902, an adenosine A1‐receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance.J Am Coll Cardiol.2007;50(16):15511560.
  54. Greenberg B,Thomas I,Banish D, et al.Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure: results of a placebo‐controlled, dose‐escalation study.J Am Coll Cardiol.2007;50(7):600606.
  55. McMurray JJ,Teerlink JR,Cotter G, et al.Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials.JAMA.2007;298(17):20092019.
  56. CK‐1827452. Cytokinetics Web site. Available at: http://www.cytokinetics.com/ck_1827452. Accessed September2008.
  57. Blair JE,Macarie C,Ruzyllo W, et al.Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON‐HF) trial.Am J Ther.2008;15(3):231240.
  58. Cleland JG,Coletta AP,Yassin A, et al.Clinical trials update from the American College of Cardiology 2008: CARISMA, TRENDS, meta‐analysis of Cox‐2 studies, HAT, ON‐TARGET, HYVET, ACCOMPLISH, MOMENTUM, PROTECT, HORIZON‐HF and REVERSE.Eur J Heart Fail.2008;10(6):614620.
  59. Mitrovic V,Seferovic PM,Simeunovic D, et al.Haemodynamic and clinical effects of ularitide in decompensated heart failure.Eur Heart J.2006;27(23):28232832.
  60. Brieke A,Cleveland J,Lindenfeld J.Mechanical support in acute and chronic heart failure.Curr Cardiol Rep.2008;10(3):168175.
  61. Kale P,Fang JC.Devices in acute heart failure.Crit Care Med.2008;36(1 suppl):S121S128.
  62. Allen LA,Felker GM.Advances in the surgical treatment of heart failure.Curr Opin Cardiol.2008;23(3):249253.
References
  1. Graves EJ,Kozak LJ.National Hospital Discharge Survey: annual summary, 1996.Vital Health Stat.1999;13(140):146.
  2. Haldeman GA,Croft JB,Giles WH,Rashidee A.Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995.Am Heart J.1999;137(2):352360.
  3. Kozak LJ,Owings MF,Hall MJ.National Hospital Discharge Survey: 2001 annual summary with detailed diagnosis and procedure data.Vital Health Stat.2004;13(156):1198.
  4. Kozak LJ,Owings MF,Hall MJ.National Hospital Discharge Survey: 2002 annual summary with detailed diagnosis and procedure data.Vital Health Stat.2005;13(158):1199.
  5. DeFrances CJ,Cullen KA,Kozak LJ.National Hospital Discharge Survey: 2005 annual summary with detailed diagnosis and procedure data.Vital Health Stat.2007;13(165):1209.
  6. Kozak LJ,DeFrances CJ,Hall MJ.National Hospital Discharge Survey: 2004 annual summary with detailed diagnosis and procedure data.Vital Health Stat.2006;13(162):1209.
  7. Kozak LJ,Lees KA,DeFrances CJ.National Hospital Discharge Survey: 2003 annual summary with detailed diagnosis and procedure data.Vital Health Stat.2006;13(160):1206.
  8. Division for Heart Disease and Stroke Prevention. Heart failure fact sheet. Available at: http://www.cdc.gov/dhdsp/library/fs_heart_failure_longdesc.htm. Accessed September2008.
  9. US Census Bureau. Projected population of the United States, by age and sex: 2000 to 2050. Available at: http://www.census.gov/population/www/projections/usinterimproj/natprojtab02a.pdf. Accessed September2008.
  10. Foot DK,Lewis RP,Pearson TA,Beller GA.Demographics and cardiology, 1950–2050.J Am Coll Cardiol.2000;35(4):10671081.
  11. 35th Bethesda Conference.Cardiology's workforce crisis: a pragmatic approach. Bethesda, Maryland, 17–18 October 2003.J Am Coll Cardiol.2004;44(2):216275.
  12. Baudendistel TE,Wachter RM.The evolution of the hospitalist movement in the USA.Clin Med.2002;2(4):327330.
  13. Wachter RM.Hospitalists in the United States—mission accomplished or work in progress?N Engl J Med.2004;350(19):19351936.
  14. Amin AN.Identifying strategies to improve outcomes and reduce costs—a role for the hospitalist.Curr Opin Pulm Med.2004;10(suppl):S19S22.
  15. Bonow RO,Smith SC.Cardiovascular manpower: the looming crisis.Circulation.2004;109(7):817820.
  16. Kereiakes DJ,Willerson JT.The United States cardiovascular care deficit.Circulation.2004;109(7):821823.
  17. Heart Failure Society of America.Evaluation and management of patients with acute decompensated heart failure.J Card Fail.2006;12(1):e86e103.
  18. Gattis WA,Hasselblad V,Whellan DJ,O'Connor CM.Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team. Results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) study.Arch Intern Med.1999;159(16):19391945.
  19. Ducharme A,Doyon O,White M,Rouleau JL,Brophy JM.Impact of care at a multidisciplinary congestive heart failure clinic: a randomized trial.CMAJ.2005;173(1):4045.
  20. Knox D,Mischke L.Implementing a congestive heart failure disease management program to decrease length of stay and cost.J Cardiovasc Nurs.1999;14(1):5574.
  21. Pistoria MJ,Amin AN,Dressler DD,McKean SCW,Budnitz TL.The core competencies in hospital medicine: a framework for curriculum development by the Society of Hospital Medicine.J Hosp Med.2006;1(suppl 1):295.
  22. Cobaugh DJ,Amin A,Brookwalter T, et al.ASHP‐SHM joint statement on hospitalist‐pharmacist collaboration.J Hosp Med.2008;3(suppl 3). doi://10.1002/jhm.315. Available at: http://www3.interscience.wiley.com.
  23. Kay D,Blue A,Pye P,Lacy A,Gray C,Moore S.Heart failure: improving the continuum of care.Care Manag J.2006;7(2):5863.
  24. Berkowitz R,Blank LJ,Powell SK.Strategies to reduce hospitalization in the management of heart failure.Lippincotts Case Manag.2005;10(6 suppl):S1S15.
  25. Amin A.Improving the management of patients after myocardial infarction, from admission to discharge.Clin Ther.2006;28(10):15091539.
  26. Amin AN.The role of hospitalists in the management of acute decompensated heart failure.Am Heart Hosp J.2005;3(2):111117.
  27. Lindenauer PK,Chehabeddine R,Pekow P,Fitzgerald J,Benjamin EM.Quality of care for patients hospitalized with heart failure: assessing the impact of hospitalists.Arch Intern Med.2002;162(11):12511256.
  28. Amin AN,Owen MM.Productive interdisciplinary team relationships: the hospitalist and the case manager.Lippincotts Case Manag.2006;11(3):160164.
  29. Collier VU.Use of pay for performance in a community hospital private hospitalist group: a preliminary report.Trans Am Clin Climatol Assoc.2007;118:263272.
  30. Roytman MM,Thomas SM,Jiang CS.Comparison of practice patterns of hospitalists and community physicians in the care of patients with congestive heart failure.J Hosp Med.2008;3(1):3541.
  31. Ozdas A,Speroff T,Waitman LR,Ozbolt J,Butler J,Miller RA.Integrating “best of care” protocols into clinicians' workflow via care provider order entry: impact on quality‐of‐care indicators for acute myocardial infarction.J Am Med Inform Assoc.2006;13(2):188196.
  32. Butler J,Speroff T,Arbogast PG, et al.Improved compliance with quality measures at hospital discharge with a computerized physician order entry system.Am Heart J.2006;151(3):643653.
  33. Kripalani S,Jackson AT,Schnipper JL,Coleman EA.Promoting effective transitions of care at hospital discharge: a review of key issues for hospitalists.J Hosp Med.2007;2(5):314323.
  34. Cornish PL,Knowles SR,Marchesano R, et al.Unintended medication discrepancies at the time of hospital admission.Arch Intern Med.2005;165(4):424429.
  35. Gleason KM,Groszek JM,Sullivan C,Rooney D,Barnard C,Noskin GA.Reconciliation of discrepancies in medication histories and admission orders of newly hospitalized patients.Am J Health Syst Pharm.2004;61(16):16891695.
  36. Schnipper JL,Kirwin JL,Cotugno MC, et al.Role of pharmacist counseling in preventing adverse drug events after hospitalization.Arch Intern Med.2006;166(5):565571.
  37. Joint Commission on Accreditation of Healthcare Organizations. Using medication reconciliation to prevent errors. Sentinel Event Alert #35. Available at: http://www.jointcommission.org/sentinelevents/sentineleventalert/sea_35.htm. Accessed September2008.
  38. Ghali JK,Kadakia S,Cooper R,Ferlinz J.Precipitating factors leading to decompensation of heart failure: traits among urban blacks.Arch Intern Med.1988;148(9):20132016.
  39. Vinson JM,Rich MW,Sperry JC,Shah AS,McNamara T.Early readmission of elderly patients with congestive heart failure.J Am Geriatr Soc.1990;38(12):12901295.
  40. Peacock WF,Albert NM.Observation unit management of heart failure.Emerg Med Clin North Am.2001;19(1):209232.
  41. Adams KF,Fonarow GC,Emerman CL, et al.Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Failure National Registry (ADHERE).Am Heart J.2005;149(2):209216.
  42. Gheorghiade M,Abraham WT,Albert NM, et al.Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure.JAMA.2006;296(18):22172226.
  43. Katz PS. Eliminating drug errors: hospitals adopt medication reconciliation to improve patient safety. Available at: http://www.acponline.org/clinical_information/journals_publications/acp_hospitalist/may07/drug_errors.htm. Accessed September2008.
  44. Butler J,Arbogast PG,BeLue R, et al.Outpatient adherence to beta‐blocker therapy after acute myocardial infarction.JAm Coll Cardiol.2002;40(9):15891595.
  45. Gattis WA,O'Connor CM.Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure.Am J Cardiol.2004;93(9A):74B76B.
  46. Fonarow GC,Gawlinski A,Moughrabi S,Tillisch JH.Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP).Am J Cardiol.2001;87(7):819822.
  47. Fonarow GC,Abraham WT,Albert NM, et al.Association between performance measures and clinical outcomes for patients hospitalized with heart failure.JAMA.2007;297(1):6170.
  48. deGoma EM,Vagelos RH,Fowler MB,Ashley EA.Emerging therapies for the management of decompensated heart failure: from bench to bedside.J Am Coll Cardiol.2006;48(12):23972409.
  49. Tang WHW,Hobbs RE.Novel strategies for the management of acute decompensated heart failure.Curr Cardiol Rev.2005;1(1):15.
  50. Konstam MA,Gheorghiade M,Burnett JC, et al.Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial.JAMA.2007;297(12):13191331.
  51. Schrier RW,Gross P,Gheorghiade M, et al.Tolvaptan, a selective oral vasopressin V2‐receptor antagonist, for hyponatremia.N Engl J Med.2006;355(20):20992112.
  52. Schweiger TA,Zdanowicz MM.Vasopressin‐receptor antagonists in heart failure.Am J Health Syst Pharm.2008;65(9):807817.
  53. Givertz MM,Massie BM,Fields TK,Pearson LL,Dittrich HC.The effects of KW‐3902, an adenosine A1‐receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance.J Am Coll Cardiol.2007;50(16):15511560.
  54. Greenberg B,Thomas I,Banish D, et al.Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure: results of a placebo‐controlled, dose‐escalation study.J Am Coll Cardiol.2007;50(7):600606.
  55. McMurray JJ,Teerlink JR,Cotter G, et al.Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials.JAMA.2007;298(17):20092019.
  56. CK‐1827452. Cytokinetics Web site. Available at: http://www.cytokinetics.com/ck_1827452. Accessed September2008.
  57. Blair JE,Macarie C,Ruzyllo W, et al.Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON‐HF) trial.Am J Ther.2008;15(3):231240.
  58. Cleland JG,Coletta AP,Yassin A, et al.Clinical trials update from the American College of Cardiology 2008: CARISMA, TRENDS, meta‐analysis of Cox‐2 studies, HAT, ON‐TARGET, HYVET, ACCOMPLISH, MOMENTUM, PROTECT, HORIZON‐HF and REVERSE.Eur J Heart Fail.2008;10(6):614620.
  59. Mitrovic V,Seferovic PM,Simeunovic D, et al.Haemodynamic and clinical effects of ularitide in decompensated heart failure.Eur Heart J.2006;27(23):28232832.
  60. Brieke A,Cleveland J,Lindenfeld J.Mechanical support in acute and chronic heart failure.Curr Cardiol Rep.2008;10(3):168175.
  61. Kale P,Fang JC.Devices in acute heart failure.Crit Care Med.2008;36(1 suppl):S121S128.
  62. Allen LA,Felker GM.Advances in the surgical treatment of heart failure.Curr Opin Cardiol.2008;23(3):249253.
Issue
Journal of Hospital Medicine - 3(6)
Issue
Journal of Hospital Medicine - 3(6)
Page Number
S1-S6
Page Number
S1-S6
Article Type
Display Headline
Who is managing acute decompensated heart failure? The need for a multidisciplinary approach
Display Headline
Who is managing acute decompensated heart failure? The need for a multidisciplinary approach
Sections
Article Source
Copyright © 2008 Society of Hospital Medicine
Disallow All Ads
Correspondence Location
Department of Medicine, Executive Director, Hospitalists Program, University of California, Irvine, 101 City Drive South, Building 26, Room 1005 ZC‐4076H Orange, California 92868
Content Gating
Gated (full article locked unless allowed per User)
Gating Strategy
First Peek Free
Article PDF Media

Bridging the Evidence/Practice Gap

Article Type
Changed
Mon, 01/02/2017 - 19:34
Display Headline
Bridging the gap between evidence and practice in acute decompensated heart failure management

Optimizing quality of care in patients with acute decompensated heart failure (ADHF) is crucial, given both the frequency and cost of hospitalization for this disorder. Several quality improvement strategies have been identified, including provider education; provider reminder systems and decision support; audit and feedback; patient education; organizational change; and financial incentives, regulation, and policy.1

To assist hospitalists in implementing these strategies, this article briefly reviews evidence‐based guidelines for the treatment of ADHF, presents a practical algorithm for patient assessment and treatment derived from these guidelines and personal experience, and discusses systems to enhance the ultimate transition of patient care from the inpatient to outpatient setting.

EVIDENCE‐BASED GUIDELINES

Evidence‐based guidelines are created in an attempt to promote optimal management of a condition or disorder based on expert analysis of all available relevant scientific data. Current guidelines for the assessment and treatment of ADHF have been developed by a national group purchasing organization,2 the European Society of Cardiology,3 the Heart Failure Society of America,4 and the American College of Emergency Physicians.5 Relevant components of these guidelines will be discussed in the patient assessment and treatment section below.

Publication of guidelines, in and of itself, however, is inadequate to ensure their acceptance and use.1 Data from the American Heart Association (AHA)/American Stroke Association (ASA) Get With The GuidelinesHeart Failure (GWTG‐HF) program continue to demonstrate a substantial gap between guideline recommendations and current care of patients with ADHF.6, 7 One way to promote systemwide adherence with published guidelines is to directly involve healthcare professionals in the implementation process. Consequently, development of local, hospital‐based procedures derived from national or international guidelines may be more effective than the simple dissemination of the guidelines themselves.1 Hospitalists have a unique insight into both patient care and the hospital setting and are frequently involved in evaluating hospital policies and procedures and implementing clinical pathways and guidelines.8 In addition, hospitalist care has been associated with greater compliance with disease‐specific guidelines compared to nonhospitalist care.9 As a result, hospitalists are uniquely suited to play a key role in the development of these procedures.

PATIENT ASSESSMENT AND TREATMENT

The differential diagnosis of any individual presenting to the emergency department (ED) with signs of systemic or pulmonary edema should include ADHF (Figure 1).25 These individuals require a rapid initial assessment to (1) establish the diagnosis, (2) determine the best location for subsequent treatment, and (3) institute the most appropriate initial therapy.

Figure 1
Algorithm for treatment of acute decompensated heart failure (ADHF) based on currently published practice guidelines2–5 and personal experience. Abbreviations: CILT, continuous infusion loop diuretic therapy; ED, emergency department; ET, endotracheal; ICU, intensive care unit; IV, intravenous; NES, nesiritide; NTG, nitroglycerin; NTP, nitroprusside; SBP, systolic blood pressure; SOB, shortness of breath.

Treatment Location

Effective and efficient management of ADHF requires determining proper treatment location. Inpatient management of ADHF is expensive, accounting for approximately 60% of the $31.7 billion spent annually on heart failure care in the United States.10 Clearly, patients with impending respiratory failure requiring ventilation assistance and patients with cardiogenic shock requiring inotropic agents and invasive monitoring are best cared for in an intensive care unit (ICU) setting. However, these patients constitute the minority of patients with ADHF. For example, systolic blood pressure (SBP) <90 mm Hg was present in only 2.3% of patients in the Acute Decompensated Heart Failure National Registry (ADHERE), a registry designed to study characteristics, management, and outcomes in a broad sample of patients hospitalized with ADHF.11

Most patients with ADHF present with congestion, not respiratory failure or cardiogenic shock,11, 12 and a select subgroup of these patients will respond to treatment within 1224 hours.13 Although this may be an inordinate amount of time to keep patients in an ED, it is not long enough to generally require full hospital admission. Instead, these patients can be effectively managed in an observation unit (OU).14 The goal of these units is to provide the required level of care over a 12‐ to 24‐hour period while simultaneously reducing costs by eliminating the need for hospital admission. Selecting patients who will respond to therapy during this time frame is a critical component in instituting effective OU management of ADHF. Key entry and exclusion criteria are listed in Table 1.14 In patients who meet these criteria, management in an OU has been shown to yield outcomes comparable to inpatient care, but at a lower cost.1416

Entry and Exclusion Criteria for Observation Unit (OU) Heart Failure Protocol*
Entry criteria
  • Abbreviations: AMI, acute myocardial infarction; CK‐MB, creatinine kinase MB isoenzyme; ECG, electrocardiogram.

  • Adapted with permission from Peacock et al.14

History (at least one of the following)
Dyspnea on exertion
Paroxysmal nocturnal dyspnea
Shortness of breath
Edema of legs or abdomen
Weight gain
Physical examination (at least one of the following)
Jugular venous distention or elevation in pulsation
Positive abdominal jugular reflux
S3/S4 gallop
Inspiratory rales
Peripheral edema
Chest x‐ray (at least one of the following)
Cardiomegaly
Pulmonary vascular congestion
Kerley B lines
Pulmonary edema
Pleural effusion
Exclusion criteria
Unstable vital signs (BP >220/120 mm Hg, respiratory rate >25 breath/min, heart rate >130 beats/min)
Temperature >38.5C
Unstable airway or need for >4 L/min supplemental O2 to keep O2 saturation >90%
Peak flow <50% of predicted with wheezing
Clinically significant arrhythmia or sustained ventricular tachycardia
Any ECG with diagnostic criteria for AMI or ischemia
Chest x‐ray with pulmonary infiltrates
Any CK‐MB >8.8 ng/mL
Any troponin T >0.1 g/L (>0.5 g/L if creatinine >2.0 mg/dL)
Requirement for continuous vasoactive medication to stabilize hemodynamics
Complex decompensation: concomitant end‐organ hypoperfusion, volume overload, and systemic vasoconstriction
Requirement for care guided by pulmonary artery catheter
Severe electrolyte imbalance
Chronic renal failure requiring dialysis
Acute mental status abnormality

Early Initiation of Therapy

Early institution of effective therapy has been shown to improve outcomes. Consequently, selection of initial therapy should occur concurrently with determination of proper treatment location. In the Prospective Randomized Outcomes Study of Acutely Decompensated Congestive Heart Failure Treated Initially as Outpatients with Nesiritide (PROACTION) trial, initiation of nesiritide in the ED/OU was associated with an 11% reduction in hospital admissions at the index visit (P = .436), a 57% reduction in hospitalizations within 30 days after discharge from the index hospitalization (P = .058), and a 62% reduction in median duration of rehospitalization (P = .032).17 The incidence of symptomatic hypotension was low and did not differ between the groups.17 Likewise, in separate analyses of data from ADHERE, ED initiation of intravenous (IV) vasoactive therapy, including nitroglycerin, nesiritide, milrinone, or dobutamine significantly reduced the risk of requiring transfer to an ICU and reduced ICU length of stay and total hospital length of stay compared with inpatient initiation of these same therapies.18, 19

Treatment Algorithm

Treatment of ADHF should proceed along a logical care pathway governed by both clinical status and response to prior therapies (Figure 1). One must first consider whether there is evidence of respiratory failure or impending respiratory failure.20 If so, patients should receive immediate ventilatory support via continuous positive airway pressure (CPAP), bilevel positive airway pressure (BiPAP), or endotracheal intubation, depending on the degree of respiratory impairment.3, 5 In prospective controlled evaluations, patients with acute respiratory failure secondary to pulmonary edema who were randomized to treatment with CPAP demonstrated significant improvement in cardiopulmonary indices21, 22 and significant reductions in need for endotracheal intubation21 and short‐term mortality22 when compared with similar patients who received standard therapy without CPAP.

Once potential respiratory issues have been addressed, the next items for consideration are circulation and perfusion. Patients with low cardiac output and hypotension (cardiogenic shock) are at risk for developing critical end‐organ dysfunction. In these patients, insertion of a pulmonary artery catheter may aid in assessment of hemodynamic status and response to therapy.4 Patients with low cardiac output and low filling pressures should receive IV fluid loading.3 In contrast, for patients with low cardiac output and high filling pressures, inotropic agents should be considered.3, 4 Also, these patients may require IV vasodilators and/or IV diuretics to treat pulmonary edema once blood pressure (BP) and cardiac output have been stabilized.2, 3, 20

For patients with ADHF who present with symptoms of congestion, but not respiratory failure or cardiogenic shock, the initial therapeutic decision is governed by their BP. Approximately 50% of patients with ADHF will have an SBP > 140 mm Hg.12, 23 These patients tend to be older and to have diastolic rather than systolic dysfunction.12, 20, 23 Symptoms typically have been present for only a short period of time (2448 hours) and are more often due to maldistribution of fluid producing pulmonary edema than total body fluid overload. Consequently, initial treatment should focus on aggressive BP control to relieve this edema. Sublingual or topical nitrates are recommended as a first step, and initial diuretic use should be minimal to avoid intravascular volume depletion leading to renal dysfunction.20 In contrast, patients presenting with SBP between 90 mm Hg and 140 mm Hg are more likely to have some degree of systolic dysfunction, leading to a gradual worsening of their heart failure symptoms and total body fluid overload over a period of weeks.20 These patients require aggressive diuresis. Although the efficacy of IV loop diuretics has not been established in randomized, controlled clinical trials, observational experience demonstrates that they can effectively reduce filling pressures, relieve volume overload, and decrease symptoms of congestion.4 They are currently the mainstay of therapy for ADHF secondary to fluid retention, and their use is recommended in all 4 guidelines.25

This initial therapeutic choice, however, is only the starting point, and it is important not to stop at this stage. No single definitive therapy for ADHF exists, and not all patients will respond to initial treatment. Optimal management requires early recognition and addressing of both an inadequate response to therapy and any adverse affects induced by this therapy. Frequent reevaluations are an essential component of treating patients with ADHF. For example, the timeline in one of the guidelines calls for assessing the patient's response at 2 and 4 hours after initiation of IV therapy and adjusting treatment as indicated based on these assessments (Figure 2).2

Figure 2
Timeline for initial assessment and management of acute decompensated heart failure (ADHF). Abbreviations: ED, emergency department; OU, observation unit. Adapted with permission from DiDomenico et al.2

If the patient has an adequate response to initial therapy, defined as SBP <140 mm Hg, stable renal function, and urine output >500 mL over 2 hours (>250 mL if serum creatinine >2.5 mg/dL), this therapy can continue unchanged, and focus shifts to long‐term management issues.2, 4, 14 However, if the response is inadequate, it is important to identify and treat the cause of this inadequate response.

Inadequate urine output secondary to diuretic resistance is common in patients with ADHF, especially in those on long‐term diuretic therapy.3 Despite a 90% prevalence of IV diuretic use in ADHERE, 70% of patients either gained weight or lost fewer than 5 pounds during hospitalization, and 42% were discharged with unresolved symptoms.24 Clearly, diuretic therapy did not produce the desired effect in many of these patients. This inadequate response to loop diuretics is a direct result of their pharmacologic properties, especially as they relate to patients with heart failure. The physiologic effects of loop diuretics are directly related to their concentration in the lumen of the nephron. This concentration depends on both the patient's renal function and the dose and half‐life of the administered diuretic.25 Comorbid renal dysfunction is common in patients with ADHF.26 In addition, even in the absence of this dysfunction, the short half‐life of loop diuretics limits the amount of time that their luminal concentration is in the effective range, and rebound sodium retention can occur whenever the diuretic concentration is below this range.25 Furthermore, the dose‐response curve of loop diuretics is S‐shaped. As a result, a threshold concentration exists beyond which no further augmentation in urine output occurs; ie, there is a maximum physiologic response that is reduced in patients with heart failure.25 Guideline recommendations for patients with diuretic resistance attempt to address these physiologic and pharmacologic limitations. These recommendations include fluid restriction to decrease the overall volume of diuresis necessary, increasing diuretic dose or instituting continuous infusion loop diuretic therapy to increase the amount of time during which the luminal concentration is within the effective range, sequential diuretic blockade to take advantage of the different mechanisms of action of the various diuretic classes to affect different components of the nephron, bypassing the kidney through the use of ultrafiltration, and when these are inadequate, adding a vasodilator in an attempt to augment cardiac output and renal perfusion.3, 4, 24, 25, 2729

Addition of an IV vasodilator is the primary means of addressing an inadequate response typified by hypertension, worsening renal function, and/or persistent symptoms, rather than diuretic resistance. Approximately 25% of patients with ADHF receive IV vasoactive therapy, including nitroglycerin, nesiritide, milrinone, or dobutamine, although predominantly vasodilators, at some point during their hospitalization.11, 12 These agents improve hemodynamics and reduce symptoms of ADHF.5, 3032 Their use, in combination with low‐dose diuretics, has been shown to be more efficacious than high‐dose diuretics alone.3, 27 Adding a vasodilator may reduce adverse, diuretic‐induced, neurohormonal activation. In an animal model, combining nesiritide with IV furosemide significantly attenuated the rise in plasma aldosterone produced by IV furosemide alone,33 and this finding has been subsequently confirmed in patients with heart failure.34 Finally, vasodilators have proven to be a safer alternative than inotropes in patients with ADHF. In an analysis of data from ADHERE, covariate‐adjusted and propensity‐adjusted mortality risk was >50% lower for patients receiving nitroglycerin or nesiritide compared with those receiving dobutamine,11 and in an analysis of data from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) trial, which evaluated patients with advanced heart failure, the risk‐adjusted mortality hazard ratio (HR) was significantly increased for inotropes (HR: 2.14; 95% confidence interval [CI]: 1.104.15) but not for vasodilators in the absence of inotropes (HR: 1.39; 95% CI: 0.643.00).35

Performance Measures

In addition to instituting effective therapy for the acute decompensation, it is important to implement measures that may improve long‐term outcomes. The Joint Commission on Accreditation of Healthcare Organizations and the AHA/ASA have identified a series of 5 core performance measures that should be completed during hospitalization for AHDF: discharge instructions relevant to patient's education, documentation of left ventricular systolic function evaluation, prescription of angiotensin‐converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) at discharge in patients with left ventricular systolic dysfunction, adult smoking cessation advice/counseling, and prescription of ‐blocker at discharge (Table 2).36, 37 In an analysis of data from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE‐HF) registry, prescription of a ‐blocker at discharge significantly reduced the risk‐adjusted odds ratio (OR) for mortality (OR: 0.48; 95% CI: 0.300.79), and prescription of an ACE inhibitor or ARB at discharge significantly reduced the risk‐adjusted OR for rehospitalization or death (OR: 0.51; 95% CI: 0.340.78) at 6090 days.38 Although no correlation was detected between outcomes and the other 3 core performance measures in this evaluation, the 60‐day to 90‐day time frame may have been too short to identify the full effects of smoking cessation counseling and left ventricular function assessment. Failure to detect a beneficial effect of discharge instructions is disappointing, especially given the proven benefit of disease management programs (see below) and may reflect a limitation of this measure, as currently implemented, to determine the thoroughness and patient understanding of the instructions provided.38, 39

Heart Failure Core Performance Measures*
Measure Description Source
  • Abbreviations: ACE, angiotensin‐converting enzyme; ARB, angiotensin receptor blocker.

  • Derived from the JCAHO guidelines and the AHA/ASA's Get With The GuidelinesHeart Failure (GWTG‐HF) program.36, 37

HF‐1 Discharge instructions relevant to patient education JCAHO; AHA/ASA
HF‐2 Documentation of left ventricular systolic function evaluation JCAHO; AHA/ASA
HF‐3 Prescription of ACE inhibitor or ARB at discharge in patients with left ventricular systolic dysfunction JCAHO; AHA/ASA
HF‐4 Adult smoking cessation advice/counseling JCAHO; AHA/ASA
HF‐5 Prescription of ‐blocker at discharge AHA/ASA

TRANSITION OF CARE

Lastly, optimal management of ADHF requires successful transition of care from an inpatient to an outpatient setting. Recidivism is both common and costly. Approximately 2% of patients with ADHF are readmitted within 2 days, 20% within 1 month, and 50% within 6 months of hospital discharge.40 Frequently, these readmissions are caused by nonadherence to the therapeutic regimen following discharge.41 In an evaluation of patients hospitalized for ADHF at a large urban medical center, noncompliance with prescribed diet and/or drugs was the most common precipitating factor for admission (64% of patients), followed by uncontrolled hypertension (44%), cardiac arrhythmia (29%), environmental factors (19%), and inadequate therapy (17%).42 Similarly, in a prospective evaluation of elderly patients hospitalized for ADHF, 53% of readmissions occurring within 90 days of discharge were deemed to be preventable, with the most common contributing factors being noncompliance with medications and/or diet (33%), inadequate discharge planning (15%), inadequate follow‐up (20%), insufficient support system (21%), and failure to seek medical attention promptly when symptoms recurred (20%).43 Consequently, patient education and arrangement for appropriate follow‐up are crucial components of successfully transitioning care to an outpatient setting.

Effective patient education is time‐consuming. Patients must be taught when, how, and why to take their medication. They need to understand their dietary guidelines and the reasons for these guidelines. They need to know how to use daily weigh‐ins as a means of monitoring their fluid status and what to do in response to a change in weight or symptoms. Finally, they need to be cognizant of what constitutes appropriate exercise and the need for this exercise.4447 To enhance understanding and retention, this information should be presented to the patient over the course of the hospitalization. Comprehension should be tested continually and education repeated until appropriate understanding is ensured. Patient education provided in a rushed or perfunctory manner at the moment of discharge is unlikely to be retained or effective.38, 39

Ideally, the patient should be referred to a comprehensive heart failure disease management program for postdischarge care. Numerous evaluations have established the effectiveness of these programs in enhancing use of appropriate medications, improving functional status, reducing readmissions and mortality, and decreasing costs.4454 For example, in separate evaluations, the prevalences of appropriate vasodilator use (93% vs. 61%; P < .001),51 ‐blocker use (71% vs. 40%; P < .001),50 and ACE inhibitor use (84% vs. 59%; P < .001)52 were significantly greater for disease management program participants compared with nonparticipants. In addition, participation in a disease management program was associated with a 52% reduction in the risk of hospitalization for cardiovascular causes (P < .001) and a 72% reduction in ED visits (P < .01) in 1 evaluation,45 a 36% reduction (95% CI: 16.7%50.9%) in the risk of heart failure admission or death in another,53 and a 67% reduction (95% CI: 41%82%) in the adjusted risk of death in yet another evaluation.52 Unfortunately, recent data indicate that these programs must be ongoing to sustain these benefits. In a prospective evaluation, patients with heart failure were randomized to either standard care or a multidisciplinary disease management program for 6 months followed by standard care.55, 56 Significantly fewer patients in the disease management group required readmission to the hospital (HR: 0.55; 95% CI: 0.350.88) during the 6‐month period in which they actively participated in the disease management program.56 However, by the end of follow‐up (mean 2.8 years), there was no significant difference between treatment groups in all‐cause mortality (HR: 1.09; 95% CI: 0.691.72) or the composite endpoint of death, ED visit, or hospitalization (HR: 1.01; 95% CI: 0.751.37).55

CONCLUSION

A gap between evidence‐based guidelines and current management of patients with ADHF exists. Multiple strategies to bridge this gap in patient management can be employed. Patients with ADHF require rapid assessment to determine appropriate treatment location and initial therapy. Clinical status should guide treatment selection. Once effective acute therapy has been established, strategies to improve long‐term outcomes should be implemented. These strategies include ensuring that care complies with established core performance measures, providing patient education in a manner suited to ensure comprehension and retention, and arranging for appropriate outpatient follow‐up, ideally in a comprehensive heart failure disease management program. Increasing the awareness of the gap between evidence‐based guidelines and current management, as well as strategies to bridge this gap, is crucial to improving the outcomes of patients with ADHF.

References
  1. Michota FA.Bridging the gap between evidence and practice in venous thromboembolism prophylaxis: the quality improvement process.J Gen Intern Med.2007;22(12):17621770.
  2. DiDomenico RJ,Park HY,Southworth MR, et al.Guidelines for acute decompensated heart failure treatment.Ann Pharmacother.2004;38(4):649660.
  3. Nieminen MS,Böhm M,Cowie MR, et al.Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology.Eur Heart J.2005;26(4):384416.
  4. Heart Failure Society of America.Executive summary: HFSA 2006 comprehensive heart failure practice guideline.J Card Fail.2006;12(1):1038.
  5. Silvers SM,Howell JM,Kosowsky JM,Rokos IC,Jagoda AS,American College of Emergency Physicians. Clinical policy: critical issues in the evaluation and management of adult patients presenting to the emergency department with acute heart failure syndromes.Ann Emerg Med.2007;49(5):627669.
  6. Fonarow GC,LaBresh KA,Yancy C, et al.Influence of the American Heart Association's Get With The Guidelines‐Heart Failure (GWTG‐HF) program on emerging performance measures for patients hospitalized with heart failure.Circulation.2006;114:II–572. Abstract 2740.
  7. Hernandez AF,Fonarow GC,Liang L, et al.Quality of care for heart failure patients with concomitant kidney disease in the American Heart Association's Get With The Guidelines‐Heart Failure (GWTG‐HF) program.Circulation.2006;114:II–859. Abstract 3993.
  8. Amin AN.The role of hospitalists in the management of acute decompensated heart failure.Am Heart Hosp J.2005;3(2):111117.
  9. Lindenauer PK,Chehabeddine R,Pekow P,Fitzgerald J,Benjamin EM.Quality of care for patients hospitalized with heart failure: assessing the impact of hospitalists.Arch Intern Med.2002;162(11):12511256.
  10. Rosamond W,Flegal K,Furie K, et al.Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.Circulation.2008;117(4):e25e146.
  11. Abraham WT,Adams KF,Fonarow GC, et al.In‐hospital mortality in patients with acute decompensated heart failure treated with intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).J Am Coll Cardiol.2005;46(1):5764.
  12. Gheorghiade M,Abraham WT,Albert NM, et al.Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure.JAMA.2006;296(18):22172226.
  13. Kosowsky JM,Gasaway MD,Hamilton CA,Storrow AB.Preliminary experience with an emergency department observation unit protocol for heart failure.Acad Emerg Med.2000;7(10):1171. Abstract 33.
  14. Peacock WF,Remer EE,Aponte J,Moffa DA,Emerman CE,Albert NM.Effective observation unit treatment of decompensated heart failure.Congest Heart Fail.2002;8(2):6873.
  15. Peacock WF,Albert NM.Patient outcome and costs following an acute heart failure (HF) management program in an emergency department (ED) observation unit (OU).J Heart Lung Transplant.1999;18(1):92. Abstract 240.
  16. Peacock WF,Aponte JH,Craig MT,Remer EE,Zacharias D,Emerman CL.Inpatient versus emergency department observation unit management of heart failure.Ann Emerg Med.1998;32(3 part 2):S46S47. Abstract 180.
  17. Peacock WF,Holland R,Gyarmathy R, et al.Observation unit treatment of heart failure with nesiritide: results from the proaction trial.J Emerg Med.2005;29(3):243252.
  18. Emerman CL,Costanzo MR,Berkowitz RL,Cheng M.Early initiation of IV vasoactive therapy improves heart failure outcomes: an analysis from the ADHERE™ registry database.Ann Emerg Med.2003;42(4 suppl):S26. Abstract 92.
  19. Peacock WF,Fonarow GC,Emerman CL, et al.Impact of early initiation of intravenous therapy for acute decompensated heart failure on outcomes in ADHERE.Cardiology.2007;107(1):4451.
  20. Collins S,Storrow AB,Kirk JD,Pang PS,Diercks DB,Gheorghiade M.Beyond pulmonary edema: diagnostic, risk stratification, and treatment challenges of acute heart failure management in the emergency department.Ann Emerg Med.2008;51(1):4557.
  21. Lin M,Yang YF,Chiang HT,Chang MS,Chiang BN,Cheitlin MD.Reappraisal of continuous positive airway pressure therapy in acute cardiogenic pulmonary edema. Short‐term results and long‐term follow‐up.Chest.1995;107(5):13791386.
  22. L'Her E,Duquesne F,Girou E, et al.Noninvasive continuous positive airway pressure in elderly cardiogenic pulmonary edema patients.Intensive Care Med.2004;30(5):882888.
  23. Yancy CW,Lopatin M,Stevenson LW,De Marco T,Fonarow GC.Clinical presentation, management, and in‐hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database.J Am Coll Cardiol.2006;47(1):7684.
  24. Costanzo MR,Saltzberg M,O'Sullivan J,Sobotka P.Early ultrafiltration in patients with decompensated heart failure and diuretic resistance.J Am Coll Cardiol.2005;46(11):20472051.
  25. Brater DC.Diuretic therapy in congestive heart failure.Congest Heart Fail.2000;6(4):197201.
  26. Heywood JT,Fonarow GC,Costanzo MR, et al.High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database.J Card Fail.2007;13(6):422430.
  27. Cotter G,Metzkor E,Kaluski E, et al.Randomised trial of high‐dose isosorbide dinitrate plus low‐dose furosemide versus high‐dose furosemide plus low‐dose isosorbide dinitrate in severe pulmonary oedema.Lancet.1998;351(9100):389393.
  28. Ellison DH.Diuretic therapy and resistance in congestive heart failure.Cardiology.2001;96(3–4):132143.
  29. Sackner‐Bernstein JD.Management of diuretic‐refractory, volume‐overloaded patients with acutely decompensated heart failure.Curr Cardiol Rep.2005;7(3):204210.
  30. Mills RM,LeJemtel TH,Horton DP, et al.Sustained hemodynamic effects of an infusion of nesiritide (human b‐type natriuretic peptide) in heart failure: a randomized, double‐blind, placebo‐controlled clinical trial.J Am Coll Cardiol.1999;34(1):155162.
  31. Colucci WS,Elkayam U,Horton DP, et al.Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure.N Engl J Med.2000;343(4):246253.
  32. Publication Committee for the VMAC Investigators.Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial.JAMA.2002;287(12):15311540.
  33. Cataliotti A,Boerrigter G,Costello‐Boerrigter LC, et al.Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide‐induced aldosterone activation in experimental heart failure.Circulation.2004;109(13):16801685.
  34. Sica DA,Gottwald M,Li YP.Nesiritide appears to inhibit the rise in plasma aldosterone associated with furosemide diuresis.J Card Fail.2006;12(6 suppl 1):S85S86. Abstract 275.
  35. Elkayam U,Tasissa G,Binanay C, et al.Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure.Am Heart J.2007;153(1):98104.
  36. Joint Commission on Accreditation of Healthcare Organizations. Specifications Manual for National Implementation of Hospital Quality Measures. Version 2.3b. http://www.jointcommission.org/PerformanceMeasurement/PerformanceMeasurement/Historical+NHQM+manuals.htm. Accessed October 10,2008.
  37. American Heart Association/American Stroke Association. Get with the guidelines–heart failure. Fact sheet. http://www.americanheart.org/downloadable/heart/1163802072170HFFactSheet.pdf. Accessed October 10,2008.
  38. Fonarow GC,Abraham WT,Albert NM, et al.Association between performance measures and clinical outcomes for patients hospitalized with heart failure.JAMA.2007;297(1):6170.
  39. Krumholz HM,Baker DW,Ashton CM, et al.Evaluating quality of care for patients with heart failure.Circulation.2000;101(12):e122e140.
  40. Aghababian RV.Acutely decompensated heart failure: opportunities to improve care and outcomes in the emergency department.Rev Cardiovasc Med.2002;3(suppl 4):S3S9.
  41. Peacock WF,Albert NM.Observation unit management of heart failure.Emerg Med Clin North Am.2001;19(1):209232.
  42. Ghali JK,Kadakia S,Cooper R,Ferlinz J.Precipitating factors leading to decompensation of heart failure. Traits among urban blacks.Arch Intern Med.1988;148(9):20132016.
  43. Vinson JM,Rich MW,Sperry JC,Shah AS,McNamara T.Early readmission of elderly patients with congestive heart failure.J Am Geriatr Soc.1990;38(12):12901295.
  44. Fonarow GC,Stevenson LW,Walden JA, et al.Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure.J Am Coll Cardiol.1997;30(3):725732.
  45. Hershberger RE,Ni H,Nauman DJ, et al.Prospective evaluation of an outpatient heart failure management program.J Card Fail.2001;7(1):6474.
  46. Holst DP,Kaye D,Richardson M, et al.Improved outcomes from a comprehensive management system for heart failure.Eur J Heart Fail.2001;3(5):619625.
  47. Whellan DJ,Gaulden L,Gattis WA, et al.The benefit of implementing a heart failure disease management program.Arch Intern Med.2001;161(18):22232228.
  48. Rich MW,Beckham V,Wittenberg C,Leven CL,Freedland KE,Carney RM.A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure.N Engl J Med.1995;333(18):11901195.
  49. O'Connell AM,Crawford MH,Abrams J.Heart failure disease management in an indigent population.Am Heart J.2001;141(2):254258.
  50. Capomolla S,Febo O,Ceresa M, et al.Cost/utility ratio in chronic heart failure: comparison between heart failure management program delivered by day‐hospital and usual care.J Am Coll Cardiol.2002;40(7):12591266.
  51. Kasper EK,Gerstenblith G,Hefter G, et al.A randomized trial of the efficacy of multidisciplinary care in heart failure outpatients at high risk of hospital readmission.J Am Coll Cardiol.2002;39(3):471480.
  52. Hebert KA,Horswell RL,Dy S, et al.Mortality benefit of a comprehensive heart failure disease management program in indigent patients.Am Heart J.2006;151(2):478483.
  53. Del Sindaco D,Pulignano G,Minardi G, et al.Two‐year outcome of a prospective, controlled study of a disease management programme for elderly patients with heart failure.J Cardiovasc Med (Hagerstown).2007;8(5):324329.
  54. Gambetta M,Dunn P,Nelson D,Herron B,Arena R.Impact of the implementation of telemanagement on a disease management program in an elderly heart failure cohort.Prog Cardiovasc Nurs.2007;22(4):196200.
  55. Nguyen V,Ducharme A,White M, et al.Lack of long‐term benefits of a 6‐month heart failure disease management program.J Card Fail.2007;13(4):287293.
  56. Ducharme A,Doyon O,White M,Rouleau JL,Brophy JM.Impact of care at a multidisciplinary congestive heart failure clinic: a randomized trial.CMAJ.2005;173(1):4045.
Article PDF
Issue
Journal of Hospital Medicine - 3(6)
Page Number
S7-S15
Legacy Keywords
acute decompensated heart failure, clinical practice guidelines, evidence‐based medicine, inpatients
Sections
Article PDF
Article PDF

Optimizing quality of care in patients with acute decompensated heart failure (ADHF) is crucial, given both the frequency and cost of hospitalization for this disorder. Several quality improvement strategies have been identified, including provider education; provider reminder systems and decision support; audit and feedback; patient education; organizational change; and financial incentives, regulation, and policy.1

To assist hospitalists in implementing these strategies, this article briefly reviews evidence‐based guidelines for the treatment of ADHF, presents a practical algorithm for patient assessment and treatment derived from these guidelines and personal experience, and discusses systems to enhance the ultimate transition of patient care from the inpatient to outpatient setting.

EVIDENCE‐BASED GUIDELINES

Evidence‐based guidelines are created in an attempt to promote optimal management of a condition or disorder based on expert analysis of all available relevant scientific data. Current guidelines for the assessment and treatment of ADHF have been developed by a national group purchasing organization,2 the European Society of Cardiology,3 the Heart Failure Society of America,4 and the American College of Emergency Physicians.5 Relevant components of these guidelines will be discussed in the patient assessment and treatment section below.

Publication of guidelines, in and of itself, however, is inadequate to ensure their acceptance and use.1 Data from the American Heart Association (AHA)/American Stroke Association (ASA) Get With The GuidelinesHeart Failure (GWTG‐HF) program continue to demonstrate a substantial gap between guideline recommendations and current care of patients with ADHF.6, 7 One way to promote systemwide adherence with published guidelines is to directly involve healthcare professionals in the implementation process. Consequently, development of local, hospital‐based procedures derived from national or international guidelines may be more effective than the simple dissemination of the guidelines themselves.1 Hospitalists have a unique insight into both patient care and the hospital setting and are frequently involved in evaluating hospital policies and procedures and implementing clinical pathways and guidelines.8 In addition, hospitalist care has been associated with greater compliance with disease‐specific guidelines compared to nonhospitalist care.9 As a result, hospitalists are uniquely suited to play a key role in the development of these procedures.

PATIENT ASSESSMENT AND TREATMENT

The differential diagnosis of any individual presenting to the emergency department (ED) with signs of systemic or pulmonary edema should include ADHF (Figure 1).25 These individuals require a rapid initial assessment to (1) establish the diagnosis, (2) determine the best location for subsequent treatment, and (3) institute the most appropriate initial therapy.

Figure 1
Algorithm for treatment of acute decompensated heart failure (ADHF) based on currently published practice guidelines2–5 and personal experience. Abbreviations: CILT, continuous infusion loop diuretic therapy; ED, emergency department; ET, endotracheal; ICU, intensive care unit; IV, intravenous; NES, nesiritide; NTG, nitroglycerin; NTP, nitroprusside; SBP, systolic blood pressure; SOB, shortness of breath.

Treatment Location

Effective and efficient management of ADHF requires determining proper treatment location. Inpatient management of ADHF is expensive, accounting for approximately 60% of the $31.7 billion spent annually on heart failure care in the United States.10 Clearly, patients with impending respiratory failure requiring ventilation assistance and patients with cardiogenic shock requiring inotropic agents and invasive monitoring are best cared for in an intensive care unit (ICU) setting. However, these patients constitute the minority of patients with ADHF. For example, systolic blood pressure (SBP) <90 mm Hg was present in only 2.3% of patients in the Acute Decompensated Heart Failure National Registry (ADHERE), a registry designed to study characteristics, management, and outcomes in a broad sample of patients hospitalized with ADHF.11

Most patients with ADHF present with congestion, not respiratory failure or cardiogenic shock,11, 12 and a select subgroup of these patients will respond to treatment within 1224 hours.13 Although this may be an inordinate amount of time to keep patients in an ED, it is not long enough to generally require full hospital admission. Instead, these patients can be effectively managed in an observation unit (OU).14 The goal of these units is to provide the required level of care over a 12‐ to 24‐hour period while simultaneously reducing costs by eliminating the need for hospital admission. Selecting patients who will respond to therapy during this time frame is a critical component in instituting effective OU management of ADHF. Key entry and exclusion criteria are listed in Table 1.14 In patients who meet these criteria, management in an OU has been shown to yield outcomes comparable to inpatient care, but at a lower cost.1416

Entry and Exclusion Criteria for Observation Unit (OU) Heart Failure Protocol*
Entry criteria
  • Abbreviations: AMI, acute myocardial infarction; CK‐MB, creatinine kinase MB isoenzyme; ECG, electrocardiogram.

  • Adapted with permission from Peacock et al.14

History (at least one of the following)
Dyspnea on exertion
Paroxysmal nocturnal dyspnea
Shortness of breath
Edema of legs or abdomen
Weight gain
Physical examination (at least one of the following)
Jugular venous distention or elevation in pulsation
Positive abdominal jugular reflux
S3/S4 gallop
Inspiratory rales
Peripheral edema
Chest x‐ray (at least one of the following)
Cardiomegaly
Pulmonary vascular congestion
Kerley B lines
Pulmonary edema
Pleural effusion
Exclusion criteria
Unstable vital signs (BP >220/120 mm Hg, respiratory rate >25 breath/min, heart rate >130 beats/min)
Temperature >38.5C
Unstable airway or need for >4 L/min supplemental O2 to keep O2 saturation >90%
Peak flow <50% of predicted with wheezing
Clinically significant arrhythmia or sustained ventricular tachycardia
Any ECG with diagnostic criteria for AMI or ischemia
Chest x‐ray with pulmonary infiltrates
Any CK‐MB >8.8 ng/mL
Any troponin T >0.1 g/L (>0.5 g/L if creatinine >2.0 mg/dL)
Requirement for continuous vasoactive medication to stabilize hemodynamics
Complex decompensation: concomitant end‐organ hypoperfusion, volume overload, and systemic vasoconstriction
Requirement for care guided by pulmonary artery catheter
Severe electrolyte imbalance
Chronic renal failure requiring dialysis
Acute mental status abnormality

Early Initiation of Therapy

Early institution of effective therapy has been shown to improve outcomes. Consequently, selection of initial therapy should occur concurrently with determination of proper treatment location. In the Prospective Randomized Outcomes Study of Acutely Decompensated Congestive Heart Failure Treated Initially as Outpatients with Nesiritide (PROACTION) trial, initiation of nesiritide in the ED/OU was associated with an 11% reduction in hospital admissions at the index visit (P = .436), a 57% reduction in hospitalizations within 30 days after discharge from the index hospitalization (P = .058), and a 62% reduction in median duration of rehospitalization (P = .032).17 The incidence of symptomatic hypotension was low and did not differ between the groups.17 Likewise, in separate analyses of data from ADHERE, ED initiation of intravenous (IV) vasoactive therapy, including nitroglycerin, nesiritide, milrinone, or dobutamine significantly reduced the risk of requiring transfer to an ICU and reduced ICU length of stay and total hospital length of stay compared with inpatient initiation of these same therapies.18, 19

Treatment Algorithm

Treatment of ADHF should proceed along a logical care pathway governed by both clinical status and response to prior therapies (Figure 1). One must first consider whether there is evidence of respiratory failure or impending respiratory failure.20 If so, patients should receive immediate ventilatory support via continuous positive airway pressure (CPAP), bilevel positive airway pressure (BiPAP), or endotracheal intubation, depending on the degree of respiratory impairment.3, 5 In prospective controlled evaluations, patients with acute respiratory failure secondary to pulmonary edema who were randomized to treatment with CPAP demonstrated significant improvement in cardiopulmonary indices21, 22 and significant reductions in need for endotracheal intubation21 and short‐term mortality22 when compared with similar patients who received standard therapy without CPAP.

Once potential respiratory issues have been addressed, the next items for consideration are circulation and perfusion. Patients with low cardiac output and hypotension (cardiogenic shock) are at risk for developing critical end‐organ dysfunction. In these patients, insertion of a pulmonary artery catheter may aid in assessment of hemodynamic status and response to therapy.4 Patients with low cardiac output and low filling pressures should receive IV fluid loading.3 In contrast, for patients with low cardiac output and high filling pressures, inotropic agents should be considered.3, 4 Also, these patients may require IV vasodilators and/or IV diuretics to treat pulmonary edema once blood pressure (BP) and cardiac output have been stabilized.2, 3, 20

For patients with ADHF who present with symptoms of congestion, but not respiratory failure or cardiogenic shock, the initial therapeutic decision is governed by their BP. Approximately 50% of patients with ADHF will have an SBP > 140 mm Hg.12, 23 These patients tend to be older and to have diastolic rather than systolic dysfunction.12, 20, 23 Symptoms typically have been present for only a short period of time (2448 hours) and are more often due to maldistribution of fluid producing pulmonary edema than total body fluid overload. Consequently, initial treatment should focus on aggressive BP control to relieve this edema. Sublingual or topical nitrates are recommended as a first step, and initial diuretic use should be minimal to avoid intravascular volume depletion leading to renal dysfunction.20 In contrast, patients presenting with SBP between 90 mm Hg and 140 mm Hg are more likely to have some degree of systolic dysfunction, leading to a gradual worsening of their heart failure symptoms and total body fluid overload over a period of weeks.20 These patients require aggressive diuresis. Although the efficacy of IV loop diuretics has not been established in randomized, controlled clinical trials, observational experience demonstrates that they can effectively reduce filling pressures, relieve volume overload, and decrease symptoms of congestion.4 They are currently the mainstay of therapy for ADHF secondary to fluid retention, and their use is recommended in all 4 guidelines.25

This initial therapeutic choice, however, is only the starting point, and it is important not to stop at this stage. No single definitive therapy for ADHF exists, and not all patients will respond to initial treatment. Optimal management requires early recognition and addressing of both an inadequate response to therapy and any adverse affects induced by this therapy. Frequent reevaluations are an essential component of treating patients with ADHF. For example, the timeline in one of the guidelines calls for assessing the patient's response at 2 and 4 hours after initiation of IV therapy and adjusting treatment as indicated based on these assessments (Figure 2).2

Figure 2
Timeline for initial assessment and management of acute decompensated heart failure (ADHF). Abbreviations: ED, emergency department; OU, observation unit. Adapted with permission from DiDomenico et al.2

If the patient has an adequate response to initial therapy, defined as SBP <140 mm Hg, stable renal function, and urine output >500 mL over 2 hours (>250 mL if serum creatinine >2.5 mg/dL), this therapy can continue unchanged, and focus shifts to long‐term management issues.2, 4, 14 However, if the response is inadequate, it is important to identify and treat the cause of this inadequate response.

Inadequate urine output secondary to diuretic resistance is common in patients with ADHF, especially in those on long‐term diuretic therapy.3 Despite a 90% prevalence of IV diuretic use in ADHERE, 70% of patients either gained weight or lost fewer than 5 pounds during hospitalization, and 42% were discharged with unresolved symptoms.24 Clearly, diuretic therapy did not produce the desired effect in many of these patients. This inadequate response to loop diuretics is a direct result of their pharmacologic properties, especially as they relate to patients with heart failure. The physiologic effects of loop diuretics are directly related to their concentration in the lumen of the nephron. This concentration depends on both the patient's renal function and the dose and half‐life of the administered diuretic.25 Comorbid renal dysfunction is common in patients with ADHF.26 In addition, even in the absence of this dysfunction, the short half‐life of loop diuretics limits the amount of time that their luminal concentration is in the effective range, and rebound sodium retention can occur whenever the diuretic concentration is below this range.25 Furthermore, the dose‐response curve of loop diuretics is S‐shaped. As a result, a threshold concentration exists beyond which no further augmentation in urine output occurs; ie, there is a maximum physiologic response that is reduced in patients with heart failure.25 Guideline recommendations for patients with diuretic resistance attempt to address these physiologic and pharmacologic limitations. These recommendations include fluid restriction to decrease the overall volume of diuresis necessary, increasing diuretic dose or instituting continuous infusion loop diuretic therapy to increase the amount of time during which the luminal concentration is within the effective range, sequential diuretic blockade to take advantage of the different mechanisms of action of the various diuretic classes to affect different components of the nephron, bypassing the kidney through the use of ultrafiltration, and when these are inadequate, adding a vasodilator in an attempt to augment cardiac output and renal perfusion.3, 4, 24, 25, 2729

Addition of an IV vasodilator is the primary means of addressing an inadequate response typified by hypertension, worsening renal function, and/or persistent symptoms, rather than diuretic resistance. Approximately 25% of patients with ADHF receive IV vasoactive therapy, including nitroglycerin, nesiritide, milrinone, or dobutamine, although predominantly vasodilators, at some point during their hospitalization.11, 12 These agents improve hemodynamics and reduce symptoms of ADHF.5, 3032 Their use, in combination with low‐dose diuretics, has been shown to be more efficacious than high‐dose diuretics alone.3, 27 Adding a vasodilator may reduce adverse, diuretic‐induced, neurohormonal activation. In an animal model, combining nesiritide with IV furosemide significantly attenuated the rise in plasma aldosterone produced by IV furosemide alone,33 and this finding has been subsequently confirmed in patients with heart failure.34 Finally, vasodilators have proven to be a safer alternative than inotropes in patients with ADHF. In an analysis of data from ADHERE, covariate‐adjusted and propensity‐adjusted mortality risk was >50% lower for patients receiving nitroglycerin or nesiritide compared with those receiving dobutamine,11 and in an analysis of data from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) trial, which evaluated patients with advanced heart failure, the risk‐adjusted mortality hazard ratio (HR) was significantly increased for inotropes (HR: 2.14; 95% confidence interval [CI]: 1.104.15) but not for vasodilators in the absence of inotropes (HR: 1.39; 95% CI: 0.643.00).35

Performance Measures

In addition to instituting effective therapy for the acute decompensation, it is important to implement measures that may improve long‐term outcomes. The Joint Commission on Accreditation of Healthcare Organizations and the AHA/ASA have identified a series of 5 core performance measures that should be completed during hospitalization for AHDF: discharge instructions relevant to patient's education, documentation of left ventricular systolic function evaluation, prescription of angiotensin‐converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) at discharge in patients with left ventricular systolic dysfunction, adult smoking cessation advice/counseling, and prescription of ‐blocker at discharge (Table 2).36, 37 In an analysis of data from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE‐HF) registry, prescription of a ‐blocker at discharge significantly reduced the risk‐adjusted odds ratio (OR) for mortality (OR: 0.48; 95% CI: 0.300.79), and prescription of an ACE inhibitor or ARB at discharge significantly reduced the risk‐adjusted OR for rehospitalization or death (OR: 0.51; 95% CI: 0.340.78) at 6090 days.38 Although no correlation was detected between outcomes and the other 3 core performance measures in this evaluation, the 60‐day to 90‐day time frame may have been too short to identify the full effects of smoking cessation counseling and left ventricular function assessment. Failure to detect a beneficial effect of discharge instructions is disappointing, especially given the proven benefit of disease management programs (see below) and may reflect a limitation of this measure, as currently implemented, to determine the thoroughness and patient understanding of the instructions provided.38, 39

Heart Failure Core Performance Measures*
Measure Description Source
  • Abbreviations: ACE, angiotensin‐converting enzyme; ARB, angiotensin receptor blocker.

  • Derived from the JCAHO guidelines and the AHA/ASA's Get With The GuidelinesHeart Failure (GWTG‐HF) program.36, 37

HF‐1 Discharge instructions relevant to patient education JCAHO; AHA/ASA
HF‐2 Documentation of left ventricular systolic function evaluation JCAHO; AHA/ASA
HF‐3 Prescription of ACE inhibitor or ARB at discharge in patients with left ventricular systolic dysfunction JCAHO; AHA/ASA
HF‐4 Adult smoking cessation advice/counseling JCAHO; AHA/ASA
HF‐5 Prescription of ‐blocker at discharge AHA/ASA

TRANSITION OF CARE

Lastly, optimal management of ADHF requires successful transition of care from an inpatient to an outpatient setting. Recidivism is both common and costly. Approximately 2% of patients with ADHF are readmitted within 2 days, 20% within 1 month, and 50% within 6 months of hospital discharge.40 Frequently, these readmissions are caused by nonadherence to the therapeutic regimen following discharge.41 In an evaluation of patients hospitalized for ADHF at a large urban medical center, noncompliance with prescribed diet and/or drugs was the most common precipitating factor for admission (64% of patients), followed by uncontrolled hypertension (44%), cardiac arrhythmia (29%), environmental factors (19%), and inadequate therapy (17%).42 Similarly, in a prospective evaluation of elderly patients hospitalized for ADHF, 53% of readmissions occurring within 90 days of discharge were deemed to be preventable, with the most common contributing factors being noncompliance with medications and/or diet (33%), inadequate discharge planning (15%), inadequate follow‐up (20%), insufficient support system (21%), and failure to seek medical attention promptly when symptoms recurred (20%).43 Consequently, patient education and arrangement for appropriate follow‐up are crucial components of successfully transitioning care to an outpatient setting.

Effective patient education is time‐consuming. Patients must be taught when, how, and why to take their medication. They need to understand their dietary guidelines and the reasons for these guidelines. They need to know how to use daily weigh‐ins as a means of monitoring their fluid status and what to do in response to a change in weight or symptoms. Finally, they need to be cognizant of what constitutes appropriate exercise and the need for this exercise.4447 To enhance understanding and retention, this information should be presented to the patient over the course of the hospitalization. Comprehension should be tested continually and education repeated until appropriate understanding is ensured. Patient education provided in a rushed or perfunctory manner at the moment of discharge is unlikely to be retained or effective.38, 39

Ideally, the patient should be referred to a comprehensive heart failure disease management program for postdischarge care. Numerous evaluations have established the effectiveness of these programs in enhancing use of appropriate medications, improving functional status, reducing readmissions and mortality, and decreasing costs.4454 For example, in separate evaluations, the prevalences of appropriate vasodilator use (93% vs. 61%; P < .001),51 ‐blocker use (71% vs. 40%; P < .001),50 and ACE inhibitor use (84% vs. 59%; P < .001)52 were significantly greater for disease management program participants compared with nonparticipants. In addition, participation in a disease management program was associated with a 52% reduction in the risk of hospitalization for cardiovascular causes (P < .001) and a 72% reduction in ED visits (P < .01) in 1 evaluation,45 a 36% reduction (95% CI: 16.7%50.9%) in the risk of heart failure admission or death in another,53 and a 67% reduction (95% CI: 41%82%) in the adjusted risk of death in yet another evaluation.52 Unfortunately, recent data indicate that these programs must be ongoing to sustain these benefits. In a prospective evaluation, patients with heart failure were randomized to either standard care or a multidisciplinary disease management program for 6 months followed by standard care.55, 56 Significantly fewer patients in the disease management group required readmission to the hospital (HR: 0.55; 95% CI: 0.350.88) during the 6‐month period in which they actively participated in the disease management program.56 However, by the end of follow‐up (mean 2.8 years), there was no significant difference between treatment groups in all‐cause mortality (HR: 1.09; 95% CI: 0.691.72) or the composite endpoint of death, ED visit, or hospitalization (HR: 1.01; 95% CI: 0.751.37).55

CONCLUSION

A gap between evidence‐based guidelines and current management of patients with ADHF exists. Multiple strategies to bridge this gap in patient management can be employed. Patients with ADHF require rapid assessment to determine appropriate treatment location and initial therapy. Clinical status should guide treatment selection. Once effective acute therapy has been established, strategies to improve long‐term outcomes should be implemented. These strategies include ensuring that care complies with established core performance measures, providing patient education in a manner suited to ensure comprehension and retention, and arranging for appropriate outpatient follow‐up, ideally in a comprehensive heart failure disease management program. Increasing the awareness of the gap between evidence‐based guidelines and current management, as well as strategies to bridge this gap, is crucial to improving the outcomes of patients with ADHF.

Optimizing quality of care in patients with acute decompensated heart failure (ADHF) is crucial, given both the frequency and cost of hospitalization for this disorder. Several quality improvement strategies have been identified, including provider education; provider reminder systems and decision support; audit and feedback; patient education; organizational change; and financial incentives, regulation, and policy.1

To assist hospitalists in implementing these strategies, this article briefly reviews evidence‐based guidelines for the treatment of ADHF, presents a practical algorithm for patient assessment and treatment derived from these guidelines and personal experience, and discusses systems to enhance the ultimate transition of patient care from the inpatient to outpatient setting.

EVIDENCE‐BASED GUIDELINES

Evidence‐based guidelines are created in an attempt to promote optimal management of a condition or disorder based on expert analysis of all available relevant scientific data. Current guidelines for the assessment and treatment of ADHF have been developed by a national group purchasing organization,2 the European Society of Cardiology,3 the Heart Failure Society of America,4 and the American College of Emergency Physicians.5 Relevant components of these guidelines will be discussed in the patient assessment and treatment section below.

Publication of guidelines, in and of itself, however, is inadequate to ensure their acceptance and use.1 Data from the American Heart Association (AHA)/American Stroke Association (ASA) Get With The GuidelinesHeart Failure (GWTG‐HF) program continue to demonstrate a substantial gap between guideline recommendations and current care of patients with ADHF.6, 7 One way to promote systemwide adherence with published guidelines is to directly involve healthcare professionals in the implementation process. Consequently, development of local, hospital‐based procedures derived from national or international guidelines may be more effective than the simple dissemination of the guidelines themselves.1 Hospitalists have a unique insight into both patient care and the hospital setting and are frequently involved in evaluating hospital policies and procedures and implementing clinical pathways and guidelines.8 In addition, hospitalist care has been associated with greater compliance with disease‐specific guidelines compared to nonhospitalist care.9 As a result, hospitalists are uniquely suited to play a key role in the development of these procedures.

PATIENT ASSESSMENT AND TREATMENT

The differential diagnosis of any individual presenting to the emergency department (ED) with signs of systemic or pulmonary edema should include ADHF (Figure 1).25 These individuals require a rapid initial assessment to (1) establish the diagnosis, (2) determine the best location for subsequent treatment, and (3) institute the most appropriate initial therapy.

Figure 1
Algorithm for treatment of acute decompensated heart failure (ADHF) based on currently published practice guidelines2–5 and personal experience. Abbreviations: CILT, continuous infusion loop diuretic therapy; ED, emergency department; ET, endotracheal; ICU, intensive care unit; IV, intravenous; NES, nesiritide; NTG, nitroglycerin; NTP, nitroprusside; SBP, systolic blood pressure; SOB, shortness of breath.

Treatment Location

Effective and efficient management of ADHF requires determining proper treatment location. Inpatient management of ADHF is expensive, accounting for approximately 60% of the $31.7 billion spent annually on heart failure care in the United States.10 Clearly, patients with impending respiratory failure requiring ventilation assistance and patients with cardiogenic shock requiring inotropic agents and invasive monitoring are best cared for in an intensive care unit (ICU) setting. However, these patients constitute the minority of patients with ADHF. For example, systolic blood pressure (SBP) <90 mm Hg was present in only 2.3% of patients in the Acute Decompensated Heart Failure National Registry (ADHERE), a registry designed to study characteristics, management, and outcomes in a broad sample of patients hospitalized with ADHF.11

Most patients with ADHF present with congestion, not respiratory failure or cardiogenic shock,11, 12 and a select subgroup of these patients will respond to treatment within 1224 hours.13 Although this may be an inordinate amount of time to keep patients in an ED, it is not long enough to generally require full hospital admission. Instead, these patients can be effectively managed in an observation unit (OU).14 The goal of these units is to provide the required level of care over a 12‐ to 24‐hour period while simultaneously reducing costs by eliminating the need for hospital admission. Selecting patients who will respond to therapy during this time frame is a critical component in instituting effective OU management of ADHF. Key entry and exclusion criteria are listed in Table 1.14 In patients who meet these criteria, management in an OU has been shown to yield outcomes comparable to inpatient care, but at a lower cost.1416

Entry and Exclusion Criteria for Observation Unit (OU) Heart Failure Protocol*
Entry criteria
  • Abbreviations: AMI, acute myocardial infarction; CK‐MB, creatinine kinase MB isoenzyme; ECG, electrocardiogram.

  • Adapted with permission from Peacock et al.14

History (at least one of the following)
Dyspnea on exertion
Paroxysmal nocturnal dyspnea
Shortness of breath
Edema of legs or abdomen
Weight gain
Physical examination (at least one of the following)
Jugular venous distention or elevation in pulsation
Positive abdominal jugular reflux
S3/S4 gallop
Inspiratory rales
Peripheral edema
Chest x‐ray (at least one of the following)
Cardiomegaly
Pulmonary vascular congestion
Kerley B lines
Pulmonary edema
Pleural effusion
Exclusion criteria
Unstable vital signs (BP >220/120 mm Hg, respiratory rate >25 breath/min, heart rate >130 beats/min)
Temperature >38.5C
Unstable airway or need for >4 L/min supplemental O2 to keep O2 saturation >90%
Peak flow <50% of predicted with wheezing
Clinically significant arrhythmia or sustained ventricular tachycardia
Any ECG with diagnostic criteria for AMI or ischemia
Chest x‐ray with pulmonary infiltrates
Any CK‐MB >8.8 ng/mL
Any troponin T >0.1 g/L (>0.5 g/L if creatinine >2.0 mg/dL)
Requirement for continuous vasoactive medication to stabilize hemodynamics
Complex decompensation: concomitant end‐organ hypoperfusion, volume overload, and systemic vasoconstriction
Requirement for care guided by pulmonary artery catheter
Severe electrolyte imbalance
Chronic renal failure requiring dialysis
Acute mental status abnormality

Early Initiation of Therapy

Early institution of effective therapy has been shown to improve outcomes. Consequently, selection of initial therapy should occur concurrently with determination of proper treatment location. In the Prospective Randomized Outcomes Study of Acutely Decompensated Congestive Heart Failure Treated Initially as Outpatients with Nesiritide (PROACTION) trial, initiation of nesiritide in the ED/OU was associated with an 11% reduction in hospital admissions at the index visit (P = .436), a 57% reduction in hospitalizations within 30 days after discharge from the index hospitalization (P = .058), and a 62% reduction in median duration of rehospitalization (P = .032).17 The incidence of symptomatic hypotension was low and did not differ between the groups.17 Likewise, in separate analyses of data from ADHERE, ED initiation of intravenous (IV) vasoactive therapy, including nitroglycerin, nesiritide, milrinone, or dobutamine significantly reduced the risk of requiring transfer to an ICU and reduced ICU length of stay and total hospital length of stay compared with inpatient initiation of these same therapies.18, 19

Treatment Algorithm

Treatment of ADHF should proceed along a logical care pathway governed by both clinical status and response to prior therapies (Figure 1). One must first consider whether there is evidence of respiratory failure or impending respiratory failure.20 If so, patients should receive immediate ventilatory support via continuous positive airway pressure (CPAP), bilevel positive airway pressure (BiPAP), or endotracheal intubation, depending on the degree of respiratory impairment.3, 5 In prospective controlled evaluations, patients with acute respiratory failure secondary to pulmonary edema who were randomized to treatment with CPAP demonstrated significant improvement in cardiopulmonary indices21, 22 and significant reductions in need for endotracheal intubation21 and short‐term mortality22 when compared with similar patients who received standard therapy without CPAP.

Once potential respiratory issues have been addressed, the next items for consideration are circulation and perfusion. Patients with low cardiac output and hypotension (cardiogenic shock) are at risk for developing critical end‐organ dysfunction. In these patients, insertion of a pulmonary artery catheter may aid in assessment of hemodynamic status and response to therapy.4 Patients with low cardiac output and low filling pressures should receive IV fluid loading.3 In contrast, for patients with low cardiac output and high filling pressures, inotropic agents should be considered.3, 4 Also, these patients may require IV vasodilators and/or IV diuretics to treat pulmonary edema once blood pressure (BP) and cardiac output have been stabilized.2, 3, 20

For patients with ADHF who present with symptoms of congestion, but not respiratory failure or cardiogenic shock, the initial therapeutic decision is governed by their BP. Approximately 50% of patients with ADHF will have an SBP > 140 mm Hg.12, 23 These patients tend to be older and to have diastolic rather than systolic dysfunction.12, 20, 23 Symptoms typically have been present for only a short period of time (2448 hours) and are more often due to maldistribution of fluid producing pulmonary edema than total body fluid overload. Consequently, initial treatment should focus on aggressive BP control to relieve this edema. Sublingual or topical nitrates are recommended as a first step, and initial diuretic use should be minimal to avoid intravascular volume depletion leading to renal dysfunction.20 In contrast, patients presenting with SBP between 90 mm Hg and 140 mm Hg are more likely to have some degree of systolic dysfunction, leading to a gradual worsening of their heart failure symptoms and total body fluid overload over a period of weeks.20 These patients require aggressive diuresis. Although the efficacy of IV loop diuretics has not been established in randomized, controlled clinical trials, observational experience demonstrates that they can effectively reduce filling pressures, relieve volume overload, and decrease symptoms of congestion.4 They are currently the mainstay of therapy for ADHF secondary to fluid retention, and their use is recommended in all 4 guidelines.25

This initial therapeutic choice, however, is only the starting point, and it is important not to stop at this stage. No single definitive therapy for ADHF exists, and not all patients will respond to initial treatment. Optimal management requires early recognition and addressing of both an inadequate response to therapy and any adverse affects induced by this therapy. Frequent reevaluations are an essential component of treating patients with ADHF. For example, the timeline in one of the guidelines calls for assessing the patient's response at 2 and 4 hours after initiation of IV therapy and adjusting treatment as indicated based on these assessments (Figure 2).2

Figure 2
Timeline for initial assessment and management of acute decompensated heart failure (ADHF). Abbreviations: ED, emergency department; OU, observation unit. Adapted with permission from DiDomenico et al.2

If the patient has an adequate response to initial therapy, defined as SBP <140 mm Hg, stable renal function, and urine output >500 mL over 2 hours (>250 mL if serum creatinine >2.5 mg/dL), this therapy can continue unchanged, and focus shifts to long‐term management issues.2, 4, 14 However, if the response is inadequate, it is important to identify and treat the cause of this inadequate response.

Inadequate urine output secondary to diuretic resistance is common in patients with ADHF, especially in those on long‐term diuretic therapy.3 Despite a 90% prevalence of IV diuretic use in ADHERE, 70% of patients either gained weight or lost fewer than 5 pounds during hospitalization, and 42% were discharged with unresolved symptoms.24 Clearly, diuretic therapy did not produce the desired effect in many of these patients. This inadequate response to loop diuretics is a direct result of their pharmacologic properties, especially as they relate to patients with heart failure. The physiologic effects of loop diuretics are directly related to their concentration in the lumen of the nephron. This concentration depends on both the patient's renal function and the dose and half‐life of the administered diuretic.25 Comorbid renal dysfunction is common in patients with ADHF.26 In addition, even in the absence of this dysfunction, the short half‐life of loop diuretics limits the amount of time that their luminal concentration is in the effective range, and rebound sodium retention can occur whenever the diuretic concentration is below this range.25 Furthermore, the dose‐response curve of loop diuretics is S‐shaped. As a result, a threshold concentration exists beyond which no further augmentation in urine output occurs; ie, there is a maximum physiologic response that is reduced in patients with heart failure.25 Guideline recommendations for patients with diuretic resistance attempt to address these physiologic and pharmacologic limitations. These recommendations include fluid restriction to decrease the overall volume of diuresis necessary, increasing diuretic dose or instituting continuous infusion loop diuretic therapy to increase the amount of time during which the luminal concentration is within the effective range, sequential diuretic blockade to take advantage of the different mechanisms of action of the various diuretic classes to affect different components of the nephron, bypassing the kidney through the use of ultrafiltration, and when these are inadequate, adding a vasodilator in an attempt to augment cardiac output and renal perfusion.3, 4, 24, 25, 2729

Addition of an IV vasodilator is the primary means of addressing an inadequate response typified by hypertension, worsening renal function, and/or persistent symptoms, rather than diuretic resistance. Approximately 25% of patients with ADHF receive IV vasoactive therapy, including nitroglycerin, nesiritide, milrinone, or dobutamine, although predominantly vasodilators, at some point during their hospitalization.11, 12 These agents improve hemodynamics and reduce symptoms of ADHF.5, 3032 Their use, in combination with low‐dose diuretics, has been shown to be more efficacious than high‐dose diuretics alone.3, 27 Adding a vasodilator may reduce adverse, diuretic‐induced, neurohormonal activation. In an animal model, combining nesiritide with IV furosemide significantly attenuated the rise in plasma aldosterone produced by IV furosemide alone,33 and this finding has been subsequently confirmed in patients with heart failure.34 Finally, vasodilators have proven to be a safer alternative than inotropes in patients with ADHF. In an analysis of data from ADHERE, covariate‐adjusted and propensity‐adjusted mortality risk was >50% lower for patients receiving nitroglycerin or nesiritide compared with those receiving dobutamine,11 and in an analysis of data from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) trial, which evaluated patients with advanced heart failure, the risk‐adjusted mortality hazard ratio (HR) was significantly increased for inotropes (HR: 2.14; 95% confidence interval [CI]: 1.104.15) but not for vasodilators in the absence of inotropes (HR: 1.39; 95% CI: 0.643.00).35

Performance Measures

In addition to instituting effective therapy for the acute decompensation, it is important to implement measures that may improve long‐term outcomes. The Joint Commission on Accreditation of Healthcare Organizations and the AHA/ASA have identified a series of 5 core performance measures that should be completed during hospitalization for AHDF: discharge instructions relevant to patient's education, documentation of left ventricular systolic function evaluation, prescription of angiotensin‐converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) at discharge in patients with left ventricular systolic dysfunction, adult smoking cessation advice/counseling, and prescription of ‐blocker at discharge (Table 2).36, 37 In an analysis of data from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE‐HF) registry, prescription of a ‐blocker at discharge significantly reduced the risk‐adjusted odds ratio (OR) for mortality (OR: 0.48; 95% CI: 0.300.79), and prescription of an ACE inhibitor or ARB at discharge significantly reduced the risk‐adjusted OR for rehospitalization or death (OR: 0.51; 95% CI: 0.340.78) at 6090 days.38 Although no correlation was detected between outcomes and the other 3 core performance measures in this evaluation, the 60‐day to 90‐day time frame may have been too short to identify the full effects of smoking cessation counseling and left ventricular function assessment. Failure to detect a beneficial effect of discharge instructions is disappointing, especially given the proven benefit of disease management programs (see below) and may reflect a limitation of this measure, as currently implemented, to determine the thoroughness and patient understanding of the instructions provided.38, 39

Heart Failure Core Performance Measures*
Measure Description Source
  • Abbreviations: ACE, angiotensin‐converting enzyme; ARB, angiotensin receptor blocker.

  • Derived from the JCAHO guidelines and the AHA/ASA's Get With The GuidelinesHeart Failure (GWTG‐HF) program.36, 37

HF‐1 Discharge instructions relevant to patient education JCAHO; AHA/ASA
HF‐2 Documentation of left ventricular systolic function evaluation JCAHO; AHA/ASA
HF‐3 Prescription of ACE inhibitor or ARB at discharge in patients with left ventricular systolic dysfunction JCAHO; AHA/ASA
HF‐4 Adult smoking cessation advice/counseling JCAHO; AHA/ASA
HF‐5 Prescription of ‐blocker at discharge AHA/ASA

TRANSITION OF CARE

Lastly, optimal management of ADHF requires successful transition of care from an inpatient to an outpatient setting. Recidivism is both common and costly. Approximately 2% of patients with ADHF are readmitted within 2 days, 20% within 1 month, and 50% within 6 months of hospital discharge.40 Frequently, these readmissions are caused by nonadherence to the therapeutic regimen following discharge.41 In an evaluation of patients hospitalized for ADHF at a large urban medical center, noncompliance with prescribed diet and/or drugs was the most common precipitating factor for admission (64% of patients), followed by uncontrolled hypertension (44%), cardiac arrhythmia (29%), environmental factors (19%), and inadequate therapy (17%).42 Similarly, in a prospective evaluation of elderly patients hospitalized for ADHF, 53% of readmissions occurring within 90 days of discharge were deemed to be preventable, with the most common contributing factors being noncompliance with medications and/or diet (33%), inadequate discharge planning (15%), inadequate follow‐up (20%), insufficient support system (21%), and failure to seek medical attention promptly when symptoms recurred (20%).43 Consequently, patient education and arrangement for appropriate follow‐up are crucial components of successfully transitioning care to an outpatient setting.

Effective patient education is time‐consuming. Patients must be taught when, how, and why to take their medication. They need to understand their dietary guidelines and the reasons for these guidelines. They need to know how to use daily weigh‐ins as a means of monitoring their fluid status and what to do in response to a change in weight or symptoms. Finally, they need to be cognizant of what constitutes appropriate exercise and the need for this exercise.4447 To enhance understanding and retention, this information should be presented to the patient over the course of the hospitalization. Comprehension should be tested continually and education repeated until appropriate understanding is ensured. Patient education provided in a rushed or perfunctory manner at the moment of discharge is unlikely to be retained or effective.38, 39

Ideally, the patient should be referred to a comprehensive heart failure disease management program for postdischarge care. Numerous evaluations have established the effectiveness of these programs in enhancing use of appropriate medications, improving functional status, reducing readmissions and mortality, and decreasing costs.4454 For example, in separate evaluations, the prevalences of appropriate vasodilator use (93% vs. 61%; P < .001),51 ‐blocker use (71% vs. 40%; P < .001),50 and ACE inhibitor use (84% vs. 59%; P < .001)52 were significantly greater for disease management program participants compared with nonparticipants. In addition, participation in a disease management program was associated with a 52% reduction in the risk of hospitalization for cardiovascular causes (P < .001) and a 72% reduction in ED visits (P < .01) in 1 evaluation,45 a 36% reduction (95% CI: 16.7%50.9%) in the risk of heart failure admission or death in another,53 and a 67% reduction (95% CI: 41%82%) in the adjusted risk of death in yet another evaluation.52 Unfortunately, recent data indicate that these programs must be ongoing to sustain these benefits. In a prospective evaluation, patients with heart failure were randomized to either standard care or a multidisciplinary disease management program for 6 months followed by standard care.55, 56 Significantly fewer patients in the disease management group required readmission to the hospital (HR: 0.55; 95% CI: 0.350.88) during the 6‐month period in which they actively participated in the disease management program.56 However, by the end of follow‐up (mean 2.8 years), there was no significant difference between treatment groups in all‐cause mortality (HR: 1.09; 95% CI: 0.691.72) or the composite endpoint of death, ED visit, or hospitalization (HR: 1.01; 95% CI: 0.751.37).55

CONCLUSION

A gap between evidence‐based guidelines and current management of patients with ADHF exists. Multiple strategies to bridge this gap in patient management can be employed. Patients with ADHF require rapid assessment to determine appropriate treatment location and initial therapy. Clinical status should guide treatment selection. Once effective acute therapy has been established, strategies to improve long‐term outcomes should be implemented. These strategies include ensuring that care complies with established core performance measures, providing patient education in a manner suited to ensure comprehension and retention, and arranging for appropriate outpatient follow‐up, ideally in a comprehensive heart failure disease management program. Increasing the awareness of the gap between evidence‐based guidelines and current management, as well as strategies to bridge this gap, is crucial to improving the outcomes of patients with ADHF.

References
  1. Michota FA.Bridging the gap between evidence and practice in venous thromboembolism prophylaxis: the quality improvement process.J Gen Intern Med.2007;22(12):17621770.
  2. DiDomenico RJ,Park HY,Southworth MR, et al.Guidelines for acute decompensated heart failure treatment.Ann Pharmacother.2004;38(4):649660.
  3. Nieminen MS,Böhm M,Cowie MR, et al.Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology.Eur Heart J.2005;26(4):384416.
  4. Heart Failure Society of America.Executive summary: HFSA 2006 comprehensive heart failure practice guideline.J Card Fail.2006;12(1):1038.
  5. Silvers SM,Howell JM,Kosowsky JM,Rokos IC,Jagoda AS,American College of Emergency Physicians. Clinical policy: critical issues in the evaluation and management of adult patients presenting to the emergency department with acute heart failure syndromes.Ann Emerg Med.2007;49(5):627669.
  6. Fonarow GC,LaBresh KA,Yancy C, et al.Influence of the American Heart Association's Get With The Guidelines‐Heart Failure (GWTG‐HF) program on emerging performance measures for patients hospitalized with heart failure.Circulation.2006;114:II–572. Abstract 2740.
  7. Hernandez AF,Fonarow GC,Liang L, et al.Quality of care for heart failure patients with concomitant kidney disease in the American Heart Association's Get With The Guidelines‐Heart Failure (GWTG‐HF) program.Circulation.2006;114:II–859. Abstract 3993.
  8. Amin AN.The role of hospitalists in the management of acute decompensated heart failure.Am Heart Hosp J.2005;3(2):111117.
  9. Lindenauer PK,Chehabeddine R,Pekow P,Fitzgerald J,Benjamin EM.Quality of care for patients hospitalized with heart failure: assessing the impact of hospitalists.Arch Intern Med.2002;162(11):12511256.
  10. Rosamond W,Flegal K,Furie K, et al.Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.Circulation.2008;117(4):e25e146.
  11. Abraham WT,Adams KF,Fonarow GC, et al.In‐hospital mortality in patients with acute decompensated heart failure treated with intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).J Am Coll Cardiol.2005;46(1):5764.
  12. Gheorghiade M,Abraham WT,Albert NM, et al.Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure.JAMA.2006;296(18):22172226.
  13. Kosowsky JM,Gasaway MD,Hamilton CA,Storrow AB.Preliminary experience with an emergency department observation unit protocol for heart failure.Acad Emerg Med.2000;7(10):1171. Abstract 33.
  14. Peacock WF,Remer EE,Aponte J,Moffa DA,Emerman CE,Albert NM.Effective observation unit treatment of decompensated heart failure.Congest Heart Fail.2002;8(2):6873.
  15. Peacock WF,Albert NM.Patient outcome and costs following an acute heart failure (HF) management program in an emergency department (ED) observation unit (OU).J Heart Lung Transplant.1999;18(1):92. Abstract 240.
  16. Peacock WF,Aponte JH,Craig MT,Remer EE,Zacharias D,Emerman CL.Inpatient versus emergency department observation unit management of heart failure.Ann Emerg Med.1998;32(3 part 2):S46S47. Abstract 180.
  17. Peacock WF,Holland R,Gyarmathy R, et al.Observation unit treatment of heart failure with nesiritide: results from the proaction trial.J Emerg Med.2005;29(3):243252.
  18. Emerman CL,Costanzo MR,Berkowitz RL,Cheng M.Early initiation of IV vasoactive therapy improves heart failure outcomes: an analysis from the ADHERE™ registry database.Ann Emerg Med.2003;42(4 suppl):S26. Abstract 92.
  19. Peacock WF,Fonarow GC,Emerman CL, et al.Impact of early initiation of intravenous therapy for acute decompensated heart failure on outcomes in ADHERE.Cardiology.2007;107(1):4451.
  20. Collins S,Storrow AB,Kirk JD,Pang PS,Diercks DB,Gheorghiade M.Beyond pulmonary edema: diagnostic, risk stratification, and treatment challenges of acute heart failure management in the emergency department.Ann Emerg Med.2008;51(1):4557.
  21. Lin M,Yang YF,Chiang HT,Chang MS,Chiang BN,Cheitlin MD.Reappraisal of continuous positive airway pressure therapy in acute cardiogenic pulmonary edema. Short‐term results and long‐term follow‐up.Chest.1995;107(5):13791386.
  22. L'Her E,Duquesne F,Girou E, et al.Noninvasive continuous positive airway pressure in elderly cardiogenic pulmonary edema patients.Intensive Care Med.2004;30(5):882888.
  23. Yancy CW,Lopatin M,Stevenson LW,De Marco T,Fonarow GC.Clinical presentation, management, and in‐hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database.J Am Coll Cardiol.2006;47(1):7684.
  24. Costanzo MR,Saltzberg M,O'Sullivan J,Sobotka P.Early ultrafiltration in patients with decompensated heart failure and diuretic resistance.J Am Coll Cardiol.2005;46(11):20472051.
  25. Brater DC.Diuretic therapy in congestive heart failure.Congest Heart Fail.2000;6(4):197201.
  26. Heywood JT,Fonarow GC,Costanzo MR, et al.High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database.J Card Fail.2007;13(6):422430.
  27. Cotter G,Metzkor E,Kaluski E, et al.Randomised trial of high‐dose isosorbide dinitrate plus low‐dose furosemide versus high‐dose furosemide plus low‐dose isosorbide dinitrate in severe pulmonary oedema.Lancet.1998;351(9100):389393.
  28. Ellison DH.Diuretic therapy and resistance in congestive heart failure.Cardiology.2001;96(3–4):132143.
  29. Sackner‐Bernstein JD.Management of diuretic‐refractory, volume‐overloaded patients with acutely decompensated heart failure.Curr Cardiol Rep.2005;7(3):204210.
  30. Mills RM,LeJemtel TH,Horton DP, et al.Sustained hemodynamic effects of an infusion of nesiritide (human b‐type natriuretic peptide) in heart failure: a randomized, double‐blind, placebo‐controlled clinical trial.J Am Coll Cardiol.1999;34(1):155162.
  31. Colucci WS,Elkayam U,Horton DP, et al.Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure.N Engl J Med.2000;343(4):246253.
  32. Publication Committee for the VMAC Investigators.Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial.JAMA.2002;287(12):15311540.
  33. Cataliotti A,Boerrigter G,Costello‐Boerrigter LC, et al.Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide‐induced aldosterone activation in experimental heart failure.Circulation.2004;109(13):16801685.
  34. Sica DA,Gottwald M,Li YP.Nesiritide appears to inhibit the rise in plasma aldosterone associated with furosemide diuresis.J Card Fail.2006;12(6 suppl 1):S85S86. Abstract 275.
  35. Elkayam U,Tasissa G,Binanay C, et al.Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure.Am Heart J.2007;153(1):98104.
  36. Joint Commission on Accreditation of Healthcare Organizations. Specifications Manual for National Implementation of Hospital Quality Measures. Version 2.3b. http://www.jointcommission.org/PerformanceMeasurement/PerformanceMeasurement/Historical+NHQM+manuals.htm. Accessed October 10,2008.
  37. American Heart Association/American Stroke Association. Get with the guidelines–heart failure. Fact sheet. http://www.americanheart.org/downloadable/heart/1163802072170HFFactSheet.pdf. Accessed October 10,2008.
  38. Fonarow GC,Abraham WT,Albert NM, et al.Association between performance measures and clinical outcomes for patients hospitalized with heart failure.JAMA.2007;297(1):6170.
  39. Krumholz HM,Baker DW,Ashton CM, et al.Evaluating quality of care for patients with heart failure.Circulation.2000;101(12):e122e140.
  40. Aghababian RV.Acutely decompensated heart failure: opportunities to improve care and outcomes in the emergency department.Rev Cardiovasc Med.2002;3(suppl 4):S3S9.
  41. Peacock WF,Albert NM.Observation unit management of heart failure.Emerg Med Clin North Am.2001;19(1):209232.
  42. Ghali JK,Kadakia S,Cooper R,Ferlinz J.Precipitating factors leading to decompensation of heart failure. Traits among urban blacks.Arch Intern Med.1988;148(9):20132016.
  43. Vinson JM,Rich MW,Sperry JC,Shah AS,McNamara T.Early readmission of elderly patients with congestive heart failure.J Am Geriatr Soc.1990;38(12):12901295.
  44. Fonarow GC,Stevenson LW,Walden JA, et al.Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure.J Am Coll Cardiol.1997;30(3):725732.
  45. Hershberger RE,Ni H,Nauman DJ, et al.Prospective evaluation of an outpatient heart failure management program.J Card Fail.2001;7(1):6474.
  46. Holst DP,Kaye D,Richardson M, et al.Improved outcomes from a comprehensive management system for heart failure.Eur J Heart Fail.2001;3(5):619625.
  47. Whellan DJ,Gaulden L,Gattis WA, et al.The benefit of implementing a heart failure disease management program.Arch Intern Med.2001;161(18):22232228.
  48. Rich MW,Beckham V,Wittenberg C,Leven CL,Freedland KE,Carney RM.A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure.N Engl J Med.1995;333(18):11901195.
  49. O'Connell AM,Crawford MH,Abrams J.Heart failure disease management in an indigent population.Am Heart J.2001;141(2):254258.
  50. Capomolla S,Febo O,Ceresa M, et al.Cost/utility ratio in chronic heart failure: comparison between heart failure management program delivered by day‐hospital and usual care.J Am Coll Cardiol.2002;40(7):12591266.
  51. Kasper EK,Gerstenblith G,Hefter G, et al.A randomized trial of the efficacy of multidisciplinary care in heart failure outpatients at high risk of hospital readmission.J Am Coll Cardiol.2002;39(3):471480.
  52. Hebert KA,Horswell RL,Dy S, et al.Mortality benefit of a comprehensive heart failure disease management program in indigent patients.Am Heart J.2006;151(2):478483.
  53. Del Sindaco D,Pulignano G,Minardi G, et al.Two‐year outcome of a prospective, controlled study of a disease management programme for elderly patients with heart failure.J Cardiovasc Med (Hagerstown).2007;8(5):324329.
  54. Gambetta M,Dunn P,Nelson D,Herron B,Arena R.Impact of the implementation of telemanagement on a disease management program in an elderly heart failure cohort.Prog Cardiovasc Nurs.2007;22(4):196200.
  55. Nguyen V,Ducharme A,White M, et al.Lack of long‐term benefits of a 6‐month heart failure disease management program.J Card Fail.2007;13(4):287293.
  56. Ducharme A,Doyon O,White M,Rouleau JL,Brophy JM.Impact of care at a multidisciplinary congestive heart failure clinic: a randomized trial.CMAJ.2005;173(1):4045.
References
  1. Michota FA.Bridging the gap between evidence and practice in venous thromboembolism prophylaxis: the quality improvement process.J Gen Intern Med.2007;22(12):17621770.
  2. DiDomenico RJ,Park HY,Southworth MR, et al.Guidelines for acute decompensated heart failure treatment.Ann Pharmacother.2004;38(4):649660.
  3. Nieminen MS,Böhm M,Cowie MR, et al.Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology.Eur Heart J.2005;26(4):384416.
  4. Heart Failure Society of America.Executive summary: HFSA 2006 comprehensive heart failure practice guideline.J Card Fail.2006;12(1):1038.
  5. Silvers SM,Howell JM,Kosowsky JM,Rokos IC,Jagoda AS,American College of Emergency Physicians. Clinical policy: critical issues in the evaluation and management of adult patients presenting to the emergency department with acute heart failure syndromes.Ann Emerg Med.2007;49(5):627669.
  6. Fonarow GC,LaBresh KA,Yancy C, et al.Influence of the American Heart Association's Get With The Guidelines‐Heart Failure (GWTG‐HF) program on emerging performance measures for patients hospitalized with heart failure.Circulation.2006;114:II–572. Abstract 2740.
  7. Hernandez AF,Fonarow GC,Liang L, et al.Quality of care for heart failure patients with concomitant kidney disease in the American Heart Association's Get With The Guidelines‐Heart Failure (GWTG‐HF) program.Circulation.2006;114:II–859. Abstract 3993.
  8. Amin AN.The role of hospitalists in the management of acute decompensated heart failure.Am Heart Hosp J.2005;3(2):111117.
  9. Lindenauer PK,Chehabeddine R,Pekow P,Fitzgerald J,Benjamin EM.Quality of care for patients hospitalized with heart failure: assessing the impact of hospitalists.Arch Intern Med.2002;162(11):12511256.
  10. Rosamond W,Flegal K,Furie K, et al.Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.Circulation.2008;117(4):e25e146.
  11. Abraham WT,Adams KF,Fonarow GC, et al.In‐hospital mortality in patients with acute decompensated heart failure treated with intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).J Am Coll Cardiol.2005;46(1):5764.
  12. Gheorghiade M,Abraham WT,Albert NM, et al.Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure.JAMA.2006;296(18):22172226.
  13. Kosowsky JM,Gasaway MD,Hamilton CA,Storrow AB.Preliminary experience with an emergency department observation unit protocol for heart failure.Acad Emerg Med.2000;7(10):1171. Abstract 33.
  14. Peacock WF,Remer EE,Aponte J,Moffa DA,Emerman CE,Albert NM.Effective observation unit treatment of decompensated heart failure.Congest Heart Fail.2002;8(2):6873.
  15. Peacock WF,Albert NM.Patient outcome and costs following an acute heart failure (HF) management program in an emergency department (ED) observation unit (OU).J Heart Lung Transplant.1999;18(1):92. Abstract 240.
  16. Peacock WF,Aponte JH,Craig MT,Remer EE,Zacharias D,Emerman CL.Inpatient versus emergency department observation unit management of heart failure.Ann Emerg Med.1998;32(3 part 2):S46S47. Abstract 180.
  17. Peacock WF,Holland R,Gyarmathy R, et al.Observation unit treatment of heart failure with nesiritide: results from the proaction trial.J Emerg Med.2005;29(3):243252.
  18. Emerman CL,Costanzo MR,Berkowitz RL,Cheng M.Early initiation of IV vasoactive therapy improves heart failure outcomes: an analysis from the ADHERE™ registry database.Ann Emerg Med.2003;42(4 suppl):S26. Abstract 92.
  19. Peacock WF,Fonarow GC,Emerman CL, et al.Impact of early initiation of intravenous therapy for acute decompensated heart failure on outcomes in ADHERE.Cardiology.2007;107(1):4451.
  20. Collins S,Storrow AB,Kirk JD,Pang PS,Diercks DB,Gheorghiade M.Beyond pulmonary edema: diagnostic, risk stratification, and treatment challenges of acute heart failure management in the emergency department.Ann Emerg Med.2008;51(1):4557.
  21. Lin M,Yang YF,Chiang HT,Chang MS,Chiang BN,Cheitlin MD.Reappraisal of continuous positive airway pressure therapy in acute cardiogenic pulmonary edema. Short‐term results and long‐term follow‐up.Chest.1995;107(5):13791386.
  22. L'Her E,Duquesne F,Girou E, et al.Noninvasive continuous positive airway pressure in elderly cardiogenic pulmonary edema patients.Intensive Care Med.2004;30(5):882888.
  23. Yancy CW,Lopatin M,Stevenson LW,De Marco T,Fonarow GC.Clinical presentation, management, and in‐hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database.J Am Coll Cardiol.2006;47(1):7684.
  24. Costanzo MR,Saltzberg M,O'Sullivan J,Sobotka P.Early ultrafiltration in patients with decompensated heart failure and diuretic resistance.J Am Coll Cardiol.2005;46(11):20472051.
  25. Brater DC.Diuretic therapy in congestive heart failure.Congest Heart Fail.2000;6(4):197201.
  26. Heywood JT,Fonarow GC,Costanzo MR, et al.High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database.J Card Fail.2007;13(6):422430.
  27. Cotter G,Metzkor E,Kaluski E, et al.Randomised trial of high‐dose isosorbide dinitrate plus low‐dose furosemide versus high‐dose furosemide plus low‐dose isosorbide dinitrate in severe pulmonary oedema.Lancet.1998;351(9100):389393.
  28. Ellison DH.Diuretic therapy and resistance in congestive heart failure.Cardiology.2001;96(3–4):132143.
  29. Sackner‐Bernstein JD.Management of diuretic‐refractory, volume‐overloaded patients with acutely decompensated heart failure.Curr Cardiol Rep.2005;7(3):204210.
  30. Mills RM,LeJemtel TH,Horton DP, et al.Sustained hemodynamic effects of an infusion of nesiritide (human b‐type natriuretic peptide) in heart failure: a randomized, double‐blind, placebo‐controlled clinical trial.J Am Coll Cardiol.1999;34(1):155162.
  31. Colucci WS,Elkayam U,Horton DP, et al.Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure.N Engl J Med.2000;343(4):246253.
  32. Publication Committee for the VMAC Investigators.Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial.JAMA.2002;287(12):15311540.
  33. Cataliotti A,Boerrigter G,Costello‐Boerrigter LC, et al.Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide‐induced aldosterone activation in experimental heart failure.Circulation.2004;109(13):16801685.
  34. Sica DA,Gottwald M,Li YP.Nesiritide appears to inhibit the rise in plasma aldosterone associated with furosemide diuresis.J Card Fail.2006;12(6 suppl 1):S85S86. Abstract 275.
  35. Elkayam U,Tasissa G,Binanay C, et al.Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure.Am Heart J.2007;153(1):98104.
  36. Joint Commission on Accreditation of Healthcare Organizations. Specifications Manual for National Implementation of Hospital Quality Measures. Version 2.3b. http://www.jointcommission.org/PerformanceMeasurement/PerformanceMeasurement/Historical+NHQM+manuals.htm. Accessed October 10,2008.
  37. American Heart Association/American Stroke Association. Get with the guidelines–heart failure. Fact sheet. http://www.americanheart.org/downloadable/heart/1163802072170HFFactSheet.pdf. Accessed October 10,2008.
  38. Fonarow GC,Abraham WT,Albert NM, et al.Association between performance measures and clinical outcomes for patients hospitalized with heart failure.JAMA.2007;297(1):6170.
  39. Krumholz HM,Baker DW,Ashton CM, et al.Evaluating quality of care for patients with heart failure.Circulation.2000;101(12):e122e140.
  40. Aghababian RV.Acutely decompensated heart failure: opportunities to improve care and outcomes in the emergency department.Rev Cardiovasc Med.2002;3(suppl 4):S3S9.
  41. Peacock WF,Albert NM.Observation unit management of heart failure.Emerg Med Clin North Am.2001;19(1):209232.
  42. Ghali JK,Kadakia S,Cooper R,Ferlinz J.Precipitating factors leading to decompensation of heart failure. Traits among urban blacks.Arch Intern Med.1988;148(9):20132016.
  43. Vinson JM,Rich MW,Sperry JC,Shah AS,McNamara T.Early readmission of elderly patients with congestive heart failure.J Am Geriatr Soc.1990;38(12):12901295.
  44. Fonarow GC,Stevenson LW,Walden JA, et al.Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure.J Am Coll Cardiol.1997;30(3):725732.
  45. Hershberger RE,Ni H,Nauman DJ, et al.Prospective evaluation of an outpatient heart failure management program.J Card Fail.2001;7(1):6474.
  46. Holst DP,Kaye D,Richardson M, et al.Improved outcomes from a comprehensive management system for heart failure.Eur J Heart Fail.2001;3(5):619625.
  47. Whellan DJ,Gaulden L,Gattis WA, et al.The benefit of implementing a heart failure disease management program.Arch Intern Med.2001;161(18):22232228.
  48. Rich MW,Beckham V,Wittenberg C,Leven CL,Freedland KE,Carney RM.A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure.N Engl J Med.1995;333(18):11901195.
  49. O'Connell AM,Crawford MH,Abrams J.Heart failure disease management in an indigent population.Am Heart J.2001;141(2):254258.
  50. Capomolla S,Febo O,Ceresa M, et al.Cost/utility ratio in chronic heart failure: comparison between heart failure management program delivered by day‐hospital and usual care.J Am Coll Cardiol.2002;40(7):12591266.
  51. Kasper EK,Gerstenblith G,Hefter G, et al.A randomized trial of the efficacy of multidisciplinary care in heart failure outpatients at high risk of hospital readmission.J Am Coll Cardiol.2002;39(3):471480.
  52. Hebert KA,Horswell RL,Dy S, et al.Mortality benefit of a comprehensive heart failure disease management program in indigent patients.Am Heart J.2006;151(2):478483.
  53. Del Sindaco D,Pulignano G,Minardi G, et al.Two‐year outcome of a prospective, controlled study of a disease management programme for elderly patients with heart failure.J Cardiovasc Med (Hagerstown).2007;8(5):324329.
  54. Gambetta M,Dunn P,Nelson D,Herron B,Arena R.Impact of the implementation of telemanagement on a disease management program in an elderly heart failure cohort.Prog Cardiovasc Nurs.2007;22(4):196200.
  55. Nguyen V,Ducharme A,White M, et al.Lack of long‐term benefits of a 6‐month heart failure disease management program.J Card Fail.2007;13(4):287293.
  56. Ducharme A,Doyon O,White M,Rouleau JL,Brophy JM.Impact of care at a multidisciplinary congestive heart failure clinic: a randomized trial.CMAJ.2005;173(1):4045.
Issue
Journal of Hospital Medicine - 3(6)
Issue
Journal of Hospital Medicine - 3(6)
Page Number
S7-S15
Page Number
S7-S15
Article Type
Display Headline
Bridging the gap between evidence and practice in acute decompensated heart failure management
Display Headline
Bridging the gap between evidence and practice in acute decompensated heart failure management
Legacy Keywords
acute decompensated heart failure, clinical practice guidelines, evidence‐based medicine, inpatients
Legacy Keywords
acute decompensated heart failure, clinical practice guidelines, evidence‐based medicine, inpatients
Sections
Article Source
Copyright © 2008 Society of Hospital Medicine
Disallow All Ads
Correspondence Location
Department of Hospital Medicine, Cleveland Clinic, 9500 Euclid Avenue, S70, Cleveland, OH 44195
Content Gating
Gated (full article locked unless allowed per User)
Gating Strategy
First Peek Free
Article PDF Media

Economic Outlook Not Good for Nonprofit Providers

Article Type
Changed
Fri, 09/14/2018 - 12:35
Display Headline
Economic Outlook Not Good for Nonprofit Providers

Despite record hospital profits a year ago, Moody's Investors Service lowered the outlook for nonprofit hospitals from "stable" to "negative" in a report issued Nov. 11 in lieu of the recent downturn in the U.S. economy.

Steven Liu, MD, founder and CEO of Atlanta-based hospitalist group Ingenous Med, says the downgrade has "tremendous repercussions" for hospitalists. As hospitals start to lose revenue and look at ways to cut costs, one of the big-ticket items administrators will look at are the subsidies paid to hospitalists, which account for 40% to 50% of hospitalists' revenue, he says.

To combat arguments for decreases in subsidies, hospital medicine group (HMG) leaders need to have data supporting the value of their practice in order to show the various benefits they provide the hospital in terms of growth and quality of care.

Dr. Liu also says HMGs must maximize or protect revenue, and examine expenses carefully. Groups building or expanding must ensure that there are enough patients to care for in order to justify expenses, he says.

"Recession is a time where you focus on the quality of your organization, and it is less a time for taking on contracts and hiring physicians," he says.

Moody's provides research data and analytic tools for assessing credit risk, and publishes market-leading credit opinions. For more information, download the report at www.moodys.com.

Issue
The Hospitalist - 2008(12)
Publications
Sections

Despite record hospital profits a year ago, Moody's Investors Service lowered the outlook for nonprofit hospitals from "stable" to "negative" in a report issued Nov. 11 in lieu of the recent downturn in the U.S. economy.

Steven Liu, MD, founder and CEO of Atlanta-based hospitalist group Ingenous Med, says the downgrade has "tremendous repercussions" for hospitalists. As hospitals start to lose revenue and look at ways to cut costs, one of the big-ticket items administrators will look at are the subsidies paid to hospitalists, which account for 40% to 50% of hospitalists' revenue, he says.

To combat arguments for decreases in subsidies, hospital medicine group (HMG) leaders need to have data supporting the value of their practice in order to show the various benefits they provide the hospital in terms of growth and quality of care.

Dr. Liu also says HMGs must maximize or protect revenue, and examine expenses carefully. Groups building or expanding must ensure that there are enough patients to care for in order to justify expenses, he says.

"Recession is a time where you focus on the quality of your organization, and it is less a time for taking on contracts and hiring physicians," he says.

Moody's provides research data and analytic tools for assessing credit risk, and publishes market-leading credit opinions. For more information, download the report at www.moodys.com.

Despite record hospital profits a year ago, Moody's Investors Service lowered the outlook for nonprofit hospitals from "stable" to "negative" in a report issued Nov. 11 in lieu of the recent downturn in the U.S. economy.

Steven Liu, MD, founder and CEO of Atlanta-based hospitalist group Ingenous Med, says the downgrade has "tremendous repercussions" for hospitalists. As hospitals start to lose revenue and look at ways to cut costs, one of the big-ticket items administrators will look at are the subsidies paid to hospitalists, which account for 40% to 50% of hospitalists' revenue, he says.

To combat arguments for decreases in subsidies, hospital medicine group (HMG) leaders need to have data supporting the value of their practice in order to show the various benefits they provide the hospital in terms of growth and quality of care.

Dr. Liu also says HMGs must maximize or protect revenue, and examine expenses carefully. Groups building or expanding must ensure that there are enough patients to care for in order to justify expenses, he says.

"Recession is a time where you focus on the quality of your organization, and it is less a time for taking on contracts and hiring physicians," he says.

Moody's provides research data and analytic tools for assessing credit risk, and publishes market-leading credit opinions. For more information, download the report at www.moodys.com.

Issue
The Hospitalist - 2008(12)
Issue
The Hospitalist - 2008(12)
Publications
Publications
Article Type
Display Headline
Economic Outlook Not Good for Nonprofit Providers
Display Headline
Economic Outlook Not Good for Nonprofit Providers
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)